
<html lang="en"     class="pb-page"  data-request-id="f0535469-077e-4044-91a3-6e1d06e58982"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;article:article:10.1021/acs.jmedchem.1c00472"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery, Structure–Activity Relationships, and In Vivo Evaluation of Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase 1 (AAK1) Inhibitors for the Treatment of Neuropathic Pain" /></meta><meta name="dc.Creator" content="Richard A  Hartz" /></meta><meta name="dc.Creator" content="Vijay T.  Ahuja" /></meta><meta name="dc.Creator" content="Susheel J.  Nara" /></meta><meta name="dc.Creator" content="C.M. Vijaya  Kumar" /></meta><meta name="dc.Creator" content="Jeffrey M.  Brown" /></meta><meta name="dc.Creator" content="Linda J.  Bristow" /></meta><meta name="dc.Creator" content="Ramkumar  Rajamani" /></meta><meta name="dc.Creator" content="Jodi K.  Muckelbauer" /></meta><meta name="dc.Creator" content="Daniel  Camac" /></meta><meta name="dc.Creator" content="Susan E.  Kiefer" /></meta><meta name="dc.Creator" content="Lisa  Hunihan" /></meta><meta name="dc.Creator" content="Michael  Gulianello" /></meta><meta name="dc.Creator" content="Martin  Lewis" /></meta><meta name="dc.Creator" content="Amy  Easton" /></meta><meta name="dc.Creator" content="Jonathan S.  Lippy" /></meta><meta name="dc.Creator" content="Neha  Surti" /></meta><meta name="dc.Creator" content="Sreenivasulu N.  Pattipati" /></meta><meta name="dc.Creator" content="Manoj  Dokania" /></meta><meta name="dc.Creator" content="Saravanan  Elavazhagan" /></meta><meta name="dc.Creator" content="Kumaran  Dandapani" /></meta><meta name="dc.Creator" content="Brian D.  Hamman" /></meta><meta name="dc.Creator" content="Jason  Allen" /></meta><meta name="dc.Creator" content="Walter  Kostich" /></meta><meta name="dc.Creator" content="Joanne J.  Bronson" /></meta><meta name="dc.Creator" content="John E.  Macor" /></meta><meta name="dc.Creator" content="Carolyn D.  Dzierba" /></meta><meta name="dc.Description" content="Effective treatment of chronic pain, in particular neuropathic pain, without the side effects that often accompany currently available treatment options is an area of significant unmet medical need..." /></meta><meta name="Description" content="Effective treatment of chronic pain, in particular neuropathic pain, without the side effects that often accompany currently available treatment options is an area of significant unmet medical need..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 16, 2021" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.1c00472" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2021 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00472" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.1c00472" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.1c00472" /></link>
        
    
    

<title>Discovery, Structure–Activity Relationships, and In Vivo Evaluation of Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase 1 (AAK1) Inhibitors for the Treatment of Neuropathic Pain | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.1c00472" /></meta><meta property="og:title" content="Discovery, Structure–Activity Relationships, and In Vivo Evaluation of Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase 1 (AAK1) Inhibitors for the Treatment of Neuropathic Pain" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0035.jpeg" /></meta><meta property="og:description" content="Effective treatment of chronic pain, in particular neuropathic pain, without the side effects that often accompany currently available treatment options is an area of significant unmet medical need. A phenotypic screen of mouse gene knockouts led to the discovery that adaptor protein 2-associated kinase 1 (AAK1) is a potential therapeutic target for neuropathic pain. The synthesis and optimization of structure–activity relationships of a series of aryl amide-based AAK1 inhibitors led to the identification of 59, a brain penetrant, AAK1-selective inhibitor that proved to be a valuable tool compound. Compound 59 was evaluated in mice for the inhibition of μ2 phosphorylation. Studies conducted with 59 in pain models demonstrated that this compound was efficacious in the phase II formalin model for persistent pain and the chronic-constriction-injury-induced model for neuropathic pain in rats. These results suggest that AAK1 inhibition is a promising approach for the treatment of neuropathic pain." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.1c00472"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00472">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.1c00472&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.1c00472&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.1c00472&amp;href=/doi/10.1021/acs.jmedchem.1c00472" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2021</span><span class="cit-fg-volume">, XXXX</span><span class="cit-fg-issue">, XXX</span><span class="cit-fg-pageRange">, XXX-XXX</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/0/0" title="Return to Articles ASAP" id="returnToASAP" class="content-navigation__btn--return"><span>RETURN TO ARTICLES ASAP</span></a><a href="/doi/10.1021/acs.jmedchem.1c00439" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.1c00510" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery, Structure–Activity Relationships, and In Vivo Evaluation of Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase 1 (AAK1) Inhibitors for the Treatment of Neuropathic Pain</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Richard A Hartz</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Richard A Hartz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Small Molecule Drug Discovery, Bristol Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</div></div><span class="conrtib-corresp"><strong>*</strong>Email: <a href="/cdn-cgi/l/email-protection#91e3f8f2f9f0e3f5bff9f0e3e5ebd1f3fce2bff2fefc"><span class="__cf_email__" data-cfemail="e89a818b80899a8cc680899a9c92a88a859bc68b8785">[email protected]</span></a>. Phone: 609-252-6107.</span><span class="conrtib-corresp"></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Richard+A++Hartz">Richard A Hartz</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-3880-6646" title="Orcid link">https://orcid.org/0000-0002-3880-6646</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Vijay T. Ahuja</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Vijay T. Ahuja</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Small Molecule Drug Discovery, Bristol Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Vijay+T.++Ahuja">Vijay T. Ahuja</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Susheel J. Nara</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Susheel J. Nara</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Biocon-Bristol Myers Squibb Research and Development Center, Biocon Park, Plot No. 2 & 3, Bommasandra Phase IV, Jigani Link Road, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Susheel+J.++Nara">Susheel J. Nara</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">C.M. Vijaya Kumar</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">C.M. Vijaya Kumar</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Biocon-Bristol Myers Squibb Research and Development Center, Biocon Park, Plot No. 2 & 3, Bommasandra Phase IV, Jigani Link Road, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=C.M.+Vijaya++Kumar">C.M. Vijaya Kumar</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jeffrey M. Brown</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jeffrey M. Brown</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Neuroscience Discovery Biology, Bristol Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey+M.++Brown">Jeffrey M. Brown</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Linda J. Bristow</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Linda J. Bristow</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Neuroscience Discovery Biology, Bristol Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Linda+J.++Bristow">Linda J. Bristow</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Ramkumar Rajamani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Ramkumar Rajamani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Structure and Design, Bristol Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Ramkumar++Rajamani">Ramkumar Rajamani</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jodi K. Muckelbauer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jodi K. Muckelbauer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Structure and Design, Bristol Myers Squibb Company, Research and Development, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jodi+K.++Muckelbauer">Jodi K. Muckelbauer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Daniel Camac</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel Camac</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Molecular Structure and Design, Bristol Myers Squibb Company, Research and Development, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Camac">Daniel Camac</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Susan E. Kiefer</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Susan E. Kiefer</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Protein Science, Bristol Myers Squibb Company, Research and Development, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Susan+E.++Kiefer">Susan E. Kiefer</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lisa Hunihan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lisa Hunihan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Neuroscience Discovery Biology, Bristol Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lisa++Hunihan">Lisa Hunihan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Gulianello</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Gulianello</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Neuroscience Discovery Biology, Bristol Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Gulianello">Michael Gulianello</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Martin Lewis</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Martin Lewis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Neuroscience Discovery Biology, Bristol Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Martin++Lewis">Martin Lewis</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Amy Easton</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Amy Easton</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Neuroscience Discovery Biology, Bristol Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Amy++Easton">Amy Easton</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jonathan S. Lippy</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jonathan S. Lippy</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Lead Evaluation, Bristol Myers Squibb Company, Research and Development, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jonathan+S.++Lippy">Jonathan S. Lippy</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Neha Surti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Neha Surti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Lead Evaluation, Bristol Myers Squibb Company, Research and Development, Princeton, New Jersey 08543, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Neha++Surti">Neha Surti</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sreenivasulu N. Pattipati</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sreenivasulu N. Pattipati</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Biocon-Bristol Myers Squibb Research and Development Center, Biocon Park, Plot No. 2 & 3, Bommasandra Phase IV, Jigani Link Road, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sreenivasulu+N.++Pattipati">Sreenivasulu N. Pattipati</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Manoj Dokania</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Manoj Dokania</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Biocon-Bristol Myers Squibb Research and Development Center, Biocon Park, Plot No. 2 & 3, Bommasandra Phase IV, Jigani Link Road, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Manoj++Dokania">Manoj Dokania</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Saravanan Elavazhagan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Saravanan Elavazhagan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Biocon-Bristol Myers Squibb Research and Development Center, Biocon Park, Plot No. 2 & 3, Bommasandra Phase IV, Jigani Link Road, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Saravanan++Elavazhagan">Saravanan Elavazhagan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kumaran Dandapani</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kumaran Dandapani</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Biocon-Bristol Myers Squibb Research and Development Center, Biocon Park, Plot No. 2 & 3, Bommasandra Phase IV, Jigani Link Road, Bangalore 560099, India</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kumaran++Dandapani">Kumaran Dandapani</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Brian D. Hamman</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brian D. Hamman</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lexicon Pharmaceuticals, 8800 Technology Forest Place, The Woodlands, Texas 77381, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brian+D.++Hamman">Brian D. Hamman</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jason Allen</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jason Allen</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Lexicon Pharmaceuticals, 8800 Technology Forest Place, The Woodlands, Texas 77381, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Allen">Jason Allen</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Walter Kostich</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Walter Kostich</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Neuroscience Discovery Biology, Bristol Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Walter++Kostich">Walter Kostich</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Joanne J. Bronson</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Joanne J. Bronson</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Small Molecule Drug Discovery, Bristol Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Joanne+J.++Bronson">Joanne J. Bronson</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">John E. Macor</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">John E. Macor</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Small Molecule Drug Discovery, Bristol Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=John+E.++Macor">John E. Macor</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Carolyn D. Dzierba</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Carolyn D. Dzierba</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Small Molecule Drug Discovery, Bristol Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Carolyn+D.++Dzierba">Carolyn D. Dzierba</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00472&amp;href=/doi/10.1021%2Facs.jmedchem.1c00472" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2021</span></span><span class="cit-volume">, XXXX</span><span class="cit-issue">, XXX</span><span class="cit-pageRange">, XXX-XXX</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 16, 2021</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 March 2021</li><li><span class="item_label"><b>Published</b> online</span>16 July 2021</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.1c00472" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00472</a></div><div class="article_header-article-copyright"><strong>© 2021 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D1%26pageCount%3D39%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRichard%2BA%2BHartz%252C%2BVijay%2BT.%2BAhuja%252C%2BSusheel%2BJ.%2BNara%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D0%26issueNum%3D0%26contentID%3Dacs.jmedchem.1c00472%26title%3DDiscovery%252C%2BStructure%25E2%2580%2593Activity%2BRelationships%252C%2Band%2BIn%2BVivo%2BEvaluation%2Bof%2BNovel%2BAryl%2BAmides%2Bas%2BBrain%2BPenetrant%2BAdaptor%2BProtein%2B2-Associated%2BKinase%2B1%2B%2528AAK1%2529%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BNeuropathic%2BPain%26numPages%3D39%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D39%26publicationDate%3DJuly%2B2021">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.1c00472"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">821</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val">-</div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.1c00472" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery, Structure–Activity Relationships, and In Vivo Evaluation of Novel Aryl Amides as Brain Penetrant Adaptor Protein 2-Associated Kinase 1 (AAK1) Inhibitors for the Treatment of Neuropathic Pain&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;A Hartz&quot;},{&quot;first_name&quot;:&quot;Vijay&quot;,&quot;last_name&quot;:&quot;T. Ahuja&quot;},{&quot;first_name&quot;:&quot;Susheel&quot;,&quot;last_name&quot;:&quot;J. Nara&quot;},{&quot;first_name&quot;:&quot;C.M.&quot;,&quot;last_name&quot;:&quot;Vijaya Kumar&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;M. Brown&quot;},{&quot;first_name&quot;:&quot;Linda&quot;,&quot;last_name&quot;:&quot;J. Bristow&quot;},{&quot;first_name&quot;:&quot;Ramkumar&quot;,&quot;last_name&quot;:&quot;Rajamani&quot;},{&quot;first_name&quot;:&quot;Jodi&quot;,&quot;last_name&quot;:&quot;K. Muckelbauer&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Camac&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;E. Kiefer&quot;},{&quot;first_name&quot;:&quot;Lisa&quot;,&quot;last_name&quot;:&quot;Hunihan&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Gulianello&quot;},{&quot;first_name&quot;:&quot;Martin&quot;,&quot;last_name&quot;:&quot;Lewis&quot;},{&quot;first_name&quot;:&quot;Amy&quot;,&quot;last_name&quot;:&quot;Easton&quot;},{&quot;first_name&quot;:&quot;Jonathan&quot;,&quot;last_name&quot;:&quot;S. Lippy&quot;},{&quot;first_name&quot;:&quot;Neha&quot;,&quot;last_name&quot;:&quot;Surti&quot;},{&quot;first_name&quot;:&quot;Sreenivasulu&quot;,&quot;last_name&quot;:&quot;N. Pattipati&quot;},{&quot;first_name&quot;:&quot;Manoj&quot;,&quot;last_name&quot;:&quot;Dokania&quot;},{&quot;first_name&quot;:&quot;Saravanan&quot;,&quot;last_name&quot;:&quot;Elavazhagan&quot;},{&quot;first_name&quot;:&quot;Kumaran&quot;,&quot;last_name&quot;:&quot;Dandapani&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;D. Hamman&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Allen&quot;},{&quot;first_name&quot;:&quot;Walter&quot;,&quot;last_name&quot;:&quot;Kostich&quot;},{&quot;first_name&quot;:&quot;Joanne&quot;,&quot;last_name&quot;:&quot;J. Bronson&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;E. Macor&quot;},{&quot;first_name&quot;:&quot;Carolyn&quot;,&quot;last_name&quot;:&quot;D. Dzierba&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2021&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;16&quot;,&quot;issue&quot;:&quot;0&quot;,&quot;volume&quot;:&quot;0&quot;,&quot;pages&quot;:&quot;&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.1c00472&quot;},&quot;abstract&quot;:&quot;Effective treatment of chronic pain, in particular neuropathic pain, without the side effects that often accompany currently available treatment options is an area of significant unmet medical need. A phenotypic screen of mouse gene knockouts led to the discovery that adaptor protein 2-associated kinase 1 (AAK1) is a potential therapeutic target for neuropathic pain. The synthesis and optimization of structure–activity relationships of a series of aryl amide-based AAK1 inhibitors led to the identification of 59, a brain penetrant, AAK1-selective inhibitor that proved to be a valuable tool compound. Compound 59 was evaluated in mice for the inhibition of μ2 phosphorylation. Studies conducted with 59 in pain models demonstrated that this compound was efficacious in the phase II formalin model for persistent pain and the chronic-constriction-injury-induced model for neuropathic pain in rats. These results suggest that AAK1 inhibition is a promising approach for the treatment of neuropathic pain.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00472&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00472" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00472&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00472" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.1c00472&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00472" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.1c00472&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.1c00472&amp;href=/doi/10.1021/acs.jmedchem.1c00472" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.1c00472" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.1c00472" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (8 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.1c00472%26sid%3Dliteratum%253Aachs%26pmid%3D34270254%26genre%3Darticle%26aulast%3DHartz%26date%3D2021%26atitle%3DDiscovery%252C%2BStructure%25E2%2580%2593Activity%2BRelationships%252C%2Band%2BIn%2BVivo%2BEvaluation%2Bof%2BNovel%2BAryl%2BAmides%2Bas%2BBrain%2BPenetrant%2BAdaptor%2BProtein%2B2-Associated%2BKinase%2B1%2B%2528AAK1%2529%2BInhibitors%2Bfor%2Bthe%2BTreatment%2Bof%2BNeuropathic%2BPain%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D0%26issue%3D0%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292461" title="Neurophysiology">Neurophysiology</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a>,</li><li><a href="/action/doSearch?ConceptID=291675" title="Stability">Stability</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/0/0" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0035.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Effective treatment of chronic pain, in particular neuropathic pain, without the side effects that often accompany currently available treatment options is an area of significant unmet medical need. A phenotypic screen of mouse gene knockouts led to the discovery that adaptor protein 2-associated kinase 1 (AAK1) is a potential therapeutic target for neuropathic pain. The synthesis and optimization of structure–activity relationships of a series of aryl amide-based AAK1 inhibitors led to the identification of <b>59</b>, a brain penetrant, AAK1-selective inhibitor that proved to be a valuable tool compound. Compound <b>59</b> was evaluated in mice for the inhibition of μ2 phosphorylation. Studies conducted with <b>59</b> in pain models demonstrated that this compound was efficacious in the phase II formalin model for persistent pain and the chronic-constriction-injury-induced model for neuropathic pain in rats. These results suggest that AAK1 inhibition is a promising approach for the treatment of neuropathic pain.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_81100" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_81100" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Pain is associated with a wide range of injuries and diseases and can be broadly classified into four different types: nociceptive pain, inflammatory pain, dysfunctional pain, and neuropathic pain.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The estimated prevalence of neuropathic pain varies considerably depending on the methodology used. In epidemiological studies based on reports of the classic symptoms, it has been estimated that 6–8% of the general population suffers from neuropathic pain.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a> Neuropathic pain is defined as ″pain caused by a lesion or disease of the somatosensory nervous system″.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Neuropathic pain is often associated with allodynia (pain due to a stimulus that does not normally evoke pain) and hyperalgesia (increased pain from a normally painful stimulus). Neuropathic pain can be caused by damage to central or peripheral nerves or by diseases, such as diabetes, trigeminal neuralgia, or HIV infection. Chronic allodynia is associated with many painful conditions, such as neuropathies, postherpetic neuralgia, and fibromyalgia.</div><div class="NLM_p">There is a significant medical need for improved treatment options for chronic pain, particularly neuropathic pain. Nociceptive pain can often be treated effectively, or at least managed, with nonsteroidal anti-inflammatory drugs (NSAIDs) or opiates, such as codeine and oxycodone. However, NSAIDs are generally not very effective for the treatment of patients suffering from neuropathic pain. Opiates may provide some relief but often have undesirable side effects along with potential addiction liabilities. Moreover, high doses are often needed to have a significant effect. Tricyclic antidepressants, serotonin and norepinephrine reuptake inhibitors (SNRIs) (e.g., duloxetine (<b>1</b>)), and the gabapentin family of drugs (gabapentin (<b>3</b>) and pregabalin (<b>4</b>), both of which are derivatives of γ-aminobutyric acid (<b>2</b>)), are commonly prescribed drugs to treat neuropathic pain (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>).<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> The antinociceptive mechanism of these drugs has been linked to the endogenous noradrenergic system. The endogenous noradrenergic system imposes powerful inhibitory effects on the spinal cord dorsal horn circuitry that processes afferent nociceptive input from the periphery, and is required for neuropathic pain.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Tricyclic antidepressants and SNRIs increase the dorsal horn concentration of serotonin and norepinephrine by inhibiting their reuptake from the synapse, resulting in an antinociceptive effect.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> Evidence from preclinical studies indicates that the primary site of action of gabapentin and pregabalin is voltage-gated calcium channels containing the α<sub>2</sub>δ-1 subunit, leading to reduced neurotransmitter release and attenuation of postsynaptic excitability, thus preventing the pain-induced increase in calcium currents.<a onclick="showRef(event, 'ref8 ref9'); return false;" href="javascript:void(0);" class="ref ref8 ref9">(8,9)</a> These drugs, however, have limited usefulness since they are only effective for certain types of neuropathic pain. In addition, duloxetine, gabapentin, and pregabalin commonly cause side effects, such as dizziness, drowsiness, and fatigue. Hence, new classes of drugs with improved efficacy and reduced side effects are urgently needed to treat and manage neuropathic pain.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of duloxetine (<b>1</b>), γ-aminobutyric acid (GABA) (<b>2</b>), gabapentin (<b>3</b>), and pregabalin (<b>4</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Adaptor protein 2-associated kinase 1 (AAK1) is a serine/threonine kinase and is a member of the family of NUMB-associated kinases (NAKs).<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Other members of this family include BMP2-inducible kinase (BIKE or BMP2K), cyclin-G-associated kinase (GAK), and myristoylated and palmitoylated serine/threonine kinase 1 (MPSK1, also known as STK16). AAK1 plays an important role in clathrin-mediated endocytosis.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Endocytosis via clathrin-coated vesicles is a ubiquitous internalization pathway for the transport of cell-surface proteins across the cell membrane and for receptor-mediated endocytosis and is mediated by clathrin and the AP2 complex.<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> Endocytic clathrin-coated vesicle formation is essential for synaptic vesicle recycling and receptor-mediated endocytosis. The APs represent a class of proteins (termed AP1, AP2, AP3, and AP4) of which the AP2 complex is found at the plasma membrane and regulates receptor-mediated endocytosis.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> AP2 is a multifunctional heterotetramer composed of two large subunits (α and β2), a medium subunit (μ2), and a small subunit (σ2)<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> and is a key component of the endocytotic machinery that links cargo membrane proteins to the clathrin lattice. Evidence suggests that the μ2 subunit is involved in the recognition of endocytic cargo<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> and the β2 subunit binds to clathrin.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> The μ2 subunit of AP2 directly interacts with the cytoplasmic tail of membrane-bound receptors marked for internalization by tyrosine-based sorting signals.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> AAK1 associates with the μ2 subunit of the AP2 complex and plays an important regulatory role in clathrin-coated endocytosis. Phosphorylation of Thr-156 of the μ2 subunit by AAK1 enhances the binding affinity of the AP2 complex to specific tyrosine-based targeting sequences located in the cytoplasmic tail of surface receptors<a onclick="showRef(event, 'ref11 ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref11 ref20 ref21">(11,20,21)</a> and is critical for AP2 function in receptor-mediated endocytosis.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> AAK1 is widely expressed in the brain and spinal cord, including the dorsal root ganglia. The GABA<sub>A</sub> Cl channel is involved in nociception, and it has been postulated that reduced endocytosis of cell surface levels of μ2-containing GABA<sub>A</sub> channels may be responsible for the antinociceptive effects of AAK1 inhibitors.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><div class="NLM_p">AAK1 was identified as a novel target for antinociception by researchers at Lexicon Pharmaceuticals by using the formalin assay<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> to characterize behavioral effects in mice with single gene knockouts. This phenotypic screen resulted in the discovery that AAK1 knockout mice exhibited a reduced number of flinches in the phase II formalin response (persistent pain) and that this reduced formalin response was not due to suppressed motor function.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Follow-up studies with AAK1 knockout mice and wild-type control mice in a spinal nerve ligation model for neuropathic pain<a onclick="showRef(event, 'ref25 ref26'); return false;" href="javascript:void(0);" class="ref ref25 ref26">(25,26)</a> showed that the AAK1 knockout mice did not develop mechanical allodynia during the 3 weeks following the spinal nerve ligation surgery.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> In addition, AAK1 knockout mice did not show additional behavioral or physiological changes in a broad phenotypic screen, suggesting that AAK1 may be a promising target for reducing neuropathic pain while avoiding other mechanism-based toxicities. We previously reported that small molecule AAK1 inhibitor <b>5</b> (LP-935509) (AAK1 IC<sub>50</sub> = 3.3 nM) recapitulated the knockout phenotype.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> This compound dose-dependently reduced the nociceptive behavioral response in rodents in several models of neuropathic pain. Importantly, AAK1 inhibition did not affect acute nociception in the phase I formalin test, hot-plate assay, and tail-flick assays, indicating that AAK1 inhibition selectively reduces neuropathic pain while leaving acute pain sensitivity unaffected. Experiments with additional small molecule AAK1 inhibitors, including <b>6</b> (AAK1 IC<sub>50</sub> = 0.7 nM) and <b>7</b> (AAK1 IC<sub>50</sub> = 4.8 nM), demonstrated that AAK1 inhibition in the spinal cord is sufficient for the antineuropathic effect (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> AAK1 inhibitors likely act indirectly on the α2-adrenergic pathway, a major inhibitory pain pathway, and do not work through or require opioid signaling, suggesting that AAK1 inhibitors should be free of opioid-drug-related liabilities.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of AAK1 inhibitors <b>5</b>–<b>10</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Literature reports indicate that AAK1 inhibitors may also be useful for other therapeutic indications. Receptor-mediated endocytosis is a common pathway for virus entry into cells. Inhibition of AAK1 has emerged as a potential approach for the treatment of SARS-CoV-2.<a onclick="showRef(event, 'ref27 ref28 ref29 ref30'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29 ref30">(27−30)</a> Baricitinib (<b>8</b>) is a JAK1/2 inhibitor (JAK1 IC<sub>50</sub> = 5.9 nM, JAK2 IC<sub>50</sub> = 5.7 nM)<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> that has been approved for the treatment rheumatoid arthritis. This compound also has a high affinity for AAK1, BIKE, and GAK (<i>K</i><sub>d</sub> = 8.2, 20, and 120 nM, respectively) and was investigated as a potential antiviral agent for the treatment of COVID-19 hospitalized patients.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> AAK1 has also been studied as a potential drug target for the treatment of dengue virus and Ebola virus.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> It was reported that <b>9</b> (AAK1 IC<sub>50</sub> = 4.0 nM) exhibited potent activity in DENV-infected primary dendritic cells and also suppressed EBOV activity. Compound <b>10</b> has been reported to be a chemical probe that is selective for AAK1 and BMP2K over other members of the NAK family of kinases (GAK and MPSK1) (<i>K</i><sub>i</sub> = 9.1, 17, 1700, and >10,000 nM, respectively) (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> This compound along with related analogs showed high kinase selectivity by KINOMEscan (DiscoverX) (S<sub>10</sub>(1 μM) = 0.005–0.022). Further evaluation showed that RIOK1, RIOK3, and PIP5K1C were the most potent off-target kinases for <b>10</b>. Inhibition of AAK1 may also be a potential drug target for the treatment of hepatitis C.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> In addition, AAK1 has been linked to amyotrophic lateral sclerosis<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> and has been reported to be a positive regulator of the Notch pathway.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> A recent review article summarizes the patent literature covering AAK1 inhibitors from 2013 to the present.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><div class="NLM_p">A collaborative effort with Lexicon Pharmaceuticals was undertaken to discover small molecule AAK1 inhibitors. Compound <b>5</b> (LP-935509) arose from Lexicon’s screening of their internal compound collection.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Concurrent with Lexicon’s screening effort, we also screened our in-house compound library to identify novel lead compounds with AAK1 inhibitory activity. This screen resulted in the identification of leads from several chemotypes, one of which was compound <b>11</b> (IC<sub>50</sub> = 69 nM) (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>), which was an attractive lead compound based on desirable drug-like properties. This compound has a molecular weight = 289, cLogP = 0.93, topological polar surface area (tPSA) = 90 Å<sup>2</sup>, ligand efficiency (LE) = 0.47, and lipophilic ligand efficiency (LLE) = 6.2. At the time this investigation was undertaken, it was not known if the AAK1 knockout mouse phenotype in the neuropathic pain models could be recapitulated with a small molecule. The previously published results described above with <b>5</b> and related compounds<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> had not yet been obtained at the time of this work. Our objective at this early stage of this program was to identify a suitable tool compound(s) that could be used to conduct in vivo proof-of-concept experiments to recapitulate the AAK1 knockout result. We primarily focused on identifying a compound(s) with improved AAK1 enzyme potency compared to <b>11</b>. In addition, a compound with an acceptable metabolic stability profile (although pharmacokinetic properties did not need to be fully optimized) and a good overall kinase selectivity profile to avoid potential confounding results due to off-target kinase activity was desirable. Structure–activity relationship (SAR) studies to follow up on the hit compound <b>11</b> were conducted and consisted of modification of the amide side chain, replacement of the oxazole moiety with other heterocycles, and a limited SAR investigation of central phenyl ring substituents. The synthesis and structure–activity relationships (SARs) of the aryl amide chemotype, along with the kinase selectivity profile and results from the in vivo evaluation of <b>59</b>, are described herein. These results, in combination with the results previously described for <b>5</b>, comprise the first in vivo proof of concept validating the inhibition of AAK1 with a small molecule as a potential approach for the treatment of neuropathic pain.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structure of compound <b>11</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31484" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31484" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Structure–Activity Relationships and X-ray Crystallography</h3><div class="NLM_p">An enzyme assay was used to determine the potency of the inhibitor test compounds by incubation of varying concentrations of these compounds with the human AAK1 kinase domain (amino acids 30–330), a fluorescent substrate, and ATP. Compound <b>11</b>, which was identified as a result of screening of our in-house compound library, had an IC<sub>50</sub> of 69 nM in this assay. We began our SAR studies of this chemotype by modifying the amide side chain. The results are shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>. Replacement of the isopropyl group with a methyl group (<b>12</b>) led to a nearly 20-fold decrease in potency. Increasing the length of the alkyl group from methyl (<b>12</b>) to ethyl (<b>13</b>), propyl (<b>14</b>), and butyl (<b>16</b>) resulted in a trend toward improved potency. Incorporation of branching, as in the case of the <span class="smallcaps smallerCapital">d</span>-isoleucine-based analog, resulted in a further improvement in potency (compare <b>18</b> to <b>14</b>). Replacement of the <span class="smallcaps smallerCapital">d</span>-isoleucine-derived amide (<b>18</b>) with a <span class="smallcaps smallerCapital">d</span>-leucine group (<b>19</b>) led to an additional improvement in potency (IC<sub>50</sub> = 12 nM). Extending the branching point out one carbon further on the amide side chain (<b>21</b>) resulted in a decrease in potency, indicating that the <span class="smallcaps smallerCapital">d</span>-leucine-derived side chain appeared be the optimal chain length. A comparison of the enantiomers of several analogs showed that the <i>R</i> enantiomer is preferred (compare <b>14</b> to <b>15</b>, <b>16</b> to <b>17</b>, and <b>19</b> to <b>20</b>). Replacement of the isopropyl group in <b>19</b> with a <i>t</i>-butyl group (<b>22</b>) resulted in a decrease in potency and similar metabolic stability compared to <b>19</b>. Monomethylation of the amine resulted in approximately a 4-fold decrease in potency (compare <b>23</b> to <b>19</b>), and homologation of the amine group on the amide side chain showed that either insertion of an additional carbon between the amine and the carbon backbone of the side chain (<b>24</b>) or moving the amine to the β-carbon (<b>25</b>) resulted in a 7- and 10-fold decrease in potency, respectively (compare <b>24</b> and <b>25</b> to <b>19</b>). Replacement of the alkyl side chain in <b>19</b> with cycloalkyl groups (<b>26</b>–<b>29</b>) showed that the analog with a cyclopentyl group directly attached to the α-carbon was equipotent to <b>19</b> (compare <b>28</b> to <b>19</b>). The results showed that the insertion of a methylene group between the α-carbon and the cyclohexyl group resulted in a ∼25-fold decrease in potency (compare <b>30</b> to <b>29</b>), indicating that there is limited space to accommodate the aliphatic side chain in the binding pocket. Replacement of the cyclohexyl group in <b>29</b> and <b>30</b> with a phenyl group showed that the phenyl group is disfavored compared to the cyclohexyl group (compare <b>31</b> to <b>29</b> and <b>32</b> to <b>30</b>). The presence of additional polar groups in the amide side chain was not well tolerated (<b>33</b>–<b>34</b>). Methylation of the amide nitrogen resulted in a large decrease in potency (<b>35</b>), suggesting that this NH forms a critical hydrogen bonding interaction with the kinase, the methyl group is not sterically tolerated, or the favorable conformation of the amide is altered. Removal of the amine present at the α-carbon of the amide side chain resulted in a 7- to 10-fold decrease in potency (compare <b>36</b>–<b>38</b> to <b>19</b>, <b>28</b>, and <b>31</b>, respectively), suggesting that the amine present at this position forms a favorable hydrogen bonding interaction that enhances potency.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structure–Activity Relationships of the Amide Substituent</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0027.gif" alt="" id="gr26" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0028.gif" alt="" id="gr27" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">Values are the means of three or more experiments ± SD unless indicated otherwise.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Values are the means of two experiments.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Value is the mean of one experiment.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Metabolic stability in human (H), rat (R), and mouse (M) liver microsomes; values are the percentage of the parent remaining after 10 min of incubation.</p></div></div><div></div></div><div class="NLM_p">The aryl amide-based compounds were also evaluated for in vitro metabolic stability. Compounds were categorized as having high (>75% remaining), medium (between 50 and 75% remaining), or low (<50% remaining) metabolic stability after incubation with human, rat, and mouse liver microsomes for 10 min. Many of the compounds shown in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> had high metabolic stability in human liver microsomes, and the majority of the compounds in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a> can be classified as having moderate to high metabolic stability in rat and mouse liver microsomes. Compound <b>12</b> had the highest metabolic stability across all species, suggesting that the alkyl side chain may be a primary site of metabolism. Compounds with alkyl groups that were larger than the methyl group present in <b>12</b> showed reduced metabolic stability, particularly in rat and mouse liver microsomes. Compound <b>22</b> was prepared to determine if replacement of the distal isopropyl group with a <i>tert</i>-butyl group would improve the metabolic stability; however, this did not result in any meaningful change (compare <b>22</b> to <b>19</b>). Compound <b>26</b>, with the cyclopropyl replacement of the isopropyl group, also had similar metabolic stability compared to <b>19</b>. Compounds containing cycloalkyl or aryl groups (<b>26</b>–<b>32</b>) also possessed similar metabolic stability characteristics to compounds with branched alkyl groups (e.g., <b>18</b>–<b>21</b>). Notably, the <i>N</i>-methyl analog (<b>23</b>) and β-amino acid analog (<b>25</b>) had reduced metabolic stability in rat and mouse liver microsomes.</div><div class="NLM_p">ATP competitive small molecule kinase inhibitors typically form hydrogen bonding interactions with the hinge region of the ATP binding site, which is characterized by a donor–acceptor–donor motif. Many kinase inhibitors form two or even three of these hydrogen bonding interactions with the hinge region. Upon initial inspection of the structure of the compounds in this chemotype, it was not immediately obvious how they bound to the ATP binding site. To provide a better understanding of the binding mode of these compounds to AAK1 and the SAR around the <span class="smallcaps smallerCapital">d</span>-leucine-derived side chain, an X-ray crystal structure of <b>19</b> bound to mouse AAK1 was obtained to 2.65 Å resolution and is shown in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>A (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LVH">7LVH</a>). Mouse AAK1 was used for X-ray crystallography studies since it gave a more robust crystal system than human AAK1. The human and mouse AAK1 ATP binding site is the same, and there are only six amino acid residue differences in the kinase domain (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00472/suppl_file/jm1c00472_si_001.pdf" class="ext-link">Table S2</a>). There is little to no significant difference in the IC<sub>50</sub> values between the human, mouse, and rat full-length enzymes (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00472/suppl_file/jm1c00472_si_001.pdf" class="ext-link">Table S3</a>). The crystal structure shows that <b>19</b> binds to the ATP binding site of AAK1 and makes the following interactions with the protein: the oxazole ring nitrogen forms a single hydrogen bond with the backbone NH of Cys129 at the kinase hinge region, the central phenyl core is sandwiched between Val60 on the P-loop and Cys193 located on the N-terminal side of the DFG-motif (Asp194-Phe195-Gly196), the amide NH forms a hydrogen bond to the side chain oxygen of Asp194 on the DFG-motif, and the amine forms a hydrogen bond to the side chain oxygen of Asn181 and orients the isopropyl group such that it projects up toward the underside of the P-loop packing tightly against it. A critical hydrophobic interaction occurs between the isopropyl group and a small lipophilic pocket in the P-loop region of the kinase resulting in improved potency and kinase selectivity. The crystal structure is consistent with the SAR findings suggesting that the <span class="smallcaps smallerCapital">d</span>-leucine-derived amide side chain appears to present optimal hydrogen bonding interactions through the amide and amine nitrogens and an appropriate alkyl side chain length to facilitate a stabilizing bridging effect between the N-terminal domain (via the P-loop) and C-terminal domain (via the DFG motif) of AAK1 kinase. The methoxy group packs up against Leu52 and Ala53 on the P-loop above and Leu183 below, resulting in  hydrophobic interactions (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). As depicted in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>, the size of the methoxy group fits well into this space, resulting in an enhancement in potency (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>). The activation loop of AAK1 is in an open conformation as was observed in previously reported crystal structures of AAK1,<a onclick="showRef(event, 'ref10 ref33'); return false;" href="javascript:void(0);" class="ref ref10 ref33">(10,33)</a> and the DFG motif is in the ″in″ conformation, consistent with the active form of the kinase.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystal structure of AAK1 in complex with compound <b>19</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LVH">7LVH</a>). Compound <b>19</b> is rendered as a stick model with orange carbon atoms. Hydrogen bonds are shown as black dashed lines. (A) Final refined 2Fo-Fc electron density map is shown contoured at 1σ around compound <b>19</b>. (B) Compound <b>19</b> bound to the ATP binding site of AAK1 with the P-loop shown. (C, D) A surface representation of protein with <b>19</b> bound to the ATP-binding site of AAK1 showing the close proximity of the isopropyl group to a small hydrophobic pocket on the underside of the P-loop (shown from two orientations). Figures were made with PyMol.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray crystal structure of AAK1 in complex with compound <b>19</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LVH">7LVH</a>). Compound <b>19</b> is rendered as a space filling model with green carbon atoms. The methoxy group packs up against Leu52 and Ala53 on the P-loop above and Leu183 below, resulting in hydrophobic interactions. The figure was made with PyMol.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">An analog was subsequently prepared that introduced a structural constraint to the <span class="smallcaps smallerCapital">d</span>-leucine-derived amide side chain wherein the flexible isobutyl group was tied back into a six-membered (piperidine) ring (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Constraining this side chain into a piperidine ring allowed for the inclusion of an isopropyl substituent at the 3-position, which overlaid well with the bioactive conformation of the isopropyl moiety on the <span class="smallcaps smallerCapital">d</span>-leucine-derived side chain. The more rigid structure also had the potential to lead to improved potency. The unsubstituted piperidine-based side chain analog <b>39</b> had an IC<sub>50</sub> of 550 nM (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). The synthesis and evaluation of an enantiomeric pair of analogs with an isopropyl group attached to the 3-position of the piperidine ring resulted in the identification of <b>(<i>R</i>,<i>R</i>)-40</b> (IC<sub>50</sub> = 10 nM), which was equipotent to <b>19</b> (IC<sub>50</sub> = 12 nM). The <i>S</i>,<i>S</i> enantiomer (<b>(<i>S</i>,<i>S</i>)-40</b>) was 36-fold less potent. It was found that compounds with the piperidine-based side chains overall have poor metabolic stability in rat and mouse liver microsomes.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structure–Activity Relationships of the Amide Substituent</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0029.gif" alt="" id="gr28" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0030.gif" alt="" id="gr29" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">Values are the means of three or more experiments ± SD.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Metabolic stability in human (H), rat (R), and mouse (M) liver microsomes; values are the percentage of the parent remaining after 10 min of incubation.</p></div></div><div></div></div><div class="NLM_p">An X-ray crystal structure of <b>(<i>R</i>,<i>R</i>)-40</b> bound to the ATP binding site of mouse AAK1 was determined to 2.2 Å resolution as shown in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LVI">7LVI</a>). <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A,B shows that the isopropyl group in the constrained analog <b>(<i>R</i>,<i>R</i>)-40</b> exists in the same orientation as the isopropyl group in <b>19</b>, and the observed interactions for <b>(<i>R</i>,<i>R</i>)-40</b> in complex with AAK1 are the same as those described above for compound <b>19</b>. These results indicate that the amine on the side chain of <b>19</b> is sufficient to orient the more flexible leucine-derived side chain to the bioactive conformation without a loss in potency compared to <b>(<i>R</i>,<i>R</i>)-40</b>, which has a more rigid piperidine-based side chain. On the basis of diffraction data obtained, two conformations of Cys193 were observed in the X-ray co-crystal structure of <b>(<i>R</i>,<i>R</i>)-40</b> with AAK1. An overlay of <b>(<i>S</i>,<i>S</i>)-40</b> that is ∼3 kcal above the apparent global minimum superimposed onto <b>(<i>R</i>,<i>R</i>)-40</b> with the isopropyl groups overlapping suggests that a suboptimal orientation of the piperidine ring in <b>(<i>S</i>,<i>S</i>)-40</b> is required to bind to AAK1 (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00472/suppl_file/jm1c00472_si_001.pdf" class="ext-link">Figure S3</a>). In addition, a steric clash of the isopropyl group of the <i>S</i>,<i>S</i>-isomer occurs with the protein (protein not shown). This may account for the reduced potency of the <b>(<i>S</i>,<i>S</i>)-40</b> isomer.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. X-ray crystal structure of AAK1 in complex with compound <b>(<i>R</i>,<i>R</i>)-40</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LVI">7LVI</a>). Compound <b>(<i>R</i>,<i>R</i>)-40</b> is rendered as a stick model with green carbon atoms. Hydrogen bonds are shown as black dashed lines. (A) Final refined 2Fo-Fc electron density map is shown contoured (1σ) around compound <b>(<i>R</i>,<i>R</i>)-40</b>. Two conformations of Cys193 were observed in the X-ray co-crystal structure. (B) A surface representation of the protein with <b>(<i>R</i>,<i>R</i>)-40</b> superimposed onto <b>19</b> (orange) bound to the ATP-binding site of AAK1. Figures were made with PyMol.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Since the X-ray co-crystal structure of <b>19</b> with AAK1 indicated that the oxazole nitrogen forms a hydrogen bonding interaction with the hinge region of the kinase, an SAR study was conducted to replace the oxazole ring with similar heterocycles with the goal of optimizing the hydrogen bonding interaction of the heterocycle with this region of the kinase. The results are shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>. Replacement of the oxazole with a pyrazole resulted in a compound with a similar potency (compare <b>41</b> to <b>19</b>). On the other hand, a 4-fold decrease in potency was observed when the oxazole was replaced with a triazole (compare <b>42</b> to <b>19</b>). Methylation of one of the pyrazole nitrogens (<b>43</b>) resulted in a 260-fold decrease in potency, indicating that this methyl group disrupts the hydrogen bonding interaction with Cys129 in the hinge region of the kinase. Several other compounds with five-membered ring heterocycles were also synthesized (<b>44</b>–<b>46</b>), but all were less potent than the oxazole analog (<b>19</b>). A series of six-membered ring heterocyclic analogs was also prepared (<b>47</b>–<b>54</b>). Compound <b>47</b> was the most potent of this group (IC<sub>50</sub> = 85 nM). The pyridazine-based analog (<b>48</b>) was similar in potency (IC<sub>50</sub> = 110 nM) to the pyridin-4-yl derivative (<b>47</b>). It was found that the pyrimidin-4-yl analog (<b>49</b>) was ∼3-fold less potent than the pyridin-4-yl derivative (<b>47</b>). Substitution of ortho to the pyridyl nitrogen with chloro, amino, or methylamino groups resulted in reduced potency compared to the unsubstituted pyridyl analog (compare <b>50</b>–<b>52</b> to <b>47</b>). The pyridin-3-yl analog (<b>53</b>) and the pyrimidin-5-yl analog (<b>54</b>) were also synthesized, and the results showed that these compounds were less potent than <b>47</b> and <b>49</b>, respectively, indicating that proper positioning of the ring nitrogen <i>para</i> to the point of attachment of the phenyl group is required for optimal potency for the six-membered ring heterocycles. The metabolic stability of the analogs shown in <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a> appeared to be fairly similar across this group of heterocycles.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Structure–Activity Relationships of Oxazole Replacements</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0031.gif" alt="" id="gr30" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0032.gif" alt="" id="gr31" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">Values are the means of three or more experiments ± SD unless indicated otherwise.</p></div><div class="footnote" id="t3fn2"><sup><sup>b</sup></sup><p class="last">Values are the means of two experiments.</p></div><div class="footnote" id="t3fn3"><sup><sup>c</sup></sup><p class="last">Metabolic stability in human (H), rat (R), and mouse (M) liver microsomes; values are the percentage of the parent remaining after 10 min of incubation.</p></div></div><div></div></div><div class="NLM_p">The synthesis of a limited number of analogs varying the substituents on the central phenyl ring was undertaken, and the SAR results are shown in <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>. In a series of compounds with the oxazole group attached to the central phenyl ring, it was found that replacement of the methoxy group with a hydrogen resulted in a 13-fold decrease in potency (compare <b>19</b> to <b>55</b>). The diminished potency of <b>55</b> can be attributed to the loss of a hydrophobic contact between the Leu52 and Ala53 on the P-loop above and Leu183 below as described above and depicted in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>. Analogs with either a methyl or ethyl group in place of the methoxy group were 4- and 12-fold less potent, respectively, than the methoxy analog (compare <b>56</b> and <b>57</b> to <b>19</b>) but were more potent than the unsubstituted analog (<b>55</b>). Compounds with either an ethoxy group or a difluoromethoxy group were equipotent with the methoxy analog (compare <b>58</b> and <b>59</b> to <b>19</b>); however, the trifluoromethoxy, fluoro, and cyano-substituted analogs were less potent (compounds <b>60</b>–<b>62</b>). The trifluoromethoxy group may not be optimal for the space occupied by the methoxy group, and the SAR results indicate that the smaller substituents do not fill the space well or are too polar, resulting in decreased potency. In contrast to the SAR observed with the oxazole-based analogs, the pyridyl-based analogs, wherein the methoxy group at R<sup>3</sup> was replaced with hydrogen (<b>63</b>), proved to be more potent than the corresponding methoxy substituted analog (compare <b>63</b> to <b>47</b>). The presence of the methoxy group results in a greater twisting of the pyridyl group out of the plane of the central phenyl ring compared to the oxazole group, which likely accounts for the reduced potency of <b>47</b>. An analog with a racemic piperidine-based amide side chain (<b>64</b>) was also prepared and was found to have an IC<sub>50</sub> of 17 nM, comparable to <b>(<i>rac)-</i>40</b> (IC<sub>50</sub> = 15 ± 7 nM), indicating that the pyridyl substituted analogs (<b>63</b> and <b>64</b>) bind in a similar fashion as the oxazole substituted analog (<b>(<i>rac</i>)-40</b>). Variation of the substituent at R<sup>3</sup> did not appear to have a major impact on the in vitro metabolic stability of compounds in this chemotype.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Structure–Activity Relationships of Substituents on the Central Phenyl Ring</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0033.gif" alt="" id="gr32" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center">R<sup>3</sup></th><th class="colsep0 rowsep0" align="center" char="±">AAK1 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">Met Stab (H/R/M)<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="char" char="±">12 ± 2</td><td class="colsep0 rowsep0" align="left">89/74/64</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>55</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">170 ± 20</td><td class="colsep0 rowsep0" align="left">87/71/45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>56</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char="±">48 ± 7</td><td class="colsep0 rowsep0" align="left">74/74/43</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>57</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="char" char="±">100 ± 10</td><td class="colsep0 rowsep0" align="left">88/70/45</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>58</b></td><td class="colsep0 rowsep0" align="left">OEt</td><td class="colsep0 rowsep0" align="char" char="±">13 ± 3</td><td class="colsep0 rowsep0" align="left">64/60/54</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="left">OCHF<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char="±">12 ± 1</td><td class="colsep0 rowsep0" align="left">84/68/46</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>60</b></td><td class="colsep0 rowsep0" align="left">OCF<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char="±">160 ± 50</td><td class="colsep0 rowsep0" align="left">69/79/53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>61</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char="±">43 ± 8</td><td class="colsep0 rowsep0" align="left">78/68/30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>62</b></td><td class="colsep0 rowsep0" align="left">CN</td><td class="colsep0 rowsep0" align="char" char="±">72 ± 23</td><td class="colsep0 rowsep0" align="left">64/50/57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>47</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="char" char="±">85 ± 11</td><td class="colsep0 rowsep0" align="left">91/77/65</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>63</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">15 ± 2</td><td class="colsep0 rowsep0" align="left">80/75/66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>64</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char="±">17 ± 3</td><td class="colsep0 rowsep0" align="left">77/60/76</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">Values are the means of three or more experiments ± SD.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Metabolic stability in human (H), rat (R), and mouse (M) liver microsomes; values are the percentage of the parent remaining after 10 min of incubation.</p></div></div></div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> In Vitro and Kinase Profiling</h3><div class="NLM_p">To test the activity of compounds in an intact cellular system, the test compounds were incubated with HEK293 cells overexpressing human AAK1 and the human μ2 protein. The extent of inhibition of AP2 phosphorylation at various compound concentrations was then determined by Western blotting. The HEK cell IC<sub>50</sub> results for <b>19</b>, <b>(<i>R</i>,<i>R</i>)-40</b>, <b>41</b>, and <b>59</b> are shown in <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>. Compound <b>59</b> was the most potent of this group with an IC<sub>50</sub> of 51 nM in this assay. LP-935509 (<b>5</b>) (HEK cell IC<sub>50</sub> = 2.8 nM) and LP-922761 (HEK cell IC<sub>50</sub> = 7.6 nM) served as both positive control and 100% inhibition control for this assay.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> It is likely that the HEK cell IC<sub>50</sub> was influenced to some extent by the permeability of these compounds. Compounds <b>19</b>, <b>(<i>R</i>,<i>R</i>)-40</b>, and <b>59</b> had good permeability in the parallel artificial membrane permeability assay (PAMPA) and Caco-2 assay and did not undergo efflux in the Caco-2 assay. Compounds <b>19</b>, <b>(<i>R</i>,<i>R</i>)-40</b>, and <b>59</b> had unbound plasma protein binding values ranging from ∼3 to 9% in mouse plasma, whereas the unbound plasma protein binding of <b>41</b> was significantly higher (20%). Although <b>41</b> had the highest overall unbound fraction in mouse plasma (<i>f</i><sub>u,p</sub>) of this group of compounds, it had a somewhat lower permeability in the Caco-2 assay and had a moderate efflux ratio of 3.3 (B–A/A–B). Compounds <b>19</b>, <b>41</b>, and <b>59</b> were subsequently evaluated in mouse pharmacokinetic studies. Compound <b>(<i>R</i>,<i>R</i>)-40</b> was not progressed due to the poor metabolic stability in mice.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. In Vitro Profiling Data for Compounds <b>19</b>, <b>(<i>R</i>,<i>R</i>)-40</b>, <b>41</b>, and <b>59</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0034.gif" alt="" id="gr33" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="/" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center" char="±">AAK1 IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">AAK1 HEK cell IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">PAMPA <i>P</i><sub>c</sub> pH 5.5/7.4 (10<sup>–6</sup> cm/s)</th><th class="colsep0 rowsep0" align="center" char="/">Caco-2 <i>P</i><sub>c</sub> A–B/B–A (10<sup>–6</sup> cm/s)</th><th class="colsep0 rowsep0" align="center">plasma protein binding (% unbound, H/R/M)<a class="ref internalNav" href="#t5fn4" aria-label="d">d</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="char" char="±">12 ± 2</td><td class="colsep0 rowsep0" align="left">60<a class="ref internalNav" href="#t5fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">56.9/58.4</td><td class="colsep0 rowsep0" align="char" char="/">13.7/15.1</td><td class="colsep0 rowsep0" align="left">6.3/2.3/8.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>(<i>R</i>,<i>R</i>)-40</b></td><td class="colsep0 rowsep0" align="char" char="±">10 ± 3</td><td class="colsep0 rowsep0" align="left">105 ± 0<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">47.1/43.5</td><td class="colsep0 rowsep0" align="char" char="/">16.7/11.9</td><td class="colsep0 rowsep0" align="left">19/5.9/2.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="char" char="±">15 ± 4</td><td class="colsep0 rowsep0" align="left">190 ± 50<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">ND</td><td class="colsep0 rowsep0" align="char" char="/">4.5/14.9</td><td class="colsep0 rowsep0" align="left">18/10/20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="char" char="±">12 ± 1</td><td class="colsep0 rowsep0" align="left">51 ± 37</td><td class="colsep0 rowsep0" align="left">91.8/96.7</td><td class="colsep0 rowsep0" align="char" char="/">12.9/11.3</td><td class="colsep0 rowsep0" align="left">3.8/2.0/4.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup><sup>a</sup></sup><p class="last">Values are the means of three or more experiments ± SD unless indicated otherwise.</p></div><div class="footnote" id="t5fn2"><sup><sup>b</sup></sup><p class="last">Values are the means of two experiments.</p></div><div class="footnote" id="t5fn3"><sup><sup>c</sup></sup><p class="last">Values are from one experiment.</p></div><div class="footnote" id="t5fn4"><sup><sup>d</sup></sup><p class="last">Human (H), rat (R), and mouse (M). ND = not determined.</p></div></div></div><div class="NLM_p">Mouse pharmacokinetic studies were conducted to provide an initial assessment of the plasma and brain exposure of each compound when dosed subcutaneously. A full pharmacokinetic study was not conducted on these compounds at this early stage of the program as our primary goal was to identify a compound that would allow us to confirm whether we would be able to recapitulate the mouse gene knockout result with a small molecule AAK1 inhibitor. Subcutaneous dosing was chosen to bypass first-pass liver metabolism and provide a higher systemic exposure without the need to fully optimize the additional parameters that are necessary to achieve high oral bioavailability with the expectation that further optimization of the pharmacokinetic parameters could be conducted after the target was validated. Compounds <b>19</b>, <b>41</b>, and <b>59</b> were administered to male C57BL6 mice at a dose of 30 mg/kg (sc), and the plasma and brain concentrations were measured at the 2 h time point. The plasma and brain exposures are shown in <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>. A comparison of these results shows that <b>19</b> had the lowest plasma concentration of the three compounds, whereas <b>41</b> had the highest plasma concentration. Compound <b>41</b>, however, had a lower brain-to-plasma (B/P) ratio. The lower brain concentration of <b>41</b> can likely be explained by the presence of an additional hydrogen bond donor on the pyrazole ring and the moderate P-gP efflux of this compound, as indicated by the Caco-2 assay results, both of which can hinder brain penetrance.<a onclick="showRef(event, 'ref40 ref41 ref42'); return false;" href="javascript:void(0);" class="ref ref40 ref41 ref42">(40−42)</a> Compound <b>59</b> had the best overall in vivo profile of these three compounds. Compound <b>59</b> achieved higher plasma and brain concentrations compared to <b>19</b>, with a B/P ratio of 1.04. The total B/P ratio can be misleading, however, when evaluating the pharmacokinetic and pharmacodynamic (PK/PD) relationships of brain penetrant small molecule drug candidates since the B/P ratio is mostly governed by nonspecific binding to lipids and/or proteins in plasma and the brain<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> and the B/P ratio can differ substantially from the unbound brain to unbound plasma ratio.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Since only unbound drug is free to bind to the target (the free drug hypothesis<a onclick="showRef(event, 'ref43 ref45'); return false;" href="javascript:void(0);" class="ref ref43 ref45">(43,45)</a>), in this case AAK1, one of the most important parameters to guide CNS compound optimization is the unbound brain to unbound plasma ratio (<i>K</i><sub>p,uu</sub>). We measured the unbound fraction of <b>59</b> in mouse brain tissue homogenate (<i>f</i><sub>u,b</sub>) to enable the estimation of the unbound brain concentration (<i>C</i><sub>b,u</sub> = <i>f</i><sub>u,b</sub> × total brain concentration) along with the unbound plasma concentration (<i>C</i><sub>p,u</sub> = <i>f</i><sub>u,p</sub> × total plasma concentration)<sub>.</sub> The fraction unbound for <b>59</b> in mouse brain tissue homogenate was determined to be 2.8%. The <i>K</i><sub>p,uu</sub> calculated from the ratio of <i>C</i><sub>b,u</sub>/<i>C</i><sub>p,u</sub> was 0.71 for <b>59</b>. Compound <b>59</b> (BMS-911172) was selected for further in vitro profiling and extensive in vivo evaluation. Compound <b>59</b> has a cLogP = 1.9, tPSA = 90 Å<sup>2</sup>, LE = 0.45, and LLE = 6.0. The aqueous solubility of <b>59</b> at pH 1 and 7.4 was 5.85 and 0.60 mg/mL, respectively.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Mouse Plasma and Brain Exposures for Compounds <b>19</b>, <b>41</b>, and <b>59</b><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">cmpd</th><th class="colsep0 rowsep0" align="center" char="±">plasma conc. (μM)</th><th class="colsep0 rowsep0" align="center" char="±">brain conc. (μM)</th><th class="colsep0 rowsep0" align="center" char="±">B/P ratio</th><th class="colsep0 rowsep0" align="center" char="±"><i>K</i><sub>p,uu</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="char" char="±">7.3 ± 7.4</td><td class="colsep0 rowsep0" align="char" char="±">6.8 ± 5.4</td><td class="colsep0 rowsep0" align="char" char="±">1.17 ± 0.38</td><td class="colsep0 rowsep0" align="left" char="±">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>41</b></td><td class="colsep0 rowsep0" align="char" char="±">29.9 ± 8.4</td><td class="colsep0 rowsep0" align="char" char="±">5.7 ± 0.9</td><td class="colsep0 rowsep0" align="char" char="±">0.21 ± 0.08</td><td class="colsep0 rowsep0" align="left" char="±">ND</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>59</b></td><td class="colsep0 rowsep0" align="char" char="±">17.7 ± 2.3</td><td class="colsep0 rowsep0" align="char" char="±">18.5 ± 3.3</td><td class="colsep0 rowsep0" align="char" char="±">1.04 ± 0.13</td><td class="colsep0 rowsep0" align="left" char="±">0.71</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Vehicle: 20 mM citrate buffer/solutol/DMSO (85:10:5), dose = 30 mg/kg (sc), <i>n</i> = 3. ND = not determined.</p></div></div></div><div class="NLM_p">The broad kinase selectivity profile of <b>59</b> was evaluated in a panel consisting of 391 kinases (Ambit/DiscoverX/Eurofins).<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> This is a single-point assay panel with a control for each kinase. Compound <b>59</b> was tested at 1 μM concentration, and the results are displayed as a radial graph in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>. AAK1 is shown in dark green. Compound <b>59</b> had good overall kinase selectivity. The kinases with remaining activity of less than 33% of control are listed in <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>. A complete list of the Ambit kinase panel heat map results is included in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00472/suppl_file/jm1c00472_si_001.pdf" class="ext-link">Table S4</a>. BIKE/BMP2K is the most closely related kinase to AAK1 in this family and shares 74% sequence identity with AAK1 within their respective kinase domains. The two remaining members of the NAK family, GAK and MPSK1, only share 39 and 30% sequence identity, respectively, with AAK1 within their respective kinase domains.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> Compound <b>59</b> was screened against an in-house panel of 219 kinases. For 78 of these 219 kinases, the IC<sub>50</sub> values were reported as greater than 2.00 μM, and for 131 of the 219 kinases, the IC<sub>50</sub> values were reported as greater than 50 μM. Ten off-target kinases had IC<sub>50</sub> values less than 2 μM and are listed in <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>. Compound <b>59</b> had a BIKE IC<sub>50</sub> of 0.120 μM and was less potent for GAK and MPSK1, with IC<sub>50</sub> values of 1.06 and 15.8 μM, respectively, for these kinases. Compound <b>59</b> was also tested in binding assays for 21 receptors and transporters to better understand its pharmacology profile. Compound <b>59</b> was not active at up to 10 μM in most assays. Several receptors and transporters associated with nociception were included in the panel including α2A and α2C adrenergic receptors (IC<sub>50</sub> > 30 μM), μ and κ opioid receptors (IC<sub>50</sub> > 30 μM), NET (IC<sub>50</sub> = 26 μM), and SERT (IC<sub>50</sub> > 30 μM). The full list of receptors and IC<sub>50</sub> values is included in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00472/suppl_file/jm1c00472_si_001.pdf" class="ext-link">Table S5</a>.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Ambit radial graph depicting the kinase selectivity profile of compound <b>59</b>. Each line represents the remaining activity of a single kinase in the presence of 1 μM of the test compound. Individual kinases are grouped into families represented by differing line colors. Starting from the center, the circles indicate 83, 33, and 0% of control binding remaining. AAK1 is shown in dark green (other).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Kinase Selectivity Results from the Ambit/DiscoverX/Eurofins Panel for <b>59</b><a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">% of control binding remaining</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">AAK1</td><td class="colsep0 rowsep0" align="left">18</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BIKE</td><td class="colsep0 rowsep0" align="left">6.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CRIK</td><td class="colsep0 rowsep0" align="left">0.7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GAK</td><td class="colsep0 rowsep0" align="left">21</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GPRK4</td><td class="colsep0 rowsep0" align="left">13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MNK1</td><td class="colsep0 rowsep0" align="left">8.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MNK2</td><td class="colsep0 rowsep0" align="left">1.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MSSK1</td><td class="colsep0 rowsep0" align="left">7.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PIP5K1A</td><td class="colsep0 rowsep0" align="left">31</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PIP5K2B</td><td class="colsep0 rowsep0" align="left">6.2</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PRKX</td><td class="colsep0 rowsep0" align="left">19</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RIOK1</td><td class="colsep0 rowsep0" align="left">7.6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RIOK2</td><td class="colsep0 rowsep0" align="left">3.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">SRPK1</td><td class="colsep0 rowsep0" align="left">12</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">Kinases with remaining activity of <33% of control in the presence of 1 μM of <b>59</b> from a panel of 391 kinases (Ambit/DiscoverX/Eurofins).</p></div></div></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Potency of <b>59</b> for Off-Target Kinases<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center" char=".">IC<sub>50</sub> (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BIKE</td><td class="colsep0 rowsep0" align="char" char=".">0.120</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CLK4</td><td class="colsep0 rowsep0" align="char" char=".">1.93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CRIK</td><td class="colsep0 rowsep0" align="char" char=".">0.120</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GAK</td><td class="colsep0 rowsep0" align="char" char=".">1.06</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">GSG2</td><td class="colsep0 rowsep0" align="char" char=".">0.922</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MNK1</td><td class="colsep0 rowsep0" align="char" char=".">0.507</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">MNK2</td><td class="colsep0 rowsep0" align="char" char=".">0.428</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PKA</td><td class="colsep0 rowsep0" align="char" char=".">0.57</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PKCθ</td><td class="colsep0 rowsep0" align="char" char=".">1.33</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PRKX</td><td class="colsep0 rowsep0" align="char" char=".">0.326</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">The potency of <b>59</b> was measured for off-target kinase activity against an in-house panel of 219 kinases. The kinases that were inhibited by <b>59</b> with an IC<sub>50</sub> < 2.00 μM are listed. The following kinases from <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a> were not included in the in-house panel: GPRK4, PIP5K1A, PIP5K2B, RIOK1, RIOK2, and SRPK1.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> In Vivo Inhibition of μ2 Phosphorylation</h3><div class="NLM_p">Compound <b>59</b> was evaluated for in vivo target engagement by measuring the inhibition of μ2 phosphorylation in the brain. We were particularly interested in confirming the inhibition of μ2 phosphorylation in the brain since, as noted above, in studies with compound <b>5</b>, it was previously found that AAK1 inhibition in the CNS is the primary site for the antineuropathic pain effect.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> C57BL6 mice were dosed at 60 mg/kg subcutaneously (sc) with <b>59</b>, and the in vivo inhibition of μ2 phosphorylation in brain lysates was measured. At 1 h post-treatment, focused beam microwave irradiation was used to inactivate enzyme activity in vivo and euthanize the mice prior to collection of brain lysate. Western blot analysis was used to measure the level of μ2 phosphorylation. Compound <b>59</b> effectively reduced μ2 phosphorylation following acute administration. Data presented in <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a> show that, when dosed at 60 mg/kg (sc), <b>59</b> reduced μ2 phosphorylation to a level similar to that observed in AAK1 knockout mice (82 vs 90% reduction of μ2 phosphorylation, respectively, vs control), suggesting maximal inhibition of AAK1 activity.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Mice were treated with <b>59</b> (60 mg/kg, sc) or vehicle and euthanized 1 h post-treatment (<i>n</i> = 5). For comparison, brain lysate was collected from AAK1 knockout mice and nontreated wild-type mice that were euthanized by focused beam microwave irradiation. Western blot analysis was used to measure the level of μ2 phosphorylation. Columns represent the mean change (±1 SD) in phospho-μ2 protein relative to control. * indicates <i>P</i> < 0.05 relative to control tissue (Student’s <i>t</i> test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To characterize this effect, both dose–response and time-course studies were conducted. C57BL6 mice were dosed with compound <b>59</b> at doses ranging from 0.3 to 60 mg/kg (sc) and were euthanized by microwave irradiation 1 h post-treatment. Data presented in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>A show that <b>59</b> dose-dependently inhibited μ2 phosphorylation (13, 56, 62, and 80% reduction in μ2 phosphorylation at 3, 10, 30, and 60 mg/kg at 30 min postdose, respectively, vs control). Statistically significant lowering of μ2 phosphorylation was achieved at doses of 10 mg/kg or higher. In the time-course study, mice were dosed at 30 mg/kg (sc). As shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>B, the inhibition of μ2 phosphorylation was rapid (within 15 min), prolonged (up to 2 h), and correlated to plasma levels of the compound. Collectively, these data show that <b>59</b> administered subcutaneously can reduce μ2 phosphorylation in the brain. The mean plasma exposures at each dose in the dose–response study were also measured. The mean values were 0.4, 1.2, 2.6, 9.1, 37, and 77 μM at 0.3, 1, 3, 10, 30, and 60 mg/kg, respectively. The EC<sub>50</sub> for in vivo inhibition of μ2 phosphorylation in this study was determined to be 8.3 μM (<a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>C), resulting in an ED<sub>50</sub> of 6 mg/kg. In separate studies to evaluate <b>59</b> in pain models, the B/P ratio ranged from 0.5 to 0.8 (<i>K</i><sub>p,uu</sub> ranged from 0.7 to 1.0) (vide infra). We also evaluated a poorly brain penetrant AAK1 inhibitor (cellular IC<sub>50</sub> = 209 nM, B/P ratio < 0.3) from another chemotype (dosed at 60 mg/kg, sc) (structure and data not shown). The results showed that the poorly brain penetrant compound had no effect on the lowering of μ2 phosphorylation, confirming that the site of action of <b>59</b> is in the central nervous system (CNS). These results are in agreement with the lack of in vivo efficacy observed with <b>7</b> (B/P ratio 0.007) in a neuropathic pain model.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Mice were treated with increasing doses of compound <b>59</b> or vehicle and euthanized 30 min postdose (<i>n</i> = 5). Western blot analysis was used to measure the level of μ2 phosphorylation. Columns represent the mean change (±1 SD) in phospho-μ2 protein relative to control. * indicates <i>P</i> < 0.05 relative to control tissue (one-way ANOVA with Dunnett’s post hoc analysis). (B) Mice were treated with compound <b>59</b> (30 mg/kg, sc) and euthanized by microwave irradiation 15–120 min postdose (<i>n</i> = 6). Closed symbols represent phospho-μ2 levels as determined by Western blot analysis. Open symbols represent the plasma exposure of <b>59</b> as determined from satellite animals (<i>n</i> = 4). (C) EC<sub>50</sub> of compound <b>59</b> for in vivo inhibition of μ2 phosphorylation (top = 85.00, LogEC<sub>50</sub> = −5.078, hill slope = 1.112, and EC<sub>50</sub> = 8.3 μM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Efficacy of Compound <b>59</b> in In Vivo Pain Models</h3><div class="NLM_p">To demonstrate efficacy in preclinical models, compound <b>59</b> was tested in the rat formalin model for persistent pain<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> and the rat chronic constriction injury (CCI) model for neuropathic pain.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Since efficacy in these models is shown by measurements related to movement, rats treated with <b>59</b> were also evaluated in the rotarod test for locomotor activity.</div><div class="NLM_p">In the formalin model, injection of dilute formalin into the dorsal surface of the hind paw produces a biphasic spontaneous, nociceptive behavioral response composed of hind paw flinching and licking/biting. The initial response (phase I) occurs within the first few minutes and results from the direct activation of TRPA1 channels on nociceptive c-fiber nerve terminals in the skin.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> The more persistent phase II response, measured from 11 to 40 min postinjection, is thought to reflect the combined effects of afferent input and central sensitization of dorsal horn neurons in the spinal cord. Rats treated with a subcutaneous (sc) injection of 30 mg/kg of <b>59</b> 60 min prior to formalin injection showed a significant reduction in phase II hind paw flinching and licking/biting (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). As expected, phase II behaviors were also significantly reduced by the dual serotonin/norepinephrine reuptake inhibitor duloxetine (10 mg/kg, sc), which is approved for the treatment of diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain (<a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>). Treatment with <b>59</b> (30 mg/kg, sc) also significantly reduced phase I flinching (mean ± SEM: vehicle = 225 ± 15; compound <b>59</b> = 117 ± 19 (<i>P</i> < 0.001); duloxetine = 72 ± 18 (<i>P</i> < 0.001)) but did not reduce phase I licking/biting duration (vehicle = 25 ± 5; compound <b>59</b> = 18 ± 6; duloxetine = 4 ± 3 (<i>P</i> < 0.05)) (data not shown).</div><figure id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0011.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Compound <b>59</b> reduces phase II formalin nociceptive behaviors in rats. Rats were treated with vehicle (sc), compound <b>59</b> (30 mg/kg, sc), or duloxetine (10 mg/kg, sc) 60 min prior to formalin injection. Results are presented as the mean ± SEM (A) number of hind paw flinches or (B) hind paw licking/biting duration determined 11–40 min after formalin injection (<i>n</i> = 6–8/group). Data were analyzed by ANOVA followed by Dunnett’s post hoc test; **<i>P</i> < 0.01 and ***<i>P</i> < 0.001 compared to vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">In the CCI model, loose ligatures are tied around the sciatic nerve to simulate the conditions of nerve compression injury.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> This procedure results in the development of hyperalgesia and allodynia that is typically measured 2–4 weeks after surgery.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> The effect of acute treatment with <b>59</b> was examined on four different measures in CCI rats: (1) thermal hyperalgesia following application of a noxious light source to the plantar surface of the hind paw (Hargreaves test),<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> (2) mechanical hyperalgesia following application of noxious blunt pressure to the paw (Randall–Selitto test),<a onclick="showRef(event, 'ref52 ref53'); return false;" href="javascript:void(0);" class="ref ref52 ref53">(52,53)</a> (3) cold allodynia following exposure to a surface cooled to a non-noxious 10 °C temperature,<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> and (4) mechanical allodynia following application of an electronic von Frey filament to the plantar surface of the hind paw.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> In all studies, rats receiving a sham surgery, i.e., the surgical procedure but without ligation of the nerve, were included to determine the control response in nonligated subjects. In the first series of studies, CCI rats were treated with vehicle (sc), compound <b>59</b> (60 mg/kg, sc), or the positive comparator gabapentin that was administered orally at a dose of 100 mg/kg (po). In comparison to sham controls, vehicle-treated CCI rats showed a marked reduction in the latency to paw withdrawal following the application of noxious heat consistent with the development of thermal hyperalgesia (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>A). Vehicle-treated CCI rats also showed a marked reduction in the mechanical pressure needed to elicit a nociceptive response (vocalization or withdrawal response) consistent with the development of mechanical hyperalgesia (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>B). Treatment with <b>59</b> (60 mg/kg, sc) significantly reduced thermal and mechanical hyperalgesia at all time points examined; the maximal reversal was 113 and 45%, respectively. In comparison, the maximal reversal observed after gabapentin treatment was 89 and 32% for thermal hyperalgesia and mechanical hyperalgesia, respectively (<a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>).</div><figure id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0012.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Compound <b>59</b> reduces thermal hyperalgesia and mechanical hyperalgesia in CCI rats. Subjects were treated with vehicle (sc), compound <b>59</b> (60 mg/kg, sc), or gabapentin (100 mg/kg, po) and then tested for (A) thermal hyperalgesia (Hargreaves test) or (B) mechanical hyperalgesia (Randall–Selitto test). Results are presented as the mean ± SEM paw withdrawal latency or nociceptive threshold (<i>n</i> = 10–12/treatment) and were analyzed by two-way repeated measures ANOVA followed by Dunnett’s post hoc test; *<i>P</i> < 0.05, **<i>P</i> < 0.01, and ***<i>P</i> < 0.001 compared to CCI/vehicle-treated subjects.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Rats receiving CCI surgery also showed a marked reduction in the latency to hind paw withdrawal from a surface cooled to 10 °C and a decrease in the threshold force required to elicit hind paw withdrawal after application of an electronic von Frey filament consistent with the development of cold allodynia and mechanical allodynia (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). Treatment with <b>59</b> (60 mg/kg, sc) significantly reduced cold allodynia and mechanical allodynia at all time points examined; the maximal reversal was 49 and 42%, respectively (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>). In comparison, the maximal reversal observed after gabapentin treatment was 54 and 34% for cold allodynia and mechanical allodynia, respectively (<a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig12" id="" class=" internalNav">12</a></a>).</div><figure id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0013.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Compound <b>59</b> reduces cold allodynia and mechanical allodynia in CCI rats. Subjects were treated with vehicle (sc), compound <b>59</b> (60 mg/kg, sc), or gabapentin (100 mg/kg, po) and then tested for (A) cold allodynia (10 °C cold plate) or (B) mechanical allodynia (electronic von Frey test). Results are presented as the mean ± SEM latency (<i>n</i> = 6–12/treatment) or force (<i>n</i> = 7–10/treatment) required to elicit a paw withdrawal response. Data were analyzed by two-way repeated measures ANOVA followed by Dunnett’s post hoc test; *<i>P</i> < 0.05, **<i>P</i> < 0.01, and ***<i>P</i> < 0.001 compared to CCI/vehicle-treated subjects.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Upon completion of each study (∼240 min postdose), plasma and brain tissue samples were collected from a subset of experimental subjects to measure the concentration of <b>59</b>. Across the four studies, the mean (SD) plasma and brain concentrations after dosing with 60 mg/kg (sc) were 83 (±9) and 39 (±3) μM, respectively, with a B/P ratio of 0.5 (mean <i>K</i><sub>p,uu</sub> = 0.7).</div><div class="NLM_p">In the final study, the dose–response to subcutaneous administration of compound <b>59</b> was examined in CCI rats with thermal hyperalgesia as the end point. Treatment with <b>59</b> significantly reduced thermal hyperalgesia, with 90% reversal achieved at the dose of 30 mg/kg (<a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig13" id="" class=" internalNav">13</a></a>). The minimally effective dose was 3 mg/kg, which produced a significant 35% reversal. In comparison, oral administration of 100 mg/kg gabapentin achieved a maximal 48% reversal of thermal hyperalgesia in this study. At the conclusion of the study (i.e., ∼180 min postdose), plasma and brain samples were collected from a subset of experimental subjects and exposures are reported in <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>. The mean B/P ratio of <b>59</b> in this study was 0.8. Unlike plasma protein binding, brain tissue binding is independent of species and brain origins.<a onclick="showRef(event, 'ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref56 ref57">(56,57)</a> Thus, on the basis of the mouse unbound fraction in brain tissue homogenate (<i>f</i><sub>u,b</sub>), the unbound concentration of <b>59</b> in rat brain tissue (<i>C</i><sub>b,u</sub>) was calculated for each dose and the results are shown in <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a></a>. The mean <i>K</i><sub>p,uu</sub> in this study was 1.0. The unbound concentration of <b>59</b> provided a 4-fold or higher coverage over the HEK cell IC<sub>50</sub> (51 nM) at doses of 10 mg/kg and higher. In conclusion, <b>59</b> was effective at reducing hyperalgesia and allodynia in CCI rats, with efficacy observed at doses of 10, 30, and 60 mg/kg at least comparable or greater than that achieved with gabapentin (100 mg/kg, po).</div><figure id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0014.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Compound <b>59</b> dose-dependently reduces thermal hyperalgesia in CCI rats. Subjects were treated with vehicle (sc), compound <b>59</b> (1–30 mg/kg, sc), or gabapentin (100 mg/kg, po) and tested for thermal hyperalgesia. Results are presented as the mean ± SEM latency to paw withdrawal (<i>n</i> = 8–9/treatment) and were analyzed by two-way repeated measures ANOVA followed by Dunnett’s post hoc test; ***<i>P</i> < 0.01 compared to CCI/vehicle-treated subjects.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Mean Plasma and Brain Exposures for Compound <b>59</b> in CCI Rats<a class="ref internalNav" href="#t9fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="±" /></col><col align="char" char="±" /></col><col /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center" char="±">plasma conc. (μM)</th><th class="colsep0 rowsep0" align="center" char="±">brain conc. (μM)</th><th class="colsep0 rowsep0" align="center" char="±">plasma unbound conc. (<i>C</i><sub>p,u</sub>) (μM)</th><th class="colsep0 rowsep0" align="center" char=".">brain unbound conc. (<i>C</i><sub>b,u</sub>) (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1</td><td class="colsep0 rowsep0" align="char" char="±">0.40 ± 0.5</td><td class="colsep0 rowsep0" align="char" char="±">0.35 ± 0.2</td><td class="colsep0 rowsep0" align="char" char="±">0.01</td><td class="colsep0 rowsep0" align="char" char=".">0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="char" char="±">1.1 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">0.90 ± 0.3</td><td class="colsep0 rowsep0" align="char" char="±">0.02</td><td class="colsep0 rowsep0" align="char" char=".">0.03</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10</td><td class="colsep0 rowsep0" align="char" char="±">11 ± 3</td><td class="colsep0 rowsep0" align="char" char="±">7.0 ± 2.0</td><td class="colsep0 rowsep0" align="char" char="±">0.22</td><td class="colsep0 rowsep0" align="char" char=".">0.20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">30</td><td class="colsep0 rowsep0" align="char" char="±">52 ± 11</td><td class="colsep0 rowsep0" align="char" char="±">33 ± 8</td><td class="colsep0 rowsep0" align="char" char="±">1.04</td><td class="colsep0 rowsep0" align="char" char=".">0.92</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t9fn1"><div class="footnote" id="t9fn1"><sup><sup>a</sup></sup><p class="last">Plasma and brain exposures for compound <b>59</b> (<i>n</i> = 8) in the dose response study with thermal hyperalgesia as the end point. Results are presented as the mean ± SD.</p></div></div></div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Rotarod Assay</h3><div class="NLM_p">To examine the potential for motor impairment, compound <b>59</b> was tested in the accelerating rotarod test in rats. The rotarod assay is widely used to assess motor coordination, balance, and ataxia in rodents<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> and to examine the therapeutic margin between efficacy in preclinical pain models and motor impairment. To exclude differences in motivation and motor learning, rats were trained on the apparatus for 3 consecutive days prior to testing. In addition, a rotarod accelerating at a constant speed from 2 to 20 rotations per minute over a 5 min test period was used to provide a sensitive method to detect motor impairment. Treatment with <b>59</b> at doses up to 60 mg/kg sc did not significantly impair accelerating rotarod performance in rats (<a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig14" id="" class=" internalNav">14</a></a>). The average plasma concentrations of <b>59</b>, determined in a subset of experimental subjects at 190 min postdose, were 7.4, 34, and 84 μM at 10, 30, and 60 mg/kg, respectively. In stark contrast, treatment with gabapentin (100 mg/kg, po) produced a significant rotarod impairment. The profile of gabapentin appears consistent with the drowsiness and dizziness or unsteadiness that have been observed as side effects at clinical doses used for the treatment of neuropathic pain. These results demonstrate that, at doses efficacious in pain models, <b>59</b> has a much lower potential to produce motor impairment compared to gabapentin.</div><figure id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0015.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Compound <b>59</b> does not impair rotarod performance in rats. Subjects were treated with vehicle (sc), compound <b>59</b> (10–60 mg/kg, sc), or gabapentin (100 mg/kg, po), and rotarod performance was determined 30, 90, or 180 min later. Results are presented as the mean ± SEM riding time determined in a 5 min test session (<i>n</i> = 8–10/group). Data were analyzed by two-way repeated measures ANOVA followed by Dunnett’s post hoc test; **<i>P</i> < 0.01 and ***<i>P</i> < 0.001 compared to vehicle-treated subjects.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i18">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_21525" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_21525" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Compounds <b>11</b>–<b>39</b> were prepared as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Treatment of <b>65</b> with toluenesulfonylmethyl isocyanide (TosMIC) in the presence of potassium carbonate followed by reduction of the nitro group afforded <b>67</b>. Compound <b>67</b> was coupled with a series of Boc, Fmoc, or Cbz-protected amino acids in the presence of HATU and <i>N</i>,<i>N</i>-diisopropylethylamine. The Boc protecting group was removed with trifluoroacetic acid (TFA), the Fmoc group was removed with piperidine, and the Cbz group was removed by hydrogenation to furnish compounds <b>11</b>–<b>34</b> and <b>39</b>. Compound <b>55</b> (<a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>) was prepared from the corresponding commercially available aniline by treatment of the aniline with Boc-<span class="smallcaps smallerCapital">d</span>-leucine in the presence of HATU and <i>N</i>,<i>N</i>-diisopropylethylamine followed by removal of the Boc group with TFA. Alkylation of the amide nitrogen was achieved by heating the product of the coupling of <b>67</b> and Boc-<span class="smallcaps smallerCapital">d</span>-leucine with methyl iodide in the presence of barium hydroxide to furnish <b>68</b>. The Boc group was then removed with TFA to provide <b>35</b>. The synthesis of analogs lacking an amine on the amide side chain was completed as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a> by the coupling of <b>67</b> with various carboxylic acids in the presence of HATU and <i>N</i>,<i>N</i>-diisopropylethylamine to furnish products <b>36</b>–<b>38</b>.</div><figure id="sch1" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0016.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Route for the Preparation of Amide Analogs<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TosMIC, K<sub>2</sub>CO<sub>3</sub>, MeOH, 86%; (b) H<sub>2</sub>, Pd/C, EtOH, 40 psi, 82%; (c) Boc, Fmoc, or Cbz-protected amino acid, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 29–100%; (d) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 40–100%, for all analogs except the following: <b>21</b> (piperidine, CH<sub>2</sub>Cl<sub>2</sub>, 87%), <b>24</b> (H<sub>2</sub>, 10% Pd/C, NH<sub>4</sub>OH, MeOH, 46%), and <b>33</b> and <b>34</b> ((i) H<sub>2</sub>, 10% Pd/C, MeOH, 40–58%; (ii) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 43–99%); (e) Boc-<span class="smallcaps smallerCapital">d</span>-leucine, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 66%; (f) Ba(OH)<sub>2</sub>, MeI, DMF, H<sub>2</sub>O, 97%; and (g) carboxylic acids, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 40–67%.</p></p></figure><div class="NLM_p">The synthesis of <b>(<i>R</i>,<i>R</i>)-40</b> and <b>(<i>S</i>,<i>S</i>)-40</b> was carried out as shown in <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Palladium catalyzed cross-coupling of <b>69</b> and <b>70</b> furnished <b>71</b> in 55% yield. The pyridine ring and the exocyclic olefin were then reduced by hydrogenation at 50 psi with catalytic platinum(IV) oxide,<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> and the resultant crude product was treated with Boc anhydride to afford <b>72</b> in 67% yield over two steps. Hydrolysis of the methyl ester with lithium hydroxide gave <b>73</b> in 98% yield, which was then coupled with <b>67</b> in the presence of HATU while heating at 40 °C in a tightly capped vial to afford <b>(<i>rac</i>)-74</b>. Removal of the Boc group in <b>(<i>rac</i>)-74</b> furnished <b>(<i>rac</i>)-40</b>. The Boc-protected intermediate <b>(<i>rac</i>)-74</b> was separated into its individual enantiomers by chiral HPLC (Chiralcel OD column) followed by the removal of the Boc group on the individual enantiomers (<b>(<i>R</i>,<i>R</i>)-74</b> and <b>(<i>S</i>,<i>S</i>)-74</b>) to furnish <b>(<i>R</i>,<i>R</i>)-40</b> and <b>(<i>S</i>,<i>S</i>)-40</b>, respectively. The stereochemical assignment was made on the basis of the results of an X-ray crystal structure of <b>(<i>R</i>,<i>R</i>)-40</b> bound to AAK1 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>).</div><figure id="sch2" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0017.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route for the Preparation of <b>(<i>R</i>,<i>R</i>)-40</b> and <b>(<i>S</i>,<i>S</i>)-40</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Xphos precatalyst, K<sub>3</sub>PO<sub>4</sub>, THF/H<sub>2</sub>O, 70 °C, 55%; (b) H<sub>2</sub>, PtO<sub>2</sub>, EtOH, 4 N HCl in 1,4-dioxane; (c) (Boc)<sub>2</sub>O, Na<sub>2</sub>CO<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>/H<sub>2</sub>O, 67% over two steps; (d) LiOH, H<sub>2</sub>O, THF/MeOH, 98%; (e) <b>67</b>, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 40 °C, 91%; (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 91–97%; and (g) the enantiomers of <b>(<i>rac</i>)-74</b> were separated by chiral HPLC (Chiralcel OD column), 28% for <b>(<i>R</i>,<i>R</i>)-74</b>; 35% for <b>(<i>S</i>,<i>S</i>)-74</b>.</p></p></figure><div class="NLM_p">The analogs to investigate the SAR of the hinge-binding heterocycle were synthesized by the routes depicted in <a class="ref internalNav" href="#sch3" aria-label="Schemes 3">Schemes 3</a>–<named-content content-type="anchor" rid="sch4" type="simple"></named-content><a class="ref internalNav" href="#sch5" aria-label="5">5</a>. The particular method chosen for each analog generally depended upon the availability of commercial starting materials as well as ease of synthesis. In <a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>, commercially available 4-bromo-3-methoxyaniline (<b>75</b>) was coupled with Boc-<span class="smallcaps smallerCapital">d</span>-leucine to form <b>76</b>. Suzuki cross-coupling of <b>76</b> with heteroarylboronic acids followed by removal of the Boc group afforded compounds <b>41</b>, <b>47</b>, <b>50</b>, and <b>54</b>. To prepare thiazole <b>44</b>, treatment of <b>76</b> with bis(pinacolato)diboron in the presence of the PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub> adduct and potassium acetate followed by Suzuki cross-coupling of the resultant pinacol boronate ester with 5-bromothiazole furnished <b>77</b>. Removal of the Boc group with TFA afforded <b>44</b>.</div><figure id="sch3" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0018.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>41</b>, <b>44</b>, <b>47</b>, <b>50</b>, and <b>54</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc-<span class="smallcaps smallerCapital">d</span>-leucine, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 85%; (b) RB(OH)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, toluene/EtOH/H<sub>2</sub>O or DME/H<sub>2</sub>O, 18–76%; (c) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 16–74%; (d) bis(pinacolato)diboron, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, KOAc, 1,4-dioxane, 28%; and (e) 5-bromothiazole, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 65%.</p></p></figure><figure id="sch4" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0019.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>42</b>, <b>43</b>, <b>45</b>, <b>46</b>, <b>48</b>, <b>49</b>, <b>51</b>, and <b>53</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethynyltrimethylsilane, CuI, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, reflux, 85%; (b) TBAF, THF, 55%; (c) azidotrimethylsilane, 125 °C, 51%; (d) (1<i>H</i>-pyrazol-4-yl)boronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, DME, 62%; (e) NaH, MeI, DMF, 88%; (f) 1<i>H</i>-imidazole, CuI, <span class="smallcaps smallerCapital">l</span>-histidine, K<sub>2</sub>CO<sub>3</sub> DMSO 100 °C, 97% (for <b>82</b>); (g) 1<i>H</i>-1,2,4-triazole, CuI, <span class="smallcaps smallerCapital">l</span>-histidine, K<sub>2</sub>CO<sub>3</sub> DMSO 100 °C, 25% (for <b>83</b>); (h) bis(pinacolato)diboron, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, KOAc, 1,4-dioxane, 70%; (i) 4-bromopyridazine, Pd(OAc)<sub>2</sub>, dppf, CuCl, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 27% (for <b>85</b>); (j) 4-chloropyrimidine, XPhos precatalyst, K<sub>3</sub>PO<sub>4</sub>, THF/water, 99% (for <b>86</b>); (k) 4-chloropyridin-2-amine, Pd(OAc)<sub>2</sub>, SPhos, K<sub>3</sub>PO<sub>4</sub>, <i>n</i>-BuOH, 63% (for <b>87</b>); (l) 3-pyridylboronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, toluene/EtOH/H<sub>2</sub>O, 76% (for <b>88</b>); (m) H<sub>2</sub>, 10% Pd/C, EtOH/CHCl<sub>3</sub>, 40 psi, 70–100% (for <b>89a</b>–<b>89e</b>, <b>89h</b>); (n) Zn, NH<sub>4</sub>Cl, EtOH, 61% (for <b>89f</b>); (o) SnCl<sub>2</sub>·H<sub>2</sub>O, EtOH, 93% (for <b>89g</b>); (p) Boc-<span class="smallcaps smallerCapital">d</span>-leucine, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 29–100%; and (q) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 17–96%.</p></p></figure><figure id="sch5" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0020.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compound <b>52</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (2-chloropyridin-4-yl)boronic acid, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, THF/H<sub>2</sub>O, 28%; (b) <i>N</i>,<i>N</i>-methylbenzylamine, Pd(OAc)<sub>2</sub>, dppp, <i>t</i>-BuOH, toluene, 35%; (c) SnCl<sub>2</sub>·2H<sub>2</sub>O, EtOH/EtOAc, 51%; (d) Boc-<span class="smallcaps smallerCapital">d</span>-leucine, TBTU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 88%; (e) ammonium formate, 10% Pd/C, EtOH, 66%; and (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 40%.</p></p></figure><div class="NLM_p">Additional members in a series of heterocyclic replacements for the oxazole moiety were prepared as shown in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a>. Coupling of commercially available 1-bromo-2-methoxy-4-nitrobenzene (<b>78</b>) with ethynyltrimethylsilane in the presence of copper iodide and Pd(PPh<sub>3</sub>)Cl<sub>2</sub> and triethylamine followed by removal of the silyl group with TBAF afforded <b>79</b> in high yield. Subsequent heating of <b>79</b> in the presence of azidotrimethylsilane provided <b>80</b> in 51% yield. Synthesis of the <i>N</i>-methylpyrazole intermediate (<b>81</b>) was completed via a Suzuki reaction of <b>78</b> with (1<i>H</i>-pyrazol-4-yl)boronic acid followed by treatment of the resultant product with sodium hydride and iodomethane to give <b>81</b>. Preparation of the analogs with <i>N</i>-linked heterocycles was carried out by heating <b>78</b> with either imidazole or 1,2,4-triazole in the presence of copper iodide, <span class="smallcaps smallerCapital">l</span>-histidine, and K<sub>2</sub>CO<sub>3</sub> in DMSO as described by Sreedhar <i>et al</i>.<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> to furnish <b>82</b> and <b>83</b>, respectively. Compounds <b>85</b>–<b>87</b> were prepared from heterocycles that were commercially available as either the heteroaryl bromide or chloride. Conversion of <b>78</b> to the pinacol boronate intermediate (<b>84</b>) followed by a Suzuki coupling reaction using the conditions indicated in <a class="ref internalNav" href="#sch4" aria-label="Scheme 4">Scheme 4</a> provided compounds <b>85</b>–<b>87</b>.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Palladium catalyzed cross-coupling of <b>78</b> with 3-pyridylboronic acid afforded <b>88</b> in 76% yield. Reduction of the nitro group in compounds <b>80</b>–<b>83</b>, <b>85</b>, and <b>88</b> with palladium on carbon under H<sub>2</sub> at 40 psi afforded the respective anilines (<b>89a</b>–<b>89e</b> and <b>89h</b>). Reduction of the nitro group in <b>86</b> was carried out by heating this compound in the presence of zinc and ammonium chloride to give <b>89f</b> since over-reduction of the pyrimidine group occurred in the presence of H<sub>2</sub> and palladium on carbon at 40 psi. The reduction of the nitro group in <b>87</b> was completed by heating with tin(II) chloride dihydrate to afford <b>89g</b>. HATU-mediated coupling of the resultant anilines (<b>89a</b>–<b>89h</b>) with Boc-<span class="smallcaps smallerCapital">d</span>-leucine followed by deprotection of the Boc group furnished compounds <b>42</b>, <b>43</b>, <b>45</b>, <b>46</b>, <b>48</b>, <b>49</b>, <b>51</b>, and <b>53</b>, respectively.</div><div class="NLM_p">Compound <b>52</b> was synthesized by the route shown in <a class="ref internalNav" href="#sch5" aria-label="Scheme 5">Scheme 5</a>. A Suzuki coupling reaction of <b>78</b> with (2-chloropyridin-4-yl)boronic acid in the presence of PdCl<sub>2</sub>(PPh<sub>3</sub>)<sub>2</sub> provided <b>90</b>. A Buchwald coupling reaction of <b>90</b> with <i>N</i>,<i>N</i>-methylbenzylamine afforded <b>91</b> in 35% yield. Reduction of the nitro group in <b>91</b> with tin(II) chloride dihydrate was followed by TBTU-mediated coupling of the resultant aniline with Boc-<span class="smallcaps smallerCapital">d</span>-leucine to afford <b>92</b> in 88% yield. Removal of the benzyl protecting group was achieved in 66% yield by treatment of <b>92</b> with ammonium formate in the presence of 10% palladium on carbon. Removal of the Boc protecting group then furnished <b>52</b>.</div><div class="NLM_p">Replacement of the methoxy group on the central phenyl ring with either a methyl or ethyl group was carried out as shown in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. Compound <b>93</b>, prepared in two steps from 2-bromo-1-methyl-4-nitrobenzene as previously described,<a onclick="showRef(event, 'ref62 ref63'); return false;" href="javascript:void(0);" class="ref ref62 ref63">(62,63)</a> was treated with TosMIC to furnish <b>94</b>. Subsequent reduction of the nitro group with tin(II) chloride dihydrate to form the corresponding aniline followed by HATU-mediated coupling with Boc-<span class="smallcaps smallerCapital">d</span>-leucine and palladium catalyzed cross-coupling of the bromide with methylboronic acid afforded <b>95</b>. Boc deprotection of the amine furnished <b>56</b> in good yield. Compound <b>96</b> was prepared in two steps by Suzuki cross-coupling of <b>93</b> with the vinylboronic anhydride pyridine complex to install the vinyl group in 62% yield followed by treatment with TosMIC to form the oxazole ring. Compound <b>57</b> was then prepared from <b>96</b> via the three-step sequence shown in <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>.</div><figure id="sch6" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0021.jpeg" id="gr20" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>56</b> and <b>57</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TosMIC, K<sub>2</sub>CO<sub>3</sub>, MeOH, 86%; (b) SnCl<sub>2</sub>·2H<sub>2</sub>O, EtOH, quantitative; (c) Boc-<span class="smallcaps smallerCapital">d</span>-leucine, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 93%; (d) MeB(OH)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub> (aq), toluene/MeOH, 87%; (e) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 71–95%; (f) vinylboronic anhydride pyridine complex, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub> (aq), toluene/MeOH, 62%; (g) TosMIC, K<sub>2</sub>CO<sub>3</sub>, MeOH, 16%; (h) H<sub>2</sub>, 10% Pd/C, EtOH, 40 psi; and (i) Boc-<span class="smallcaps smallerCapital">d</span>-leucine, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 49% over two steps.</p></p></figure><div class="NLM_p">Replacement of the methoxy group on the central phenyl ring with either an ethoxy or difluoromethoxy group was carried out as shown in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>. Treatment of <b>66</b> with BBr<sub>3</sub> at 80 °C resulted in demethylation to furnish <b>98</b>. Alkylation with either ethyl iodide or methyl 2-chloro-2,2-difluoroacetate furnished <b>99</b> and <b>100</b>, respectively. Compounds <b>58</b> and <b>59</b> were then prepared via the three-step sequence shown in <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>.</div><figure id="sch7" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0022.jpeg" id="gr21" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compounds <b>58</b> and <b>59</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 80 °C, 51%; (b) EtI, K<sub>2</sub>CO<sub>3</sub>, DMF, 96% (for <b>99</b>); (c) K<sub>2</sub>CO<sub>3</sub>, methyl 2-chloro-2,2-difluoroacetate, DMF, 90 °C, 80% (for <b>100</b>); (d) H<sub>2</sub>, 10% Pd/C, EtOH/CHCl<sub>3</sub>, 40 psi, 65–99%; (e) Boc-<span class="smallcaps smallerCapital">d</span>-leucine, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 52–90%; and (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 43–95%.</p></p></figure><div class="NLM_p">Compound <b>60</b> was synthesized from 4-bromo-3-(trifluoromethoxy)aniline (<b>103</b>)<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> in five steps as shown in <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>. Treatment of <b>103</b> with Boc-<span class="smallcaps smallerCapital">d</span>-leucine in the presence of HATU afforded the amide product. Stille coupling of the resultant amide intermediate with tributyl(vinyl)stannane in the presence of Pd(PPh<sub>3</sub>)<sub>4</sub> followed by treatment of the resultant olefin with osmium tetroxide and sodium periodate furnished aldehyde <b>104</b>. Reaction of <b>104</b> with TosMIC followed by removal of the Boc group with TFA afforded <b>60</b>.</div><figure id="sch8" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0023.jpeg" id="gr22" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Compound <b>60</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc-<span class="smallcaps smallerCapital">d</span>-leucine, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 77%; (b) tributyl(vinyl)stannane, Pd(PPh<sub>3</sub>)<sub>4</sub>, toluene, 61%; (c) OsO<sub>4</sub>. NaIO<sub>4</sub>, 2,6-lutidine, 1,4-dioxane/H<sub>2</sub>O, 68%; (d) TosMIC, K<sub>2</sub>CO<sub>3</sub>, MeOH, 60%; and (e) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 81%.</p></p></figure><div class="NLM_p">Compound <b>61</b> was prepared from 2-fluoro-4-nitrobenzoic acid in six steps as shown in <a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>. Reduction of the carboxylic acid in <b>106</b> to the alcohol with borane·THF complex followed by Swern oxidation gave <b>107</b> in high yield. The oxazole was then installed by treatment of the aldehyde with TosMIC. Reduction of the nitro group by treatment with 10% palladium on carbon under H<sub>2</sub> at 40 psi afforded <b>108</b>. Treatment of <b>108</b> with Boc-<span class="smallcaps smallerCapital">d</span>-leucine in the presence of HATU followed by removal of the Boc group with TFA furnished <b>61</b> in good yield.</div><figure id="sch9" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0024.jpeg" id="gr23" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Compound <b>61</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BH<sub>3</sub>·THF, THF, 94%; (b) (COCl)<sub>2</sub>, DMSO, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 97%; (c) TosMIC, K<sub>2</sub>CO<sub>3</sub>, MeOH, 68%; (d) H<sub>2</sub>, 10% Pd/C, EtOH/CHCl<sub>3</sub>, 40 psi, 97%; (e) Boc-<span class="smallcaps smallerCapital">d</span>-leucine, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 55%; and (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 76%.</p></p></figure><div class="NLM_p">The synthesis of <b>62</b> was completed in four steps from 5-(2-bromo-4-nitrophenyl)oxazole (<b>94</b>) as shown in <a class="ref internalNav" href="#sch10" aria-label="Scheme 10">Scheme 10</a>. Coupling of <b>94</b> with potassium cyanide in the presence of tributyltin chloride and Pd(PPh<sub>3</sub>)<sub>4</sub> furnished <b>109</b> in 52% yield. Selective reduction of the nitro group provided <b>110</b> in 83% yield. The synthesis of <b>62</b> was then completed in two additional steps.</div><figure id="sch10" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0025.jpeg" id="gr24" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of Compound <b>62</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) KCN, Bu<sub>3</sub>SnCl, Pd(PPh<sub>3</sub>)<sub>4</sub>, MeCN, 95 °C, 52%; (b) H<sub>2</sub>, Pd(OAc)<sub>2</sub>, KF (aq), PMHS, THF, 83%; (c) Boc-<span class="smallcaps smallerCapital">d</span>-leucine, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>; and (d) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 50%, over two steps.</p></p></figure><div class="NLM_p">Compounds <b>63</b> and <b>64</b> were prepared by the coupling of 4-(pyridin-4-yl)aniline (<b>111</b>) with either Boc-<span class="smallcaps smallerCapital">d</span>-leucine or <b>73</b> in the presence of HATU to form the respective amide products (<a class="ref internalNav" href="#sch11" aria-label="Scheme 11">Scheme 11</a>). The Boc protecting group in each compound was removed by stirring with TFA to afford <b>63</b> and <b>64</b>, respectively.</div><figure id="sch11" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0026.jpeg" id="gr25" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of Compounds <b>63</b> and <b>64</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc-<span class="smallcaps smallerCapital">d</span>-leucine, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 100%; (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 50–73%; and (c) <b>73</b>, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 40 °C, 81%.</p></p></figure></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i30">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04455" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04455" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">Inhibition of AAK1 represents a potential novel method for the treatment of neuropathic pain, an area of significant unmet medical need. A series of aryl amide-based compounds was identified as selective AAK1 inhibitors. SAR studies resulted in the identification of compound <b>59</b>, which was used as a tool compound to validate AAK1 as a target for neuropathic pain. An X-ray crystal structure of a closely related analog (<b>19</b>) bound to AAK1 showed that hydrogen bonding interactions occur between the oxazole nitrogen and the backbone NH of Cys129 in the hinge region of the kinase, between the amide NH and Asp194 residue, and between the amine and Asn181 residue. The X-ray crystal structure also revealed the presence of a small lipophilic pocket in the P-loop region of the kinase where a critical hydrophobic interaction resulted in improved potency and kinase selectivity. Screening in an Ambit panel of 391 kinases showed that <b>59</b> had good overall kinase selectivity. Compound <b>59</b> was evaluated for in vivo target engagement by measuring the inhibition of phosphorylation of μ2. It was found that <b>59</b> inhibited μ2 phosphorylation to a level comparable to that observed in AAK1 knockout mice. A dose–response effect was also observed. Compound <b>59</b> was efficacious in the formalin model for persistent pain (phase II) in mice and in the CCI model for neuropathic pain in rats. In addition, the level of inhibition of μ2 phosphorylation in the dose–response study strongly correlated with the results of a dose–response study in the rat chronic constriction injury (CCI) of neuropathic pain with thermal hyperalgesia as the end point. Measurement of the plasma and brain concentrations across several studies showed that <b>59</b> is a brain penetrant compound (B/P ratio = 0.5–1, <i>K</i><sub>p,uu</sub> = 0.7−1.0). The results obtained from the rotarod model suggest that <b>59</b> has the potential to avoid the dose-limiting side effects seen with the current standard-of-care drugs. The in vivo results obtained with <b>59</b>, in combination with the results previously published with <b>5</b>, provided our first in vivo proof-of-concept results demonstrating that the AAK1 knockout phenotype can be recapitulated in animals with small molecule AAK1 inhibitors. Moreover, the structural dissimilarity of <b>59</b> and <b>5</b> provided additional confidence that the observed effects can be attributed to the inhibition of AAK1. Further optimization of AAK1 inhibitors will be reported in due course.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_20104" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_20104" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> General Chemistry Details</h3><div class="NLM_p">All procedures were carried out under a nitrogen atmosphere unless otherwise indicated using anhydrous solvents purchased from commercial sources without further purification. Reactions requiring anhydrous conditions were performed in glassware, which was oven-dried and placed under a nitrogen atmosphere. Normal phase column chromatography was performed on silica gel using a Biotage system and the solvent systems indicated. Solvent systems are reported as v/v percent ratios. Reverse phase chromatography was performed using preparative HPLC instruments (Varian or Shimadzu). All reactions were monitored by TLC using EM Science, 0.25 mm, precoated silica gel plates or by LC/MS. TLC plates were visualized by UV light or staining agents (phosphomolybdic acid, <i>p</i>-anisaldehyde, or KMnO<sub>4</sub>). For LC/MS monitoring, samples were run on a Shimadzu Nexera series UPLC with a single quadrupole LCMS-2020 mass spectrometer. Yields refer to chromatographically and spectroscopically pure compounds, except as otherwise indicated. Proton NMR spectra were recorded on either a Bruker 400 or 500 MHz NMR spectrometer. Chemical shifts are reported in δ values relative to tetramethylsilane. Electrospray ionization (ESI) low-resolution mass spectra were obtained on a Shimadzu Nexera series UPLC with a single quadrupole LCMS-2020 mass spectrometer. Electrospray ionization (ESI) high-resolution mass spectra were obtained on a Finnigan MAT95S or Thermo Scientific MAT900 mass spectrometer. The purity of final products was determined by HPLC. All final products had a purity of ≥95% unless noted otherwise.</div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i33" class="anchor-spacer"></div><h4 class="article-section__title" id="_i33"> Analytical HPLC Methods</h4><div class="NLM_p last">The following analytical HPLC methods were used for determining the purity of final products.</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i34" class="anchor-spacer"></div><h4 class="article-section__title" id="_i34"> Analytical HPLC Method A</h4><div class="NLM_p last">Column: Phenominex Gemini C18 (4.6 × 150 mm, 3.5 μm); mobile phase A: 10% methanol/90% water with 0.1% TFA; mobile phase B: 90% methanol/10% water with 0.1% TFA; gradient: 0% B to 100% B over 15 min, hold at 100% B for 3 min; flow rate: 1 mL/min; detector wavelength: 254 nm.</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i35" class="anchor-spacer"></div><h4 class="article-section__title" id="_i35"> Analytical HPLC Method B</h4><div class="NLM_p last">Column: Phenominex Luna Phenyl-Hex (4.6 × 150 mm, 3.5 μm); mobile phase A: 10% methanol/90% water with 0.1% TFA; mobile phase B: 90% methanol/10% water with 0.1% TFA; gradient: 0% B to 100% B over 15 min, hold at 100% B for 3 min; flow rate: 1 mL/min; detector wavelength: 254 nm.</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i36" class="anchor-spacer"></div><h4 class="article-section__title" id="_i36"> Analytical HPLC Method C</h4><div class="NLM_p last">Column: Waters BEH C18 (2.0 ×  50 mm, 1.7 μm); mobile phase A: 5% acetonitrile/95% water with 10 mM ammonium acetate; mobile phase B: 95% acetonitrile/5% water with 10 mM ammonium acetate; gradient: 0% B to 100% B over 3 min, hold at 100% B for 0.5 min; flow rate: 1 mL/min; detector wavelength: 220 nm; temperature: 50 °C.</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Analytical HPLC Method D</h4><div class="NLM_p last">Column: Waters BEH C18 (2.0 × 50 mm, 1.7 μm); mobile phase A: 5% methanol/95% water with 10 mM ammonium acetate; mobile phase B: 95% methanol/5% water with 10 mM ammonium acetate; gradient: 0% B to 100% B over 3 min, hold at 100% B for 0.5 min; flow rate: 1 mL/min; detector wavelength: 220 nm; temperature: 50 °C.</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i38" class="anchor-spacer"></div><h4 class="article-section__title" id="_i38"> Analytical HPLC Method E</h4><div class="NLM_p last">Column: Waters Sunfire C18 (4.6 × 150 mm, 3.5 μm); mobile phase A: water with 0.1% TFA; mobile phase B: acetonitrile with 0.1% TFA; gradient: 10% B to 95% B over 15 min, hold at 95% B for 5 min; flow rate: 1 mL/min; detector wavelength: 254 nm.</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i39" class="anchor-spacer"></div><h4 class="article-section__title" id="_i39"> Analytical HPLC Method F</h4><div class="NLM_p last">Column: Waters Xbridge Phenyl (4.6 × 150 mm, 3.5 μm); mobile phase A: water with 0.1% TFA; mobile phase B: acetonitrile with 0.1% TFA; gradient: 10% B to 95% B over 15 min, hold at 95% B for 5 min; flow rate: 1 mL/min; detector wavelength: 254 nm.</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> Analytical HPLC Method G</h4><div class="NLM_p last">Column: Waters C18 Sunfire C18 (4.6 × 150 mm, 3.5 μm); mobile phase A: 5% acetonitrile/95% water with 0.05% TFA, pH = 2.5 adjusted with ammonia; mobile phase B: 95% acetonitrile/5% water with 0.05% TFA, pH = 2.5 adjusted with ammonia; gradient: 10% B to 100% B over 12 min, hold at 100% B for 3 min; flow rate: 1 mL/min; detector wavelength: 220 and 254 nm.</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_3"><div id="ac_i41" class="anchor-spacer"></div><h4 class="article-section__title" id="_i41"> Analytical HPLC Method H</h4><div class="NLM_p last">Column: Waters Phenyl Xbridge C18 (4.6 × 150 mm, 3.5 μm); mobile phase A: 5% acetonitrile/95% water with 0.05% TFA, pH = 2.5 adjusted with ammonia; mobile phase B: 95% acetonitrile/5% water with 0.05% TFA, pH = 2.5 adjusted with ammonia; gradient: 10% B to 100% B over 12 min, hold at 100% B for 3 min; flow rate: 1 mL/min; detector wavelength: 220 and 254 nm.</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> Analytical HPLC Method I</h4><div class="NLM_p last">Column: Waters C18 Sunfire C18 (4.6 × 150 mm, 3.5 μm); mobile phase A: 5% acetonitrile/95% water with 0.05% TFA, pH = 2.5 adjusted with ammonia; mobile phase B: 95% acetonitrile/5% water with 0.05% TFA, pH = 2.5 adjusted with ammonia; gradient: 0% B to 50% B over 15 min, 50% B to 100% B over 3 min, hold at 100% B for 5 min; flow rate: 1 mL/min; detector wavelength: 220 and 254 nm.</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> Analytical HPLC Method J</h4><div class="NLM_p last">Column: Waters Phenyl Xbridge C18 (4.6 × 150 mm, 3.5 μm); mobile phase A: 5% acetonitrile/95% water with 0.05% TFA, pH = 2.5 adjusted with ammonia; mobile phase B: 95% acetonitrile/5% water with 0.05% TFA, pH = 2.5 adjusted with ammonia; gradient: 0% B to 50% B over 15 min, 50% B to 100% B over 3 min, hold at 100% B for 5 min; flow rate: 1 mL/min; detector wavelength: 220 and 254 nm.</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> Analytical HPLC Method K</h4><div class="NLM_p last">Column: Waters Sunfire C18 (3.0 × 150 mm, 3.5 μm); mobile phase A: 5% acetonitrile/95% water with 0.1% TFA; mobile phase B: 95% acetonitrile/5% water with 0.1% TFA; gradient: 10% B to 100% B over 10 min, hold at 100% B for 2 min; flow rate: 0.5 mL/min; detector wavelength: 254 nm.</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> Analytical HPLC Method L</h4><div class="NLM_p last">Column: Waters Xbridge phenyl (3.0 × 150 mm, 3.5 μm); mobile phase A: 5% acetonitrile/95% water with 0.1% TFA; mobile phase B: 95% acetonitrile/5% water with 0.1% TFA; gradient: 10% B to 100% B over 10 min, hold at 100% B for 2 min; flow rate: 0.5 mL/min; detector wavelength: 254 nm.</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> Preparative HPLC Methods</h4><div class="NLM_p last">The following preparative HPLC methods were used for the purification of final products.</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> Prep HPLC Method A</h4><div class="NLM_p last">Column: Waters Sunfire C18 (30 × 150 mm, 5 μm); mobile phase A: 5% acetonitrile/95% water with 0.1% TFA; mobile phase B: 95% acetonitrile/5% water with 0.1% TFA; gradient: 5% B to 50% B over 15 min, 50 to 100% over 3 min, hold at 100% B for 4 min; flow rate: 40 mL/min; detector wavelength: 220 nm.</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_3"><div id="ac_i48" class="anchor-spacer"></div><h4 class="article-section__title" id="_i48"> Prep HPLC Method B</h4><div class="NLM_p last">Column: Waters XBridge C18 (19 × 200 mm, 5 μm); mobile phase A: 5% acetonitrile/95% water with 10 mM ammonium acetate; mobile phase B: 95% acetonitrile/5% water with 10 mM ammonium acetate; gradient: 10 to 50% B over 15 min, hold at 100% B for 5 min; flow rate: 20 mL/min; detector wavelength: 220 nm.</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_3"><div id="ac_i49" class="anchor-spacer"></div><h4 class="article-section__title" id="_i49"> Prep HPLC Method C</h4><div class="NLM_p last">Column: Waters Sunfire C18 (30 × 150 mm, 5 μm); mobile phase A: 10% methanol/90% water with 0.1% TFA; mobile phase B: 90% methanol/10% water with 0.1% TFA; gradient: 0 to 100% over 20 min, hold at 100% B for 2 min; flow rate: 40 mL/min; detector wavelength: 220 nm.</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> Prep HPLC Method D</h4><div class="NLM_p last">Column: Waters XBridge C18 (19 × 200 mm, 5 μm); mobile phase A: 5% acetonitrile/95% water with 10 mM ammonium acetate; mobile phase B: 95% acetonitrile/5% water with 10 mM ammonium acetate; gradient: 20 to 60% B over 15 min, then hold at 100% B for 5 min; flow rate: 20 mL/min; detector wavelength: 220 nm.</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> Prep HPLC Method E</h4><div class="NLM_p last">Column: Waters XBridge C18 (19 × 200 mm, 5 μm); mobile phase A: 5% acetonitrile/95% water with 10 mM ammonium acetate; mobile phase B: 95% acetonitrile/5% water with 10 mM ammonium acetate; gradient: 25 to 65% B over 10 min, then hold at 100% B for 5 min; flow rate: 20 mL/min; detector wavelength: 220 nm.</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_3"><div id="ac_i52" class="anchor-spacer"></div><h4 class="article-section__title" id="_i52"> Prep HPLC Method F</h4><div class="NLM_p last">Column: Waters XBridge C18 (19 × 200 mm, 5 μm); mobile phase A: 5% acetonitrile/95% water with 10 mM ammonium acetate; mobile phase B: 95% acetonitrile/5% water with 10 mM ammonium acetate; gradient: 45 to 85% over 20 min, then hold at 100% B for 5 min; flow rate: 20 mL/min; detector wavelength: 220 nm.</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> Prep HPLC Method G</h4><div class="NLM_p last">Column: Waters Xbridge Phenyl (30 × 100 mm, 5 μm); mobile phase A: 5% acetonitrile/95% water with 0.1% TFA; mobile phase B: 95% acetonitrile/5% water with 0.1% TFA; gradient: 0 to 25% B over 15 min; flow rate: 30 mL/min; detector wavelength: 220 nm.</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> Prep HPLC Method H</h4><div class="NLM_p">Column: Waters Sunfire C18 (30 × 150 mm, 5 μm); mobile phase A: 5% acetonitrile/95% water with 0.1% TFA; mobile phase B: 95% acetonitrile/5% water with 0.1% TFA; gradient: 5 to 50% over 15 min, 50 to 100% over 3 min; hold at 100% B for 4 min; flow rate: 40 mL/min; detector wavelength: 254 nm.</div><div id="sec5_1_22_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> (<i>R</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)-3-methylbutanamide, TFA (<b>11</b>)</h5><div class="NLM_p">Step 1: To a solution of 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) (40 mg, 0.210 mmol), (<i>R</i>)-2-((<i>tert-</i>butoxycarbonyl)amino)-3-methylbutanoic acid (68.5 mg, 0.315 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.147 mL, 0.841 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) at room temperature was added HATU (120 mg, 0.315 mmol). The reaction mixture was stirred at room temperature for 16 h. The reaction mixture was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (5 mL). The aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine (5 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (25% EtOAc with 1% MeOH/75% hexanes–50% EtOAc with 1% MeOH/50% hexanes; 24 g column) to afford (<i>R</i>)-<i>tert</i>-butyl (1-((3-methoxy-4-(oxazol-5-yl)phenyl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (56.7 mg, 0.146 mmol, 69% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.32 (br. s., 1H), 7.88 (s, 1H), 7.66 (d, <i>J</i> = 8.5 Hz, 1H), 7.53 (br. s., 1H), 7.48 (s, 1H), 6.98 (dd, <i>J</i> = 8.4, 1.9 Hz, 1H), 5.10 (br. s., 1H), 4.10–4.01 (m, 1H), 3.96 (s, 3H), 2.28 (dq, <i>J</i> = 12.8, 6.5 Hz, 1H), 1.50 (s, 9H), 1.08 (d, <i>J</i> = 6.8 Hz, 3H), 1.04 (d, <i>J</i> = 6.8 Hz, 3H). MS (ESI) <i>m/z</i>: 390.2 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Step 2: To a solution of (<i>R</i>)-<i>tert</i>-butyl (1-((3-methoxy-4-(oxazol-5-yl)phenyl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (48 mg, 0.123 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was added TFA (0.5 mL, 6.49 mmol). The reaction mixture was stirred at room temperature for 2 h. The mixture was concentrated. The product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>11</b> (49.8 mg, 0.122 mmol, 99% yield) as a white amorphous solid. [α]<sub>D</sub><sup>22</sup> −39.4 (<i>c</i> 0.380, MeOH). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.69 (s, 1H), 8.42 (s, 1H), 8.26 (d, <i>J</i> = 3.8 Hz, 3H), 7.71 (d, <i>J</i> = 8.5 Hz, 1H), 7.50 (s, 1H), 7.49 (d, <i>J</i> = 1.8 Hz, 1H), 7.38 (dd, <i>J</i> = 8.5, 1.8 Hz, 1H), 3.94 (s, 3H), 3.76 (t, <i>J</i> = 5.4 Hz, 1H), 2.21 (dq, <i>J</i> = 13.3, 6.7 Hz, 1H), 1.02 (d, <i>J</i> = 7.0 Hz, 3H), 1.00 (d, <i>J</i> = 7.0 Hz, 3H). HRMS (ESI) <i>m/z</i>: 290.1494 [(M + H)<sup>+</sup>, calcd for C<sub>15</sub>H<sub>20</sub>N<sub>3</sub>O<sub>3</sub> 290.1505]. HPLC purity: >99, <i>t</i><sub>R</sub> = 12.69 min (method A); >99, <i>t</i><sub>R</sub> = 13.13 min (method B).</div></div><div id="sec5_1_22_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> (<i>R</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)propanamide, TFA (<b>12</b>)</h5><div class="NLM_p last">Compound <b>12</b> was prepared from 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) and (<i>R</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)propanoic acid according to the representative two-step procedure described for the synthesis of <b>11</b>. The product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>12</b> (29 mg, 0.076 mmol, 49% yield, two steps) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.64 (s, 1H), 8.42 (s, 1H), 8.23 (br. s., 3H), 7.70 (d, <i>J</i> = 8.5 Hz, 1H), 7.50 (s, 2H), 7.35 (dd, <i>J</i> = 8.4, 1.9 Hz, 1H), 4.08–3.99 (m, 1H), 3.94 (s, 3H), 1.48 (d, <i>J</i> = 7.0 Hz, 3H). HRMS (ESI) <i>m/z</i>: 262.1181 [(M + H)<sup>+</sup>, calcd for C<sub>13</sub>H<sub>16</sub>N<sub>3</sub>O<sub>3</sub> 262.1192]. HPLC purity: >99, <i>t</i><sub>R</sub> = 11.65 min (method A); >99, <i>t</i><sub>R</sub> = 12.47 min (method B).</div></div><div id="sec5_1_22_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> (<i>R</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)butanamide, TFA (<b>13</b>)</h5><div class="NLM_p last">Compound <b>13</b> was prepared from 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) and (<i>R</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)butanoic acid according to the representative two-step procedure described for the synthesis of <b>11</b>. The product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>13</b> (51 mg, 0.130 mmol, 87% yield, two steps) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.67 (s, 1H), 8.42 (s, 1H), 8.32–8.19 (m, 3H), 7.71 (d, <i>J</i> = 8.5 Hz, 1H), 7.51–7.47 (m, 2H), 7.37 (dd, <i>J</i> = 8.5, 1.8 Hz, 1H), 3.94 (s, 3H), 3.93–3.87 (m, <i>J</i> = 5.3 Hz, 1H), 1.88 (quin, <i>J</i> = 7.5 Hz, 2H), 0.97 (t, <i>J</i> = 7.5 Hz, 3H). HRMS (ESI) <i>m/z</i>: 276.1336 [(M + H)<sup>+</sup>, calcd for C<sub>14</sub>H<sub>18</sub>N<sub>3</sub>O<sub>3</sub> 276.1348]. HPLC purity: >99, <i>t</i><sub>R</sub> = 12.37 min (method A); >99, <i>t</i><sub>R</sub> = 12.98 min (method B).</div></div><div id="sec5_1_22_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> (<i>R</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)pentanamide, TFA (<b>14</b>)</h5><div class="NLM_p last">Compound <b>14</b> was prepared from 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) and (<i>R</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)pentanoic acid according to the representative two-step procedure described for the synthesis of <b>11</b>. The product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>14</b> (39 mg, 0.096 mmol, 77% yield, two steps) as a white amorphous solid. [α]<sub>D</sub><sup>22</sup> −24.1 (<i>c</i> 0.355, MeOH). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.23 (s, 1H), 7.77 (d, <i>J</i> = 8.5 Hz, 1H), 7.62 (d, <i>J</i> = 1.8 Hz, 1H), 7.50 (s, 1H), 7.27 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 4.04–3.97 (m, 4H), 2.01–1.86 (m, 2H), 1.53 (dtd, <i>J</i> = 9.7, 7.0, 4.4 Hz, 2H), 1.06 (t, <i>J</i> = 7.3 Hz, 3H). HRMS (ESI) <i>m/z</i>: 290.1507 [(M + H)<sup>+</sup>, calcd for C<sub>15</sub>H<sub>20</sub>N<sub>3</sub>O<sub>3</sub> 290.1505]. HPLC purity: >99, <i>t</i><sub>R</sub> = 13.18 min (method A); >99, <i>t</i><sub>R</sub> = 13.73 min (method B).</div></div><div id="sec5_1_22_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> (<i>S</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)pentanamide, TFA (<b>15</b>)</h5><div class="NLM_p last">Compound <b>15</b> was prepared from 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) and (<i>S</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)pentanoic acid according to the representative two-step procedure described for the synthesis of <b>11</b>. The product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>15</b> (43 mg, 0.106 mmol, 68% yield, two steps) as a white amorphous solid. [α]<sub>D</sub><sup>22</sup> +27.4 (<i>c</i> 0.355, MeOH). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.23 (s, 1H), 7.77 (d, <i>J</i> = 8.5 Hz, 1H), 7.62 (d, <i>J</i> = 2.0 Hz, 1H), 7.50 (s, 1H), 7.27 (dd, <i>J</i> = 8.5, 1.8 Hz, 1H), 4.05–3.99 (m, 4H), 2.03–1.87 (m, 2H), 1.59–1.46 (m, 2H), 1.05 (t, <i>J</i> = 7.4 Hz, 3H). HRMS (ESI) <i>m/z</i>: 290.1508 [(M + H)<sup>+</sup>, calcd for C<sub>15</sub>H<sub>20</sub>N<sub>3</sub>O<sub>3</sub> 290.1505]. HPLC purity: >99, <i>t</i><sub>R</sub> = 13.20 min (method A); >99, <i>t</i><sub>R</sub> = 13.76 min (method B).</div></div><div id="sec5_1_22_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> (<i>R</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)hexanamide, TFA (<b>16</b>)</h5><div class="NLM_p last">Compound <b>16</b> was prepared from 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) and (<i>R</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)hexanoic acid according to the representative two-step procedure described for the synthesis of <b>11</b>. The product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>16</b> (39 mg, 0.094 mmol, 62% yield, two steps) as a white amorphous solid. [α]<sub>D</sub><sup>22</sup> −28.5 (<i>c</i> 0.300, MeOH). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.68 (s, 1H), 8.42 (s, 1H), 8.25 (br. s., 3H), 7.71 (d, <i>J</i> = 8.5 Hz, 1H), 7.50 (s, 1H), 7.49 (d, <i>J</i> = 2.0 Hz, 1H), 7.37 (dd, <i>J</i> = 8.5, 1.8 Hz, 1H), 3.94 (s, 3H), 3.94–3.88 (m, 1H), 1.88–1.78 (m, 2H), 1.39–1.29 (m, 4H), 0.92–0.84 (m, 3H). HRMS (ESI) <i>m/z</i>: 304.1653 [(M + H)<sup>+</sup>, calcd for C<sub>16</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub> 304.1661]. HPLC purity: >99, <i>t</i><sub>R</sub> = 14.07 min (method A); >99, <i>t</i><sub>R</sub> = 14.43 min (method B).</div></div><div id="sec5_1_22_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> (<i>S</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)hexanamide, TFA (<b>17</b>)</h5><div class="NLM_p last">Compound <b>17</b> was prepared from 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) and (<i>S</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)hexanoic acid according to the representative two-step procedure described for the synthesis of <b>11</b>. The product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford to afford <b>17</b> (46 mg, 0.110 mmol, 70% yield, two steps) as a white amorphous solid. [α]<sub>D</sub><sup>22</sup> +34.0 (<i>c</i> 0.280, MeOH). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.22 (s, 1H), 7.77 (d, <i>J</i> = 8.5 Hz, 1H), 7.62 (d, <i>J</i> = 2.0 Hz, 1H), 7.50 (s, 1H), 7.27 (dd, <i>J</i> = 8.4, 1.9 Hz, 1H), 4.06–3.97 (m, 4H), 2.06–1.89 (m, 2H), 1.53–1.38 (m, 4H), 1.03–0.94 (m, 3H). HRMS (ESI) <i>m/z</i>: 304.1664 [(M + H)<sup>+</sup>, calcd for C<sub>16</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub> 304.1661]. HPLC purity: >99, <i>t</i><sub>R</sub> = 14.06 min (method A); >99, <i>t</i><sub>R</sub> = 14.51 min (method B).</div></div><div id="sec5_1_22_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> (2<i>R</i>,3<i>R</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)-3-methylpentanamide, TFA (<b>18</b>)</h5><div class="NLM_p last">Compound <b>18</b> was prepared from 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) and (2<i>R</i>,3<i>R</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)-3-methylpentanoic acid according to the representative two-step procedure described for the synthesis of <b>11</b>. The product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>18</b> (40 mg, 0.095 mmol, 63% yield, two steps) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.67 (s, 1H), 8.42 (s, 1H), 8.27 (d, <i>J</i> = 4.0 Hz, 3H), 7.71 (d, <i>J</i> = 8.5 Hz, 1H), 7.50 (s, 1H), 7.48 (d, <i>J</i> = 2.0 Hz, 1H), 7.38 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 3.94 (s, 3H), 3.79 (t, <i>J</i> = 5.4 Hz, 1H), 2.01–1.90 (m, 1H), 1.57 (ddd, <i>J</i> = 13.6, 7.5, 3.5 Hz, 1H), 1.25–1.13 (m, 1H), 0.99 (d, <i>J</i> = 7.0 Hz, 3H), 0.90 (t, <i>J</i> = 7.3 Hz, 3H). HRMS (ESI) <i>m/z</i>: 304.1656 [(M + H)<sup>+</sup>, calcd for C<sub>16</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub> 304.1661]. HPLC purity: >99, <i>t</i><sub>R</sub> = 13.77 min (method A); >99, <i>t</i><sub>R</sub> = 14.08 min (method B).</div></div><div id="sec5_1_22_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> (<i>R</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)-4-methylpentanamide, TFA (<b>19</b>)</h5><div class="NLM_p">Step 1: To a mixture of 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) (70 mg, 0.368 mmol), (<i>R</i>)-2-(<i>tert</i>-butoxycarbonylamino)-4-methylpentanoic acid (128 mg, 0.552 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.257 mL, 1.47 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was added HATU (210 mg, 0.552 mmol). The reaction mixture was stirred at room temperature for 18 h. The reaction mixture was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (5 mL). The aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine (5 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (40–70% EtOAc in hexanes) to afford (<i>R</i>)-<i>tert</i>-butyl 1-(3-methoxy-4-(oxazol-5-yl)phenylamino)-4-methyl-1-oxopentan-2-ylcarbamate (102 mg, 0.253 mmol, 69% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.15 (s, 1H), 8.38 (s, 1H), 7.63 (d, <i>J</i> = 8.6 Hz, 1H), 7.52 (d, <i>J</i> = 1.8 Hz, 1H), 7.44 (s, 1H), 7.36 (dd, <i>J</i> = 8.4, 1.9 Hz, 1H), 7.08 (d, <i>J</i> = 7.8 Hz, 1H), 4.17–4.09 (m, 1H), 3.91 (s, 3H), 1.72–1.59 (m, 1H), 1.59–1.48 (m, 1H), 1.44 (dd, <i>J</i> = 8.4, 5.2 Hz, 1H), 1.38 (s, 9H), 0.91 (br d, <i>J</i> = 6.5 Hz, 1H), 0.91 (br d, <i>J</i> = 6.3 Hz, 1H). MS (ESI) <i>m/z</i>: 404.3 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Step 2: To a suspension of (<i>R</i>)-<i>tert</i>-butyl 1-(3-methoxy-4-(oxazol-5-yl)phenylamino)-4-methyl-1-oxopentan-2-ylcarbamate (92 mg, 0.228 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) at 0 °C was added TFA (0.50 mL, 6.49 mmol). The cooling bath was removed, and the mixture was stirred at room temperature under N<sub>2</sub> for 1.5 h. The mixture was concentrated. The product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>19</b> (67 mg, 0.161 mmol, 71% yield) as a white amorphous solid. [α]<sub>D</sub><sup>22</sup> −34.2 (<i>c</i> 0.250, MeOH). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.22 (s, 1H), 7.77 (d, <i>J</i> = 8.5 Hz, 1H), 7.62 (d, <i>J</i> = 2.0 Hz, 1H), 7.50 (s, 1H), 7.29 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 4.05 (dd, <i>J</i> = 7.8, 6.3 Hz, 1H), 4.01 (s, 3H), 1.88–1.75 (m, 3H), 1.07 (d, <i>J</i> = 6.0 Hz, 6H). HRMS (ESI) <i>m/z</i>: 304.1651 [(M + H)<sup>+</sup>, calcd for C<sub>16</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub> 304.1661]. HPLC purity: 99.8, <i>t</i><sub>R</sub> = 8.01 min (method E); 99.8, <i>t</i><sub>R</sub> = 8.03 min (method F).</div></div><div id="sec5_1_22_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> (<i>S</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)-4-methylpentanamide, TFA (<b>20</b>)</h5><div class="NLM_p last">Compound <b>20</b> was prepared from 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) and (<i>S</i>)-2-(<i>tert</i>-butoxycarbonylamino)-4-methylpentanoic acid according to the representative two-step procedure described for the synthesis of <b>11</b>. The product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>20</b> (49 mg, 0.117 mmol, 75% yield, two steps) as a white amorphous solid. [α]<sub>D</sub><sup>22</sup> +34.5 (<i>c</i> 0.280, MeOH). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.71 (s, 1H), 8.42 (s, 1H), 8.34–8.23 (m, 2H), 7.71 (d, <i>J</i> = 8.5 Hz, 1H), 7.50 (s, 1H), 7.48 (d, <i>J</i> = 1.8 Hz, 1H), 7.39 (dd, <i>J</i> = 8.5, 1.8 Hz, 1H), 3.98–3.92 (m, 1H), 3.94 (s, 3H), 1.73–1.64 (m, 3H), 0.95 (d, <i>J</i> = 5.8 Hz, 6H). HRMS (ESI) <i>m/z</i>: 304.1656 [(M + H)<sup>+</sup>, calcd for C<sub>16</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub> 304.1661]. HPLC purity: >99, <i>t</i><sub>R</sub> = 13.90 min (method A); >99, <i>t</i><sub>R</sub> = 14.16 min (method B).</div></div><div id="sec5_1_22_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> (<i>R</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)-5-methylhexanamide, TFA (<b>21</b>)</h5><div class="NLM_p">Step 1: To a solution of 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) (35 mg, 0.184 mmol), (<i>R</i>)-2-((((9<i>H</i>-fluoren-9-yl)methoxy)carbonyl)amino)-5-methylhexanoic acid (101 mg, 0.276 mmol), and <i>N</i>,<i>N</i> diisopropylethylamine (0.129 mL, 0.736 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) at room temperature was added HATU (105 mg, 0.276 mmol). The reaction mixture was stirred at room temperature for 60 h. The mixture was transferred to a separatory funnel containing EtOAc (20 mL). The organic layer was washed with saturated aqueous NaHCO<sub>3</sub> solution (5 mL)/water (5 mL) and brine (10 mL). The organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (30% EtOAc with 1% MeOH/70% hexanes–60% EtOAc with 1% MeOH/30% hexanes; 24 g column) to afford (<i>R</i>)-(9<i>H</i>-fluoren-9-yl)methyl (1-((3-methoxy-4-(oxazol-5-yl)phenyl)amino)-5-methyl-1-oxohexan-2-yl)carbamate (59.1 mg, 0.110 mmol, 60% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.24 (s, 1H) 8.38 (s, 1H) 7.89 (d, <i>J</i> = 7.6 Hz, 2H) 7.75 (dd, <i>J</i> = 7.3, 3.0 Hz, 2H) 7.71 (d, <i>J</i> = 8.1 Hz, 1H) 7.64 (d, <i>J</i> = 8.3 Hz, 1H) 7.56 (d, <i>J</i> = 1.8 Hz, 1H) 7.45 (s, 1H) 7.44–7.38 (m, 2H) 7.36–7.29 (m, 3H) 4.35–4.19 (m, 3H) 4.15–4.07 (m, 1H) 3.91 (s, 3H) 1.75–1.50 (m, 3H) 1.36–1.25 (m, 1H) 1.25–1.14 (m, 1H), 0.87 (d, <i>J</i> = 6.5 Hz, 6H). MS (ESI) <i>m/z</i> 540.3 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Step 2: To a solution of (<i>R</i>)-(9<i>H</i>-fluoren-9-yl)methyl (1-((3-methoxy-4-(oxazol-5-yl)phenyl)amino)-5-methyl-1-oxohexan-2-yl)carbamate (55 mg, 0.102 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) at room temperature was added piperidine (0.101 mL, 1.02 mmol). The mixture was stirred at room temperature for 24 h. The mixture was concentrated. The product was purified by preparative reverse phase HPLC (method C) and lyophilized to afford <b>21</b> (39 mg, 0.089 mmol, 87% yield) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.63 (s, 1H), 8.40 (s, 1H), 8.23 (br. s., 3H), 7.71 (d, <i>J</i> = 8.5 Hz, 1H), 7.51–7.47 (m, 2H), 7.36 (dd, <i>J</i> = 8.4, 1.9 Hz, 1H), 3.94 (s, 3H), 3.93–3.87 (m, <i>J</i> = 4.3 Hz, 1H), 1.89–1.79 (m, 2H), 1.56 (dt, <i>J</i> = 13.3, 6.7 Hz, 1H), 1.30–1.22 (m, 2H), 0.89 (d, <i>J</i> = 2.0 Hz, 3H), 0.88 (d, <i>J</i> = 2.0 Hz, 3H). HRMS (ESI) <i>m/z</i>: 318.1813 [(M + H)<sup>+</sup>, calcd for C<sub>17</sub>H<sub>24</sub>N<sub>3</sub>O<sub>3</sub> 318.1818]. HPLC purity: >99, <i>t</i><sub>R</sub> = 14.66 min (method A); >99, <i>t</i><sub>R</sub> = 14.47 min HPLC (method B).</div></div><div id="sec5_1_22_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> (<i>R</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)-4,4-dimethylpentanamide (<b>22</b>)</h5><div class="NLM_p last">Compound <b>22</b> was prepared from 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) and (<i>R</i>)-2-(<i>tert</i>-butoxycarbonylamino)-4,4-dimethylpentanoic acid according to the representative two-step procedure described for the synthesis of <b>11</b>. The product was purified by preparative reverse phase HPLC (method A). The organic solvent was removed in vacuo, and the product was taken up in EtOAc and converted to the free base by washing with saturated aqueous K<sub>2</sub>CO<sub>3</sub>. The product was taken up in acetonitrile/water and was lyophilized to afford <b>22</b> (80 mg, 0.252 mmol) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.22 (s, 1H), 7.74 (d, <i>J</i> = 8.8 Hz, 1H), 7.64 (d, <i>J</i> = 1.6 Hz, 1H), 7.48 (s, 1H), 7.25 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H), 4.00 (s, 3H), 3.57–3.50 (m, 1H), 2.00–1.90 (m, 1H), 1.52–1.41 (m, 1H), 1.03 (s, 9H). HRMS (ESI) <i>m/z</i>: 318.1812 [(M + H)<sup>+</sup>, calcd for C<sub>17</sub>H<sub>24</sub>N<sub>3</sub>O<sub>3</sub>, 318.1818]. HPLC purity: 97%, <i>t</i><sub>R</sub> = 5.90 min (method G); 97%, <i>t</i><sub>R</sub> = 6.25 min (method H).</div></div><div id="sec5_1_22_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> (<i>R</i>)-<i>N</i>-(3-Methoxy-4-(oxazol-5-yl)phenyl)-4-methyl-2-(methylamino)pentanamide (<b>23</b>)</h5><div class="NLM_p last">Compound <b>23</b> was prepared from 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) and (<i>R</i>)-2-((<i>tert</i>-butoxycarbonyl)(methyl)amino)-4-methylpentanoic acid according to the representative two-step procedure described for the synthesis of <b>11</b>. The product was purified by preparative reverse phase HPLC (method B) to afford <b>23</b> (20 mg, 0.046 mmol, 44% yield, two steps). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.41 (s, 1H), 7.71 (d, <i>J</i> = 8.4 Hz, 1H), 7.50 (s, 2H), 7.39 (d, <i>J</i> = 9.5 Hz, 1H), 3.94 (s, 3H), 3.86 (t, <i>J</i> = 6.2 Hz, 1H), 2.57 (s, 3H), 1.80–1.61 (m, 3H), 0.96 (d, <i>J</i> = 6.2 Hz, 3H), 0.93 (d, <i>J</i> = 5.9 Hz, 3H). HRMS (ESI) <i>m/z</i>: 318.1818 [(M + H)<sup>+</sup>, calcd for C<sub>17</sub>H<sub>24</sub>N<sub>3</sub>O<sub>3</sub>, 318.1818]. HPLC purity: 99%, <i>t</i><sub>R</sub> = 1.20 min (method C); 99%, <i>t</i><sub>R</sub> = 2.32 min (method D).</div></div><div id="sec5_1_22_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> 2-(Aminomethyl)-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)-4-methylpentanamide (<b>24</b>)</h5><div class="NLM_p">Step 1: To a mixture of 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) (147 mg, 0.773 mmol) and 2-((benzyloxycarbonylamino)methyl)-4-methylpentanoic acid (180 mg, 0.644 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) at room temperature were added HATU (368 mg, 0.967 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.563 mL, 3.22 mmol). The reaction mixture was stirred at room temperature for 12 h. The reaction mixture was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution. The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 25 mL). The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (40–50% EtOAc in hexanes) to afford benzyl 2-(3-methoxy-4-(oxazol-5-yl)phenylcarbamoyl)-4-methylpentylcarbamate (200 mg, 0.443 mmol, 57% yield) as a yellow solid. MS (ESI) <i>m</i>/<i>z</i>: 452.4 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Step 2: A mixture of benzyl 2-(3-methoxy-4-(oxazol-5-yl)phenylcarbamoyl)-4-methylpentylcarbamate (200 mg, 0.443 mmol), 10% palladium on carbon (236 mg, 0.221 mmol), and ammonium hydroxide (1 mL, 25.7 mmol) in MeOH (20 mL) was stirred under a H<sub>2</sub> atmosphere for 12 h. The catalyst was removed by filtration through a pad of Celite. The filtrate was concentrated, and the product was purified by column chromatography on silica gel (10% 2 M NH<sub>3</sub> in MeOH/90% CH<sub>2</sub>Cl<sub>2</sub>) to afford <b>24</b> (65 mg, 0.205 mmol, 46% yield) as a red solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.16 (s, 1H), 7.66 (d, <i>J</i> = 8.3 Hz, 1H), 7.61 (d, <i>J</i> = 2.0 Hz, 1H), 7.43–7.39 (m, 1H), 7.19 (dd, <i>J</i> = 8.4, 1.9 Hz, 1H), 3.94 (s, 3H), 2.94–2.86 (m, 1H), 2.75 (d, <i>J</i> = 11.8 Hz, 1H), 2.66–2.54 (m, 1H), 1.69–1.54 (m, 2H), 1.35–1.25 (m, 1H), 0.96 (d, <i>J</i> = 6.3 Hz, 3H), 0.92 (d, <i>J</i> = 6.3 Hz, 3H). HRMS (ESI) <i>m/z</i>: 318.1817 [(M + H)<sup>+</sup>, calcd for C<sub>17</sub>H<sub>24</sub>N<sub>3</sub>O<sub>3</sub> 318.1818]. HPLC purity: 96%, <i>t</i><sub>R</sub> = 11.85 min (method E); 96, <i>t</i><sub>R</sub> = 12.85 min (method F).</div></div><div id="sec5_1_22_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> (<i>R</i>)-3-Amino<i>-N-</i>(3-methoxy-4-(oxazol-5-yl)phenyl)-4-methylpentanamide (<b>25</b>)</h5><div class="NLM_p last">Compound <b>25</b> was prepared from 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) and (<i>R</i>)-3-(<i>tert</i>-butoxycarbonylamino)-4-methylpentanoic acid according to the representative two-step procedure described for the synthesis of <b>11</b>. The product was purified by preparative reverse phase HPLC (method B) to afford <b>25</b>, which was isolated as the free base (45 mg, 0.149 mmol) as an off-white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.21 (s, 1H), 7.72 (d, <i>J</i> = 8.4 Hz, 1H), 7.64 (d, <i>J</i> = 2.0 Hz, 1H), 7.48 (s, 1H), 7.21 (dd, <i>J</i> = 8.4, 2.0 Hz, 1H), 4.0 (s, 3H), 3.40–3.10 (m, 1H), 2.80–2.74 (m, 1H), 2.59–2.51 (m, 1H), 1.96 (m, 1H), 1.07–1.04 (m, 6H). HRMS (ESI) <i>m/z</i>: 304.1661 [(M + H)<sup>+</sup>, calcd for C<sub>16</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub>, 304.1661]. HPLC purity: 97%, <i>t</i><sub>R</sub> = 9.71 min (method I); 97%, <i>t</i><sub>R</sub> = 10.37 min (method J).</div></div><div id="sec5_1_22_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> (<i>R</i>)-2-Amino-3-cyclopropyl-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)propanamide, TFA (<b>26</b>)</h5><div class="NLM_p last">Compound <b>26</b> was prepared from 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) and (<i>R</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)-3-cyclopropylpropanoic acid according to the representative two-step procedure described for the synthesis of <b>11</b>. The product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>26</b> (145 mg, 0.349 mmol, 46% yield, two steps) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.67 (s, 1H), 8.42 (s, 1H), 8.37–8.27 (m, 3H), 7.71 (d, <i>J</i> = 8.3 Hz, 1H), 7.50 (s, 1H), 7.47 (d, <i>J</i> = 2.0 Hz, 1H), 7.37 (dd, <i>J</i> = 8.5, 1.8 Hz, 1H), 4.01 (d, <i>J</i> = 5.3 Hz, 1H), 3.94 (s, 3H), 1.83 (dt, <i>J</i> = 14.2, 7.0 Hz, 1H), 1.73–1.62 (m, 1H), 0.85–0.74 (m, 1H), 0.55–0.40 (m, 2H), 0.17–0.11 (m, 2H). HRMS (ESI) <i>m/z</i>: 302.1498 [(M + H)<sup>+</sup>, calcd for C<sub>16</sub>H<sub>20</sub>N<sub>3</sub>O<sub>3</sub> 302.1505]. HPLC purity: >99, <i>t</i><sub>R</sub> = 13.29 min (method A); >99, <i>t</i><sub>R</sub> = 13.80 min (method B).</div></div><div id="sec5_1_22_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> (<i>R</i>)-2-Amino-3-cyclobutyl-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)propanamide, TFA (<b>27</b>)</h5><div class="NLM_p last">Compound <b>27</b> was prepared from 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) and (<i>R</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)-3-cyclobutylpropanoic acid according to the representative two-step procedure described for the synthesis of <b>11</b>. The product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>27</b> (49 mg, 0.113 mmol, 40% yield, two steps) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.67 (s, 1H), 8.42 (s, 1H), 8.29–8.17 (m, 2H), 7.71 (d, <i>J</i> = 8.3 Hz, 1H), 7.50 (s, 1H), 7.47 (d, <i>J</i> = 1.8 Hz, 1H), 7.37 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 3.94 (s, 3H), 3.82 (br. s., 1H), 2.42 (dt, <i>J</i> = 15.5, 7.7 Hz, 1H), 2.13–1.96 (m, 2H), 1.93 (t, <i>J</i> = 7.0 Hz, 2H), 1.87–1.74 (m, 2H), 1.72–1.57 (m, 2H). HRMS (ESI) <i>m/z</i>: 316.1655 [(M + H)<sup>+</sup>, calcd for C<sub>17</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub> 316.1661]. HPLC purity: >99, <i>t</i><sub>R</sub> = 14.22 min (method A); >99, <i>t</i><sub>R</sub> = 14.62 min (method B).</div></div><div id="sec5_1_22_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> (<i>R</i>)-2-Amino-2-cyclopentyl-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)acetamide, TFA (<b>28</b>)</h5><div class="NLM_p last">Compound <b>28</b> was prepared from 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) and (<i>R</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)-2-cyclopentylacetic acid according to the representative two-step procedure described for the synthesis of <b>11</b>. The product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>28</b> (40 mg, 0.093 mmol, 13% yield, two steps) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.69 (s, 1H), 8.42 (s, 1H), 8.38–8.27 (m, 2H), 7.71 (d, <i>J</i> = 8.3 Hz, 1H), 7.53–7.46 (m, 2H), 7.37 (dd, <i>J</i> = 8.5, 1.8 Hz, 1H), 3.94 (s, 3H), 3.77 (br. s., 1H), 2.30–2.21 (m, 1H), 1.85–1.73 (m, 1H), 1.71–1.34 (m, 7H). HRMS (ESI) <i>m/z</i>: 316.1654 [(M + H)<sup>+</sup>, calcd for C<sub>17</sub>H<sub>22</sub>N<sub>3</sub>O<sub>3</sub> 316.1661]. HPLC purity: 99%, <i>t</i><sub>R</sub> = 13.98 min (method A); 99%, <i>t</i><sub>R</sub> = 14.46 min (method B).</div></div><div id="sec5_1_22_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> (<i>R</i>)-2-Amino-2-cyclohexyl-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)acetamide (<b>29</b>)</h5><div class="NLM_p last">Compound <b>29</b> was prepared from 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) and (<i>R</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)-2-cyclohexylacetic acid according to the representative two-step procedure described for the synthesis of <b>11</b>. The product was purified by preparative reverse phase HPLC (method D) to afford <b>29</b> (15 mg, 0.034 mmol, 32% yield, two steps). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.38 (s, 1H), 7.66 (d, <i>J</i> = 8.4 Hz, 1H), 7.56 (s, 1H), 7.46 (s, 1H), 7.37 (d, <i>J</i> = 8.8 Hz, 1H), 3.92 (s, 3H), 3.34 (d, <i>J</i> = 5.9 Hz, 1H), 1.78–1.55 (m, 6H), 1.25–0.99 (m, 5H) (exchangeable protons not observed). HRMS (ESI) <i>m/z</i>: 330.1819 [(M + H)<sup>+</sup>, calcd for C<sub>18</sub>H<sub>24</sub>N<sub>3</sub>O<sub>3</sub> 330.1818]. HPLC purity: 99%, <i>t</i><sub>R</sub> = 1.28 min (method C); 99%, <i>t</i><sub>R</sub> = 2.43 min (method D).</div></div><div id="sec5_1_22_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> (<i>R</i>)-2-Amino-3-cyclohexyl-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)propanamide, TFA (<b>30</b>)</h5><div class="NLM_p last">Compound <b>30</b> was prepared from 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) and (<i>R</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)-3-cyclohexylpropanoic acid according to the representative two-step procedure described for the synthesis of <b>11</b>. The product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>30</b> (32 mg, 0.070 mmol, 51% yield, two steps) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.67 (s, 1H), 8.42 (s, 1H), 8.31–8.22 (m, 2H), 7.71 (d, <i>J</i> = 8.3 Hz, 1H), 7.50 (s, 1H), 7.47 (d, <i>J</i> = 2.0 Hz, 1H), 7.38 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 3.98 (br. s., 1H), 3.94 (s, 3H), 1.82–1.59 (m, 7H), 1.40 (br. s., 1H), 1.27–1.08 (m, 3H), 1.00–0.86 (m, 2H). HRMS (ESI) <i>m/z</i>: 344.1969 [(M + H)<sup>+</sup>, calcd for C<sub>19</sub>H<sub>26</sub>N<sub>3</sub>O<sub>3</sub> 344.1974]. HPLC purity: >99%, <i>t</i><sub>R</sub> = 15.38 min (method A); >99%, <i>t</i><sub>R</sub> = 15.56 min (method B).</div></div><div id="sec5_1_22_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> (<i>R</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)-2-phenylacetamide (<b>31</b>)</h5><div class="NLM_p last">Compound <b>31</b> was prepared from 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) and (<i>R</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)-2-phenylacetic acid according to the representative two-step procedure described for the synthesis of <b>11</b>. The product was purified by preparative reverse phase HPLC (method E) to afford <b>31</b> (12 mg, 0.038 mmol, 36% yield, two steps). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.35 (s, 1H), 7.63 (d, <i>J</i> = 8.4 Hz, 1H), 7.58 (s, 1H), 7.50 (d, <i>J</i> = 7.3 Hz, 2H), 7.45 (s, 1H), 7.36 (t, <i>J</i> = 7.2 Hz, 3H), 7.31–7.25 (m, 1H), 4.61 (s, 1H), 3.90 (s, 3H). HRMS (ESI) <i>m/z</i>: 324.1329 [(M + H)<sup>+</sup>, calcd for C<sub>18</sub>H<sub>18</sub>N<sub>3</sub>O<sub>3</sub> 324.1348]. HPLC purity: 99%, <i>t</i><sub>R</sub> = 1.26 min (method C); 99%, <i>t</i><sub>R</sub> = 2.21 min (method D).</div></div><div id="sec5_1_22_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> (<i>R</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)-3-phenylpropanamide, TFA (<b>32</b>)</h5><div class="NLM_p last">Compound <b>32</b> was prepared from 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) and (<i>R</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)-3-phenylpropanoic acid according to the representative two-step procedure described for the synthesis of <b>11</b>. The product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>32</b> (38 mg, 0.084 mmol, 78% yield, two steps) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.60 (s, 1H), 8.42 (s, 1H), 8.39–8.30 (m, 2H), 7.70 (d, <i>J</i> = 8.3 Hz, 1H), 7.50 (s, 1H), 7.40–7.33 (m, 3H), 7.32–7.25 (m, 4H), 4.17 (br. s., 1H), 3.93 (s, 3H), 3.20 (dd, <i>J</i> = 14.1, 6.5 Hz, 1H), 3.10 (dd, <i>J</i> = 13.8, 7.5 Hz, 1H). HRMS (ESI) <i>m/z</i>: 338.1496 [(M + H)<sup>+</sup>, calcd for C<sub>19</sub>H<sub>20</sub>N<sub>3</sub>O<sub>3</sub> 338.1505]. HPLC purity: >99%, <i>t</i><sub>R</sub> = 13.91 min (method A); >99%, <i>t</i><sub>R</sub> = 14.45 min (method B).</div></div><div id="sec5_1_22_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> (<i>R</i>)-2-Amino-3-hydroxy<i>-N-</i>(3-methoxy-4-(oxazol-5-yl)phenyl)propanamide (<b>33</b>)</h5><div class="NLM_p">Step 1: To a solution of 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) (200 mg, 1.05 mmol), (<i>R</i>)-3-(benzyloxy)-2-(<i>tert</i>-butoxycarbonylamino)propanoic acid (456 mg, 1.58 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.735 mL, 4.20 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) at room temperature was added HATU (600 mg, 1.58 mmol). The reaction mixture was stirred at room temperature for 16 h. The reaction mixture was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (5 mL). The aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine (5 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (25% EtOAc with 1% MeOH/75% hexanes–50% EtOAc with 1% MeOH/50% hexanes; 40 g column) to afford (<i>R</i>)-<i>tert</i>-butyl (3-(benzyloxy)-1-((3-methoxy-4-(oxazol-5-yl)phenyl)amino)-1-oxopropan-2-yl)carbamate (300 mg, 0.642 mmol, 61% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.29 (s, 1H), 8.40 (s, 1H), 7.66 (d, <i>J</i> = 8.5 Hz, 1H), 7.56 (d, <i>J</i> = 1.5 Hz, 1H), 7.47 (s, 1H), 7.36 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 7.33–7.25 (m, 5H), 7.12 (br d, <i>J</i> = 7.8 Hz, 1H), 4.53 (d, <i>J</i> = 1.8 Hz, 2H), 4.42 (q, <i>J</i> = 6.6 Hz, 1H), 3.92 (s, 3H), 3.67 (qd, <i>J</i> = 9.6, 6.7 Hz, 2H), 1.41 (s, 9H). MS (ESI) <i>m</i>/<i>z</i>: 468.2 (M + H)<sup>+</sup>.</div><div class="NLM_p">Step 2: A solution of (<i>R</i>)-<i>tert</i>-butyl 3-(benzyloxy)-1-(3-methoxy-4-(oxazol-5-yl)phenylamino)-1-oxopropan-2-ylcarbamate (250 mg, 0.530 mmol) in MeOH (25 mL) was stirred for 5 min at room temperature and treated with 10% palladium on carbon (50 mg, 0.05 mmol). The resultant mixture was stirred under 45 psi hydrogen atmosphere for 14 h, after which the mixture was filtered through a pad of Celite. The filtrate was concentrated under reduced pressure, and the product was purified by column chromatography on silica gel (4–8% MeOH in CH<sub>2</sub>Cl<sub>2</sub>; 24 g column) to afford (<i>R</i>)-<i>tert</i>-butyl 3-hydroxy-1-(3-methoxy-4-(oxazol-5-yl)phenylamino)-1-oxopropan-2-ylcarbamate (80 mg, 0.212 mmol, 40% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.05 (br s, 1H), 7.90 (s, 1H), 7.67 (d, <i>J</i> = 8.3 Hz, 1H), 7.53 (d, <i>J</i> = 1.8 Hz, 1H), 7.48 (s, 1H), 6.98 (dd, <i>J</i> = 8.3, 1.8 Hz, 1H), 5.78 (br d, <i>J</i> = 7.3 Hz, 1H), 4.34 (br s, 1H), 4.29–4.22 (m, 1H), 3.96 (s, 3H), 3.82–3.73 (m, 1H), 1.51 (s, 9H). MS (ESI) <i>m</i>/<i>z</i>: 378.0 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Step 3: To a solution of (<i>R</i>)-<i>tert</i>-butyl 3-hydroxy-1-(3-methoxy-4-(oxazol-5-yl)phenylamino)-1-oxopropan-2-ylcarbamate (30 mg, 0.079 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) at 0 °C was added TFA, and the mixture was stirred for 3 h at room temperature. Upon completion of the reaction, the volatiles were removed under reduced pressure and the residue was washed with Et<sub>2</sub>O (2 × 3 mL). The residue was transferred to a separatory funnel containing saturated aqueous Na<sub>2</sub>CO<sub>3</sub> solution (10 mL), and the aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (5 × 3 mL). The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure to afford <b>33</b> (9.5 mg, 0.034 mmol, 43% yield) as an off-white solid, which was isolated as the free base. The product was purified further by preparative reverse phase HPLC (mobile phase: MeOH/water with 20 mM ammonium acetate; column: Waters 19 × 100 mm, C18, 5 μm; λ = 220 nm). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.22 (s, 1H), 7.74 (d, <i>J</i> = 8.4 Hz, 1H), 7.67 (d, <i>J</i> = 1.6 Hz, 1H), 7.49 (s, 1H), 7.26 (dd, <i>J</i> = 8.4, 2 Hz, 1H), 4.01 (s, 3H), 3.84 (d, <i>J</i> = 5.2 Hz, 2H), 3.67–3.61 (m, 1H). HRMS (ESI) <i>m/</i>z: 278.1135 [(M + H)<sup>+</sup>, calcd for C<sub>13</sub>H<sub>16</sub>N<sub>3</sub>O<sub>4</sub>, 278.1141]. HPLC purity: 97%, <i>t</i><sub>R</sub> = 7.09 min (method I); 97%, <i>t</i><sub>R</sub> = 8.09 min (method J).</div></div><div id="sec5_1_22_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> (2<i>R</i>,3<i>S</i>)-2-Amino-3-hydroxy<i>-N-</i>(3-methoxy-4-(oxazol-5-yl)phenyl)butanamide, TFA (<b>34</b>)</h5><div class="NLM_p">Step 1: To a solution of 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) (50 mg, 0.263 mmol) and <i>O</i>-benzyl-<i>N</i>-(<i>tert</i>-butoxycarbonyl)-<span class="smallcaps smallerCapital">d</span>-threonine (122 mg, 0.394 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was added <i>N</i>,<i>N</i>-diisopropylethylamine (0.230 mL, 1.314 mmol) followed by HATU (150 mg, 0.394 mmol). The reaction mixture was stirred at room temperature for 14 h. The mixture was transferred to a separatory funnel containing water (10 mL). The aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine (10 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (30% EtOAc with 1% MeOH/70% hexanes–60% EtOAc with 1% MeOH/40% hexanes; 40 g column) to afford <i>tert</i>-butyl ((2<i>R</i>,3<i>S</i>)-3-(benzyloxy)-1-((3-methoxy-4-(oxazol-5-yl)phenyl)amino)-1-oxobutan-2-yl)carbamate (120 mg, 0.249 mmol, 95% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.16 (s, 1H), 8.40 (s, 1H), 7.67 (d, <i>J</i> = 8.5 Hz, 1H), 7.51 (d, <i>J</i> = 1.8 Hz, 1H), 7.47 (s, 1H), 7.33 (dd, <i>J</i> = 8.7, 1.6 Hz, 1H), 7.31–7.21 (m, 5H), 6.70 (br d, <i>J</i> = 9.0 Hz, 1H), 4.61–4.54 (m, 1H), 4.50–4.43 (m, 1H), 4.26 (br dd, <i>J</i> = 8.9, 4.6 Hz, 1H), 3.96–3.89 (m, 4H), 1.41 (s, 9H), 1.18 (br d, <i>J</i> = 6.0 Hz, 3H). MS (ESI) <i>m</i>/<i>z</i>: 482.2 (M + H)<sup>+</sup>.</div><div class="NLM_p">Step 2: To a solution of <i>tert</i>-butyl ((2<i>R</i>,3<i>S</i>)-3-(benzyloxy)-1-((3-methoxy-4-(oxazol-5-yl)phenyl)amino)-1-oxobutan-2-yl)carbamate (105 mg, 0.218 mmol) in MeOH (15 mL) in a Parr bottle was added 10% palladium on carbon (Degussa type) (46.4 mg, 0.022 mmol). The mixture was placed under a H<sub>2</sub> atmosphere (45 psi) on the Parr shaker for 14 h. The mixture was filtered through a pad of Celite, and the filtrate was concentrated. The product was purified by column chromatography on silica gel (4–8% MeOH in CH<sub>2</sub>Cl<sub>2</sub>; 24 g column) to afford <i>tert</i>-butyl ((2<i>R</i>,3<i>S</i>)-3-hydroxy-1-((3-methoxy-4-(oxazol-5-yl)phenyl)amino)-1-oxobutan-2-yl)carbamate (49.1 mg, 0.125 mmol, 58% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.10 (s, 1H), 8.43–8.35 (m, 1H), 7.65 (d, <i>J</i> = 8.5 Hz, 1H), 7.55 (d, <i>J</i> = 1.8 Hz, 1H), 7.46 (s, 1H), 7.34 (dd, <i>J</i> = 8.7, 1.6 Hz, 1H), 6.48 (br d, <i>J</i> = 8.3 Hz, 1H), 4.89 (d, <i>J</i> = 6.3 Hz, 1H), 4.06–4.00 (m, 1H), 3.92 (s, 3H), 1.41 (s, 9H), 1.12 (br d, <i>J</i> = 5.8 Hz, 3H). MS (ESI) <i>m</i>/<i>z</i>: 392.1 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Step 3: To a solution of <i>tert</i>-butyl ((2<i>R</i>,3<i>S</i>)-3-hydroxy-1-((3-methoxy-4-(oxazol-5-yl)phenyl)amino)-1-oxobutan-2-yl)carbamate (35 mg, 0.089 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was added TFA (0.5 mL, 6.49 mmol). The reaction mixture was stirred at room temperature for 2 h. The mixture was concentrated and was purified by reverse phase HPLC (method H) and lyophilized to afford <b>34</b> (36 mg, 0.089 mmol, 99% yield) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.70 (s, 1H), 8.42 (s, 1H), 8.24 (br d, <i>J</i> = 3.8 Hz, 3H), 7.71 (d, <i>J</i> = 8.5 Hz, 1H), 7.54–7.45 (m, 2H), 7.36 (dd, <i>J</i> = 8.5, 1.8 Hz, 1H), 4.07 (br t, <i>J</i> = 6.1 Hz, 1H), 3.94 (s, 3H), 3.76 (br t, <i>J</i> = 5.5 Hz, 1H), 1.22 (d, <i>J</i> = 6.5 Hz, 3H). HRMS (ESI) <i>m/</i>z: 292.1297 [(M + H)<sup>+</sup>, calcd for C<sub>14</sub>H<sub>18</sub>N<sub>3</sub>O<sub>4</sub>, 292.1297]. HPLC purity: 98.3%, <i>t</i><sub>R</sub> = 3.67 min (method K); 99.2%, <i>t</i><sub>R</sub> = 4.03 min (method L).</div></div><div id="sec5_1_22_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> (<i>R</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)-<i>N</i>,4-dimethylpentanamide (<b>35</b>)</h5><div class="NLM_p last">(<i>R</i>)-<i>tert</i>-Butyl 1-((3-methoxy-4-(oxazol-5-yl)phenyl)(methyl)amino)-4-methyl-1-oxopentan-2-ylcarbamate (<b>68</b>) (160 mg, 0.383 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) and cooled to 0 °C. To this solution was added TFA (0.295 mL, 3.83 mmol). The reaction mixture was stirred at room temperature for 12 h. The solvent was evaporated, and the reaction mixture was purified by column chromatography on silica gel (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford <b>35</b> (115 mg, 0.360 mmol, 94% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.49 (s, 1H), 8.09 (d, <i>J</i> = 5.54 Hz, 3H), 7.82 (d, <i>J</i> = 8.31 Hz, 1H), 7.62 (s, 1H), 7.32 (s, 1H), 7.16 (d, <i>J</i> = 8.31 Hz, 1H), 3.97 (s, 3H), 3.93–3.83 (m, 1H), 3.28 (s, 3H), 1.62–1.36 (m, 3H), 0.65 (d, <i>J</i> = 6.30 Hz, 3H), 0.38 (d, <i>J</i> = 6.30 Hz, 3H). HRMS (ESI) <i>m/z</i>: 318.1819 [(M + H)<sup>+</sup>, calcd for C<sub>17</sub>H<sub>24</sub>N<sub>3</sub>O<sub>3</sub> 318.1818]. HPLC purity: 95%, <i>t</i><sub>R</sub> = 8.04 min (method E); 97%, <i>t</i><sub>R</sub> = 8.29 min (method F).</div></div><div id="sec5_1_22_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> <i>N</i>-(3-Methoxy-4-(oxazol-5-yl)phenyl)-4-methylpentanamide (<b>36</b>)</h5><div class="NLM_p last">To a mixture of 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) (50 mg, 0.263 mmol), 4-methylpentanoic acid (45.8 mg, 0.394 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.184 mL, 1.052 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) was added HATU (150 mg, 0.394 mmol). The reaction mixture was stirred at room temperature for 18 h. The reaction mixture was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (5 mL). The aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine (10 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (40–70% EtOAc in hexanes; 12 g column) to afford <b>36</b> (51 mg, 0.177 mmol, 67% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.08 (s, 1H), 8.37 (s, 1H), 7.61 (d, <i>J</i> = 8.3 Hz, 1H), 7.55 (d, <i>J</i> = 1.5 Hz, 1H), 7.43 (s, 1H), 7.28 (dd, <i>J</i> = 8.6, 1.8 Hz, 1H), 3.90 (s, 3H), 2.33 (t, <i>J</i> = 7.6 Hz, 2H), 1.62–1.46 (m, 3H), 0.90 (d, <i>J</i> = 6.3 Hz, 6H). HRMS (ESI) <i>m/z</i>: 289.1552 [(M + H)<sup>+</sup>, calcd for C<sub>16</sub>H<sub>21</sub>N<sub>2</sub>O<sub>3</sub> 289.1552]. HPLC purity: >99%, <i>t</i><sub>R</sub> = 12.81 min (method E); >99%, <i>t</i><sub>R</sub> = 11.27 min (method F).</div></div><div id="sec5_1_22_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> 2-Cyclopentyl-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)acetamide (<b>37</b>)</h5><div class="NLM_p last">Compound <b>37</b> was prepared from 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) (100 mg, 0.526 mmol) and 2-cyclopentylacetic acid (101 mg, 0.789 mmol) according to the procedure described for the synthesis of <b>36</b>. The product was purified by column chromatography on silica gel (20–40% EtOAc in hexanes; 25 g column) to afford <b>37</b> (65 mg, 0.216 mmol, 41% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.07 (s, 1H), 8.38 (s, 1H), 7.62 (d, <i>J</i> = 8.5 Hz, 1H), 7.58 (d, <i>J</i> = 1.8 Hz, 1H), 7.45 (s, 1H), 7.30 (dd, <i>J</i> = 8.5, 1.8 Hz, 1H), 3.91 (s, 3H), 2.37–2.31 (m, 2H), 2.25 (dt, <i>J</i> = 14.8, 7.4 Hz, 1H), 1.83–1.71 (m, 2H), 1.67–1.48 (m, 4H), 1.27–1.14 (m, 2H). HRMS (ESI) <i>m/z</i>: 301.1553 [(M + H)<sup>+</sup>, calcd for C<sub>17</sub>H<sub>21</sub>N<sub>2</sub>O<sub>3</sub> 301.1552]. HPLC purity: 98%, <i>t</i><sub>R</sub> = 13.25 min (method E); 98%, <i>t</i><sub>R</sub> = 12.00 min (method F).</div></div><div id="sec5_1_22_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> <i>N</i>-(3-Methoxy-4-(oxazol-5-yl)phenyl)-2-phenylacetamide (<b>38</b>)</h5><div class="NLM_p last">Compound <b>38</b> was prepared from 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) (20 mg, 0.105 mmol) and 2-phenylacetic acid (22 mg, 0.158 mmol) according to the procedure described for the synthesis of <b>36</b>. The product was purified by preparative reverse phase HPLC (method F) to afford <b>38</b> (13 mg, 0.042 mmol, 40% yield). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.38 (s, 1H), 8.37 (s, 1H), 7.63 (d, <i>J</i> = 8.4 Hz, 1H), 7.57 (s, 1H), 7.44 (s, 1H), 7.37–7.31 (m, 4H), 7.31–7.22 (m, 2H), 3.90 (s, 3H), 3.67 (s, 2H). HRMS (ESI) <i>m/z</i>: 309.1240 [(M + H)<sup>+</sup>, calcd for C<sub>18</sub>H<sub>17</sub>N<sub>2</sub>O<sub>3</sub> 309.1239]. HPLC purity: >99%, <i>t</i><sub>R</sub> = 1.52 min (method C); >99%, <i>t</i><sub>R</sub> = 2.35 min (method D).</div></div><div id="sec5_1_22_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> (<i>R</i>)-<i>N</i>-(3-Methoxy-4-(oxazol-5-yl)phenyl)piperidine-2-carboxamide, TFA (<b>39</b>)</h5><div class="NLM_p last">Compound <b>39</b> was prepared from 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) and (<i>R</i>)-1-(<i>tert</i>-butoxycarbonyl)piperidine-2-carboxylic acid according to the representative two-step procedure described for the synthesis of <b>11</b>. The product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>39</b> (36 mg, 0.086 mmol, 61% yield, two steps) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.69 (s, 1H), 8.99 (d, <i>J</i> = 10.5 Hz, 1H), 8.90–8.81 (m, <i>J</i> = 10.8 Hz, 1H), 8.42 (s, 1H), 7.71 (d, <i>J</i> = 8.5 Hz, 1H), 7.50 (s, 1H), 7.46 (d, <i>J</i> = 1.8 Hz, 1H), 7.37 (dd, <i>J</i> = 8.5, 1.8 Hz, 1H), 3.94 (s, 3H), 3.94–3.87 (m, 1H), 3.32 (d, <i>J</i> = 11.5 Hz, 1H), 3.10–2.95 (m, <i>J</i> = 11.3 Hz, 1H), 2.25 (d, <i>J</i> = 12.0 Hz, 1H), 1.86 (d, <i>J</i> = 12.3 Hz, 1H), 1.80–1.72 (m, 1H), 1.70–1.49 (m, 3H). HRMS (ESI) <i>m/z</i>: 302.1497 [(M + H)<sup>+</sup>, calcd for C<sub>16</sub>H<sub>20</sub>N<sub>3</sub>O<sub>3</sub> 302.1505]. HPLC purity: >99%, <i>t</i><sub>R</sub> = 12.25 min (method A); >99%, <i>t</i><sub>R</sub> = 13.01 min (method B).</div></div><div id="sec5_1_22_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> (<i>rac</i>)-3-Isopropyl-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)piperidine-2-carboxamide, TFA (<b>(<i>rac</i>)-40</b>)</h5><div class="NLM_p last">To a solution of <i>tert</i>-butyl 3-isopropyl-2-((3-methoxy-4-(oxazol-5-yl)phenyl)carbamoyl)piperidine-1-carboxylate (<b>(<i>rac</i>)-74</b>) (45 mg, 0.101 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was added TFA (0.5 mL, 6.49 mmol). The reaction mixture was stirred at room temperature for 2 h. The mixture was concentrated and was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>(<i>rac</i>)-40</b> (35.2 mg, 0.076 mmol, 75% yield) as a white amorphous solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>, 60 °C) δ 10.63 (br s, 1H), 8.35 (s, 1H), 7.69 (br d, <i>J</i> = 8.4 Hz, 1H), 7.49–7.45 (m, 2H), 7.37–7.32 (m, 1H), 4.12 (br s, 1H), 3.94 (s, 3H), 3.51–3.41 (m, 1H), 3.17–3.08 (m, 1H), 2.00–1.90 (m, 2H), 1.8–1.81 (m, 2H), 1.70–1.61 (m, 2H), 0.94 (br d, <i>J</i> = 6.4 Hz, 3H), 0.89 (br d, <i>J</i> = 6.7 Hz, 3H). HRMS (ESI) <i>m/z</i>: 344.1968 [(M + H)<sup>+</sup>, calcd for C<sub>19</sub>H<sub>26</sub>N<sub>3</sub>O<sub>3</sub> 344.1974]. HPLC purity: >99%, <i>t</i><sub>R</sub> = 14.49 min (method A); >99%, <i>t</i><sub>R</sub> = 14.89 min (method B).</div></div><div id="sec5_1_22_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85"> (2<i>R</i>,3<i>R</i>)-3-Isopropyl-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)piperidine-2-carboxamide, TFA (<b>(2<i>R</i>,3<i>R</i>)-40</b>)</h5><div class="NLM_p last">To a solution of <i>tert</i>-butyl (<i>2R</i>,<i>3R</i>)-3-isopropyl-2-((3-methoxy-4-(oxazol-5-yl)phenyl)carbamoyl)piperidine-1-carboxylate (<b>(2<i>R</i>,3<i>R</i>)-74</b>) (75 mg, 0.169 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was added TFA (0.5 mL, 6.49 mmol). The reaction mixture was stirred at room temperature for 2 h. The mixture was concentrated, and the product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>(2<i>R</i>,3<i>R</i>)-40</b> (75.5 mg, 0.163 mmol, 97% yield) as a white amorphous solid. [α]<sub>D</sub><sup>22</sup> −22.3 (<i>c</i> 0.275, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.69 (s, 1H), 9.08–8.95 (m, 2H), 8.39 (s, 1H), 7.70 (d, <i>J</i> = 8.4 Hz, 1H), 7.49 (s, 1H), 7.46 (d, <i>J</i> = 1.7 Hz, 1H), 7.35 (dd, <i>J</i> = 8.5, 1.7 Hz, 1H), 4.11 (br. s., 1H), 3.94 (s, 3H), 3.42 (br. s., 1H), 3.12 (br. s., 1H), 1.98–1.88 (m, 2H), 1.87–1.73 (m, 2H), 1.68–1.59 (m, 2H), 0.92 (d, <i>J</i> = 6.6 Hz, 3H), 0.88 (d, <i>J</i> = 6.6 Hz, 3H). HRMS (ESI) <i>m/z</i>: 344.1968 (M + H)<sup>+</sup>, calcd for C<sub>19</sub>H<sub>26</sub>N<sub>3</sub>O<sub>3</sub> 344.1974]. HPLC purity: >99%, <i>t</i><sub>R</sub> = 14.53 min (method A); >99%, <i>t</i><sub>R</sub> = 14.97 min (method B). The absolute stereochemistry was determined by an X-ray crystal structure of <b>(2<i>R</i>,3<i>R</i>)-40</b> complexed with AAK1.</div></div><div id="sec5_1_22_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i86" class="anchor-spacer"></div><h5 class="article-section__title" id="_i86"> (2<i>S</i>,3<i>S</i>)-3-Isopropyl-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)piperidine-2-carboxamide, TFA <b>(2<i>S</i>,3<i>S</i>)-40</b>)</h5><div class="NLM_p last">To a solution of <i>tert</i>-butyl (<i>2S</i>,<i>3S</i>)-3-isopropyl-2-((3-methoxy-4-(oxazol-5-yl)phenyl)carbamoyl)piperidine-1-carboxylate (<b>(2<i>S</i>,3<i>S</i>)-74</b>) (82 mg, 0.185 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was added TFA (0.5 mL, 6.49 mmol). The reaction mixture was stirred at room temperature for 2 h. The mixture was concentrated, and the product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>(2<i>S</i>,3<i>S</i>)-40</b> (83.0 mg, 0.180 mmol, 97% yield) as a white amorphous solid. [α]<sub>D</sub><sup>22</sup> +22.9 (<i>c</i> 0.285, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.69 (s, 1H), 9.07–8.95 (m, 2H), 8.39 (s, 1H), 7.70 (d, <i>J</i> = 8.5 Hz, 1H), 7.49 (s, 1H), 7.46 (s, 1H), 7.35 (d, <i>J</i> = 8.5 Hz, 1H), 4.11 (br. s., 1H), 3.94 (s, 3H), 3.42 (br. s., 1H), 3.12 (br. s., 1H), 1.97–1.89 (m, 2H), 1.87–1.73 (m, 2H), 1.68–1.57 (m, 2H), 0.92 (d, <i>J</i> = 6.4 Hz, 3H), 0.88 (d, <i>J</i> = 6.6 Hz, 3H). HRMS (ESI) <i>m/z</i>: 344.1969 [(M + H)<sup>+</sup>, calcd for C<sub>19</sub>H<sub>26</sub>N<sub>3</sub>O<sub>3</sub> 344.1974]. HPLC purity: >99%, <i>t</i><sub>R</sub> = 14.53 min (method A); >99%, <i>t</i><sub>R</sub> = 14.96 min (method B).</div></div><div id="sec5_1_22_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i87" class="anchor-spacer"></div><h5 class="article-section__title" id="_i87"> (<i>R</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(1<i>H</i>-pyrazol-4-yl)phenyl)-4-methylpentanamide, TFA (<b>41</b>)</h5><div class="NLM_p">Step 1: A mixture of (<i>R</i>)-<i>tert</i>-butyl (1-((4-bromo-3-methoxyphenyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (<b>76</b>) (200 mg, 0.482 mmol), 1<i>H</i>-pyrazol-4-ylboronic acid (81 mg, 0.722 mmol), Na<sub>2</sub>CO<sub>3</sub> (2 M aq) (0.722 mL, 1.45 mmol), and tetrakis(triphenylphosphine)palladium(0) (27.8 mg, 0.024 mmol) in DME (4 mL) was heated to 90 °C under a N<sub>2</sub> atmosphere for 16 h. The mixture was cooled to room temperature. The mixture was transferred to a separatory funnel containing water (25 mL). The aqueous layer was extracted with EtOAc (3 × 25 mL). The combined organic layers were washed with brine (25 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (30% EtOAc in hexanes followed by 10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>, 12 g column) to afford (<i>R</i>)-<i>tert</i>-butyl (1-((3-methoxy-4-(1<i>H</i>-pyrazol-4-yl)phenyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (90 mg, 0.224 mmol, 46% yield) as a yellow solid. MS (ESI) <i>m</i>/<i>z</i>: 403.2 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Step 2: (<i>R</i>)-<i>tert</i>-Butyl (1-((3-methoxy-4-(1<i>H</i>-pyrazol-4-yl)phenyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (70 mg, 0.174 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) and cooled to 0 °C. To this solution was added TFA (1 mL, 12.98 mmol). The reaction mixture was stirred at room temperature for 2 h. The solvent was evaporated, and the product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>41</b> (18 mg, 0.043 mmol, 25% yield). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 8.09 (br s, 2H), 7.58 (d, <i>J</i> = 8.2 Hz, 1H), 7.50 (d, <i>J</i> = 2.1 Hz, 1H), 7.19 (dd, <i>J</i> = 8.2, 1.8 Hz, 1H), 4.05–4.00 (m, 1H), 3.94 (s, 3H), 1.86–1.75 (m, 3H), 1.08 (d, <i>J</i> = 2.4 Hz, 3H), 1.06 (d, <i>J</i> = 2.4 Hz, 3H). HRMS (ESI) <i>m/z</i>: 303.1824 [(M + H)<sup>+</sup>, calcd for C<sub>16</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub> 303.1821]. HPLC purity: 100%, <i>t</i><sub>R</sub> = 7.01 min (method E); 100%, <i>t</i><sub>R</sub> = 7.01 min (method F).</div></div><div id="sec5_1_22_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i88" class="anchor-spacer"></div><h5 class="article-section__title" id="_i88"> (<i>R</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(2<i>H</i>-1,2,3-triazol-4-yl)phenyl)-4-methylpentanamide, TFA (<b>42</b>)</h5><div class="NLM_p last">Compound <b>42</b> was prepared from 3-methoxy-4-(2<i>H</i>-1,2,3-triazol-4-yl)aniline (<b>89a</b>) (100 mg, 0.526 mmol) and (<i>R</i>)-2-(<i>tert</i>-butoxycarbonylamino)-4-methylpentanoic acid (304 mg, 1.31 mmol) according to the representative two-step procedure described for the synthesis of <b>11</b> from <b>67</b><i>,</i> except that the HATU-mediated amide forming reaction was carried out at 40 °C. The product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>42</b> (76 mg, 0.182 mmol, 40% yield, two steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.68 (s, 1H), 8.28 (br s, 3H), 8.16 (br s, 1H), 7.97 (d, <i>J</i> = 8.3 Hz, 1H), 7.47 (d, <i>J</i> = 2.0 Hz, 1H), 7.34 (dd, <i>J</i> = 8.4, 1.9 Hz, 1H), 3.95 (d, <i>J</i> = 5.3 Hz, 1H), 3.91 (s, 3H), 1.75–1.63 (m, 3H), 0.95 (d, <i>J</i> = 4.3 Hz, 6H). HRMS (ESI) <i>m/z</i>: 304.1768 [(M + H)<sup>+</sup>, calcd for C<sub>15</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub> 304.1773]. HPLC purity: 100%, <i>t</i><sub>R</sub> = 7.44 min (method E); 99.9%, <i>t</i><sub>R</sub> = 7.18 min (method F).</div></div><div id="sec5_1_22_35" class="NLM_sec NLM_sec_level_4"><div id="ac_i89" class="anchor-spacer"></div><h5 class="article-section__title" id="_i89"> (<i>R</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(1-methyl-1<i>H</i>-pyrazol-4-yl)phenyl)-4-methylpentanamide (<b>43</b>)</h5><div class="NLM_p last">Compound <b>43</b> was prepared from 3-methoxy-4-(1-methyl-1<i>H</i>-pyrazol-4-yl)aniline (<b>89b)</b> (130 mg, 0.640 mmol) and (<i>R</i>)-2-(<i>tert</i>-butoxycarbonylamino)-4-methylpentanoic acid (444 mg, 1.92 mmol) according to the representative two-step procedure described for the synthesis of <b>11</b> from <b>67</b>, except that the HATU-mediated amide forming reaction was carried out at 40 °C. The product was purified by preparative reverse phase HPLC (method A). The solvent was removed in vacuo, and the product was taken up in EtOAc and converted to the free base by washing with saturated aqueous K<sub>2</sub>CO<sub>3</sub>. After concentration, the product was taken up in acetonitrile/water and was lyophilized to afford <b>43</b> (67 mg, 0.212 mmol, 46% yield, two steps) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.03 (s, 1H), 7.82 (s, 1H), 7.53–7.46 (m, 2H), 7.24 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 3.85 (s, 3H), 3.84 (s, 3H), 3.32–3.28 (m, 1H), 1.81–1.70 (m, 1H), 1.48 (ddd, <i>J</i> = 13.5, 8.2, 5.5 Hz, 1H), 1.37–1.28 (m, 1H), 0.92 (d, <i>J</i> = 6.5 Hz, 3H), 0.89 (d, <i>J</i> = 6.5 Hz, 3H). HRMS (ESI) <i>m/z</i>: 317.1982 [(M + H)<sup>+</sup>, calcd for C<sub>17</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub> 317.1978]. HPLC purity: >99%, <i>t</i><sub>R</sub> = 7.87 min (method E): >99%, <i>t</i><sub>R</sub> = 7.86 min (method F).</div></div><div id="sec5_1_22_36" class="NLM_sec NLM_sec_level_4"><div id="ac_i90" class="anchor-spacer"></div><h5 class="article-section__title" id="_i90"> (<i>R</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(thiazol-5-yl)phenyl)-4-methylpentanamide (<b>44</b>)</h5><div class="NLM_p last">To a suspension of (<i>R</i>)-<i>tert</i>-butyl 1-(3-methoxy-4-(thiazol-5-yl)phenylamino)-4-methyl-1-oxopentan-2-ylcarbamate (<b>77</b>) (40 mg, 0.095 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) at 0 °C was added TFA (0.50 mL, 6.49 mmol). The cooling bath was removed, and the mixture was stirred at room temperature under N<sub>2</sub> for 1.5 h. The reaction mixture was concentrated, and the product was purified by preparative reverse phase HPLC (method A). The organic solvent was removed in vacuo, and the product was taken up in EtOAc and converted to the free base by washing with saturated aqueous K<sub>2</sub>CO<sub>3</sub>. The product was taken up in acetonitrile/water and was lyophilized to afford <b>44</b> (23 mg, 0.070 mmol, 74% yield) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.01 (s, 1H), 8.31 (s, 1H), 7.71 (d, <i>J</i> = 8.6 Hz, 1H), 7.60 (d, <i>J</i> = 2.0 Hz, 1H), 7.34 (dd, <i>J</i> = 8.6, 2.0 Hz, 1H), 3.89 (s, 3H), 3.36 (dd, <i>J</i> = 8.8, 5.5 Hz, 1H), 1.83–1.70 (m, 1H), 1.49 (ddd, <i>J</i> = 13.5, 8.2, 5.5 Hz, 1H), 1.39–1.30 (m, 1H), 0.92 (d, <i>J</i> = 6.5 Hz, 3H), 0.89 (d, <i>J</i> = 6.5 Hz, 3H). HRMS (ESI) <i>m/</i>z: 320.1434 [(M + H)<sup>+</sup>, calcd for C<sub>16</sub>H<sub>22</sub>N<sub>3</sub>O<sub>2</sub>S 320.1433]. HPLC purity: >99%, <i>t</i><sub>R</sub> = 7.64 min (method A); >99%, <i>t</i><sub>R</sub> = 7.78 min (method B).</div></div><div id="sec5_1_22_37" class="NLM_sec NLM_sec_level_4"><div id="ac_i91" class="anchor-spacer"></div><h5 class="article-section__title" id="_i91"> (<i>R</i>)-<i>N</i>-(4-(1<i>H</i>-Imidazol-1-yl)-3-methoxyphenyl)-2-amino-4-methylpentanamide, TFA (<b>45</b>)</h5><div class="NLM_p last">Compound <b>45</b> was prepared from 4-(1<i>H</i>-imidazol-1-yl)-3-methoxyaniline (<b>89c</b>) (180 mg, 0.951 mmol) and (<i>R</i>)-2-(<i>tert</i>-butoxycarbonylamino)-4-methylpentanoic acid (330 mg, 1.43 mmol) in two steps in a similar fashion as described for the synthesis of <b>11</b> from <b>67</b>. The product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>45</b> (70 mg, 0.168 mmol, 18% yield, two steps) as a green solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 9.21 (br. s., 1H), 7.80 (br. s., 1H), 7.74 (d, <i>J</i> = 1.8 Hz, 1H), 7.69 (br. s., 1H), 7.52 (d, <i>J</i> = 8.6 Hz, 1H), 7.38 (dd, <i>J</i> = 8.6, 1.8 Hz, 1H), 4.06 (t, <i>J</i> = 6.9 Hz, 1H), 3.90 (s, 3H), 1.86–1.70 (m, 3H), 1.02 (d, <i>J</i> = 6.3 Hz, 6H). HRMS (ESI) <i>m/z</i>: 303.1823 [(M + H)<sup>+</sup>, calcd for C<sub>16</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub> 303.1821]. HPLC purity: 96.4%, <i>t</i><sub>R</sub> = 5.63 min (method E); 98.4%, <i>t</i><sub>R</sub> = 5.75 min (method F).</div></div><div id="sec5_1_22_38" class="NLM_sec NLM_sec_level_4"><div id="ac_i92" class="anchor-spacer"></div><h5 class="article-section__title" id="_i92"> (<i>R</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(1<i>H</i>-1,2,4-triazol-1-yl)phenyl)-4-methylpentanamide, TFA (<b>46</b>)</h5><div class="NLM_p last">Compound <b>46</b> was prepared from 3-methoxy-4-(1<i>H</i>-1,2,4-triazol-1-yl)aniline (<b>89d</b>) (50 mg, 0.263 mmol) and (<i>R</i>)-2-(<i>tert</i>-butoxycarbonylamino)-4-methylpentanoic acid (182 mg, 0.789 mmol) in two steps in a similar fashion as described for the synthesis of <b>11</b> from <b>67</b>. The product was purified by column chromatography on silica gel (10% 2 M ammonia in MeOH/90% CH<sub>2</sub>Cl<sub>2</sub>) to afford <b>46</b> (60 mg, 0.144 mmol, 55% yield, two steps) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.85 (s, 1H), 8.11 (s, 1H), 7.70 (br. s., 1H), 7.63 (d, <i>J</i> = 8.6 Hz, 1H), 7.30 (d, <i>J</i> = 8.3 Hz, 1H), 3.99 (br. s., 1H), 3.91 (s, 3H), 1.78 (d, <i>J</i> = 3.0 Hz, 3H), 1.02 (d, <i>J</i> = 3.8 Hz, 6H). HRMS (ESI) <i>m/z</i>: 304.1761 [(M + H)<sup>+</sup>, calcd for C<sub>15</sub>H<sub>22</sub>N<sub>5</sub>O<sub>2</sub> 304.1773]. HPLC purity: >99%, <i>t</i><sub>R</sub> = 7.23 min (method E); >99%, <i>t</i><sub>R</sub> = 7.17 min (method F).</div></div><div id="sec5_1_22_39" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> (<i>R</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(pyridin-4-yl)phenyl)-4-methylpentanamide (<b>47</b>)</h5><div class="NLM_p">Step 1: To a mixture of (<i>R</i>)-<i>tert</i>-butyl 1-(4-bromo-3-methoxyphenylamino)-4-methyl-1-oxopentan-2-ylcarbamate (<b>76</b>) (200 mg, 0.482 mmol) and 4-pyridinylboronic acid (65.1 mg, 0.530 mmol) in toluene (4 mL) and ethanol (1 mL) under N<sub>2</sub> was added a solution of Na<sub>2</sub>CO<sub>3</sub> (153 mg, 1.445 mmol) in water (1 mL). Tetrakis(triphenylphosphine)palladium(0) (27.8 mg, 0.024 mmol) was added, and the reaction was heated at reflux for 12 h. The mixture was transferred to a separatory funnel containing water. The aqueous layer was extracted with EtOAc (3 × 25 mL). The combined organic layers were concentrated, and the product was purified by column chromatography on silica gel (10–50% EtOAc in hexanes) to afford (<i>R</i>)-<i>tert</i>-butyl 1-(3-methoxy-4-(pyridin-4-yl)phenylamino)-4-methyl-1-oxopentan-2-ylcarbamate (151 mg, 0.366 mmol, 76% yield) as a yellow solid. MS (ESI) <i>m</i>/<i>z</i>: 414.3 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Step 2: To a solution of (<i>R</i>)-<i>tert</i>-butyl 1-(3-methoxy-4-(pyridin-4-yl)phenylamino)-4-methyl-1-oxopentan-2-ylcarbamate (150 mg, 0.363 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) at 0 °C was added TFA (1 mL, 13.0 mmol). The reaction mixture was stirred at room temperature for 2 h. The mixture was concentrated in vacuo and was purified by preparative reverse phase HPLC (method A). The organic solvent was removed in vacuo, and the product was taken up in EtOAc and converted to the free base by washing with saturated aqueous NaHCO<sub>3</sub> to afford <b>47</b> (71 mg, 0.227 mmol, 63% yield) as a colorless viscous oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.55 (d, <i>J</i> = 6.0 Hz, 2H), 7.56 (d, <i>J</i> = 1.5 Hz, 1H), 7.51 (dd, <i>J</i> = 4.5, 1.5 Hz, 2H), 7.42–7.32 (m, 2H), 3.79 (s, 3H), 3.38–3.34 (m, 1H), 1.82–1.73 (m, 1H), 1.49 (ddd, <i>J</i> = 13.4, 8.1, 5.4 Hz, 1H), 1.40–1.30 (m, 1H), 0.92 (d, <i>J</i> = 6.5 Hz, 3H), 0.90 (d, <i>J</i> = 6.5 Hz, 3H). HRMS (ESI) <i>m/z</i>: 314.1863 [(M + H)<sup>+</sup>, calcd for C<sub>18</sub>H<sub>24</sub>N<sub>3</sub>O<sub>2</sub> 314.1869]. HPLC purity: 97%, <i>t</i><sub>R</sub> = 6.18 min (method E); 98%, <i>t</i><sub>R</sub> = 6.09 min (method F).</div></div><div id="sec5_1_22_40" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> (<i>R</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(pyridazin-4-yl)phenyl)-4-methylpentanamide (<b>48</b>)</h5><div class="NLM_p last">Compound <b>48</b> was prepared from 3-methoxy-4-(pyridazin-4-yl)aniline (<b>89e</b>) (142 mg, 0.706 mmol) and (<i>R</i>)-2-(<i>tert</i>-butoxycarbonylamino)-4-methylpentanoic acid (490 mg, 2.12 mmol) in two steps in a similar fashion as described for the synthesis of <b>11</b> from <b>67</b>, except that the HATU-mediated amide forming reaction was carried out at 40 °C. The product was purified by preparative reverse phase HPLC (method A). The solvent was removed in vacuo, and the product was taken up in EtOAc and converted to the free base by washing with saturated aqueous K<sub>2</sub>CO<sub>3</sub>. The product was taken up in acetonitrile/water and was lyophilized to afford <b>48</b> (40 mg, 0.123 mmol, 17% yield, two steps) as a white amorphous solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.42 (br s, 1H), 9.20 (d, <i>J</i> = 5.5 Hz, 1H), 7.85–7.78 (m, 1H), 7.61 (s, 1H), 7.52 (d, <i>J</i> = 8.5 Hz, 1H), 7.44 (d, <i>J</i> = 8.5 Hz, 1H), 3.84 (s, 3H), 3.45–3.36 (m, 1H), 1.83–1.72 (m, 1H), 1.57–1.47 (m, 1H), 1.44–1.31 (m, 1H), 0.93 (d, <i>J</i> = 6.7 Hz, 3H), 0.91 (d, <i>J</i> = 6.4 Hz, 3H). HRMS (ESI) <i>m/z</i>: 315.1803 [(M + H)<sup>+</sup>, calcd for C<sub>17</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub> 315.1821]. HPLC purity: 98%, <i>t</i><sub>R</sub> = 6.81 min (method E); HPLC 98%, <i>t</i><sub>R</sub> = 6.41 min (method F).</div></div><div id="sec5_1_22_41" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> (<i>R</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(pyrimidin-4-yl)phenyl)-4-methylpentanamide, TFA (<b>49</b>)</h5><div class="NLM_p last">Compound <b>49</b> was prepared from 3-methoxy-4-(pyrimidin-4-yl)aniline (<b>89f</b>) (44 mg, 0.219 mmol) and (<i>R</i>)-2-(<i>tert</i>-butoxycarbonylamino)-4-methylpentanoic acid in two steps in a similar fashion as described for the synthesis of <b>11</b> from <b>67</b>. The product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>49</b> (50 mg, 0.117 mmol, 74% yield, two steps) as a yellow amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.77 (s, 1H), 9.22 (d, <i>J</i> = 1.3 Hz, 1H), 8.78 (d, <i>J</i> = 5.5 Hz, 1H), 8.29 (br. s., 2H), 8.11–8.01 (m, 2H), 7.54 (d, <i>J</i> = 2.0 Hz, 1H), 7.41 (dd, <i>J</i> = 8.7, 1.9 Hz, 1H), 3.98 (br. s., 1H), 3.91 (s, 3H), 1.76–1.68 (m, 3H), 0.96 (d, <i>J</i> = 5.8 Hz, 6H). MS (ESI) <i>m/z</i>: 315.2 (M + H)<sup>+</sup>. HPLC purity: >99%, <i>t</i><sub>R</sub> = 13.20 min (method A); >99%, <i>t</i><sub>R</sub> = 13.61 min (method B).</div></div><div id="sec5_1_22_42" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96"> (<i>R</i>)-2-Amino-<i>N</i>-(4-(2-chloropyridin-4-yl)-3-methoxyphenyl)-4-methylpentanamide, TFA (<b>50</b>)</h5><div class="NLM_p">Step 1: To a mixture of (<i>R</i>)-<i>tert</i>-butyl 1-(4-bromo-3-methoxyphenylamino)-4-methyl-1-oxopentan-2-ylcarbamate (<b>76</b>) (500 mg, 1.20 mmol), 2-chloropyridin-4-ylboronic acid (208 mg, 1.32 mmol), and tetrakis(triphenylphosphine)palladium(0) (69.6 mg, 0.060 mmol) in toluene (6 mL) and ethanol (1.5 mL) under N<sub>2</sub> was added a solution of sodium carbonate (383 mg, 3.61 mmol) in water (1 mL). The reaction mixture was heated at reflux for 12 h. The reaction mixture was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (25 mL). The aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with brine (15 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (40–50% EtOAc in hexanes; 12 g column) to afford (<i>R</i>)-<i>tert</i>-butyl 1-(4-(2-chloropyridin-4-yl)-3-methoxyphenylamino)-4-methyl-1-oxopentan-2-ylcarbamate (95 mg, 0.212 mmol, 18% yield) as a white solid. MS (ESI) <i>m</i>/<i>z</i>: 448.3 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Step 2: (<i>R</i>)-<i>tert</i>-Butyl 1-(4-(2-chloropyridin-4-yl)-3-methoxyphenylamino)-4-methyl-1-oxopentan-2-ylcarbamate (95 mg, 0.212 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) and cooled to 0 °C. To this solution was added TFA (0.163 mL, 2.121 mmol). The reaction mixture was stirred at room temperature for 12 h. The solvent was evaporated, and the product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>50</b> (60 mg, 0.130 mmol, 61% yield) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.80 (s, 1H), 8.41 (d, <i>J</i> = 5.3 Hz, 1H), 8.31 (br. s., 3H), 7.63 (d, <i>J</i> = 1.3 Hz, 1H), 7.56 (dd, <i>J</i> = 5.3, 1.5 Hz, 1H), 7.51–7.44 (m, 2H), 7.41–7.36 (m, 1H), 3.97 (d, <i>J</i> = 5.0 Hz, 1H), 3.82 (s, 3H), 1.74–1.64 (m, 3H), 0.94 (d, <i>J</i> = 5.5 Hz, 6H). HRMS (ESI) <i>m/z</i>: 348.1460 [(M + H)<sup>+</sup>, calcd for C<sub>18</sub>H<sub>23</sub>N<sub>3</sub>O<sub>2</sub>Cl 348.1479]. HPLC purity: >95%, <i>t</i><sub>R</sub> = 9.16 min (method A); >95%, <i>t</i><sub>R</sub> = 9.38 min (method B).</div></div><div id="sec5_1_22_43" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97"> (<i>R</i>)-2-Amino-<i>N</i>-(4-(2-aminopyridin-4-yl)-3-methoxyphenyl)-4-methylpentanamide, TFA (<b>51</b>)</h5><div class="NLM_p last">Compound <b>51</b> was prepared from 4-(4-amino-2-methoxyphenyl)pyridin-2-amine (<b>89g</b>) (130 mg, 0.303 mmol) and (<i>R</i>)-2-(<i>tert</i>-butoxycarbonylamino)-4-methylpentanoic acid (116 mg, 0.502 mmol) in two steps in a similar fashion as described for the synthesis of <b>11</b> from <b>67</b>. The product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>51</b> (90 mg, 0.201 mmol, 48% yield, two steps). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.87 (s, 1H), 8.32 (br s, 3H), 8.00 (br s, 2H), 7.95 (d, <i>J</i> = 6.8 Hz, 1H), 7.51 (d, <i>J</i> = 6.5 Hz, 1H), 7.50 (s, 1H), 7.43 (dd, <i>J</i> = 8.5, 1.8 Hz, 1H), 7.16 (d, <i>J</i> = 1.3 Hz, 1H), 7.03 (dd, <i>J</i> = 6.8, 1.8 Hz, 1H), 4.00 (d, <i>J</i> = 9.3 Hz, 1H), 3.85 (s, 3H), 1.70 (d, <i>J</i> = 5.8 Hz, 3H), 0.96 (d, <i>J</i> = 5.8 Hz, 6H). HRMS (ESI) <i>m/z</i>: 329.1957 [(M + H)<sup>+</sup>, calcd for C<sub>18</sub>H<sub>25</sub>N<sub>4</sub>O<sub>2</sub> 329.1978]. HPLC purity: >99%, <i>t</i><sub>R</sub> = 6.50 min (method E); >99%, <i>t</i><sub>R</sub> = 7.95 min (method F).</div></div><div id="sec5_1_22_44" class="NLM_sec NLM_sec_level_4"><div id="ac_i98" class="anchor-spacer"></div><h5 class="article-section__title" id="_i98"> 2-(4-Aminopiperidin-1-yl)-<i>N</i>-(3-methoxy-4-(oxazol-5-yl)phenyl)-4-methylpentanamide, TFA (<b>52</b>)</h5><div class="NLM_p">Step 1: A mixture of (<i>R</i>)-<i>tert</i>-butyl 1-(4-(2-(benzyl(methyl)amino)pyridin-4-yl)-3-methoxyphenylamino)-4-methyl-1-oxopentan-2-ylcarbamate (<b>92</b>) (110 mg, 0.207 mmol), ammonium formate (65.1 mg, 1.03 mmol), and 10% palladium on carbon (88 mg, 0.083 mmol) in ethanol (10 mL) was heated at reflux for 2 h. The mixture was filtered through Celite, and the filtrate was concentrated. The product was purified by column chromatography on silica gel (5% MeOH in CH<sub>2</sub>Cl<sub>2</sub>; 25 g column) to afford (<i>R</i>)-<i>tert</i>-butyl 1-(3-methoxy-4-(2-(methylamino)pyridin-4-yl)phenylamino)-4-methyl-1-oxopentan-2-ylcarbamate (60 mg, 0.136 mmol, 66% yield) as a white solid. MS (ESI) <i>m</i>/<i>z</i>: 443.2 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Step 2: (<i>R</i>)-<i>tert</i>-Butyl 1-(3-methoxy-4-(2-(methylamino)pyridin-4-yl)phenylamino)-4-methyl-1-oxopentan-2-ylcarbamate (60 mg, 0.136 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) and cooled to 0 °C. To this solution was added TFA (0.104 mL, 1.356 mmol). The reaction mixture was stirred at room temperature for 12 h. The solvent was evaporated, and the product was purified by preparative reverse phase HPLC (method A) to afford <b>52</b> (25 mg, 0.055 mmol, 40% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD-<i>d</i><sub>4</sub>) δ 7.77 (d, <i>J</i> = 6.8 Hz, 1H), 7.60 (d, <i>J</i> = 1.8 Hz, 1H), 7.47 (d, <i>J</i> = 8.6 Hz, 1H), 7.31 (dd, <i>J</i> = 8.4, 1.9 Hz, 1H), 7.18 (s, 1H), 7.09 (dd, <i>J</i> = 6.9, 1.6 Hz, 1H), 3.90–3.87 (m, 1H), 3.87 (s, 3H), 3.03 (s, 3H), 2.03 (ddd, <i>J</i> = 9.7, 6.5, 3.4 Hz, 1H), 1.71–1.58 (m, 1H), 1.32–1.19 (m, 1H), 1.09 (d, <i>J</i> = 7.1 Hz, 3H), 0.99 (t, <i>J</i> = 7.4 Hz, 3H). MS (ESI) <i>m</i>/<i>z</i>: 343.2 [(M + H)<sup>+</sup>. HPLC purity: 92.3%, <i>t</i><sub>R</sub> = 6.62 min (method E); 95.5%, <i>t</i><sub>R</sub> = 6.79 (method F).</div></div><div id="sec5_1_22_45" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99"> (<i>R</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(pyridin-3-yl)phenyl)-4-methylpentanamide (<b>53</b>)</h5><div class="NLM_p last">Compound <b>53</b> was prepared from 3-methoxy-4-(pyridin-3-yl)aniline (<b>89h</b>) (135 mg, 0.674 mmol) and (<i>R</i>)-2-(<i>tert</i>-butoxycarbonylamino)-4-methylpentanoic acid (234 mg, 1.01 mmol) according to the representative two-step procedure described for the synthesis of <b>11</b> from <b>67</b>. The product was purified by preparative reverse phase HPLC (method A). The solvent was removed in vacuo, and the product was taken up in EtOAc and converted to the free base by washing with saturated aqueous K<sub>2</sub>CO<sub>3</sub>. After concentration, the product was taken up in acetonitrile/water and was lyophilized to afford <b>53</b> (60 mg, 0.191 mmol, 29% yield, two steps) as a yellow viscous oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.85 (s, 1H), 7.67–7.60 (m, 1H), 7.21–7.13 (m, 1H), 6.80 (d, <i>J</i> = 1.8 Hz, 1H), 6.66 (dd, <i>J</i> = 7.9, 4.9 Hz, 1H), 6.54–6.48 (m, 1H), 6.47–6.42 (m, 1H), 3.04 (s, 3H), 2.73 (t, <i>J</i> = 7.1 Hz, 1H), 1.04–0.93 (m, 1H), 0.91–0.80 (m, 1H), 0.77–0.66 (m, 1H), 0.20 (t, <i>J</i> = 7.3 Hz, 6H). HRMS (ESI) <i>m/z</i>: 314.1855 [(M + H)<sup>+</sup>, calcd for C<sub>18</sub>H<sub>24</sub>N<sub>3</sub>O<sub>2</sub> 314.1869]. HPLC purity: 100%, <i>t</i><sub>R</sub> = 5.83 min (method E); 96%, <i>t</i><sub>R</sub> = 4.33 min (method F).</div></div><div id="sec5_1_22_46" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100"> (<i>R</i>)-2-Amino-<i>N</i>-(3-methoxy-4-(pyrimidin-5-yl)phenyl)-4-methylpentanamide, TFA (<b>54</b>)</h5><div class="NLM_p">Step 1: To a mixture of (<i>R</i>)-<i>tert</i>-butyl (1-((4-bromo-3-methoxyphenyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (<b>76</b>) (200 mg, 0.482 mmol), 5-pyrimidinylboronic acid (65.6 mg, 0.530 mmol), and tetrakis(triphenylphosphine)palladium(0) (27.8 mg, 0.024 mmol) in toluene (4 mL) and ethanol (1 mL) under N<sub>2</sub> was added a solution of Na<sub>2</sub>CO<sub>3</sub> (153 mg, 1.45 mmol) in water (1 mL). The reaction mixture was heated at reflux for 12 h. The mixture was transferred to a separatory funnel containing water. The aqueous layer was extracted with EtOAc (3 × 25 mL). The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (10–50% EtOAc in hexanes, 40 g column) to afford (<i>R</i>)-<i>tert</i>-butyl (1-((3-methoxy-4-(pyrimidin-5-yl)phenyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (90 mg, 0.217 mmol, 45% yield) as a white solid. MS (ESI) <i>m/z</i>: 415.4 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Step 2: To a solution of (<i>R</i>)-<i>tert</i>-butyl (1-((3-methoxy-4-(pyrimidin-5-yl)phenyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (90 mg, 0.217 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) at 0 °C was added TFA (1 mL, 12.98 mmol). The reaction mixture was stirred at room temperature for 2 h. The mixture was concentrated, and the product was purified by reverse phase HPLC (method A) and lyophilized to afford <b>54</b> (32 mg, 0.075 mmol, 34% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 9.04 (s, 1H), 8.92 (s, 2H), 7.59 (s, 1H), 7.44–7.37 (m, 1H), 7.30 (d, <i>J</i> = 8.1 Hz, 1H), 4.01 (t, <i>J</i> = 6.8 Hz, 1H), 3.85 (s, 3H), 1.85–1.71 (m, 3H), 1.04 (d, <i>J</i> = 6.0 Hz, 6H). HRMS (ESI) <i>m/z</i>: 315.1802 [(M + H)<sup>+</sup>, calcd for C<sub>17</sub>H<sub>23</sub>N<sub>4</sub>O<sub>2</sub> 315.1821]. HPLC purity: >99%, <i>t</i><sub>R</sub> = 7.67 min (method A); >99%, <i>t</i><sub>R</sub> = 7.56 min (method B).</div></div><div id="sec5_1_22_47" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101"> (<i>R</i>)-2-Amino-4-methyl-<i>N</i>-(4-(oxazol-5-yl)phenyl)pentanamide, TFA (<b>55</b>)</h5><div class="NLM_p last">Compound <b>55</b> was prepared from 4-(oxazol-5-yl)aniline (200 mg, 1.25 mmol) and (<i>R</i>)-2-(<i>tert</i>-butoxycarbonylamino)-4-methylpentanoic acid (433 mg, 1.87 mmol) in a similar fashion as described for the two-step synthesis of <b>11</b> from <b>67</b>. The product was purified by column chromatography on silica gel (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford <b>55</b> (264 mg, 0.668 mmol, 94% yield) as a yellow solid. An analytical portion was purified further by preparative reverse phase HPLC (method A) and lyophilized to afford <b>55</b> as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.65 (s, 1H), 8.43 (s, 1H), 8.26 (br. s., 3H), 7.74 (s, 4H), 7.62 (s, 1H), 3.95 (br. s., 1H), 1.74–1.65 (m, <i>J</i> = 6.3 Hz, 3H), 0.96 (d, <i>J</i> = 2.5 Hz, 3H), 0.94 (d, <i>J</i> = 2.3 Hz, 3H). HRMS (ESI) <i>m/z</i>: 274.1548 [(M + H)<sup>+</sup>, calcd for C<sub>15</sub>H<sub>20</sub>N<sub>3</sub>O<sub>2</sub> 274.1556]. HPLC purity: >99%, <i>t</i><sub>R</sub> = 12.80 min (method A); >99%, <i>t</i><sub>R</sub> = 12.92 min (method B).</div></div><div id="sec5_1_22_48" class="NLM_sec NLM_sec_level_4"><div id="ac_i102" class="anchor-spacer"></div><h5 class="article-section__title" id="_i102"> (<i>R</i>)-2-Amino-4-methyl-<i>N</i>-(3-methyl-4-(oxazol-5-yl)phenyl)pentanamide (<b>56</b>)</h5><div class="NLM_p last">To a solution of (<i>R</i>)-<i>tert</i>-butyl (4-methyl-1-((3-methyl-4-(oxazol-5-yl)phenyl)amino)-1-oxopentan-2-yl)carbamate (<b>95</b>) (58 mg, 0.150 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was added TFA (0.5 mL, 6.49 mmol). The reaction mixture was stirred at room temperature for 2 h. The mixture was concentrated and purified by preparative reverse phase HPLC (method A). The organic solvent was removed in vacuo, and the product was taken up in EtOAc and converted to the free base by washing with saturated aqueous K<sub>2</sub>CO<sub>3</sub>. After concentration of the organic layer, the product was lyophilized from acetonitrile/water to afford <b>56</b> (43 mg, 0.142 mmol, 95% yield) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.44 (s, 1H), 7.60–7.64 (m, 3H), 7.40 (s, 1H), 3.38 (dd, <i>J</i> = 8.4, 5.7 Hz, 1H), 2.41 (s, 3H), 1.70–1.79 (m, 1H), 1.49 (ddd, <i>J</i> = 13.4, 8.0, 5.5 Hz, 1H), 1.31–1.40 (m, 1H), 0.91 (d, <i>J</i> = 6.5 Hz, 3H), 0.89 (d, <i>J</i> = 6.8 Hz, 3H). HRMS (ESI) <i>m/z</i>: 288.1704 [(M + H)<sup>+</sup>, calcd for C<sub>16</sub>H<sub>22</sub>N<sub>3</sub>O<sub>2</sub> 288.1712]. HPLC purity: >99%, <i>t</i><sub>R</sub> = 13.34 min (method A); >99%, <i>t</i><sub>R</sub> = 13.52 min (method B).</div></div><div id="sec5_1_22_49" class="NLM_sec NLM_sec_level_4"><div id="ac_i103" class="anchor-spacer"></div><h5 class="article-section__title" id="_i103"> (<i>R</i>)-2-Amino-<i>N</i>-(3-ethyl-4-(oxazol-5-yl)phenyl)-4-methylpentanamide (<b>57</b>)</h5><div class="NLM_p last">To a suspension of (<i>R</i>)-<i>tert</i>-butyl 1-(3-ethyl-4-(oxazol-5-yl)phenylamino)-4-methyl-1-oxopentan-2-ylcarbamate (<b>97</b>) (45 mg, 0.112 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL) at 0 °C was added TFA (0.5 mL, 6.49 mmol). The cooling bath was removed, and the mixture was stirred at room temperature under N<sub>2</sub> for 1.5 h. The reaction mixture was concentrated, and the product was purified by preparative reverse phase HPLC (method A). The organic solvent was removed in vacuo, and the product was taken up in EtOAc and converted to the free base by washing with saturated aqueous K<sub>2</sub>CO<sub>3</sub>. After concentration of the organic layer, the product was lyophilized from acetonitrile/water to afford <b>57</b> (24 mg, 0.080 mmol, 71% yield) as an off-white amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.44 (s, 1H), 7.69–7.61 (m, 2H), 7.55 (d, <i>J</i> = 8.3 Hz, 1H), 7.37 (s, 1H), 3.37 (dd, <i>J</i> = 8.7, 5.7 Hz, 1H), 2.73 (q, <i>J</i> = 7.6 Hz, 2H), 1.82–1.70 (m, 1H), 1.49 (ddd, <i>J</i> = 13.5, 8.2, 5.5 Hz, 1H), 1.41–1.30 (m, 1H), 1.17 (t, <i>J</i> = 7.4 Hz, 3H), 0.92 (d, <i>J</i> = 6.5 Hz, 3H), 0.89 (d, <i>J</i> = 6.5 Hz, 3H). HRMS (ESI) <i>m/z</i>: 302.1850 [(M + H)<sup>+</sup>, calcd for C<sub>17</sub>H<sub>24</sub>N<sub>3</sub>O<sub>2</sub> 302.1869]. HPLC purity: >99%, <i>t</i><sub>R</sub> = 8.46 min (method E); >99%, <i>t</i><sub>R</sub> = 8.54 min (method F).</div></div><div id="sec5_1_22_50" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104"> (<i>R</i>)-2-Amino-<i>N</i>-(3-ethoxy-4-(oxazol-5-yl)phenyl)-4-methylpentanamide (<b>58</b>)</h5><div class="NLM_p last">(<i>R</i>)-<i>tert</i>-Butyl (1-((3-ethoxy-4-(oxazol-5-yl)phenyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (<b>101</b>) (100 mg, 0.240 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (1 mL) and cooled to 0 °C. To this cooled solution was added TFA (0.5 mL, 6.49 mmol). The reaction mixture was stirred at 0 °C for 1 h. The reaction mixture was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution. The aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (10% 2 M NH<sub>3</sub> in MeOH/90% CH<sub>2</sub>Cl<sub>2</sub>, 12 g column) to afford <b>58</b> (72 mg, 0.227 mmol, 95% yield) as an off-white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.74 (s, 1H), 8.41 (s, 1H), 8.29 (br s, 3H), 7.70 (d, <i>J</i> = 8.6 Hz, 1H), 7.43–7.50 (m, 2H), 7.36 (dd, <i>J</i> = 8.6, 1.8 Hz, 1H), 4.16 (q, <i>J</i> = 7.0 Hz, 2H), 3.90–4.00 (m, 1H), 1.66–1.76 (m, 3H), 1.48 (t, <i>J</i> = 6.9 Hz, 3H), 0.92 (d, <i>J</i> = 4.8 Hz, 6H). HRMS (ESI) <i>m/z</i>: 318.1799 [(M + H)<sup>+</sup>, calcd for C<sub>17</sub>H<sub>24</sub>N<sub>3</sub>O<sub>3</sub> 318.1818]. HPLC purity: 95.6%, <i>t</i><sub>R</sub> = 8.44 min (method E); 96.5%, <i>t</i><sub>R</sub> = 8.52 min (method F).</div></div><div id="sec5_1_22_51" class="NLM_sec NLM_sec_level_4"><div id="ac_i105" class="anchor-spacer"></div><h5 class="article-section__title" id="_i105"> (<i>R</i>)-2-Amino-<i>N</i>-(3-(difluoromethoxy)-4-(oxazol-5-yl)phenyl)-4-methylpentanamide, TFA (<b>59</b>)</h5><div class="NLM_p last">(<i>R</i>)-<i>tert</i>-Butyl 1-(3-(difluoromethoxy)-4-(oxazol-5-yl)phenylamino)-4-methyl-1-oxopentan-2-ylcarbamate (<b>102</b>) (600 mg, 1.37 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) and cooled to 0 °C. To this solution was added TFA (1.05 mL, 13.7 mmol). The reaction mixture was stirred at room temperature for 12 h. The mixture was concentrated, and the product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>59</b> (200 mg, 0.589 mmol, 43% yield) as a white amorphous solid. [α]<sub>D</sub><sup>22</sup> −25.6 (<i>c</i> 0.245, MeOH). <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.90 (br s, 1H), 8.51 (s, 1H), 8.30 (br s, 3H), 7.84 (d, <i>J</i> = 8.7 Hz, 1H), 7.78 (d, <i>J</i> = 0.8 Hz, 1H), 7.62 (dd, <i>J</i> = 8.6, 1.9 Hz, 1H), 7.48 (s, 1H), 7.35 (d, <i>J</i> = 73.1 Hz, 1H), 3.98–3.95 (m, 1H), 1.75–1.64 (m, 3H), 0.95 (d, <i>J</i> = 5.7 Hz, 6H); <sup>19</sup>F NMR (471 MHz, DMSO-<i>d</i><sub>6</sub>) δ −73.53 (s), −81.41 (d, <i>J</i> = 25.4 Hz); <sup>13</sup>C NMR (126 MHz, DMSO-<i>d</i><sub>6</sub>) δ 169.0, 152.0, 147.3 (t, <i>J</i> = 2.9 Hz), 146.3, 139.7, 127.7, 125.1, 117.0, 115.3, 116.9 (t, <i>J</i> = 260.4 Hz), 110.3, 52.4, 24.2, 23.2, 22.2 (TFA salt carbons: 158.4 (q, <i>J</i> = 30.5 Hz), 117.8 (q, <i>J</i> = 301.4 Hz)). HRMS (ESI) <i>m/z</i>: 340.1467 [(M + H)<sup>+</sup>, calcd for C<sub>16</sub>H<sub>20</sub>N<sub>3</sub>O<sub>3</sub>F<sub>2</sub> 340.1473]. HPLC purity: 99.2%, <i>t</i><sub>R</sub> = 8.71 min (method E); 100%, <i>t</i><sub>R</sub> = 8.24 min (method F).</div></div><div id="sec5_1_22_52" class="NLM_sec NLM_sec_level_4"><div id="ac_i106" class="anchor-spacer"></div><h5 class="article-section__title" id="_i106"> (<i>R</i>)-2-Amino-4-methyl-<i>N</i>-(4-(oxazol-5-yl)-3-(trifluoromethoxy)phenyl)pentanamide (<b>60</b>)</h5><div class="NLM_p last">To a solution of (<i>R</i>)-<i>tert</i>-butyl (4-methyl-1-((4-(oxazol-5-yl)-3-(trifluoromethoxy)phenyl)amino)-1-oxopentan-2-yl)carbamate (<b>105</b>) (150 mg, 0.328 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was added TFA (0.5 mL, 6.49 mmol). The reaction mixture was stirred at room temperature for 2 h. The mixture was concentrated, and the product was purified by preparative reverse phase HPLC (acetonitrile/water with 0.1% TFA) to give <b>60</b>, which was subsequently isolated as the free base (95 mg, 0.266 mmol, 81% yield) as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.54 (s, 1H), 8.10 (s, 1H), 7.86–7.81 (m, 1H), 7.74 (dd, <i>J</i> = 8.8, 1.6 Hz, 1H), 7.44 (s, 1H), 3.38–3.33 (m, 1H), 1.82–1.73 (m, 1H), 1.55–1.45 (m, 1H), 1.40–1.31 (m, 1H), 0.92 (d, <i>J</i> = 6.7 Hz, 3H), 0.90 (d, <i>J</i> = 6.7 Hz, 3H). HRMS (ESI) <i>m/z</i>: 358.1373 [(M + H)<sup>+</sup>, calcd for C<sub>16</sub>H<sub>19</sub>F<sub>3</sub>N<sub>3</sub>O<sub>3</sub>, 358.1379]. HPLC purity: 98%, <i>t</i><sub>R</sub> = 6.12 min (method G); 98%, <i>t</i><sub>R</sub> = 6.81 min (method H).</div></div><div id="sec5_1_22_53" class="NLM_sec NLM_sec_level_4"><div id="ac_i107" class="anchor-spacer"></div><h5 class="article-section__title" id="_i107"> (<i>R</i>)-2-Amino-<i>N</i>-(3-fluoro-4-(oxazol-5-yl)phenyl)-4-methylpentanamide, TFA (<b>61</b>)</h5><div class="NLM_p last">Compound <b>61</b> was prepared from 3-fluoro-4-(oxazol-5-yl)aniline (<b>108</b>) (250 mg, 1.40 mmol) and (<i>R</i>)-2-(<i>tert</i>-butoxycarbonylamino)-4-methylpentanoic acid (487 mg, 2.11 mmol) according to the representative two-step procedure described for the synthesis of <b>11</b> from <b>67</b>. The product was purified by preparative reverse phase HPLC (method A) and lyophilized to afford <b>61</b> (170 mg, 0.420 mmol, 55% yield, two steps) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.92 (s, 1H), 8.55 (s, 1H), 8.37–8.25 (m, 3H), 7.85–7.76 (m, 2H), 7.54–7.46 (m, 2H), 3.95 (br. s., 1H), 1.69 (d, <i>J</i> = 4.5 Hz, 3H), 0.94 (d, <i>J</i> = 6.0 Hz, 6H). HRMS (ESI) <i>m/z</i>: 292.1442 [(M + H)<sup>+</sup>, calcd for C<sub>15</sub>H<sub>19</sub>FN<sub>3</sub>O<sub>2</sub> 292.1461]. HPLC purity: >99%, <i>t</i><sub>R</sub> = 13.68 min (method A); 99%, <i>t</i><sub>R</sub> = 13.86 min (method B).</div></div><div id="sec5_1_22_54" class="NLM_sec NLM_sec_level_4"><div id="ac_i108" class="anchor-spacer"></div><h5 class="article-section__title" id="_i108"> (<i>R</i>)-2-Amino<i>-N-</i>(3-cyano-4-(oxazol-5-yl)phenyl)-4-methylpentanamide, TFA (<b>62</b>)</h5><div class="NLM_p last">Compound <b>62</b> was prepared from 5-amino-2-(oxazol-5-yl)benzonitrile (<b>110</b>) and (<i>R</i>)-2-(<i>tert</i>-butoxycarbonylamino)-4-methyl pentanoic acid according to the representative two-step procedure described for the synthesis of <b>11</b> from <b>67</b> to give <b>62</b> (40 mg, 0.097 mmol, 50% yield, two steps) as a white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.39 (s, 1H), 8.30–8.28 (m, 1H), 7.97–7.95 (m, 2H), 7.86 (s, 1H), 4.09–4.06 (m, 1H), 1.88–1.76 (m, 3H), 1.09–1.06 (m, 6H). HRMS (ESI) <i>m/z</i>: 299.1503 [(M + H)<sup>+</sup>, calcd for C<sub>16</sub>H<sub>19</sub>N<sub>4</sub>O<sub>2</sub>, 299.1508]. HPLC purity: 98%, <i>t</i><sub>R</sub> = 10.11 min; (method I); 98%, <i>t</i><sub>R</sub> = 10.52 min (method J).</div></div><div id="sec5_1_22_55" class="NLM_sec NLM_sec_level_4"><div id="ac_i109" class="anchor-spacer"></div><h5 class="article-section__title" id="_i109"> (<i>R</i>)-2-Amino-4-methyl-<i>N</i>-(4-(pyridin-4-yl)phenyl)pentanamide, TFA (<b>63</b>)</h5><div class="NLM_p last">Compound <b>63</b> was prepared from 4-(pyridin-4-yl)aniline (<b>111</b>) and (<i>R</i>)-2-(<i>tert</i>-butoxycarbonylamino)-4-methylpentanoic acid in two steps in a similar fashion as described for the synthesis of <b>11</b> from <b>67</b>. The product was purified by preparative reverse phase HPLC (method A) followed by a second HPLC purification (method G) due to the presence of an impurity. The organic solvent was removed in vacuo, and the aqueous mixture was lyophilized to afford <b>63</b> (67 mg, 0.129 mmol, 56% yield, two steps) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.85 (s, 1H), 8.80 (d, <i>J</i> = 6.3 Hz, 2H), 8.38–8.27 (m, 3H), 8.06 (d, <i>J</i> = 6.3 Hz, 2H), 8.00 (d, <i>J</i> = 8.8 Hz, 2H), 7.83 (d, <i>J</i> = 8.8 Hz, 2H), 3.99 (br. s., 1H), 1.77–1.64 (m, 3H), 0.95 (d, <i>J</i> = 4.5 Hz, 6H). HRMS (ESI) <i>m/z</i>: 284.1744 [(M + H)<sup>+</sup>, calcd for C<sub>17</sub>H<sub>22</sub>N<sub>3</sub>O 284.1763]. HPLC purity: >99%, <i>t</i><sub>R</sub> = 10.01 min (method A); >99%, <i>t</i><sub>R</sub> = 10.01 min (method B).</div></div><div id="sec5_1_22_56" class="NLM_sec NLM_sec_level_4"><div id="ac_i110" class="anchor-spacer"></div><h5 class="article-section__title" id="_i110"> 3-Isopropyl-<i>N</i>-(4-(pyridin-4-yl)phenyl)piperidine-2-carboxamide, TFA (<b>64</b>)</h5><div class="NLM_p">Step 1: To a solution of 4-(pyridin-4-yl)aniline (<b>111</b>) (40 mg, 0.235 mmol), 1-(<i>tert</i>-butoxycarbonyl)-3-isopropylpiperidine-2-carboxylic acid (<b>73</b>) (96 mg, 0.353 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.164 mL, 0.940 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) at room temperature was added HATU (134 mg, 0.353 mmol). The reaction mixture was stirred at room temperature for 16 h. The mixture was then heated at 50 °C for 24 h. The mixture was transferred to a separatory funnel containing EtOAc (20 mL). The organic layer was washed with saturated aqueous NaHCO<sub>3</sub> solution (5 mL)/water (5 mL) and brine (10 mL). The organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (30% EtOAc with 1% MeOH/70% hexanes–70% EtOAc with 1% MeOH/30% hexanes; 24 g column) to afford <i>tert</i>-butyl 3-isopropyl-2-((4-(pyridin-4-yl)phenyl)carbamoyl)piperidine-1-carboxylate (81 mg, 0.191 mmol, 81% yield) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.71–8.62 (m, 3H), 7.68–7.59 (m, 4H), 7.52–7.47 (m, 2H), 4.91 (d, <i>J</i> = 5.0 Hz, 1H), 3.96 (d, <i>J</i> = 13.3 Hz, 1H), 2.93 (td, <i>J</i> = 13.0, 2.9 Hz, 1H), 2.05–1.94 (m, 1H), 1.92–1.75 (m, 2H), 1.70–1.61 (m, 1H), 1.53 (s, 9H), 1.35–1.25 (m, 2H), 1.01 (d, <i>J</i> = 2.3 Hz, 3H), 1.00 (d, <i>J</i> = 2.0 Hz, 3H). MS (ESI) <i>m/z</i>: 424.3 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Step 2: To a solution of <i>tert</i>-butyl 3-isopropyl-2-((4-(pyridin-4-yl)phenyl)carbamoyl)piperidine-1-carboxylate (56 mg, 0.132 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (2 mL) was added TFA (0.5 mL, 6.49 mmol). The reaction mixture was stirred at room temperature for 2 h. The mixture was concentrated, dissolved in MeOH (2 mL), and purified by preparative reverse phase HPLC (method A) followed by a second HPLC purification (method G) due to the presence of an impurity. The organic solvent was removed in vacuo, and the aqueous mixture was lyophilized to afford <b>64</b> (42 mg, 0.096 mmol, 73% yield) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.92 (s, 1H), 9.17 (br. s., 1H), 9.04 (br. s., 1H), 8.86–8.76 (m, 2H), 8.07 (d, <i>J</i> = 6.3 Hz, 2H), 8.00 (d, <i>J</i> = 8.8 Hz, 2H), 7.81 (d, <i>J</i> = 9.0 Hz, 2H), 4.17 (br. s., 1H), 3.40 (br. s., 1H), 3.12 (br. s., 1H), 2.03–1.70 (m, 4H), 1.68–1.56 (m, 2H), 0.90 (d, <i>J</i> = 6.5 Hz, 3H), 0.87 (d, <i>J</i> = 6.5 Hz, 3H). HRMS (ESI) <i>m/z</i>: 324.2057 [(M + H)<sup>+</sup>, calcd for C<sub>20</sub>H<sub>26</sub>N<sub>3</sub>O 324.2076]. HPLC purity: 98.8%, <i>t</i><sub>R</sub> = 10.92 min (method A); 98.3%, <i>t</i><sub>R</sub> = 11.29 min (method B).</div></div><div id="sec5_1_22_57" class="NLM_sec NLM_sec_level_4"><div id="ac_i111" class="anchor-spacer"></div><h5 class="article-section__title" id="_i111"> 5-(2-Methoxy-4-nitrophenyl)oxazole (<b>66</b>)</h5><div class="NLM_p last">To a solution of 2-methoxy-4-nitrobenzaldehyde (<b>65</b>) (700 mg, 3.86 mmol) and TosMIC (754 mg, 3.86 mmol) in MeOH (7 mL) was added potassium carbonate (561 mg, 4.06 mmol). The reaction mixture was heated at reflux for 3 h. The reaction mixture was cooled to room temperature and transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (25 mL). The aqueous layer was extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine (25 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (30–40% EtOAc in hexanes) to afford <b>66</b> (732 mg, 3.33 mmol, 86% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.98 (s, 1H), 7.93 (d, <i>J</i> = 1.8 Hz, 1H), 7.92 (s, 1H), 7.84 (d, <i>J</i> = 1.8 Hz, 1H), 7.75 (s, 1H), 4.08 (s, 3H). MS (ESI) <i>m/z</i>: 221.3 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_58" class="NLM_sec NLM_sec_level_4"><div id="ac_i112" class="anchor-spacer"></div><h5 class="article-section__title" id="_i112"> 3-Methoxy-4-(oxazol-5-yl)aniline (<b>67</b>)</h5><div class="NLM_p last">5-(2-Methoxy-4-nitrophenyl)oxazole (<b>66</b>) (700 mg, 3.18 mmol) was dissolved in EtOH (30 mL) and CHCl<sub>3</sub> (15 mL) in a Parr bottle. 10% Palladium on carbon (677 mg, 0.318 mmol, Degussa type) was added, and the mixture was placed on the Parr shaker under H<sub>2</sub> at 40 psi for 1.5 h. The catalyst was removed by filtration through a pad of Celite, and the filtrate was concentrated. The product was crystallized from EtOAc/ethanol to afford <b>67</b> (496 mg, 2.61 mmol, 82% yield) as a gray solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.34 (s, 1H), 7.55 (d, <i>J</i> = 8.3 Hz, 1H), 7.37 (s, 1H), 6.70 (s, 1H), 6.63 (d, <i>J</i> = 8.1 Hz, 1H), 3.89 (s, 3H). MS (ESI) <i>m/z</i>: 191.3 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_59" class="NLM_sec NLM_sec_level_4"><div id="ac_i113" class="anchor-spacer"></div><h5 class="article-section__title" id="_i113"> (<i>R</i>)-<i>tert</i>-Butyl 1-((3-Methoxy-4-(oxazol-5-yl)phenyl)(methyl)amino)-4-methyl-1-oxopentan-2-ylcarbamate (<b>68</b>)</h5><div class="NLM_p">Step 1: To a mixture of 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) (100 mg, 0.526 mmol) and (<i>R</i>)-2-(<i>tert</i>-butoxycarbonylamino)-4-methylpentanoic acid (182 mg, 0.789 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) at room temperature were added HATU (300 mg, 0.789 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.459 mL, 2.63 mmol). The reaction mixture was stirred at room temperature for 12 h. The reaction mixture was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution. The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 25 mL). The organic layer was dried over MgSO<sub>4</sub> and concentrated. The product was purified by column chromatography on silica gel (30–40% EtOAc in hexanes) to afford (<i>R</i>)-<i>tert</i>-butyl 1-(3-methoxy-4-(oxazol-5-yl)phenylamino)-4-methyl-1-oxopentan-2-ylcarbamate (140 mg, 0.347 mmol, 66% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.16 (s, 1H), 8.39 (s, 1H), 7.64 (d, <i>J</i> = 8.5 Hz, 1H), 7.53 (d, <i>J</i> = 1.8 Hz, 1H), 7.45 (s, 1H), 7.37 (dd, <i>J</i> = 8.4, 1.9 Hz, 1H), 7.09 (br d, <i>J</i> = 7.8 Hz, 1H), 4.19–4.09 (m, 1H), 3.92 (s, 3H), 1.74–1.61 (m, 1H), 1.60–1.42 (m, 2H), 1.39 (s, 9H), 0.91 (d, <i>J</i> = 6.5 Hz, 1H), 0.91 (d, <i>J</i> = 6.3 Hz, 1H). MS (ESI) <i>m/z</i>: 404.3 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Step 2: To a mixture of (<i>R</i>)-<i>tert</i>-butyl 1-(3-methoxy-4-(oxazol-5-yl)phenylamino)-4-methyl-1-oxopentan-2-ylcarbamate (160 mg, 0.397 mmol) and barium hydroxide (408 mg, 2.38 mmol) in DMF (5 mL) and water (1.667 mL) was added iodomethane (0.893 mL, 14.3 mmol). The suspension was stirred at room temperature for 12 h. The reaction mixture was transferred to a separatory funnel containing Et<sub>2</sub>O. The organic layer was washed with water (20 mL) and brine (20 mL), dried over Na<sub>2</sub>SO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (30–40% EtOAc in hexanes) to afford <b>68</b> (160 mg, 0.383 mmol, 97% yield) as a green solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.47 (s, 1H), 7.78 (d, <i>J</i> = 8.3 Hz, 1H), 7.59 (s, 1H), 7.30 (br s, 1H), 7.12 (br d, <i>J</i> = 7.8 Hz, 1H), 6.98 (br d, <i>J</i> = 7.5 Hz, 1H), 4.31–4.16 (m, 1H), 3.99 (s, 3H), 3.20 (br s, 3H), 1.52–1.43 (m, 1H), 1.37 (s, 9H), 1.24–1.07 (m, 2H), 0.68 (br d, <i>J</i> = 4.5 Hz, 3H), 0.32 (br s, 3H). MS (ESI) <i>m/z</i>: 418.3 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_60" class="NLM_sec NLM_sec_level_4"><div id="ac_i114" class="anchor-spacer"></div><h5 class="article-section__title" id="_i114"> Methyl 3-(Prop-1-en-2-yl)picolinate (<b>71</b>)</h5><div class="NLM_p last">To a reaction vessel containing methyl 3-bromopicolinate (<b>69</b>) (2.00 g, 9.26 mmol), 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-1,3,2-dioxaborolane (<b>70</b>) (2.33 g, 13.9 mmol), and K<sub>3</sub>PO<sub>4</sub> (5.90 g, 27.8 mmol) were added THF (40 mL) and water (8 mL). The reaction vessel was evacuated and refilled with argon three times. The mixture was then degassed by sonication for 5 min. A second-generation XPhos precatalyst (0.291 g, 0.370 mmol) was added. The vessel was sealed, and the mixture was then heated to 70 °C for 16 h. The mixture was cooled to room temperature and was filtered through a pad of Celite. The filtrate was transferred to a separatory funnel containing 10% aqueous NaHCO<sub>3</sub> solution (50 mL). The aqueous layer was extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine (50 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (30–50% EtOAc in hexanes; 220 g column) to afford <b>71</b> (1.12 g, 5.06 mmol, 55% yield) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.61 (dd, <i>J</i> = 4.8, 1.5 Hz, 1H), 7.65 (dd, <i>J</i> = 7.8, 1.8 Hz, 1H), 7.42 (dd, <i>J</i> = 7.8, 4.8 Hz, 1H), 5.22 (quin, <i>J</i> = 1.5 Hz, 1H), 4.96–4.93 (m, 1H), 3.97 (s, 3H), 2.14 (dd, <i>J</i> = 1.5, 1.0 Hz, 3H) (<sup>1</sup>H NMR showed that the product was a 4:1 mixture of desired product and starting material). MS (ESI) <i>m</i>/<i>z</i>: 178.2 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_61" class="NLM_sec NLM_sec_level_4"><div id="ac_i115" class="anchor-spacer"></div><h5 class="article-section__title" id="_i115"> 1-<i>tert</i>-Butyl 2-Methyl 3-isopropylpiperidine-1,2-dicarboxylate (<b>72</b>)</h5><div class="NLM_p">Step 1: To a solution of methyl 3-(prop-1-en-2-yl)picolinate (<b>71</b>) (950 mg, 5.36 mmol) in ethanol (50 mL) was added 4 N HCl in 1,4-dioxane (5 mL) followed by platinum(IV) oxide (122 mg, 0.536 mmol). The mixture was placed under H<sub>2</sub> on the Parr shaker at 50 psi for 16 h. The mixture was filtered through a pad of Celite and was then concentrated to give methyl 3-isopropylpiperidine-2-carboxylate (1.71 g) (impure). The product was used directly in the next step. MS (ESI) <i>m</i>/<i>z</i>: 186.3 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Step 2: The crude methyl 3-isopropylpiperidine-2-carboxylate (1.71 g) (0.993 g, 5.36 mmol, based on the theoretical yield of the above reaction) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (8 mL) and water (8 mL) and was treated with Na<sub>2</sub>CO<sub>3</sub> (2.84 g, 26.8 mmol). Di-<i>tert</i>-butyl dicarbonate (1.87 mL, 8.04 mmol) was added, and the reaction mixture was stirred at room temperature for 1.5 h. The mixture was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (25 mL). The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 50 mL). The combined organic layers were washed with brine (25 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (5–30% EtOAc in hexanes; 220 g column) to afford <b>72</b> (1.03 g, 3.61 mmol, 67% yield, two steps) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.10–4.84 (m, 1H), 4.04–3.85 (m, 1H), 3.71 (s, 3H), 3.28–3.03 (m, 1H), 1.87–1.71 (m, 2H), 1.69–1.60 (m, 1H), 1.48 (s, 9H), 1.44–1.23 (m, 3H), 1.04 (d, <i>J</i> = 6.3 Hz, 3H), 0.92 (d, <i>J</i> = 6.5 Hz, 3H). MS (ESI) <i>m/z</i>: 186.2 (M + H-Boc)<sup>+</sup>.</div></div><div id="sec5_1_22_62" class="NLM_sec NLM_sec_level_4"><div id="ac_i116" class="anchor-spacer"></div><h5 class="article-section__title" id="_i116"> 1-(<i>tert</i>-Butoxycarbonyl)-3-isopropylpiperidine-2-carboxylic acid (<b>73</b>)</h5><div class="NLM_p last">To a solution of 1-<i>tert</i>-butyl 2-methyl 3-isopropylpiperidine-1,2-dicarboxylate (<b>72</b>) (860 mg, 3.01 mmol) in THF (6 mL) and MeOH (6 mL) was added a solution of lithium hydroxide (1 N aq) (15.1 mL, 15.1 mmol). The reaction mixture was heated at 50 °C for 20 h. The organic solvents were removed under vacuum, and the remaining aqueous layer was washed with Et<sub>2</sub>O (20 mL). The aqueous layer was then adjusted to pH 5 with saturated aqueous citric acid and was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 25 mL). The combined organic extracts were dried over MgSO<sub>4</sub> and concentrated to give <b>73</b> (803 mg, 2.96 mmol, 98% yield) as a colorless oil. The product was used directly in the next step. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 5.09–4.87 (m, 1H), 4.02–3.86 (m, 1H), 3.13 (td, <i>J</i> = 12.7, 3.1 Hz, 1H), 1.91–1.71 (m, 3H), 1.49 (s, 9H), 1.39–1.27 (m, 3H), 1.06 (d, <i>J</i> = 6.5 Hz, 3H), 0.95 (d, <i>J</i> = 6.8 Hz, 3H). MS (ESI) <i>m</i>/<i>z</i>: 172.3 (M + H-Boc)<sup>+</sup>.</div></div><div id="sec5_1_22_63" class="NLM_sec NLM_sec_level_4"><div id="ac_i117" class="anchor-spacer"></div><h5 class="article-section__title" id="_i117"> (<i>rac</i>)-<i>tert</i>-Butyl 3-Isopropyl-2-((3-methoxy-4-(oxazol-5-yl)phenyl)carbamoyl)piperidine-1-carboxylate (<b>(<i>rac</i>)-74</b>)</h5><div class="NLM_p last">To a solution of 3-methoxy-4-(oxazol-5-yl)aniline (<b>67</b>) (150 mg, 0.789 mmol), 1-(<i>tert</i>-butoxycarbonyl)-3-isopropylpiperidine-2-carboxylic acid (<b>73</b>) (321 mg, 1.18 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.551 mL, 3.15 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (6 mL) at room temperature was added HATU (450 mg, 1.183 mmol). The reaction mixture was stirred at room temperature for 16 h. The mixture was then heated at 40 °C for 32 h. The mixture was transferred to a separatory funnel containing EtOAc (20 mL). The organic layer was washed with saturated aqueous NaHCO<sub>3</sub> solution (5 mL)/water (5 mL) and brine (10 mL). The organic layer was dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (10–30% EtOAc in hexanes; 24 g column) to afford <b>(<i>rac</i>)-74</b> (318 mg, 0.717 mmol, 72% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.68 (s, 1H), 7.89 (s, 1H), 7.69 (d, <i>J</i> = 8.5 Hz, 1H), 7.56 (d, <i>J</i> = 2.0 Hz, 1H), 7.50 (s, 1H), 6.95 (dd, <i>J</i> = 8.4, 1.9 Hz, 1H), 4.90 (d, <i>J</i> = 5.0 Hz, 1H), 3.99 (s, 3H), 2.98–2.88 (m, 1H), 2.04–1.93 (m, 2H), 1.91–1.83 (m, 1H), 1.79 (dt, <i>J</i> = 13.2, 3.0 Hz, 1H), 1.52 (s, 9H), 1.34–1.24 (m, 3H), 1.01 (d, <i>J</i> = 2.8 Hz, 3H), 0.99 (d, <i>J</i> = 2.8 Hz, 3H). MS (ESI) <i>m</i>/<i>z</i>: 444.3 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_64" class="NLM_sec NLM_sec_level_4"><div id="ac_i118" class="anchor-spacer"></div><h5 class="article-section__title" id="_i118"> <i>tert</i>-Butyl (2<i>R</i>,3<i>R</i>)-3-Isopropyl-2-((3-methoxy-4-(oxazol-5-yl)phenyl)carbamoyl)piperidine-1-carboxylate (<b>(2<i>R</i>,3<i>R</i>)-74</b>) and <i>tert</i>-Butyl (2<i>S</i>,3<i>S</i>)-3-Isopropyl-2-((3-methoxy-4-(oxazol-5-yl)phenyl)carbamoyl)piperidine-1-carboxylate (<b>2<i>S</i>,3<i>S</i></b>)-(<b>74</b>)</h5><div class="NLM_p last"><i>tert</i>-Butyl 3-isopropyl-2-((3-methoxy-4-(oxazol-5-yl)phenyl)carbamoyl)piperidine-1-carboxylate (<b>(<i>rac</i>)-74</b>) (260 mg) was separated into its enantiomers by chiral HPLC using the following conditions—column: Chiralcel OD, 21 × 250 mm, 10 μm; mobile phase A: 0.1% diethylamine in heptane; mobile phase B: 100% ethanol; gradient: 1% solvent B, 15 mL/min; run time: 35 min; λ = 254 nm—to give 87 mg of peak 1 (<i>t</i><sub>R</sub> = 12.01 min) and 92 mg of peak 2 (<i>t</i><sub>R</sub> = 16.27 min). The % ee was confirmed by analytical chiral HPLC using the following conditions: column: Chiralcel OD, 4.6 × 100 mm, 5 μm; mobile phase A: 0.1% diethylamine in heptane; mobile phase B: 100% ethanol; gradient: 1% solvent B, 2 mL/min; run time: 20 min; λ = 254 nm.</div></div><div id="sec5_1_22_65" class="NLM_sec NLM_sec_level_4"><div id="ac_i119" class="anchor-spacer"></div><h5 class="article-section__title" id="_i119"> <i>tert</i>-Butyl (2<i>R</i>,3<i>R</i>)-3-Isopropyl-2-((3-methoxy-4-(oxazol-5-yl)phenyl)carbamoyl)piperidine-1-carboxylate <b>((2<i>R</i>,3<i>R</i>)-74)</b> (Peak 1)</h5><div class="NLM_p last">[α]<sub>D</sub><sup>22</sup> +111.9 (<i>c</i> 0.245, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.66 (s, 1H), 7.88 (s, 1H), 7.69 (d, <i>J</i> = 8.4 Hz, 1H), 7.55 (d, <i>J</i> = 1.7 Hz, 1H), 7.49 (s, 1H), 6.95 (dd, <i>J</i> = 8.4, 1.8 Hz, 1H), 4.90 (d, <i>J</i> = 4.9 Hz, 1H), 4.04–3.93 (m, 1H), 3.98 (s, 3H), 2.93 (td, <i>J</i> = 13.0, 2.7 Hz, 1H), 2.04–1.96 (m, 2H), 1.91–1.84 (m, 1H), 1.82–1.76 (m, 1H), 1.52 (s, 9H), 1.34–1.25 (m, 2H), 1.01 (d, <i>J</i> = 4.3 Hz, 3H), 0.99 (d, <i>J</i> = 4.3 Hz, 3H). MS (ESI) <i>m/z</i>: 444.3 (M + H)<sup>+</sup>. Analytical chiral HPLC: 100% ee, <i>t</i><sub>R</sub> = 3.82 min.</div></div><div id="sec5_1_22_66" class="NLM_sec NLM_sec_level_4"><div id="ac_i120" class="anchor-spacer"></div><h5 class="article-section__title" id="_i120"> <i>tert</i>-Butyl (2<i>S</i>,3<i>S</i>)-3-Isopropyl-2-((3-methoxy-4-(oxazol-5-yl)phenyl)carbamoyl)piperidine-1-carboxylate <b>(2<i>S</i>,3<i>S</i>)-(74)</b> (Peak 2)</h5><div class="NLM_p last">[α]<sub>D</sub><sup>22</sup> −116.6 (<i>c</i> 0.220, CHCl<sub>3</sub>). <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 8.66 (s, 1H), 7.88 (s, 1H), 7.69 (d, <i>J</i> = 8.4 Hz, 1H), 7.55 (d, <i>J</i> = 1.7 Hz, 1H), 7.49 (s, 1H), 6.95 (dd, <i>J</i> = 8.4, 1.8 Hz, 1H), 4.90 (d, <i>J</i> = 4.9 Hz, 1H), 4.04–3.92 (m, 1H), 3.99 (s, 3H), 2.93 (td, <i>J</i> = 13.0, 2.7 Hz, 1H), 2.04–1.96 (m, 2H), 1.90–1.83 (m, 1H), 1.82–1.75 (m, 1H), 1.52 (s, 9H), 1.33–1.25 (m, 2H), 1.01 (d, <i>J</i> = 4.0 Hz, 3H), 0.99 (d, <i>J</i> = 4.0 Hz, 3H). MS (ESI) <i>m/z</i>: 444.3 (M + H)<sup>+</sup>. Analytical chiral HPLC: 100% ee, <i>t</i><sub>R</sub> = 5.39 min.</div></div><div id="sec5_1_22_67" class="NLM_sec NLM_sec_level_4"><div id="ac_i121" class="anchor-spacer"></div><h5 class="article-section__title" id="_i121"> (<i>R</i>)-<i>tert</i>-Butyl (1-((4-Bromo-3-methoxyphenyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (<b>76</b>)</h5><div class="NLM_p last">To a mixture of 4-bromo-3-methoxyaniline (<b>75</b>) (4.00 g, 19.8 mmol) and (<i>R</i>)-2-(<i>tert</i>-butoxycarbonylamino)-4-methylpentanoic acid (6.87 g, 29.7 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (40 mL) at room temperature were added HATU (11.29 g, 29.7 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (17.3 mL, 99 mmol). The reaction mixture was stirred at room temperature for 12 h. The reaction mixture was transferred to a separatory funnel containing NaHCO<sub>3</sub> solution. The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 100 mL). The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (30–40% EtOAc in hexanes) to afford <b>76</b> (7.00 g, 16.9 mmol, 85% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.09 (s, 1H), 7.47–7.44 (m, 1H), 7.19 (dd, <i>J</i> = 8.8, 2.3 Hz, 1H), 7.06 (d, <i>J</i> = 7.8 Hz, 1H), 4.15–4.06 (m, 1H), 3.81 (s, 3H), 1.72–1.58 (m, 1H), 1.58–1.47 (m, 1H), 1.45–1.40 (m, 1H), 1.38 (s, 9H), 0.89 (br d, <i>J</i> = 6.5 Hz, 3H), 0.89 (br d, <i>J</i> = 6.5 Hz, 3H). MS (ESI) <i>m</i>/<i>z</i>: 415.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_68" class="NLM_sec NLM_sec_level_4"><div id="ac_i122" class="anchor-spacer"></div><h5 class="article-section__title" id="_i122"> <i>tert</i>-Butyl (<i>R</i>)-(1-((3-Methoxy-4-(thiazol-5-yl)phenyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (<b>77</b>)</h5><div class="NLM_p">Step 1: (<i>R</i>)-<i>tert</i>-Butyl 1-(4-bromo-3-methoxyphenylamino)-4-methyl-1-oxopentan-2-ylcarbamate (<b>76</b>) (300 mg, 0.722 mmol), bispinacolato(diboron) (275 mg, 1.08 mmol), potassium acetate (213 mg, 2.17 mmol), and 1,4-dioxane (4 mL) were combined, and dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (59.4 mg, 0.072 mmol) was added to the suspension. The reaction mixture was placed under N<sub>2</sub> and heated at 80 °C overnight. The mixture was cooled to room temperature and filtered through a pad of Celite. The filtrate was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (10 mL). The aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine (10 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (20–35% EtOAc in hexanes) to afford (<i>R</i>)-<i>tert</i>-butyl 1-(3-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylamino)-4-methyl-1-oxopentan-2-ylcarbamate (95 mg, 0.206 mmol, 28% yield) as a white amorphous solid. <sup>1</sup>H NMR (500 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.49 (d, <i>J</i> = 7.9 Hz, 1H), 7.30 (d, <i>J</i> = 1.5 Hz, 1H), 7.21 (dd, <i>J</i> = 6.3, 2.0 Hz, 1H), 4.12 (br s, 1H), 3.72 (s, 3H), 1.65 (br s, 1H), 1.57–1.49 (m, 1H), 1.46–1.40 (m, 1H), 1.39 (s, 9H), 1.26 (s, 6H), 1.18 (s, 6H), 0.90 (d, <i>J</i> = 6.7 Hz, 3H), 0.90 (d, <i>J</i> = 6.1 Hz, 3H).</div><div class="NLM_p last">Step 2: 5-Bromothiazole (23.5 mg, 0.143 mmol), (<i>R</i>)-<i>tert</i>-butyl 1-(3-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenylamino)-4-methyl-1-oxopentan-2-ylcarbamate (53 mg, 0.115 mmol), potassium phosphate (97 mg, 0.458 mmol), and 1,4-dioxane were combined in a vial. Nitrogen was bubbled through the reaction mixture for several minutes. Dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloromethane adduct (9.4 mg, 0.011 mmol) was added. The cap was sealed, and the reaction mixture was heated at 100 °C for 4 h. The reaction mixture was cooled to room temperature and transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (2 mL). The aqueous layer was extracted with EtOAc (3 × 5 mL). The combined organic layers were washed with brine (2 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (20–60% EtOAc in hexanes) to afford <b>77</b> (31 mg, 0.074 mmol, 65% yield) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.15 (s, 1H), 9.02 (s, 1H), 8.31 (s, 1H), 7.71 (d, <i>J</i> = 8.6 Hz, 1H), 7.53 (d, <i>J</i> = 2.0 Hz, 1H), 7.31 (dd, <i>J</i> = 8.4, 1.9 Hz, 1H), 7.08 (d, <i>J</i> = 8.1 Hz, 1H), 4.17–4.09 (m, 1H), 3.89 (s, 3H), 1.72–1.61 (m, 1H), 1.59–1.48 (m, 1H), 1.47–1.42 (m, 1H), 1.38 (s, 9H), 0.90 (d, <i>J</i> = 6.3 Hz, 3H), 0.90 (d, <i>J</i> = 6.5 Hz, 3H). MS (ESI) <i>m/z</i>: 420.2 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_69" class="NLM_sec NLM_sec_level_4"><div id="ac_i123" class="anchor-spacer"></div><h5 class="article-section__title" id="_i123"> 1-Ethynyl-2-methoxy-4-nitrobenzene (<b>79</b>)</h5><div class="NLM_p">Step 1: 1-Bromo-2-methoxy-4-nitrobenzene (<b>78</b>) (3.00 g, 12.9 mmol), ethynyltrimethylsilane (1.27 g, 12.9 mmol), triethylamine (5.41 mL, 38.8 mmol), and CH<sub>2</sub>Cl<sub>2</sub> (60 mL) were combined, and N<sub>2</sub> was bubbled into the reaction mixture for 5 min. Copper(I) iodide (0.172 g, 0.905 mmol) and Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub> (0.908 g, 1.29 mmol) were then added, and the mixture was heated at reflux for 16 h. The mixture was cooled to room temperature and transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (50 mL). The aqueous layer was extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine (50 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (5–10% EtOAc in hexanes) to afford ((2-methoxy-4-nitrophenyl)ethynyl)trimethylsilane (2.75 g, 10.99 mmol, 85% yield) as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.77 (dd, <i>J</i> = 8.3, 2.3 Hz, 1H), 7.73–7.68 (m, 1H), 7.53 (d, <i>J</i> = 8.6 Hz, 1H), 3.95 (s, 3H), 0.28–0.25 (m, 9H). MS (ESI) <i>m/z</i>: 249.43 M<sup>+</sup>.</div><div class="NLM_p last">Step 2: A solution of ((2-methoxy-4-nitrophenyl)ethynyl)trimethylsilane (2.65 g, 10.6 mmol) in THF (70 mL) was treated with tetrabutylammonium fluoride (15.9 mL, 15.9 mmol). The mixture was stirred at room temperature for 1 h. The reaction mixture was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (50 mL). The aqueous layer was extracted with Et<sub>2</sub>O (3 × 100 mL). The combined organic layers were washed with brine (50 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (5–10% EtOAc in hexanes) to afford <b>79</b> (1.04 g, 5.88 mmol, 55% yield) as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.80 (dd, <i>J</i> = 8.4, 2.1 Hz, 1H), 7.73 (d, <i>J</i> = 2.0 Hz, 1H), 7.58 (d, <i>J</i> = 8.3 Hz, 1H), 3.99 (s, 3H), 3.53 (s, 1H).</div></div><div id="sec5_1_22_70" class="NLM_sec NLM_sec_level_4"><div id="ac_i124" class="anchor-spacer"></div><h5 class="article-section__title" id="_i124"> 4-(2-Methoxy-4-nitrophenyl)-2<i>H</i>-1,2,3-triazole (<b>80</b>)</h5><div class="NLM_p last">A mixture of 1-ethynyl-2-methoxy-4-nitrobenzene (<b>79</b>) (200 mg, 1.13 mmol) and azidotrimethylsilane (3.00 mL, 22.6 mmol) in a pressure tube was heated at 125 °C for 16 h. The reaction mixture was cooled to 0 °C and diluted with hexanes (3 mL). The solid was collected on a Buchner funnel to afford <b>80</b> (100 mg). The filtrate was concentrated and taken up in cold Et<sub>2</sub>O/hexane (1:1), and the solid was collected on a Buchner funnel to afford additional <b>80</b> (26 mg). In total, 126 mg (0.573 mmol, 51% yield) of <b>80</b> was isolated as a yellow solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 15.05 (br s, 1H), 8.32 (s, 1H), 8.27 (d, <i>J</i> = 8.8 Hz, 1H), 7.98–7.87 (m, 2H), 4.08 (s, 3H). MS (ESI) <i>m/z</i>: 221.26 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_71" class="NLM_sec NLM_sec_level_4"><div id="ac_i125" class="anchor-spacer"></div><h5 class="article-section__title" id="_i125"> 4-(2-Methoxy-4-nitrophenyl)-1<i>H</i>-pyrazole (<b>81</b>)</h5><div class="NLM_p">Step 1: 1-Bromo-2-methoxy-4-nitrobenzene (<b>78</b>) (500 mg, 2.16 mmol), 1<i>H</i>-pyrazol-4-ylboronic acid (362 mg, 3.23 mmol), sodium carbonate (2 M aq) (3.23 mL, 6.46 mmol), and DME (10 mL) were combined, and N<sub>2</sub> was bubbled through the reaction mixture for ca. 5 min. Tetrakis(triphenylphosphine)palladium(0) (249 mg, 0.215 mmol) was then added, and the reaction mixture was heated at 80 °C for 20 h. The reaction mixture was cooled to room temperature and transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (10 mL). The aqueous layer was extracted with EtOAc (3 × 25 mL). The combined organic layers were washed with brine (10 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The solid was triturated with hexanes/EtOAc. The suspension was cooled to 0 °C and collected on a Buchner funnel to afford 4-(2-methoxy-4-nitrophenyl)-1<i>H</i>-pyrazole (219 mg) as a yellow solid. The filtrate was concentrated and purified by column chromatography on silica gel to afford additional 4-(2-methoxy-4-nitrophenyl)-1<i>H</i>-pyrazole (73 mg) as a yellow solid. In total, 4-(2-methoxy-4-nitrophenyl)-1<i>H</i>-pyrazole (292 mg, 1.34 mmol, 62% yield) was isolated as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.18 (br. s., 1H), 8.37 (s, 1H), 8.14 (d, <i>J</i> = 1.3 Hz, 1H), 7.96–7.90 (m, 1H), 7.88–7.81 (m, 2H), 4.03 (s, 3H). MS (ESI) <i>m/z</i>: 220.1 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Step 2: To a solution of 4-(2-methoxy-4-nitrophenyl)-1<i>H</i>-pyrazole (200 mg, 0.912 mmol) in DMF (6 mL) at room temperature was added NaH (91 mg, 2.28 mmol). The reaction mixture was stirred at room temperature for 10 min. Iodomethane (0.143 mL, 2.28 mmol) was then added via a syringe, and the reaction mixture was stirred at room temperature for 30 min. The reaction was quenched by the addition of water (2 mL) with ice-water cooling. The reaction mixture was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (15 mL). The aqueous layer was extracted with EtOAc (3 × 25 mL). The combined organic layers were washed with water (2 × 15 mL) and brine (15 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (50–90% EtOAc in hexanes; 12 g column) to afford <b>81</b> (187 mg, 0.802 mmol, 88% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.35 (s, 1H), 8.08 (s, 1H), 7.91–7.81 (m, 3H), 4.02 (s, 3H), 3.90 (s, 3H). MS (ESI) <i>m/z</i>: 234.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_72" class="NLM_sec NLM_sec_level_4"><div id="ac_i126" class="anchor-spacer"></div><h5 class="article-section__title" id="_i126"> 1-(2-Methoxy-4-nitrophenyl)-1<i>H</i>-imidazole (<b>82</b>)</h5><div class="NLM_p last">Copper(I) iodide (24.6 mg, 0.129 mmol) and <span class="smallcaps smallerCapital">l</span>-histidine (40.1 mg, 0.259 mmol) in DMSO (8 mL) were stirred at 100 °C for 30 min. To this mixture, 1-bromo-2-methoxy-4-nitrobenzene (<b>78</b>) (300 mg, 1.29 mmol), 1<i>H</i>-imidazole (106 mg, 1.55 mmol), and K<sub>2</sub>CO<sub>3</sub> (357 mg, 2.59 mmol) were added. The reaction mixture was stirred at 100 °C for 48 h. The mixture was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution. The aqueous layer was extracted with EtOAc (3 × 25 mL). The combined organic layers were concentrated, and the product was purified by column chromatography on silica gel (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford <b>82</b> (300 mg, 1.25 mmol 97% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.04–7.93 (m, 3H), 7.49 (d, <i>J</i> = 8.5 Hz, 1H), 7.31 (s, 1H), 7.25 (s, 1H), 4.03 (s, 3H). MS (ESI) <i>m</i>/<i>z</i>: 220.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_73" class="NLM_sec NLM_sec_level_4"><div id="ac_i127" class="anchor-spacer"></div><h5 class="article-section__title" id="_i127"> 1-(2-Methoxy-4-nitrophenyl)-1<i>H</i>-1,2,4-triazole (<b>83</b>)</h5><div class="NLM_p last">A mixture of copper(I) iodide (24.6 mg, 0.129 mmol) and <span class="smallcaps smallerCapital">l</span>-histidine (40.1 mg, 0.259 mmol) in DMSO (8 mL) was stirred at 100 °C for 30 min. To this mixture were added 1-bromo-2-methoxy-4-nitrobenzene (<b>78</b>) (300 mg, 1.29 mmol), 1<i>H</i>-1,2,4-triazole (107 mg, 1.55 mmol), and K<sub>2</sub>CO<sub>3</sub> (357 mg, 2.59 mmol). The reaction mixture was stirred at 100 °C for 48 h. The reaction mixture was then transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution. The aqueous layer was extracted with EtOAc (3 × 25 mL). The combined organic extracts were dried over MgSO<sub>4</sub>, filtered, and concentrated in vacuo. The product was purified by column chromatography on silica gel (10% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford <b>83</b> (70 mg, 0.318 mmol, 25% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 9.14 (s, 1H), 8.18 (s, 1H), 8.09 (d, <i>J</i> = 2.3 Hz, 1H), 8.05 (s, 1H), 8.02 (d, <i>J</i> = 2.3 Hz, 1H). MS (ESI) <i>m</i>/<i>z</i>: 221.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_74" class="NLM_sec NLM_sec_level_4"><div id="ac_i128" class="anchor-spacer"></div><h5 class="article-section__title" id="_i128"> 2-(2-Methoxy-4-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (<b>84</b>)</h5><div class="NLM_p last">1-Bromo-2-methoxy-4-nitrobenzene (<b>78</b>) (4.00 g, 17.2 mmol), bis(pinacolato)diboron (6.57 g, 25.9 mmol), potassium acetate (5.08 g, 51.7 mmol), and 1,4-dioxane (100 mL) were combined. (1,1’-Bis(diphenylphosphino)ferrocene)-dichloropalladium(II) dichloromethane complex (1.41 g, 1.72 mmol) was added, and the reaction mixture was heated at 80 °C for 16 h. The mixture was cooled to room temperature and filtered through a pad of Celite. The filtrate was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (100 mL). The aqueous layer was extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with brine (50 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (30–70% EtOAc in hexanes) to afford <b>84</b> (3.35 g, 12.0 mmol, 70% yield) as a light brown solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.81 (d, <i>J</i> = 1.0 Hz, 2H), 7.69 (s, 1H), 3.95 (s, 3H), 1.39 (s, 12H).</div></div><div id="sec5_1_22_75" class="NLM_sec NLM_sec_level_4"><div id="ac_i129" class="anchor-spacer"></div><h5 class="article-section__title" id="_i129"> 4-(2-Methoxy-4-nitrophenyl)pyridazine (<b>85</b>)</h5><div class="NLM_p last">2-(2-Methoxy-4-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (<b>84</b>) (0.750 g, 2.69 mmol), 4-bromopyridazine (0.427 g, 2.69 mmol), cesium carbonate (1.75 g, 5.37 mmol), copper(I) chloride (0.266 g, 2.69 mmol), and DMF (18 mL) were combined. N<sub>2</sub> was bubbled into the reaction mixture for 5 min. Dppf (0.149 g, 0.269 mmol) and Pd(OAc)<sub>2</sub> (0.030 g, 0.134 mmol) were then added, and the reaction mixture was stirred at 100 °C for 16 h. The mixture was cooled to room temperature and filtered through a pad of Celite with EtOAc rinsing. The filtrate was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (25 mL). The aqueous layer was extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine (25 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (1–7% MeOH in CH<sub>2</sub>Cl<sub>2</sub>) to afford <b>85</b> (0.169 g, 0.726 mmol, 27% yield) as a light brown solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.42 (dd, <i>J</i> = 2.3, 1.3 Hz, 1H), 9.31 (dd, <i>J</i> = 5.4, 1.1 Hz, 1H), 8.02 (dd, <i>J</i> = 8.3, 2.0 Hz, 1H), 7.92 (d, <i>J</i> = 2.3 Hz, 1H), 7.68 (dd, <i>J</i> = 5.4, 2.4 Hz, 1H), 7.56 (d, <i>J</i> = 8.3 Hz, 1H), 4.01 (s, 3H). MS (ESI) <i>m/z</i>: 232.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_76" class="NLM_sec NLM_sec_level_4"><div id="ac_i130" class="anchor-spacer"></div><h5 class="article-section__title" id="_i130"> 4-(2-Methoxy-4-nitrophenyl)pyrimidine (<b>86</b>)</h5><div class="NLM_p last">To a reaction vessel containing 2-(2-methoxy-4-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (<b>84</b>) (300 mg, 1.08 mmol), 4-chloropyrimidine (222 mg, 1.94 mmol), and K<sub>3</sub>PO<sub>4</sub> (684 mg, 3.22 mmol) were added THF (5 mL) and water (1 mL). The reaction vessel was evacuated and refilled with argon three times. The mixture was then degassed by sonication for 2 min. A second-generation XPhos precatalyst (42.2 mg, 0.054 mmol) was then added. The vessel was sealed, and the mixture was then heated to 70 °C for 16 h. The mixture was transferred to a separatory funnel containing water (20 mL). The aqueous layer was extracted with EtOAc (3 × 25 mL). The combined organic layers were washed with brine (20 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (20–60% EtOAc in hexanes; 40 g column) to afford <b>86</b> (245 mg, 1.06 mmol, 99% yield) as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.35 (d, <i>J</i> = 1.3 Hz, 1H), 8.82 (d, <i>J</i> = 5.3 Hz, 1H), 8.23 (d, <i>J</i> = 8.5 Hz, 1H), 8.03–7.97 (m, 2H), 7.91 (d, <i>J</i> = 2.0 Hz, 1H), 4.05 (s, 3H). MS (ESI) <i>m/z</i>: 232.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_77" class="NLM_sec NLM_sec_level_4"><div id="ac_i131" class="anchor-spacer"></div><h5 class="article-section__title" id="_i131"> 4-(2-Methoxy-4-nitrophenyl)pyridin-2-amine (<b>87</b>)</h5><div class="NLM_p last">To a mixture of 4-chloropyridin-2-amine (100 mg, 0.778 mmol), K<sub>3</sub>PO<sub>4</sub> (413 mg, 1.95 mmol), palladium(II) acetate (17.5 mg, 0.078 mmol), and 2-dicyclohexylphosphino-2′,6′-dimethoxy-1,1′-biphenyl (SPhos) (63.9 mg, 0.156 mmol) under N<sub>2</sub> in a vial was added 2-(2-methoxy-4-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (<b>84</b>) (239 mg, 0.856 mmol) in <i>n</i>-butanol (2 mL). The reaction mixture was heated at 100 °C for 4.5 h. The mixture was cooled to room temperature and filtered through a pad of Celite with MeOH rinsing, and the filtrate was concentrated. The product was purified by column chromatography on silica gel (1–4% MeOH in CH<sub>2</sub>Cl<sub>2</sub>; 12 g column) to afford <b>87</b> (120 mg, 0.539 mmol, 63% yield) as a pale yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.97 (dd, <i>J</i> = 5.3, 0.8 Hz, 1H), 7.92 (dd, <i>J</i> = 8.3, 2.3 Hz, 1H), 7.89 (d, <i>J</i> = 2.3 Hz, 1H), 7.57 (d, <i>J</i> = 8.5 Hz, 1H), 6.61 (dd, <i>J</i> = 5.3, 1.5 Hz, 1H), 6.58 (dd, <i>J</i> = 1.3, 0.8 Hz, 1H), 6.04 (s, 2H), 3.93 (s, 3H). MS (ESI) <i>m</i>/<i>z</i>: 246.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_78" class="NLM_sec NLM_sec_level_4"><div id="ac_i132" class="anchor-spacer"></div><h5 class="article-section__title" id="_i132"> 3-(2-Methoxy-4-nitrophenyl)pyridine (<b>88</b>)</h5><div class="NLM_p last">To a mixture of 1-bromo-2-methoxy-4-nitrobenzene (<b>78</b>) (1.00 g, 4.31 mmol), 3-pyridylboronic acid (0.583 g, 4.74 mmol), and tetrakis(triphenylphosphine)palladium(0) (0.249 g, 0.215 mmol) in toluene (30 mL) and ethanol (7.50 mL) was added a solution of Na<sub>2</sub>CO<sub>3</sub> (1.370 g, 12.9 mmol) in water (10 mL). The reaction mixture was heated at reflux for 12 h. The mixture was transferred to a separatory funnel containing water. The aqueous layer was extracted with EtOAc (3 × 50 mL). The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (10–50% EtOAc in hexanes, 40 g column) to afford <b>88</b> (750 mg, 3.26 mmol, 76% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.74 (d, <i>J</i> = 1.8 Hz, 1H), 8.61 (dd, <i>J</i> = 4.8, 1.5 Hz, 1H), 8.01–7.92 (m, 2H), 7.91 (d, <i>J</i> = 2.0 Hz, 1H), 7.67 (d, <i>J</i> = 8.3 Hz, 1H), 7.54–7.48 (m, 1H), 3.93 (s, 3H). MS (ESI) <i>m/z</i>: 231.2 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_79" class="NLM_sec NLM_sec_level_4"><div id="ac_i133" class="anchor-spacer"></div><h5 class="article-section__title" id="_i133"> 3-Methoxy-4-(2<i>H</i>-1,2,3-triazol-4-yl)aniline (<b>89a</b>)</h5><div class="NLM_p">4-(2-Methoxy-4-nitrophenyl)-2<i>H</i>-1,2,3-triazole (<b>80</b>) (120 mg, 0.545 mmol) was dissolved in ethanol (25 mL) and chloroform (5 mL) in a Parr bottle. Palladium on carbon (10%, Degussa type) (100 mg, 0.047 mmol) was added, and the mixture was placed on the Parr shaker under H<sub>2</sub> at 40 psi for 1.5 h. The catalyst was removed by filtration through a pad of Celite, and the filtrate was concentrated. The product was purified by column chromatography on silica gel (2–15% MeOH in CH<sub>2</sub>Cl<sub>2</sub>; 12 g column) to afford <b>89a</b> (100 mg, 0.526 mmol, 96% yield) as a brown amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.06 (s, 1H), 7.79 (d, <i>J</i> = 7.6 Hz, 1H), 6.69 (s, 1H), 6.61 (d, <i>J</i> = 7.8 Hz, 1H), 3.86 (s, 3H), 3.16 (s, 2H). MS (ESI) <i>m/z</i>: 191.3 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Reduction of the nitro group in compounds <b>81</b>–<b>83</b>, <b>85</b>, and <b>88</b> to form compounds <b>89b</b>–<b>89e</b> and <b>89h</b>, respectively, was carried out as described in the representative procedure for the preparation of <b>89a</b> above.</div></div><div id="sec5_1_22_80" class="NLM_sec NLM_sec_level_4"><div id="ac_i134" class="anchor-spacer"></div><h5 class="article-section__title" id="_i134"> 3-Methoxy-4-(1-methyl-1<i>H</i>-pyrazol-4-yl)aniline (<b>89b</b>)</h5><div class="NLM_p last">Light brown solid (99% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.65 (br. s., 2H), 8.09 (s, 1H), 7.86 (s, 1H), 7.60 (d, <i>J</i> = 8.3 Hz, 1H), 6.94 (d, <i>J</i> = 2.0 Hz, 1H), 6.83 (dd, <i>J</i> = 8.2, 1.9 Hz, 1H), 3.86 (s, 3H), 3.86 (s, 3H). MS (ESI) <i>m/z</i>: 204.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_81" class="NLM_sec NLM_sec_level_4"><div id="ac_i135" class="anchor-spacer"></div><h5 class="article-section__title" id="_i135"> 4-(1<i>H</i>-Imidazol-1-yl)-3-methoxyaniline (<b>89c</b>)</h5><div class="NLM_p last">Gray solid (70% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.94 (s, 1H), 7.11 (s, 1H), 7.06 (s, 1H), 6.87 (d, <i>J</i> = 8.3 Hz, 1H), 6.27 (d, <i>J</i> = 2.3 Hz, 1H), 6.20–6.16 (m, 1H), 3.62 (s, 3H). MS (ESI) <i>m/z</i>: 190.2 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_82" class="NLM_sec NLM_sec_level_4"><div id="ac_i136" class="anchor-spacer"></div><h5 class="article-section__title" id="_i136"> 3-Methoxy-4-(1<i>H</i>-1,2,4-triazol-1-yl)aniline (<b>89d</b>)</h5><div class="NLM_p last">Gray solid (83% yield). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.51 (s, 1H), 8.05 (s, 1H), 7.45–7.38 (m, 1H), 6.39–6.33 (m, 2H), 3.83 (s, 3H). MS (ESI) <i>m/</i>z: 191.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_83" class="NLM_sec NLM_sec_level_4"><div id="ac_i137" class="anchor-spacer"></div><h5 class="article-section__title" id="_i137"> 3-Methoxy-4-(pyridazin-4-yl)aniline (<b>89e</b>)</h5><div class="NLM_p last">Light brown solid (100% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.64 (d, <i>J</i> = 2.0 Hz, 1H), 9.28 (d, <i>J</i> = 6.0 Hz, 1H), 8.33 (dd, <i>J</i> = 6.0, 2.5 Hz, 1H), 7.66 (d, <i>J</i> = 8.8 Hz, 1H), 6.59 (d, <i>J</i> = 1.8 Hz, 1H), 6.54 (dd, <i>J</i> = 8.7, 1.9 Hz, 1H), 3.87 (s, 3H). MS (ESI) <i>m/z</i>: 202.2 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_84" class="NLM_sec NLM_sec_level_4"><div id="ac_i138" class="anchor-spacer"></div><h5 class="article-section__title" id="_i138"> 3-Methoxy-4-(pyridin-3-yl)aniline (<b>89h</b>)</h5><div class="NLM_p last">Gray solid (92% yield). <sup>1</sup>H NMR (500 MHz, CD<sub>3</sub>OD) δ 8.66 (dd, <i>J</i> = 2.1, 0.6 Hz, 1H), 8.38 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H), 7.97–7.90 (m, 1H), 7.43 (ddd, <i>J</i> = 8.1, 5.0, 0.8 Hz, 1H), 7.07 (d, <i>J</i> = 8.2 Hz, 1H), 6.47 (d, <i>J</i> = 2.0 Hz, 1H), 6.41 (dd, <i>J</i> = 8.1, 2.1 Hz, 1H), 3.75 (s, 3H). MS (ESI) <i>m/</i>z: 205.2 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_85" class="NLM_sec NLM_sec_level_4"><div id="ac_i139" class="anchor-spacer"></div><h5 class="article-section__title" id="_i139"> 3-Methoxy-4-(pyrimidin-4-yl)aniline (<b>89f</b>)</h5><div class="NLM_p last">To a solution of 4-(2-methoxy-4-nitrophenyl)pyrimidine (<b>86</b>) (95 mg, 0.411 mmol) in ethanol (4 mL) were added ammonium chloride (264 mg, 4.93 mmol) and zinc powder (376 mg, 5.75 mmol). The reaction mixture was heated at 70 °C for 1.5 h. The reaction mixture was cooled to room temperature and filtered through a pad of Celite. The filtrate was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (10 mL). The aqueous layer was extracted with 5% MeOH in CH<sub>2</sub>Cl<sub>2</sub> (3 × 10 mL). The combined organic layers were washed with brine (10 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (90% EtOAc with 2% MeOH/10% hexanes; 24 g column) to afford <b>89f</b> (50.6 mg, 0.251 mmol, 61% yield) as an off-white solid. <sup>1</sup>H NMR (500 MHz, CDCl<sub>3</sub>) δ 9.18 (d, <i>J</i> = 1.2 Hz, 1H), 8.61 (d, <i>J</i> = 5.5 Hz, 1H), 8.02 (d, <i>J</i> = 8.4 Hz, 1H), 7.96 (dd, <i>J</i> = 5.6, 1.4 Hz, 1H), 6.43 (dd, <i>J</i> = 8.4, 2.1 Hz, 1H), 6.30 (d, <i>J</i> = 2.1 Hz, 1H), 3.90 (s, 3H). MS (ESI) <i>m/z</i>: 202.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_86" class="NLM_sec NLM_sec_level_4"><div id="ac_i140" class="anchor-spacer"></div><h5 class="article-section__title" id="_i140"> 4-(4-Amino-2-methoxyphenyl)pyridin-2-amine (<b>89g</b>)</h5><div class="NLM_p last">A mixture of 4-(2-methoxy-4-nitrophenyl)pyridin-2-amine (<b>87</b>) (110 mg, 0.449 mmol) and tin(II) chloride dihydrate (595 mg, 3.14 mmol) in ethanol (10 mL) was heated to 70 °C for 20 min. To this mixture was added ammonium hydroxide solution (10 mL), and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was transferred to a separatory funnel containing brine (20 mL). The aqueous layer was extracted with EtOAc (2 × 20 mL). The combined organic layers were dried over MgSO<sub>4</sub>, filtered, and concentrated to afford <b>89g</b> (90 mg, 0.418 mmol, 93% yield) as red oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.92–7.65 (m, 1H), 7.08–6.91 (m, 1H), 6.63–6.46 (m, 2H), 6.37–6.13 (m, 2H), 5.68 (s, 2H), 5.44–5.25 (m, 2H), 3.70 (s, 3H). MS (ESI) <i>m</i>/<i>z</i>: 216.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_87" class="NLM_sec NLM_sec_level_4"><div id="ac_i141" class="anchor-spacer"></div><h5 class="article-section__title" id="_i141"> 2-Chloro-4-(2-methoxy-4-nitrophenyl)pyridine (<b>90</b>)</h5><div class="NLM_p last">To a mixture of 1-bromo-2-methoxy-4-nitrobenzene (<b>78</b>) (1.00 g, 4.31 mmol) and 2-chloropyridin-4-ylboronic acid (1.02 g, 6.46 mmol) in THF (20 mL) were added sodium carbonate (2 M in H<sub>2</sub>O) (6.46 mL, 12.9 mmol) and bis(triphenylphosphine)palladium(II) chloride (0.151 g, 0.215 mmol). N<sub>2</sub> was bubbled into the reaction mixture for 2 min. The reaction mixture was heated at 70 °C for 2 h. The mixture was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (25 mL). The aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with brine (20 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (20–50% EtOAc in hexanes; 40 g column) to afford <b>90</b> (320 mg, 1.21 mmol, 28% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.51 (d, <i>J</i> = 5.5 Hz, 1H), 7.96–7.92 (m, 2H), 7.74–7.70 (m, 2H), 7.61 (dd, <i>J</i> = 5.0, 1.5 Hz, 1H), 3.95 (s, 3H). MS (ESI) <i>m</i>/<i>z</i>: 265.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_88" class="NLM_sec NLM_sec_level_4"><div id="ac_i142" class="anchor-spacer"></div><h5 class="article-section__title" id="_i142"> <i>N</i>-Benzyl-4-(2-methoxy-4-nitrophenyl)-<i>N</i>-methylpyridin-2-amine (<b>91</b>)</h5><div class="NLM_p last">A mixture of 2-chloro-4-(2-methoxy-4-nitrophenyl)pyridine (<b>90</b>) (320 mg, 1.21 mmol), <i>N</i>-methyl-1-phenylmethanamine (0.187 mL, 1.45 mmol), and sodium <i>t</i>-butoxide (256 mg, 2.66 mmol) in toluene (10 mL) was placed in a round bottom flask. N<sub>2</sub> gas was bubbled into the reaction mixture for 2 min. Palladium(II) acetate (27.1 mg, 0.121 mmol) and 1,3-bis(diphenylphosphino)propane (100 mg, 0.242 mmol) were added. The dark red mixture was heated at reflux for 14 h. The reaction mixture was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (25 mL). The aqueous layer was extracted with Et<sub>2</sub>O (3 × 25 mL). The combined organic layers were washed with brine (25 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (30% EtOAc in hexanes; 25 g column) to afford a mixture of the desired product and the starting material. This mixture was then purified by preparative reverse phase HPLC (acetonitrile/water with 0.1% TFA) to afford <b>91</b> (150 mg, 0.430 mmol, 35% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.16–8.13 (m, 1H), 7.90 (dd, <i>J</i> = 8.3, 2.3 Hz, 1H), 7.86 (d, <i>J</i> = 2.0 Hz, 1H), 7.62 (d, <i>J</i> = 8.3 Hz, 1H), 7.35–7.29 (m, 2H), 7.27–7.20 (m, 3H), 6.74–6.70 (m, 2H), 4.82 (s, 2H), 3.86 (s, 3H), 3.07 (s, 3H). MS (ESI) <i>m</i>/<i>z</i>: 350.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_89" class="NLM_sec NLM_sec_level_4"><div id="ac_i143" class="anchor-spacer"></div><h5 class="article-section__title" id="_i143"> (<i>R</i>)-<i>tert</i>-Butyl 1-(4-(2-(Benzyl(methyl)amino)pyridin-4-yl)-3-methoxyphenylamino)-4-methyl-1-oxopentan-2-ylcarbamate (<b>92</b>)</h5><div class="NLM_p">Step 1: A mixture of <i>N</i>-benzyl-4-(2-methoxy-4-nitrophenyl)-<i>N</i>-methylpyridin-2-amine (<b>91</b>) (150 mg, 0.429 mmol) and tin(II) chloride dihydrate (484 mg, 2.15 mmol) in EtOAc (10 mL) and ethanol (5.00 mL) was heated to 70 °C for 3 h. The mixture was poured in a flask containing saturated aqueous NaHCO<sub>3</sub> solution (20 mL). The mixture was filtered through Celite. The filtrate was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (15 mL). The aqueous layer was extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with brine (20 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated to afford 4-(4-amino-2-methoxyphenyl)-<i>N</i>-benzyl-<i>N</i>-methylpyridin-2-amine (70 mg, 0.219 mmol, 51% yield) as a green oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.19 (dd, <i>J</i> = 5.3, 0.5 Hz, 1H), 7.39–7.23 (m, 5H), 7.16 (d, <i>J</i> = 8.1 Hz, 1H), 6.77 (dd, <i>J</i> = 5.2, 1.4 Hz, 1H), 6.72 (s, 1H), 6.35 (dd, <i>J</i> = 8.1, 2.0 Hz, 1H), 6.31 (d, <i>J</i> = 2.0 Hz, 1H), 4.84 (s, 2H), 3.82 (s, 2H), 3.74 (s, 3H), 3.12 (s, 3H). MS (ESI) <i>m</i>/<i>z</i>: 320.2 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Step 2: To a mixture of 4-(4-amino-2-methoxyphenyl)-<i>N</i>-benzyl-<i>N</i>-methylpyridin-2-amine (75 mg, 0.235 mmol) and (<i>R</i>)-2-(<i>tert</i>-butoxycarbonylamino)-4-methylpentanoic acid (109 mg, 0.470 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) were added <i>N</i>,<i>N</i>-diisopropylethylamine (0.205 mL, 1.17 mmol) and <i>O</i>-benzotriazol-1-yl-<i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyluronium tetrafluoroborate (TBTU) (151 mg, 0.470 mmol). The reaction mixture was stirred at room temperature for 12 h. The reaction mixture was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (25 mL). The aqueous layer was extracted with EtOAc (3 × 25 mL). The combined organic layers were washed with brine (25 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (50–70% EtOAc in hexanes; 25 g column) to afford <b>92</b> (110 mg, 0.207 mmol, 88% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.19 (br. s., 1H), 8.13 (d, <i>J</i> = 5.3 Hz, 1H), 8.01 (s, 1H), 7.33–7.29 (m, 1H), 7.28–7.25 (m, 2H), 7.24–7.19 (m, 3H), 7.09 (d, <i>J</i> = 9.3 Hz, 1H), 7.06–7.01 (m, 1H), 6.64 (d, <i>J</i> = 4.8 Hz, 1H), 6.56 (br. s., 1H), 4.73 (s, 2H), 4.20 (t, <i>J</i> = 7.3 Hz, 1H), 3.65 (s, 3H), 3.00 (s, 3H), 1.90 (br. s., 1H), 1.64 (br. s., 1H), 1.45 (s, 9H), 1.30–1.21 (m, 1H), 1.01 (d, <i>J</i> = 6.8 Hz, 3H), 0.95–0.89 (m, 3H). MS (ESI) <i>m</i>/<i>z</i>: 533.3 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_90" class="NLM_sec NLM_sec_level_4"><div id="ac_i144" class="anchor-spacer"></div><h5 class="article-section__title" id="_i144"> 5-(2-Bromo-4-nitrophenyl)oxazole (<b>94</b>)</h5><div class="NLM_p last">To a solution of 2-bromo-4-nitrobenzaldehyde (<b>93</b>) (700 mg, 3.04 mmol) and TosMIC (594 mg, 3.04 mmol) in MeOH (7 mL) was added potassium carbonate (442 mg, 3.20 mmol). The reaction mixture was heated at reflux for 3 h. The reaction mixture was cooled to room temperature and transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (25 mL). The aqueous layer was extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with brine (25 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (30–40% EtOAc in hexanes; 80 g column) to afford <b>94</b> (701 mg, 2.61 mmol, 86% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.56 (d, <i>J</i> = 2.3 Hz, 1H), 8.25 (dd, <i>J</i> = 8.8, 2.3 Hz, 1H), 8.13 (s, 1H), 8.05 (s, 1H), 7.97 (d, <i>J</i> = 8.8 Hz, 1H). MS (ESI) <i>m/z</i>: 269.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_91" class="NLM_sec NLM_sec_level_4"><div id="ac_i145" class="anchor-spacer"></div><h5 class="article-section__title" id="_i145"> (<i>R</i>)-<i>tert</i>-Butyl (4-Methyl-1-((3-methyl-4-(oxazol-5-yl)phenyl)amino)-1-oxopentan-2-yl)carbamate (<b>95</b>)</h5><div class="NLM_p">Step 1: 5-(2-Bromo-4-nitrophenyl)oxazole (<b>94</b>) (310 mg, 1.15 mmol), tin(II) chloride dihydrate (0.959 mL, 11.5 mmol), and EtOH (8 mL) were combined and heated at 75 °C for 1 h. The reaction mixture was cooled to room temperature and concentrated. The residue was dissolved in EtOAc and slowly poured into an Erlenmeyer flask containing saturated aqueous NaHCO<sub>3</sub> solution. The mixture was then filtered through a pad of Celite to remove the solids (rinsed with EtOAc). The filtrate was poured into a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (50 mL). The aqueous layer was extracted with EtOAc (3 × 25 mL). The combined organic layers were washed with brine (25 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (30–50% EtOAc in hexanes; 12 g column) to afford 3-bromo-4-(oxazol-5-yl)aniline (293 mg, 1.23 mmol, quantitative yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.37 (s, 1H), 7.45 (s, 1H), 7.37 (d, <i>J</i> = 8.3 Hz, 1H), 6.91 (d, <i>J</i> = 2.3 Hz, 1H), 6.64 (dd, <i>J</i> = 8.6, 2.3 Hz, 1H), 5.78 (s, 2H). MS (ESI) <i>m/z</i>: 239.1 (M + H)<sup>+</sup>.</div><div class="NLM_p">Step 2: To a mixture of 3-bromo-4-(oxazol-5-yl)aniline (0.272 g, 1.14 mmol), (<i>R</i>)-2-(<i>tert</i>-butoxycarbonylamino)-4-methylpentanoic acid (0.789 g, 3.41 mmol), and <i>N</i>,<i>N</i>-diisopropylethylamine (0.994 mL, 5.69 mmol) in DCE (8 mL) was added HATU (1.30 g, 3.41 mmol). The reaction mixture was stirred at room temperature for 10 min and was then heated at 40 °C for 18 h. The reaction mixture was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (10 mL). The aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine (10 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (30–45% EtOAc in hexanes; 80 g column) to afford (<i>R</i>)-<i>tert</i>-butyl 1-(3-bromo-4-(oxazol-5-yl)phenylamino)-4-methyl-1-oxopentan-2-ylcarbamate (0.480 g, 1.06 mmol, 93% yield) as a white amorphous solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.32 (s, 1H), 8.52 (s, 1H), 8.17 (d, <i>J</i> = 1.8 Hz, 1H), 7.78–7.63 (m, 3H), 7.14 (d, <i>J</i> = 7.6 Hz, 1H), 4.16–4.07 (m, 1H), 1.73–1.60 (m, 1H), 1.59–1.49 (m, 1H), 1.47–1.40 (m, 1H), 1.38 (s, 9H), 0.90 (d, <i>J</i> = 6.3 Hz, 3H), 0.89 (d, <i>J</i> = 6.6 Hz, 3H). MS (ESI) <i>m/z</i>: 452.2 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Step 3: (<i>R</i>)-<i>tert</i>-Butyl (1-((3-bromo-4-(oxazol-5-yl)phenyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (65 mg, 0.144 mmol), methylboronic acid (21.5 mg, 0.359 mmol), sodium carbonate (2 M, aq) (0.144 mL, 0.287 mmol), toluene (1.0 mL), and MeOH (0.2 mL) were combined in a vial. Argon was bubbled into the reaction mixture for 5 min. Tetrakis(triphenylphosphine)palladium(0) (16.6 mg, 0.014 mmol) was then added to the mixture, and it was heated at 90 °C for 8 h. The reaction mixture was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (5 mL). The aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine (5 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (30–50% EtOAc in hexanes; 24 g column) to afford <b>95</b> (48.7 mg, 0.126 mmol, 87% yield) as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.92 (s, 1H), 7.57 (d, <i>J</i> = 8.0 Hz, 1H), 7.49–7.40 (m, 2H), 7.18 (s, 1H), 5.04 (d, <i>J</i> = 8.0 Hz, 1H), 4.31 (br. s., 1H), 2.42 (s, 3H), 1.84–1.74 (m, 2H), 1.66–1.56 (m, 1H), 1.49 (s, 9H), 1.01 (d, <i>J</i> = 6.8 Hz, 3H), 0.99 (d, <i>J</i> = 5.8 Hz, 3H). MS (ESI) <i>m</i>/<i>z</i>: 410.3 (M + Na)<sup>+</sup>.</div></div><div id="sec5_1_22_92" class="NLM_sec NLM_sec_level_4"><div id="ac_i146" class="anchor-spacer"></div><h5 class="article-section__title" id="_i146"> 5-(4-Nitro-2-vinylphenyl)oxazole (<b>96</b>)</h5><div class="NLM_p">Step 1: To a solution of 2-bromo-4-nitrobenzaldehyde (<b>93</b>) (500 mg, 2.17 mmol) in anhydrous toluene (15 mL) were added vinylboronic anhydride pyridine complex (785 mg, 3.26 mmol) and sodium carbonate (2 M aq.) (3.26 mL, 6.52 mmol). The solution was degassed with N<sub>2</sub> for 3 min. Tetrakis(triphenylphosphine)palladium(0) (251 mg, 0.217 mmol) was subsequently added to the reaction mixture, and the mixture was heated at 100 °C under N<sub>2</sub> for 6.5 h. The reaction mixture was cooled to room temperature and transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (5 mL). The aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine (5 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (5–20% EtOAc in hexanes) to afford 4-nitro-2-vinylbenzaldehyde (237 mg, 1.35 mmol, 62% yield) as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 10.42 (s, 1H), 8.44 (d, <i>J</i> = 2.3 Hz, 1H), 8.26 (dd, <i>J</i> = 8.4, 2.1 Hz, 1H), 8.04 (d, <i>J</i> = 8.3 Hz, 1H), 7.54 (dd, <i>J</i> = 17.4, 11.1 Hz, 1H), 5.91 (d, <i>J</i> = 17.4 Hz, 1H), 5.75 (d, <i>J</i> = 11.1 Hz, 1H).</div><div class="NLM_p last">Step 2: To a solution of 4-nitro-2-vinylbenzaldehyde (235 mg, 1.33 mmol) and TosMIC (259 mg, 1.33 mmol) in MeOH (5 mL) was added potassium carbonate (192 mg, 1.40 mmol). The reaction mixture was heated at reflux for 2 h. The reaction mixture was cooled to room temperature and was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (50 mL). The aqueous layer was extracted with EtOAc (3 × 75 mL). The combined organic layers were washed with brine (50 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (10–40% EtOAc in hexanes) to afford <b>96</b> (46 mg, 0.213 mmol, 16% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.42 (d, <i>J</i> = 2.3 Hz, 1H), 8.22 (dd, <i>J</i> = 8.7, 2.4 Hz, 1H), 8.07 (s, 1H), 7.86 (d, <i>J</i> = 8.8 Hz, 1H), 7.45 (s, 1H), 7.05 (dd, <i>J</i> = 17.4, 11.1 Hz, 1H), 5.91 (d, <i>J</i> = 17.4 Hz, 1H), 5.62 (d, <i>J</i> = 11.1 Hz, 1H). MS (ESI) <i>m/z</i>: 217.2 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_93" class="NLM_sec NLM_sec_level_4"><div id="ac_i147" class="anchor-spacer"></div><h5 class="article-section__title" id="_i147"> (<i>R</i>)-<i>tert</i>-Butyl 1-(3-Ethyl-4-(oxazol-5-yl)phenylamino)-4-methyl-1-oxopentan-2-ylcarbamate (<b>97</b>)</h5><div class="NLM_p">Step 1: To a solution of 5-(4-nitro-2-vinylphenyl)oxazole (<b>96</b>) (45 mg, 0.208 mmol) in ethanol (20 mL) was added 10% palladium on carbon (44.3 mg, 0.021 mmol). The mixture was placed under H<sub>2</sub> on a Parr shaker at 40 psi for 2 h. The catalyst was then removed by filtration through a pad of Celite, and the filtrate was concentrated to give 3-ethyl-4-(oxazol-5-yl)aniline (45 mg, 0.239 mmol, quantitative yield) as a light brown solid. The crude product was used directly in the next step. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.38 (s, 1H), 7.80 (d, <i>J</i> = 8.3 Hz, 1H), 7.45 (s, 1H), 7.39 (d, <i>J</i> = 2.3 Hz, 1H), 7.34 (dd, <i>J</i> = 8.3, 2.5 Hz, 1H), 2.88 (q, <i>J</i> = 7.6 Hz, 2H), 1.26 (t, <i>J</i> = 7.6 Hz, 3H). MS (ESI) <i>m/z</i>: 189.2 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Step 2: To a mixture of 3-ethyl-4-(oxazol-5-yl)aniline (45 mg, 0.239 mmol), (<i>R</i>)-2-(<i>tert</i>-butoxycarbonylamino)-4-methylpentanoic acid (138 mg, 0.598 mmol), and <i>N</i>,<i>N</i>,-diisopropylethylamine (0.209 mL, 1.20 mmol) in DCE (1.5 mL) was added HATU (227 mg, 0.598 mmol). The reaction mixture was stirred at 40 °C for 16 h. The reaction mixture was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (10 mL). The aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organic layers were washed with brine (10 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (40–70% EtOAc in hexanes; 12 g column) to afford <b>97</b> (47 mg, 0.117 mmol, 49% yield) as a colorless oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.52 (br. s., 1H), 7.94 (s, 1H), 7.63–7.43 (m, 3H), 7.19 (s, 1H), 4.94 (br. s., 1H), 4.27 (br. s., 1H), 2.77 (q, <i>J</i> = 7.6 Hz, 2H), 1.88–1.73 (m, 2H), 1.62–1.56 (m, 1H), 1.49 (s, 9H), 1.25 (t, <i>J</i> = 7.4 Hz, 3H), 1.01 (d, <i>J</i> = 6.5 Hz, 3H), 0.99 (d, <i>J</i> = 6.5 Hz, 3H). MS (ESI) <i>m/z</i>: 302.4 (M + H-C<sub>5</sub>H<sub>8</sub>O<sub>2</sub>)<sup>+</sup>.</div></div><div id="sec5_1_22_94" class="NLM_sec NLM_sec_level_4"><div id="ac_i148" class="anchor-spacer"></div><h5 class="article-section__title" id="_i148"> 5-Nitro-2-(oxazol-5-yl)phenol (<b>98</b>)</h5><div class="NLM_p last">To a solution of 5-(2-methoxy-4-nitrophenyl)oxazole (<b>66</b>) (250 mg, 1.14 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (5 mL) in a pressure vessel was added BBr<sub>3</sub> (0.429 mL, 4.54 mmol, 1 M in CH<sub>2</sub>Cl<sub>2</sub>). The vessel was heated to 80 °C for 12 h. The mixture was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution. The aqueous layer was extracted with EtOAc (3 × 25 mL). The combined organic layers were concentrated, and the product was purified by column chromatography on silica gel (40–70% EtOAc in hexanes) to afford <b>98</b> (120 mg, 0.582 mmol, 51% yield) as a gray solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.31 (s, 1H), 7.89 (d, <i>J</i> = 8.6 Hz, 1H), 7.79 (dd, <i>J</i> = 8.6, 2.3 Hz, 1H), 7.77–7.73 (m, 2H). MS (ESI) <i>m</i>/<i>z</i>: 207.2 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_95" class="NLM_sec NLM_sec_level_4"><div id="ac_i149" class="anchor-spacer"></div><h5 class="article-section__title" id="_i149"> 5-(2-Ethoxy-4-nitrophenyl)oxazole (<b>99</b>)</h5><div class="NLM_p last">A mixture of 5-nitro-2-(oxazol-5-yl)phenol (<b>98</b>) (110 mg, 0.534 mmol) and K<sub>2</sub>CO<sub>3</sub> (81 mg, 0.587 mmol) in DMF (3 mL) was stirred at room temperature for 30 min. To this mixture was added iodoethane (0.047 mL, 0.587 mmol), and the mixture was then heated at 50 °C for 2 h. The mixture was transferred to a separatory funnel containing saturated aqueous NH<sub>4</sub>Cl. The aqueous layer was extracted with EtOAc (3 × 10 mL). The combined organic layers were concentrated, and the product was purified by column chromatography on silica gel (10–30% EtOAc in hexanes) to afford <b>99</b> (120 mg, 0.513 mmol, 96% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.03 (s, 1H), 7.96 (s, 2H), 7.85 (s, 1H), 7.84 (s, 1H), 4.33 (q, <i>J</i> = 6.9 Hz, 2H), 1.64 (t, <i>J</i> = 7.0 Hz, 3H). MS (ESI) <i>m/z</i>: 235.2 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_96" class="NLM_sec NLM_sec_level_4"><div id="ac_i150" class="anchor-spacer"></div><h5 class="article-section__title" id="_i150"> 5-(2-(Difluoromethoxy)-4-nitrophenyl)oxazole (<b>100</b>)</h5><div class="NLM_p last">To a solution of 5-nitro-2-(oxazol-5-yl)phenol (<b>98</b>) (1.40 g, 6.79 mmol) in DMF (15 mL) at room temperature was added potassium carbonate (3.28 g, 23.8 mmol). The resulting suspension was stirred for 20 min and then treated with methyl 2-chloro-2,2-difluoroacetate (1.79 mL, 17.0 mmol). The reaction mixture was heated to 90 °C for 2 h. The reaction mixture was transferred to a flask containing 100 mL water, resulting in the formation of a precipitate that was collected by filtration. The solid was collected and dried in vacuo to afford <b>100</b> (1.40 g, 5.43 mmol, 80% yield) as a yellow solid, which was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.22 (dd, <i>J</i> = 8.8, 2.0 Hz, 1H), 8.15–8.12 (m, 1H), 8.08 (s, 1H), 8.06 (d, <i>J</i> = 8.5 Hz, 1H), 7.83 (s, 1H), 6.78 (t, <i>J</i> = 72.0 Hz, 1H). MS (ESI) <i>m</i>/<i>z</i>: 257.0 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_97" class="NLM_sec NLM_sec_level_4"><div id="ac_i151" class="anchor-spacer"></div><h5 class="article-section__title" id="_i151"> (<i>R</i>)-<i>tert</i>-Butyl (1-((3-Ethoxy-4-(oxazol-5-yl)phenyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (<b>101</b>)</h5><div class="NLM_p">Step 1: 5-(2-Ethoxy-4-nitrophenyl)oxazole (<b>99</b>) (120 mg, 0.512 mmol) was dissolved in ethanol (6 mL) and chloroform (3.00 mL) in a Parr bottle. Ten percent palladium on carbon (109 mg, 0.102 mmol) was added, and the mixture was placed on the Parr shaker under H<sub>2</sub> at 40 psi for 1.5 h. The catalyst was removed by filtration, and the filtrate was concentrated to afford 3-ethoxy-4-(oxazol-5-yl)aniline (104 mg, 0.509 mmol, 99% yield) as a gray solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.33 (s, 1H), 7.58–7.46 (m, 1H), 7.33 (s, 1H), 6.61 (br s, 1H), 6.55 (br d, <i>J</i> = 7.3 Hz, 1H), 5.77 (s, 2H), 4.11 (q, <i>J</i> = 6.9 Hz, 2H), 1.46 (t, <i>J</i> = 6.9 Hz, 3H). MS (ESI) <i>m/z</i>: 205.2 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Step 2: To a mixture of 3-ethoxy-4-(oxazol-5-yl)aniline (104 mg, 0.509 mmol) and (<i>R</i>)-2-(<i>tert</i>-butoxycarbonylamino)-4-methylpentanoic acid (187 mg, 0.808 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (3 mL) at room temperature were added HATU (307 mg, 0.808 mmol) and <i>N</i>,<i>N</i>-diisopropylethylamine (0.470 mL, 2.69 mmol). The reaction mixture was stirred at room temperature for 12 h. The reaction mixture was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution. The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 10 mL). The combined organic layers dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (30–40% EtOAc in hexanes) to afford <b>101</b> (110 mg, 0.263 mmol, 52% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.81 (s, 1H), 7.51 (d, <i>J</i> = 7.3 Hz, 1H), 7.41 (br. s., 1H), 7.33 (br. s., 1H), 6.90 (dd, <i>J</i> = 8.4, 1.9 Hz, 1H), 5.24 (d, <i>J</i> = 7.1 Hz, 1H), 4.34 (br. s., 1H), 4.12–3.89 (m, 2H), 1.79–1.56 (m, 3H), 1.43 (s, 9H), 1.43–1.38 (m, 3H), 0.94 (d, <i>J</i> = 6.5 Hz, 3H), 0.92 (d, <i>J</i> = 6.3 Hz, 3H). MS (ESI) <i>m/z</i>: 418.4 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_98" class="NLM_sec NLM_sec_level_4"><div id="ac_i152" class="anchor-spacer"></div><h5 class="article-section__title" id="_i152"> (<i>R</i>)-<i>tert</i>-Butyl 1-(3-(Difluoromethoxy)-4-(oxazol-5-yl)phenylamino)-4-methyl-1-oxopentan-2-ylcarbamate (<b>102</b>)</h5><div class="NLM_p">Step 1: (5-(2-(Difluoromethoxy)-4-nitrophenyl)oxazole (<b>100</b>) (1.40 g, 5.47 mmol) was dissolved in ethanol (30 mL) and CHCl<sub>3</sub> (15.00 mL) in a Parr bottle. Ten percent palladium on carbon (1.16 g, 1.09 mmol) was added, and the mixture was placed on the Parr shaker under H<sub>2</sub> at 45 psi for 1.5 h. The catalyst was removed by filtration through a pad of Celite, and the filtrate was concentrated to afford 3-(difluoromethoxy)-4-(oxazol-5-yl)aniline (800 mg, 3.54 mmol, 64% yield) as a yellow solid. The product was used in the next step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.88 (s, 1H), 7.61 (d, <i>J</i> = 8.6 Hz, 1H), 7.40 (s, 1H), 6.60 (dd, <i>J</i> = 8.4, 2.1 Hz, 1H), 6.52–6.48 (m, 1H), 6.54 (t, <i>J</i> = 73.8 Hz, 1H), 3.98 (br s, 2H). MS (ESI) <i>m</i>/<i>z</i>: 227.1 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Step 2: To a mixture of 3-(difluoromethoxy)-4-(oxazol-5-yl)aniline (800 mg, 3.54 mmol) and (<i>R</i>)-2-(<i>tert</i>-butoxycarbonylamino)-4-methylpentanoic acid (1.63 g, 7.07 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) were added <i>N</i>,<i>N</i>-diisopropylethylamine (3.09 mL, 17.7 mmol) and HATU (2.69 g, 7.07 mmol). The reaction mixture was stirred at room temperature for 12 h. The reaction mixture was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (150 mL). The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 75 mL). The combined organic layers were washed with brine (100 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (20–50% EtOAc in hexanes; 40 g column) to afford <b>102</b> (1.40 g, 3.19 mmol, 90% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 9.34 (br. s., 1H), 7.84 (s, 1H), 7.53 (d, <i>J</i> = 7.1 Hz, 1H), 7.43 (br. s., 1H), 7.35 (d, <i>J</i> = 8.8 Hz, 1H), 7.20 (br. s., 1H), 6.72 (t, <i>J</i> = 73.3 Hz, 1H), 5.14 (d, <i>J</i> = 7.6 Hz, 1H), 4.40 (d, <i>J</i> = 5.0 Hz, 1H), 1.86–1.76 (m, 1H), 1.74–1.64 (m, 2H), 1.50 (s, 9H), 1.00 (d, <i>J</i> = 6.3 Hz, 3H), 0.97 (d, <i>J</i> = 6.0 Hz, 3H). MS (ESI) <i>m</i>/<i>z</i>: 440.3 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_99" class="NLM_sec NLM_sec_level_4"><div id="ac_i153" class="anchor-spacer"></div><h5 class="article-section__title" id="_i153"> <i>tert</i>-Butyl (<i>R</i>)-(1-((4-Formyl-3-(trifluoromethoxy)phenyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (<b>104</b>)</h5><div class="NLM_p">Step 1: To stirred solution of (<i>R</i>)-2-((<i>tert</i>-butoxycarbonyl)amino)-4-methylpentanoic acid (1.0 g, 4.32 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (10 mL) were added <i>N</i>,<i>N</i>,-diisopropylethylamine (3.78 mL, 21.6 mmol) and HATU (1.64 g, 4.32 mmol) followed by 4-bromo-3-(trifluoromethoxy)aniline (<b>103</b>) (1.22 g, 4.76 mmol). The reaction mixture was stirred at room temperature for 4 h. The mixture was concentrated under reduced pressure. The product was purified by column chromatography on silica gel to afford product (<i>R</i>)-<i>tert</i>-butyl (1-((4-bromo-3-(trifluoromethoxy)phenyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (1.65 g, 3.34 mmol, 77% yield) as an off-white solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.37 (s, 1H), 7.95 (s, 1H), 7.74 (d, <i>J</i> = 8.7 Hz, 1H), 7.54 (dd, <i>J</i> = 8.7, 2.3 Hz, 1H), 7.12 (d, <i>J</i> = 7.6 Hz, 1H), 4.15–4.03 (m, 1H), 1.73–1.48 (m, 2H), 1.48–1.21 (m, 10H), 0.94–0.82 (m, 6H). MS (ESI) <i>m/z</i>: 469.0 (M + H)<sup>+</sup>.</div><div class="NLM_p">Step 2: To a solution of (<i>R</i>)-<i>tert</i>-butyl (1-((4-bromo-3-(trifluoromethoxy)phenyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (1.0 g, 2.13 mmol) in toluene (20 mL) were added tetrakis(triphenylphosphine)palladium(0) (0.246 g, 0.213 mmol) and tributyl(vinyl)stannane (0.878 g, 2.77 mmol). Argon gas was bubbled through the reaction mixture for several minutes, and the mixture was heated at 110 °C for 14 h. The reaction mixture was cooled to room temperature and filtered through a pad of Celite. The filtrate was concentrated under reduced pressure, and the product was purified by silica gel column chromatography (hexane/EtOAc gradient) to afford (<i>R</i>)-<i>tert</i>-butyl (4-methyl-1-oxo-1-((3-(trifluoromethoxy)-4-vinylphenyl)amino)pentan-2-yl)carbamate (0.55 g, 1.31 mmol, 61% yield) as an off white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d<sub>6</sub></i>) δ 10.31 (s, 1H), 7.85–7.79 (m, 1H), 7.75 (d, <i>J</i> = 9.0 Hz, 1H), 7.56 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 7.11 (d, <i>J</i> = 8.0 Hz, 1H), 6.81 (dd, <i>J</i> = 17.6, 11.0 Hz, 1H), 5.87 (dd, <i>J</i> = 17.6, 1.0 Hz, 1H), 5.41–5.36 (m, 1H), 4.16–4.03 (m, 1H), 1.72–1.47 (m, 3H), 1.44–1.33 (m, 9H), 0.90 (d, <i>J</i> = 6.4 Hz, 3H), 0.89 (d, <i>J</i> = 6.4 Hz, 3H). MS (ESI) <i>m/z</i>: 415.0 (M-H)<sup>+</sup>.</div><div class="NLM_p last">Step 3: A solution of (<i>R</i>)-<i>tert</i>-butyl (4-methyl-1-oxo-1-((3-(trifluoromethoxy)-4-vinylphenyl)amino)pentan-2-yl)carbamate (0.50 g, 1.20 mmol) in 1,4-dioxane (20 mL) and water (5 mL) was cooled to 0 °C for 5 min. 2,6-Lutidine (0.280 mL, 2.40 mmol), osmium tetroxide (0.603 mL, 0.048 mmol), and sodium periodate (0.770 g, 3.60 mmol) were added, and the mixture was stirred at room temperature for 4 h. The reaction mixture was transferred to a separatory funnel containing saturated sodium carbonate solution (20 mL). The aqueous layer was extracted with EtOAc (2 × 25 mL). The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. The product was purified by column chromatography on silica gel to afford <b>104</b> (350 mg, 0.820 mmol, 68% yield) as an off white solid. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 10.19 (s, 1H), 7.99 (s, 1H), 7.91 (d, <i>J</i> = 8.5 Hz, 1H), 7.65 (dd, <i>J</i> = 8.5, 2.0 Hz, 1H), 4.23 (br. s., 1H), 1.75 (br. s., 1H), 1.69–1.53 (m, 2H), 1.45 (s, 9H), 1.04–0.93 (m, 6H). MS (ESI) <i>m/z</i>: 419.5 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_100" class="NLM_sec NLM_sec_level_4"><div id="ac_i154" class="anchor-spacer"></div><h5 class="article-section__title" id="_i154"> (<i>R</i>)-<i>tert</i>-Butyl (4-Methyl-1-((4-(oxazol-5-yl)-3-(trifluoromethoxy)phenyl)amino)-1-oxopentan-2-yl)carbamate (<b>105</b>)</h5><div class="NLM_p last">To a solution of (<i>R</i>)-<i>tert</i>-butyl (1-((4-formyl-3-(trifluoromethoxy)phenyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (<b>104</b>) (230 mg, 0.550 mmol) in MeOH (5 mL) were added TosMIC (107 mg, 0.550 mmol) and potassium carbonate (76 mg, 0.550 mmol). The mixture was heated at reflux for 3 h. The mixture was cooled to room temperature and concentrated under reduced pressure. The residue was transferred to a separatory funnel containing saturated sodium carbonate solution (5 mL). The aqueous layer was extracted with EtOAc (2 × 20 mL). The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure. The residue was suspended in hexanes, and the solid was filtered to afford <b>105</b> (150 mg, 0.327 mmol, 60% yield). <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ 8.31 (s, 1H), 7.98 (s, 1H), 7.86 (d, <i>J</i> = 8.00 Hz, 1H), 7.66 (dd, <i>J</i> = 4.00, 8.00 Hz, 1H), 7.55 (s, 1H), 4.26–4.22 (m, 1H), 1.78–1.74 (m, 1H), 1.68–1.58 (m, 2H), 1.47 (s, 9H), 1.01 (d, <i>J</i> = 6.8 Hz, 3H), 1.00 (d, <i>J</i> = 6.4 Hz, 3H). MS (ESI) <i>m/z</i>: 456.1 (M-H)<sup>+</sup>.</div></div><div id="sec5_1_22_101" class="NLM_sec NLM_sec_level_4"><div id="ac_i155" class="anchor-spacer"></div><h5 class="article-section__title" id="_i155"> 2-Fluoro-4-nitrobenzaldehyde (<b>107</b>)</h5><div class="NLM_p">Step 1: To a solution of 2-fluoro-4-nitrobenzoic acid (<b>106</b>) (3.00 g, 16.21 mmol) in THF (60 mL) at room temperature was added BH<sub>3</sub>·THF (64.8 mL, 64.8 mmol) dropwise via an addition funnel. The reaction mixture was stirred at room temperature for 12 h. The mixture was then cooled in an ice bath and quenched by the slow addition of MeOH (200 mL). The mixture was concentrated, and the residue was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (150 mL). The aqueous layer was extracted with Et<sub>2</sub>O (3 × 200 mL). The combined organic layers were washed with brine (150 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated to afford (2-fluoro-4-nitrophenyl)methanol (2.60 g, 15.2 mmol, 94% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.12 (dd, <i>J</i> = 8.4, 2.1 Hz, 1H), 8.06 (dd, <i>J</i> = 9.9, 2.1 Hz, 1H), 7.76 (t, <i>J</i> = 7.9 Hz, 1H), 5.62 (t, <i>J</i> = 5.8 Hz, 1H), 4.66 (d, <i>J</i> = 5.8 Hz, 2H).</div><div class="NLM_p last">Step 2: Oxalyl chloride (3.20 mL, 36.5 mmol) was added to a solution of DMSO (5.18 mL, 73.0 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (150 mL) at −78 °C. The reaction mixture was stirred at −78 °C for 15 min. (2-Fluoro-4-nitrophenyl)methanol (2.5 g, 14.6 mmol) in CH<sub>2</sub>Cl<sub>2</sub> (20 mL) was added via cannula while the temperature of the reaction mixture was kept under −68 °C. The solution was stirred at −78 °C for 1 h. Et<sub>3</sub>N (20.4 mL, 146 mmol) was then added via syringe, and the reaction mixture was stirred at −78 °C for 1 h and then allowed to warm up to room temperature over 60 min. The mixture was transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (150 mL). The aqueous layer was extracted with CH<sub>2</sub>Cl<sub>2</sub> (3 × 150 mL). The combined organic layers were washed with brine (150 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was triturated with 10% EtOAc in hexanes and cooled to 0 °C. The solid was collected on a Buchner funnel to give <b>107</b> (2.40 g, 14.2 mmol, 97% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 10.27 (s, 1H), 8.31 (dd, <i>J</i> = 10.3, 2.0 Hz, 1H), 8.21 (dd, <i>J</i> = 8.6, 1.8 Hz, 1H), 8.12–8.05 (m, 1H).</div></div><div id="sec5_1_22_102" class="NLM_sec NLM_sec_level_4"><div id="ac_i156" class="anchor-spacer"></div><h5 class="article-section__title" id="_i156"> 3-Fluoro-4-(oxazol-5-yl)aniline (<b>108</b>)</h5><div class="NLM_p">Step 1: To a solution of 2-fluoro-4-nitrobenzaldehyde (<b>107</b>) (2.40 g, 14.2 mmol) and TosMIC (3.32 g, 17.0 mmol) in MeOH (40 mL) was added potassium carbonate (2.45 g, 17.7 mmol). The reaction mixture was heated at reflux for 2.5 h. The reaction mixture was cooled to room temperature and transferred to a separatory funnel containing saturated aqueous NaHCO<sub>3</sub> solution (150 mL). The aqueous layer was extracted with EtOAc (3 × 150 mL). The combined organic layers were washed with brine (100 mL), dried over MgSO<sub>4</sub>, filtered, and concentrated. The product was purified by column chromatography on silica gel (40–60% EtOAc in hexanes; 65 g column) to afford 5-(2-fluoro-4-nitrophenyl)oxazole (2.00 g, 9.61 mmol, 68% yield) as a yellow solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.72 (s, 1H), 8.32 (dd, <i>J</i> = 10.8, 2.3 Hz, 1H), 8.21 (dd, <i>J</i> = 8.8, 2.3 Hz, 1H), 8.10–8.00 (m, 1H), 7.84 (d, <i>J</i> = 3.8 Hz, 1H). MS (ESI) <i>m</i>/<i>z</i>: 209.1 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Step 2: 5-(2-Fluoro-4-nitrophenyl)oxazole (300 mg, 1.44 mmol) was dissolved in ethanol (10 mL) and CHCl<sub>3</sub> (5 mL) in a Parr bottle. Ten percent palladium on carbon (307 mg, 0.288 mmol) was added, and the mixture was placed on the Parr shaker under H<sub>2</sub> atmosphere at 40 psi for 1.5 h. The catalyst was removed by filtration, and the filtrate was concentrated to afford <b>108</b> (250 mg, 1.40 mmol, 97% yield) as a gray solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.49 (s, 1H), 7.68 (t, <i>J</i> = 8.2 Hz, 1H), 7.41 (d, <i>J</i> = 3.5 Hz, 1H), 7.10–6.99 (m, 2H). MS (ESI) <i>m</i>/<i>z</i>: 179.1 (M + H)<sup>+</sup>.</div></div><div id="sec5_1_22_103" class="NLM_sec NLM_sec_level_4"><div id="ac_i157" class="anchor-spacer"></div><h5 class="article-section__title" id="_i157"> 5-Nitro-2-(oxazol-5-yl)benzonitrile (<b>109</b>)</h5><div class="NLM_p last">To a solution of 5-(2-bromo-4-nitrophenyl)oxazole (<b>94</b>) (50 mg, 0.190 mmol) in acetonitrile (5 mL) were added potassium cyanide (25 mg, 0.380 mmol), tributyltin chloride (0.062 g, 0.190 mmol) and tetrakis(triphenylphosphine)palladium(0) (4 mg, 0.004 mmol), and the mixture was degassed for 10 min at room temperature followed by further degassing at 50 °C. The resultant mixture was then heated at 95 °C for 12 h. The reaction mixture was then cooled to room temperature and partitioned between water (5 mL) and EtOAc (5 mL). The organic layer was separated and dried over sodium sulfate and concentrated under reduced pressure to afford the crude product that was purified by preparative TLC (40% EtOAc in hexanes) to afford <b>109</b> (21 mg, 0.098 mmol, 52% yield). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.87 (s, 1H), 8.81 (s, 1H), 8.59 (m, 1H), 8.21 (d, <i>J</i> = 8.8 Hz, 1H), 8.16 (s, 1H).</div></div><div id="sec5_1_22_104" class="NLM_sec NLM_sec_level_4"><div id="ac_i158" class="anchor-spacer"></div><h5 class="article-section__title" id="_i158"> 5-Amino-2-(oxazol-5-yl)benzonitrile (<b>110</b>)</h5><div class="NLM_p last">To a solution of 5-nitro-2-(oxazol-5-yl)benzonitrile (<b>109</b>) (50 mg, 0.230 mmol) in dry THF (3 mL) were added palladium acetate (3 mg, 0.012 mmol), aqueous potassium fluoride solution (27 mg in 0.5 mL water), and polymethylhydrosiloxane (PMHS) (0.24 mL), and the mixture was stirred under a H<sub>2</sub> atmosphere at room temperature for 12 h. The reaction was quenched with water (2 mL) and extracted with EtOAc (5 mL). The organic layer was separated, dried with sodium sulfate, and concentrated under reduced pressure. The crude product was purified on a neutral alumina column to afford <b>110</b> (10 mg, 0.191 mmol, 83% yield). MS (ESI) <i>m/z</i>: 186.1 (M + H)<sup>+</sup>.</div></div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i159" class="anchor-spacer"></div><h3 class="article-section__title" id="_i159"> AAK1 Enzyme Assay (IC<sub>50</sub> Determination)</h3><div class="NLM_p last">Recombinant GST-Xa-hAAK1 (amino acids 30–330) was combined with a fluorescent substrate ((5-FAM)-Aha-KEEQSQITSQVTGQIGWR-NH<sub>2</sub>) (CPC Scientific), ATP, and varying concentrations of inhibitors in a 384-well plate (Thermo Scientific). The final reaction volume (0.030 mL) contained 10 mM Tris–HCl pH 7.4, 10 mM MgCl<sub>2</sub>, 0.01% Tween-20, 1.0 mM DTT, 22 μM ATP, 1.5 μM (5-FAM)-AhaKEEQSQITSQVTGQIGWR-NH<sub>2</sub>, 3.5 nM GST-Xa-hAAK1, 1.6% DMSO, and varying concentrations of inhibitors (from 2 μM to 33 pM). Compound stock solutions (10 mM) were prepared in DMSO. Kinase reactions were incubated at room temperature for 3 h and terminated by adding 60 μL of 35 mM EDTA buffer to each sample. Reaction solutions were analyzed on the Caliper LabChip 3000 (Caliper, Hopkinton, MA) by electrophoretic separation of the fluorescent substrate and phosphorylated product. IC<sub>50</sub> values were derived by nonlinear regression analysis of the concentration response data. The experimentally determined AAK1 ATP Km value was 22 μM.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i160" class="anchor-spacer"></div><h3 class="article-section__title" id="_i160"> AAK1 Cellular Assay</h3><div class="NLM_p last">HEK293F cells were cultured in media containing DMEM (Gibco, cat. #11965), 10% FBS (SAFC Biosciences, cat. #12103C), and 1× GPS (glutamine, penicillin, and streptomycin). On day one, 12 million cells were plated on a 10 cm dish at ∼80% confluent. On day two, each 10 cm dish was transfected with 48 μg DNA (3 μg AAK1/HA/pIRES (full-length human, NCBI accession no. NP_055726.2)), 45 μg Flag/AP2MI/pcDNA (full-length human, NCBI accession no. NM_004068.3), 144 μL Lipofectamine 2000 (Invitrogen, cat. #11668-019), and 1.5 mL OPTI-MEM per manufacturer’s instructions. On day three, cells were resuspended, pelleted by centrifugation at 1000 rpm for 5 min, and resuspended in 2.75 mL DMEM + 0.5% FBS. An aliquot of cells (100 μL) was transferred to each well in a 96-well plate. Compounds were dissolved in DMSO and diluted in DMSO to 1000 times the final concentration. Compound solutions (1 μL) were then mixed in 500 μL DMEM + 0.5% FBS, and 100 μL of the diluted compound was added to each well. Plates were then incubated at 37 °C and 5% CO<sub>2</sub> for 3 h. Cells were then resuspended and pelleted in a tube. For Western blot analysis, cell pellets were resuspended in 40 μL of 1× LDS PAGE sample buffer (Invitrogen, cat. #NP0008) + 2× Halt phosphatase and protease inhibitor cocktail (Thermo Scientific, cat. #1861284) followed by sonication with a microtip sonicator set at 5 for 8–10 s. Five microliters of 10× NuPage Sample Reducing Agent (with 50 mM DTT) was added to each sample followed by heat denaturing at 70 °C for 10 min. Each sample (10 μL) was loaded on a 4–20% Tris-Glycine Criterion 26-well gel (Biorad, cat. #345-0034) for the phospho-μ2 blot and 10 μL per lane in a 4–12% Bis-Tris (+MES buffer) NuPAGE 26-well gel (Invitrogen, cat. #WG1403BX10) for the μ2 blot. For controls, 2 ng of phospho-μ2 or 20 ng of μ2/Flag proteins was loaded on each gel. After SDS-PAGE, samples were transferred to PVDF membrane and membranes were blocked for 1 h in TBST + 5% milk followed by washing three times for 5–10 min with TBST. Membranes were probed with rabbit anti-phospho-μ2 (1:5000; a rabbit polyclonal antibody produced by New England Peptide and affinity purified at Lexicon) in TBST + 5% BSA. NuPAGE gels were probed with mouse anti-Flag (1:500; Sigma, cat. #F1804) in TBST + 5% milk, and these primary antibodies were incubated overnight at 4 °C on a rocker. On day four, Western blots were washed three times for 5–10 min with TBST, probed with anti-rabbit-HRP (1:2000; BioRad, cat. #170-6515) or anti-mouse-HRP (1:2000; Biorad, cat. #170-6516) in TBST + 5% milk for 1 h at RT, washed three times for 10 min with TBST, and developed with an ECL reagent (GE Healthcare, cat. #RPN2132) on a Versadoc. Images were captured with a camera, and percent inhibition was calculated for each sample by first normalizing to total μ2 expression levels and then comparing to 0 and 100% controls. IC<sub>50</sub> values were then calculated using the Excel fitting software.</div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i161" class="anchor-spacer"></div><h3 class="article-section__title" id="_i161"> Metabolic Stability in Liver Microsomes<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></h3><div class="NLM_p last">The metabolic stability (Met Stab) assay evaluates the cytochrome P450 (CYP)-mediated metabolism of test compounds in vitro using human and rat microsomes after a 10 min incubation. The incubation was automated on a Biomek FX automation workstation (Beckman Coulter, Fullerton, CA, USA). Each compound was incubated in duplicate in the respective species at a concentration of 0.5 μM. Compounds were received as 3.5 mM solutions in DMSO and diluted with CH<sub>3</sub>CN to 50 μM before being added to the prewarmed (37 °C) microsomal suspension (1 mg/mL) prepared in 100 mM sodium phosphate, pH 7.4, and 6.6 mM MgCl<sub>2</sub>. The reaction was initiated by adding 17 μL of prewarmed 5 mM NADPH in 100 mM sodium phosphate, pH 7.4, into 153 μL of the reaction mix. The concentration of DMSO in the incubation mixture was 0.014%. Reaction components were mixed well, and 75 μL was transferred into 150 μL of the quench solution at the 0 min time point (t0) and again at the 10 min incubation time point (t10). Quenched mixtures were centrifuged at 1500 rpm in an Allegra X-12 centrifuge (Beckman Coulter) for 15 min, and 90 μL of the supernatant was then transferred to a separate 96-well plate for analysis. Metabolism rate was determined based on the parent compound disappearance over time as measured by LC–MS/MS.</div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i162" class="anchor-spacer"></div><h3 class="article-section__title" id="_i162"> PAMPA Evaluation</h3><div class="NLM_p last">Compounds and controls are utilized as 10 mM stocks in 100% DMSO. Compounds are diluted 1:100 in pH 7.4 or 5.5 donor-well buffer (pION, catalog no. 110151), providing a 100 μM assay solution in 1% DMSO. Compounds diluted in donor-well buffer were transferred to Whatman Unifilter plates and filtered prior to 200 μL being dispensed into the donor wells of the assay plates (pION, catalog no. 110163). The PAMPA membrane was formed by pipetting 4 μL of the lipid solution (pION, catalog no. 110169) onto the filter plate (VWR CAT #13503). The membrane was then covered with 200 μL of acceptor-well buffer at pH 7.4 (pION, catalog no. 110139). The PAMPA-assay plate (donor and acceptor sides) was combined and allowed to incubate at room temperature for 4 h. The plate was then disassembled, and spectrophotometer plates (VWR, catalog no. 655801) were filled (150 μL/well). The donor, acceptor, reference, and blank plates were read in a SpectraMax UV plate reader. Data were captured by the pION software, which analyzed the spectra and generated <i>P</i><sub>c</sub> values. The control compounds in this assay are as follows (mean ± SD): ketoprofen (pH 5.5, <i>P</i><sub>c</sub> 34.2 ± 3.1 cm<sup>–6</sup>/s; pH 7.4, <i>P</i><sub>c</sub> 1.1 ± 0.3 cm<sup>–6</sup>/s); metoprolol (pH 5.5, <i>P</i><sub>c</sub> 10.2 ± 1.1 cm<sup>–6</sup>/s; pH 7.4, <i>P</i><sub>c</sub> 83.5 ± 4.7 cm<sup>–6</sup>/s); and ranitidine (pH 5.5, <i>P</i><sub>c</sub> 0 ± 0 cm<sup>–6</sup>/s; pH 7.4, <i>P</i><sub>c</sub> 0.2 ± 0.1 cm<sup>–6</sup>/s).</div></div><div id="sec5_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i163" class="anchor-spacer"></div><h3 class="article-section__title" id="_i163"> Caco-2 Assay<a onclick="showRef(event, 'ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref67 ref68">(67,68)</a></h3><div class="NLM_p last">Caco-2 cells were seeded on collagen-coated polycarbonate 24-well Transwell plates and cultured to grow for 21 days to form a confluent monolayer. The monolayer integrity was assessed using a transepithelial electric resistance (TEER) before commencing the assay to ensure that it met acceptable criteria (>600 Ω·cm<sup>2</sup>). A stock solution of test compounds was prepared in dimethyl sulfoxide (DMSO), and these were spiked in the assay buffer Hanks balanced salt solution (HBSS) containing 0.5% bovine serum albumin (pH 7.4). The final concentration of test compounds in the assay buffer was 3 μM. The bidirectional permeability assay [apical to basolateral (A–B) and basolateral to apical (B–A)] was conducted by adding the compound in the assay buffer on the donor side and the blank buffer on the receiver side. The volume added to the apical side was 200 μL, and that to the basolateral side was 600 μL. Transwell plates were incubated for 2 h at 37 °C in a 95% humidity and 5% CO<sub>2</sub> atmosphere. Aliquots (100 μL) were collected from each apical and basolateral compartment. These aliquots were quenched with acetonitrile/methanol (1:1) containing the internal standard and were analyzed by LC–MS/MS to assess permeability. The control compounds used in this assay along with the typical range for each compound are as follows: digoxin, nadolol, verapamil, and atenolol (pH 7.4, <i>P</i><sub>c</sub> A–B/B–A (10<sup>–6</sup> cm/s)); 0–2.5/10.0–30.0 (low permeability, P-gp effluxed), 0–4.0/0–4.0 (low permeability), 10.0–40.0/10.0–40.0 (high permeability), and 0–4.0/0–4.0 (low permeability), respectively.</div></div><div id="sec5_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i164" class="anchor-spacer"></div><h3 class="article-section__title" id="_i164"> Serum Protein Binding Assay</h3><div class="NLM_p last">The serum protein binding assay was performed using a standard equilibrium dialysis method. In brief, a stock solution of compounds was prepared by solubilizing in 100% DMSO (1 mM). These were spiked in serum so that the final test compound concentration was 10 μM (final DMSO concentration 1%). Serum with the compound was added to one of two chambered rapid equilibrium dialysis (RED) assay plates (8000-Da molecular weight cutoff), and sodium phosphate buffer was added to the other chamber. Dialysis was performed at 37 °C for 5 h in a 10% CO<sub>2</sub> atmosphere. Samples were collected from serum and buffer chambers at pre- and postincubation periods. These were analyzed using liquid chromatography with tandem mass spectrometry (LC–MS/MS) to evaluate the fraction of compound (percentage) free to diffuse and equilibrate between the buffer and serum chambers in the RED device. Percent free was calculated using the ratio of the compound concentration in the buffer to the compound concentration in the serum at the end of the dialysis period (5 h).</div></div><div id="sec5_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i165" class="anchor-spacer"></div><h3 class="article-section__title" id="_i165"> Brain Tissue Binding Assay</h3><div class="NLM_p last">Mouse brain homogenates were harvested and prepared from frozen brain tissue and diluted 20× with Dulbecco’s phosphate-buffered saline (DPBS). A Rapid Equilibrium Dialysis (RED) device (Thermo-Fisher Scientific, Waltham, MA) was used according to vendor instructions as follows. Brain homogenate was spiked with compounds at a final concentration of 1 μM. A 200 μL aliquot of the brain homogenate spiked with 1 μM of compound was added to one side of the chamber (donor), and 350 μL of DPBS was added to the other side of the dialysis insert (receiver). Compounds were assessed in triplicate (using three RED inserts for each experiment) to determine the extent of brain tissue binding. The RED plate was covered with a sealing tape obtained from Thermo-Fisher Scientific and placed on a shaking plate at 350 rpm and incubated at 37 °C for 4 h. After incubation, 50 μL was removed from both the donor and receiver wells, and each sample was matched with 50 μL of the opposite matrix before quenching with the acetonitrile-containing internal standard. Samples were then filtered and analyzed by LC/MS.</div></div><div id="sec5_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i166" class="anchor-spacer"></div><h3 class="article-section__title" id="_i166"> X-ray Crystallography</h3><div id="sec5_9_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i167" class="anchor-spacer"></div><h4 class="article-section__title" id="_i167"> Protein Expression and Purification</h4><div class="NLM_p">Mouse AAK1 (26-330), which contained a His<sub>6</sub>-tag at the N-terminus and a thrombin site between the His-tag and the mAAK1 protein, was expressed in <i>Escherichia coli</i> BL21 (DE3) cells in a defined M9-glucose medium with casamino acids (Difco) and trace minerals.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> The cells were grown at 37 °C until they reached an optical density at 600 nm of 0.8. The cells were chilled on ice for 30 min and induced with 0.5 mM IPTG for 18.5 h at 20 °C. Cells were harvested by centrifugation and stored at −80 °C.</div><div class="NLM_p last">All purification steps were performed at 4 °C unless noted otherwise. Frozen BL21/DE3 cells from 4 L of culture were suspended in 300 mL of buffer A (25 mM Na-HEPES pH 7.5, 300 mM NaCl, 5% glycerol, 20 mM imidazole, 2 mM dithiothreitol) plus six tablets of complete EDTA-free protease inhibitor cocktail (Roche Applied Science) and 20 U/mL of benzonase nuclease (EMD Millipore). Cells were lysed by homogenization using one pass through a microfluidizer (Rannie) at 10,000 psi. The lysate was clarified by sedimentation at 100,000<i>g</i> for 40 min (Beckman 45Ti rotor), and the supernatant was loaded onto a Nickel-Sepharose 6 Fast Flow (GE Healthcare) column (2.5 × 2.1 cm) equilibrated with buffer A. The column was washed with 15 vol of buffer A, and the protein was eluted with a linear gradient of 20 to 350 mM imidazole in buffer A. Fractions were pooled (60 mL) from the gradient between 90 and 150 mM imidazole and concentrated to a volume of 7 mL using a Millipore Ultra 15 mL concentration unit with a 10,000 Da cutoff. The concentrated sample was loaded onto a HiLoad 26/60 Superdex 200 column (GE Healthcare) equilibrated with buffer B (25 mM Na-HEPES pH 7.5, 0.2 M NaCl, 5% glycerol, 0.1 mM EDTA, 2 mM DTT). The purified protein was pooled from a peak centered at 233 mL. The final yield of purified His-Tb-mAAK1 (26-330) was 20 mg per liter of culture. The protein purity was ≥95% as determined by SDS-PAGE analysis and Coomassie Brilliant Blue staining. For the protein used in crystallization trials, samples were buffer exchanged using a HiLoad 16/60 Superdex 75 column (GE Healthcare) equilibrated with buffer C (25 mM Na-HEPES pH 7.5, 100 mM NaCl, 5 mM DTT).</div></div><div id="sec5_9_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i168" class="anchor-spacer"></div><h4 class="article-section__title" id="_i168"> Protein Crystallization and Structure Determination</h4><div class="NLM_p">Co-crystallization of mAAK1 (26-330) was often compound dependent; therefore, crystal structures with compounds of interest were obtained by co-crystallizing mAAK1 (26-330) with a compound that resulted in robust crystal growth. This compound (<b>112</b>) will be referred to as the parent compound.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Fresh DTT to 5 mM and 4-fold molar excess of the parent compound was added to a 1 mL aliquot of 3 mg/mL mAAK1 (26-330) protein. The complex was incubated on ice for 4 h and was then clarified by centrifugation. The complex was concentrated to 8 mg/mL using an Amicon Ultra 10,000 MWCO concentrator. Crystallization experiments were carried out at 22 °C using the hanging-drop, vapor-diffusion method. The hanging drop consisted of 1 μL of protein overlaid with 1 μL of the reservoir solution (0.8–1.0 M ammonium sulfate, 0.14 M sodium chloride, 0.1 M Bis-Tris pH 5.5, and 1% PEG 3350). Crystals appeared after 24 h. To promote crystal nucleation, one large crystal was crushed and used for streak seeding. Crystals of mAAK1 with the parent compound were transferred to a soaking drop consisting of a stabilizing solution (1.3 M ammonium sulfate, 0.1 M Bis-Tris pH 5.5, 1% PEG 3350, and 0.1 M sodium chloride) and the compound of interest (5 mM compound <b>13</b>, 5 mM compound <b>(<i>R</i>,<i>R</i>)-40</b>). The crystals were harvested after 24 h and transferred briefly into the stabilizing solution plus 25% ethylene glycol and flash-cooled for cryodata collection.</div><div class="NLM_p last">Data sets of mAAK1 with compound <b>19</b> and <b>(<i>R</i>,<i>R</i>)-40</b> were collected by Shamrock Structures, Inc., at APS, IMCA-CAT beam line 17-ID. Structures were determined by molecular replacement using the program Phaser<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> with a previously determined structure of mAAK1 with the parent compound.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Soaks of co-crystals with the compound of interest resulted in the displacement of the parent compound from only one of the two molecules of mAAK1 in the asymmetric unit. Compounds <b>19</b> and <b>(<i>R</i>,<i>R</i>)-40</b> are associated with molecule A, while the parent compound is associated with molecule B. Data and refinement statistics for crystallographic data analysis of mAAK1 with compounds <b>19</b> and <b>(<i>R</i>,<i>R</i>)-40</b> are shown in <a href="/doi/suppl/10.1021/acs.jmedchem.1c00472/suppl_file/jm1c00472_si_001.pdf" class="ext-link">Table S1</a>.</div></div><div id="sec5_9_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i169" class="anchor-spacer"></div><h4 class="article-section__title" id="_i169"> Mouse Pharmacokinetic Studies</h4><div class="NLM_p">All animal experiments were performed in accordance with protocols approved by the Institutional Animal Ethics Committee (Syngene International Ltd., Bangalore) and in a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). Male C57BL6 mice (9–11 weeks of age) were purchased from Vivo Bio Tech Ltd., India. Animals were housed at 21 ± 3 °C and relative humidity 50 ± 20%. A 12:12 h light/dark cycle was maintained with animals given free access to food and water. Formulation was prepared by dissolving the test compound in 85% 20 mM citrate buffer, 5% dimethylsulfoxide, and 10% Solutol. It was dosed subcutaneously at the dose volume of 10 mL/kg to mouse (<i>n</i> = 3). The mouse was manually restrained, the needle was inserted under the skin of the interscapular area, and then the formulation was subcutaneously administered. Two hours after dose administration, blood and brain tissues were collected. Blood samples were collected into tubes containing K<sub>2</sub>EDTA as anticoagulant (1.33 mM). Samples were centrifuged at 10,000<i>g</i> for 5 min at 4 °C within 30 min of collection, and plasma was harvested. Plasma samples were stored at −80 °C until analysis. For brain collection, animals were sacrificed by CO<sub>2</sub> euthanasia. Immediately, the brain tissue was separated, and it was washed properly with cold buffer, ensuring that there was no blood contamination. The tissue was homogenized with 2× PBS (pH 7.4) and then submitted for analysis.</div><div id="sec5_9_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i170" class="anchor-spacer"></div><h5 class="article-section__title" id="_i170"> Sample Preparation</h5><div class="NLM_p last">A 25 μL aliquot of plasma study samples and calibration standards was added to 125 μL of acetonitrile (with internal standard) contained in Millipore Hydrophilic Solvinert plates. Plates were shaken on a plate shaker for 5 min at 300 rpm and centrifuged at 3000 rpm for 5 min, and the eluent was collected into a 96 well, 1 mL Waters collection plate and injected onto an LC column. Brain samples were diluted 10× with blank plasma and extracted in a similar manner as plasma samples and analyzed by LC–MS/MS.</div></div><div id="sec5_9_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i171" class="anchor-spacer"></div><h5 class="article-section__title" id="_i171"> Liquid Chromatography and Mass Spectrometry Conditions</h5><div class="NLM_p last">The quantitative assessment of <b>59</b> was performed by LC–MS/MS with ultraperformance liquid chromatography (UPLC) (Waters Acquity) using an Acquity BEH C18 column (2.1 × 50 mm, 1.7 mm, Waters, Milford, MA); mobile phase A: 0.1% formic acid in water; mobile phase B: 0.1% formic acid in acetonitrile; gradient: 0 to 0.8 min, 95% A/5% B; 0.8 to 1.1 min, 5% B to 95% B; 1.1 to 1.5 min, 95% B; 1.5 to 1.8 min, 95% B to 5% B; 1.8 to 2.4 min, 95% A/5% B; flow rate = 0.6 mL/min; run time = 2.4 min. For the assay, the UPLC was interfaced to an SCIEX Triple quad 4000 mass spectrometer (SCIEX, Concord, Ontario, Canada) equipped with a turbo ion spray interface operating in the positive ionization mode. The detection of analyte was achieved through multiple reaction monitoring. Ions representing the precursor (M + H)<sup>+</sup> species for analyte and internal standard were selected and collisionally dissociated with ultra high purity nitrogen to generate specific product ions, which were subsequently monitored. The mass transitions monitored by multiple reaction monitoring were 340.2 > 227.2 for <b>59</b> and 313.2 > 214.0 for an internal standard.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Compounds <b>19</b> and <b>41</b> were analyzed in a similar fashion as <b>59</b>.</div></div></div><div id="sec5_9_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i172" class="anchor-spacer"></div><h4 class="article-section__title" id="_i172"> In Vivo μ2 Phosphorylation Inhibition Studies</h4><div class="NLM_p">All of the animals were kept in an American Association for the Accreditation of Laboratory Animal Care-accredited animal holding facility maintained at controlled temperature (23 ± 1 °C) and humidity (50 ± 20%) under a 12:12 h light/dark cycle (lights on at 7:00 a.m.). Food and water were provided ad libitum. All experimental procedures were reviewed and approved by the Institutional Animal Ethics Committee and conducted in accordance with procedures set by the Committee for the Purpose of Control and Supervision on Experiments on Animals.</div><div id="sec5_9_4_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i173" class="anchor-spacer"></div><h5 class="article-section__title" id="_i173"> Drug Preparation and Tissue Collection</h5><div class="NLM_p last">Compound <b>59</b> was prepared fresh by dissolving in an 85:10:5 mixture of saline/Solutol/DMSO at a top concentration of 3 mg/mL. C57BL6 mice dosed subcutaneously with <b>59</b> were euthanized using focused beam microwave irradiation. Mice were restrained in a water jacketed plastic restraining device that was then positioned to focus a microwave beam directly onto the head region. Mice were irradiated using a power setting of 5.0 kW for 0.90 s to inactivate enzyme activity. The mouse was removed from the restraining device and placed onto ice to allow cooling before the removal of brain. Fresh water was flushed into the water jacket after each round of irradiation. The mouse brain was collected minus the cerebellum and placed into a 1% SDS solution containing a 1:100 dilution of both phosphatase inhibitor cocktails #2 and #3 (Sigma P5726 and P0044). Samples were stored on ice until all samples were collected for Western blot analysis.</div></div><div id="sec5_9_4_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i174" class="anchor-spacer"></div><h5 class="article-section__title" id="_i174"> Western Blot</h5><div class="NLM_p last">Brain homogenates were diluted to 1 μg/1 μL in 1× NuPage loading dye containing 20 mM sodium fluoride (NaF) and 1 mM beta-glycerophosphate (BGP), fractionated on 12% NuPage gels using a MES buffer system (Invitrogen, NP0343 for gel and NP0002 for buffer), and transferred to 0.2 μm nitrocellulose membranes using a Novex XCell II blotting apparatus using the NuPage transfer buffer (Invitrogen, NP0006) with 20% methanol. Membranes were blocked for 1 h using the Sigma Western Block reagent (WB-0138) plus 20 mM NaF/1 mM BGP prior to incubating overnight at 4 °C in primary antibodies (1:500 rabbit phospho-μ2, Cell Signaling; 1:1000 mouse beta-actin, Sigma Aldrich). The next day, blots were washed three times for 15 min at room temperature in TBS + 0.1% Tween (TBST) and incubated for 1 h in secondary antibodies (1:10,000 anti-rabbit HRP, GE Healthcare; 1:10,000 anti-mouse HRP, Pierce) diluted in the Sigma Western reagent at room temperature, washed three times in TBST, and developed using the Pierce Supersignal Femto chemiluminescent detection reagent (Thermo). Blots were imaged and quantitated on an LAS3000 imager (FujiFilm).</div></div><div id="sec5_9_4_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i175" class="anchor-spacer"></div><h5 class="article-section__title" id="_i175"> Data Analysis</h5><div class="NLM_p last">Data were analyzed using the GraphPad Prism software (GraphPad Software, Inc., La Jolla, CA). All values are shown as the mean ± SD unless otherwise indicated. Multiple comparisons were made using an ANOVA followed by Dunnett’s post hoc analysis. In all cases, <i>P</i> < 0.05 was considered to be statistically significant.</div></div></div></div><div id="sec5_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i176" class="anchor-spacer"></div><h3 class="article-section__title" id="_i176"> Formalin Assay</h3><div id="sec5_10_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i177" class="anchor-spacer"></div><h4 class="article-section__title" id="_i177"> Rat Formalin-Induced Pain Model</h4><div class="NLM_p last">All animal experiments were performed in accordance with protocols approved by the Institutional Animal Ethics Committee (Syngene International Ltd., Bangalore) and in a facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC). Male C57BL6 mice (9–11 weeks of age) were purchased from Vivo Bio Tech Ltd., India. Animals were housed at 21 ± 3 °C and relative humidity of 50 ± 20%. A 12:12 h light/dark cycle was maintained with animals given free access to food and water. Male SD rats with body weight ranging from 220 to 270 g were included in this study. The rats were first administered with a vehicle, compound <b>59</b> (30 mg/kg), or duloxetine (10 mg/kg) subcutaneously. Twenty minutes post-treatment, rats were placed individually into the test chambers to enable acclimatization to the test chamber for 40 min before initiation of the behavioral measurements. The test chamber was transparent, and a mirror was placed on the backside to aid in the observation of study end points. At the end of the acclimatization period, each rat was gently restrained and 50 μL of 2.5% formalin was injected into the dorsal surface of the right hind paw using a 30-gauge needle. Immediately after the formalin injection, individual rats were returned to their respective test chambers and observed continuously for the subsequent 40 min. The characteristic biphasic nociceptive behavior induced by formalin, namely, paw flinching, was quantified by a blinded observer.<a onclick="showRef(event, 'ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref73 ref74">(73,74)</a> The behavioral measure was recorded in 5 min bins; the total number was calculated at the end of the study for each phase: phase I (i.e., 0–10 min post formalin injection) and phase II (i.e., 10–40 min post formalin injection).<a onclick="showRef(event, 'ref73 ref74'); return false;" href="javascript:void(0);" class="ref ref73 ref74">(73,74)</a> Only the phase II data were included in the analysis because of the minimal/no effect of duloxetine on the first phase of the pain responses.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> Rats were euthanized by rapid decapitation immediately at the end of the study to collect brain and plasma samples for exposure analysis. Data were plotted and analyzed in GraphPad Prism (version 5.02), and the statistical significance of treatment groups was tested using one-way ANOVA followed by Dunnett’s post hoc multiple comparison test.</div></div></div><div id="sec5_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i178" class="anchor-spacer"></div><h3 class="article-section__title" id="_i178"> Chronic Constriction Injury (CCI) Model</h3><div class="NLM_p last">The experimental procedures that were used for the chronic constriction injury (CCI) model and subsequent evaluation for thermal hyperalgesia, mechanical hyperalgesia, cold allodynia, and mechanical allodynia in rats were previously reported.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> For brain collection, animals were sacrificed by CO<sub>2</sub> euthanasia. Immediately, the brain tissue was separated, and it was washed properly with cold buffer, ensuring that there was no blood contamination. The tissue was homogenized with PBS two times (pH 7.4) and then submitted for analysis. Quantitative assessment of <b>59</b> was conducted as described above in the experimental procedures of the mouse pharmacokinetic studies.</div></div><div id="sec5_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i179" class="anchor-spacer"></div><h3 class="article-section__title" id="_i179"> Rotarod Assay</h3><div class="NLM_p last">The experimental procedure that was used for the rotarod assay was previously reported.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i180"><a href="/doi/suppl/10.1021/acs.jmedchem.1c00472" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_04733" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_04733" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.1c00472?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00472</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Crystallographic data and refinement statistics for X-ray crystal structures of <b>19</b> and <b>(<i>R</i>,<i>R</i>)-40</b> complexed with AAK1, the structure of the parent compound in the X-ray co-crystal structures (<b>112</b>), amino acid residue differences between mouse and human AAK1 kinase domains; a comparison of the IC<sub>50</sub> values of AAK1 inhibitors for human, mouse, and rat AAK1; IC<sub>50</sub> curves for human, mouse, and rat full-length AAK1; an overlay of <b>(<i>S</i>,<i>S</i>)-40</b> superimposed onto the X-ray structure of <b>(<i>R</i>,<i>R</i>)-40</b>; the Ambit kinase panel heat map for <b>59</b>; binding assay results for off-target activity for compound <b>59</b>; Western blots associated with Figure 9; analytical HPLC traces for compounds <b>19</b>, <b>41</b>, and <b>59</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00472/suppl_file/jm1c00472_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and SAR data (<a href="/doi/suppl/10.1021/acs.jmedchem.1c00472/suppl_file/jm1c00472_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00472/suppl_file/jm1c00472_si_001.pdf">jm1c00472_si_001.pdf (1.82 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00472/suppl_file/jm1c00472_si_002.csv">jm1c00472_si_002.csv (3.27 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for the X-ray structures of compound <b>19</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LVH">7LVH</a>) and <b>(<i>R</i>,<i>R</i>)-40</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LVI">7LVI</a>) bound to AAK1 are available from the RSCB Protein Data Bank (<a href="http://www.rscb.org" class="extLink">www.rscb.org</a>). The authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.1c00472" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23547" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23547" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard A Hartz</span> - <span class="hlFld-Affiliation affiliation">Department
of Small Molecule Drug Discovery, Bristol
Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</span>; 
    <span>Present Address:
                        Department of Small Molecule Drug Discovery, Bristol Myers Squibb Company, Research and Development, Princeton, New Jersey 08543, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="https://orcid.org/0000-0002-3880-6646" title="Orcid link">https://orcid.org/0000-0002-3880-6646</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#8efce7ede6effceaa0e6effcfaf4ceece3fda0ede1e3"><span class="__cf_email__" data-cfemail="93e1faf0fbf2e1f7bdfbf2e1e7e9d3f1fee0bdf0fcfe">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Vijay T. Ahuja</span> - <span class="hlFld-Affiliation affiliation">Department
of Small Molecule Drug Discovery, Bristol
Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susheel J. Nara</span> - <span class="hlFld-Affiliation affiliation">Biocon-Bristol
Myers Squibb Research and Development Center, Biocon Park, Plot No. 2 & 3,
Bommasandra Phase IV, Jigani Link Road, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">C.M. Vijaya Kumar</span> - <span class="hlFld-Affiliation affiliation">Biocon-Bristol
Myers Squibb Research and Development Center, Biocon Park, Plot No. 2 & 3,
Bommasandra Phase IV, Jigani Link Road, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey M. Brown</span> - <span class="hlFld-Affiliation affiliation">Department
of Neuroscience Discovery Biology, Bristol
Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Linda J. Bristow</span> - <span class="hlFld-Affiliation affiliation">Department
of Neuroscience Discovery Biology, Bristol
Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Ramkumar Rajamani</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Structure and Design, Bristol
Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jodi K. Muckelbauer</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Structure and Design, Bristol
Myers Squibb Company, Research and Development, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Camac</span> - <span class="hlFld-Affiliation affiliation">Department
of Molecular Structure and Design, Bristol
Myers Squibb Company, Research and Development, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan E. Kiefer</span> - <span class="hlFld-Affiliation affiliation">Department
of Protein Science, Bristol Myers Squibb
Company, Research and Development, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lisa Hunihan</span> - <span class="hlFld-Affiliation affiliation">Department
of Neuroscience Discovery Biology, Bristol
Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Gulianello</span> - <span class="hlFld-Affiliation affiliation">Department
of Neuroscience Discovery Biology, Bristol
Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Martin Lewis</span> - <span class="hlFld-Affiliation affiliation">Department
of Neuroscience Discovery Biology, Bristol
Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Amy Easton</span> - <span class="hlFld-Affiliation affiliation">Department
of Neuroscience Discovery Biology, Bristol
Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jonathan S. Lippy</span> - <span class="hlFld-Affiliation affiliation">Department
of Lead Evaluation, Bristol Myers Squibb
Company, Research and Development, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Neha Surti</span> - <span class="hlFld-Affiliation affiliation">Department
of Lead Evaluation, Bristol Myers Squibb
Company, Research and Development, Princeton, New Jersey 08543, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sreenivasulu N. Pattipati</span> - <span class="hlFld-Affiliation affiliation">Biocon-Bristol
Myers Squibb Research and Development Center, Biocon Park, Plot No. 2 & 3,
Bommasandra Phase IV, Jigani Link Road, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Manoj Dokania</span> - <span class="hlFld-Affiliation affiliation">Biocon-Bristol
Myers Squibb Research and Development Center, Biocon Park, Plot No. 2 & 3,
Bommasandra Phase IV, Jigani Link Road, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Saravanan Elavazhagan</span> - <span class="hlFld-Affiliation affiliation">Biocon-Bristol
Myers Squibb Research and Development Center, Biocon Park, Plot No. 2 & 3,
Bommasandra Phase IV, Jigani Link Road, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kumaran Dandapani</span> - <span class="hlFld-Affiliation affiliation">Biocon-Bristol
Myers Squibb Research and Development Center, Biocon Park, Plot No. 2 & 3,
Bommasandra Phase IV, Jigani Link Road, Bangalore 560099, India</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian D. Hamman</span> - <span class="hlFld-Affiliation affiliation">Lexicon
Pharmaceuticals, 8800
Technology Forest Place, The Woodlands, Texas 77381, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Allen</span> - <span class="hlFld-Affiliation affiliation">Lexicon
Pharmaceuticals, 8800
Technology Forest Place, The Woodlands, Texas 77381, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Walter Kostich</span> - <span class="hlFld-Affiliation affiliation">Department
of Neuroscience Discovery Biology, Bristol
Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joanne J. Bronson</span> - <span class="hlFld-Affiliation affiliation">Department
of Small Molecule Drug Discovery, Bristol
Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John E. Macor</span> - <span class="hlFld-Affiliation affiliation">Department
of Small Molecule Drug Discovery, Bristol
Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Carolyn D. Dzierba</span> - <span class="hlFld-Affiliation affiliation">Department
of Small Molecule Drug Discovery, Bristol
Myers Squibb Company, Research and Development, Wallingford, Connecticut 06492, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>L.J.B. wrote the section describing the in vivo pain model results. The section describing the in vivo inhibition of μ2 phosphorylation was co-authored with J.M.B.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br><p class="inlineNote">All animal experiments performed in the paper were conducted in compliance with institutional guidelines.</p></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i185">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_68551" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_68551" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Ryan Westphal for contributions to this work, Randi Brown for assistance with lead evaluation, Tara Simmons for measuring the brain tissue homogenate unbound fraction, and the Spectrix group for obtaining optical rotations.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">AAK1</td><td class="NLM_def"><p class="first last">adaptor-associated kinase 1</p></td></tr><tr><td class="NLM_term">AP2</td><td class="NLM_def"><p class="first last">adaptor protein 2</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">B/P</td><td class="NLM_def"><p class="first last">brain to plasma</p></td></tr><tr><td class="NLM_term">CCI</td><td class="NLM_def"><p class="first last">chronic constriction injury</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">DME</td><td class="NLM_def"><p class="first last">dimethoxyethane</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last">dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethylsulfoxide</p></td></tr><tr><td class="NLM_term">Dppf</td><td class="NLM_def"><p class="first last">diphenylphosphinoferrocene</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">Et<sub>2</sub>O</td><td class="NLM_def"><p class="first last">diethyl ether</p></td></tr><tr><td class="NLM_term">GABA</td><td class="NLM_def"><p class="first last">γ-aminobutyric acid</p></td></tr><tr><td class="NLM_term">HATU</td><td class="NLM_def"><p class="first last">hexafluorophosphate azabenzotriazole tetramethyluronium</p></td></tr><tr><td class="NLM_term">HCl</td><td class="NLM_def"><p class="first last">hydrochloric acid</p></td></tr><tr><td class="NLM_term">Met Stab</td><td class="NLM_def"><p class="first last">metabolic stability</p></td></tr><tr><td class="NLM_term">NSAIDs</td><td class="NLM_def"><p class="first last">nonsteroidal anti-inflammatory drugs</p></td></tr><tr><td class="NLM_term">PHMS</td><td class="NLM_def"><p class="first last">polymethylhydrosiloxane</p></td></tr><tr><td class="NLM_term">PK/PD</td><td class="NLM_def"><p class="first last">pharmacokinetic/pharmacodynamic</p></td></tr><tr><td class="NLM_term">PO</td><td class="NLM_def"><p class="first last">oral</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SC</td><td class="NLM_def"><p class="first last">subcutaneous</p></td></tr><tr><td class="NLM_term">SNRIs</td><td class="NLM_def"><p class="first last">serotonin and norepinephrine inhibitors</p></td></tr><tr><td class="NLM_term">TBAF</td><td class="NLM_def"><p class="first last">tetrabutyl ammonium fluoride</p></td></tr><tr><td class="NLM_term">TBTU</td><td class="NLM_def"><p class="first last">2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TosMIC</td><td class="NLM_def"><p class="first last">toluenesulfonylmethyl isocyanide</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i187">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_18662" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_18662" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 75 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Costigan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolf, C. J.</span></span> <span> </span><span class="NLM_article-title">Neuropathic pain: a maladaptive response of the nervous system to damage</span>. <i>Annu. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1146/annurev.neuro.051508.135531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1146%2Fannurev.neuro.051508.135531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=19400724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsV2nur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2009&pages=1-32&author=M.+Costiganauthor=J.+Scholzauthor=C.+J.+Woolf&title=Neuropathic+pain%3A+a+maladaptive+response+of+the+nervous+system+to+damage&doi=10.1146%2Fannurev.neuro.051508.135531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Neuropathic pain: a maladaptive response of the nervous system to damage</span></div><div class="casAuthors">Costigan, Michael; Scholz, Joachim; Woolf, Clifford J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Neuroscience</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-32</span>CODEN:
                <span class="NLM_cas:coden">ARNSD5</span>;
        ISSN:<span class="NLM_cas:issn">0147-006X</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Neuropathic pain is triggered by lesions to the somatosensory nervous system that alter its structure and function so that pain occurs spontaneously and responses to noxious and innocuous stimuli are pathol. amplified.  The pain is an expression of maladaptive plasticity within the nociceptive system, a series of changes that constitute a neural disease state.  Multiple alterations distributed widely across the nervous system contribute to complex pain phenotypes.  These alterations include ectopic generation of action potentials, facilitation and disinhibition of synaptic transmission, loss of synaptic connectivity and formation of new synaptic circuits, and neuroimmune interactions.  Although neural lesions are necessary, they are not sufficient to generate neuropathic pain; genetic polymorphisms, gender, and age all influence the risk of developing persistent pain.  Treatment needs to move from merely suppressing symptoms to a disease-modifying strategy aimed at both preventing maladaptive plasticity and reducing intrinsic risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodJvh-ROUpD7Vg90H21EOLACvtfcHk0ljInROHNXcKGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsV2nur8%253D&md5=7869abfea9d20587dd6894eba3669cd2</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1146%2Fannurev.neuro.051508.135531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.neuro.051508.135531%26sid%3Dliteratum%253Aachs%26aulast%3DCostigan%26aufirst%3DM.%26aulast%3DScholz%26aufirst%3DJ.%26aulast%3DWoolf%26aufirst%3DC.%2BJ.%26atitle%3DNeuropathic%2520pain%253A%2520a%2520maladaptive%2520response%2520of%2520the%2520nervous%2520system%2520to%2520damage%26jtitle%3DAnnu.%2520Rev.%2520Neurosci.%26date%3D2009%26volume%3D32%26spage%3D1%26epage%3D32%26doi%3D10.1146%2Fannurev.neuro.051508.135531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruccu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truini, A.</span></span> <span> </span><span class="NLM_article-title">Neuropathic pain: the scope of the problem</span>. <i>Pain Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">S1</span>– <span class="NLM_lpage">S3</span>, <span class="refDoi"> DOI: 10.1007/s40122-017-0086-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1007%2Fs40122-017-0086-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=29178038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADC%252BC1M3lt1egtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=S1-S3&author=G.+Cruccuauthor=A.+Truini&title=Neuropathic+pain%3A+the+scope+of+the+problem&doi=10.1007%2Fs40122-017-0086-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Neuropathic Pain: The Scope of the Problem</span></div><div class="casAuthors">Cruccu Giorgio; Truini Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Pain and therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">Suppl 1</span>),
    <span class="NLM_cas:pages">1-3</span>
        ISSN:<span class="NLM_cas:issn">2193-8237</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyTuLMvUnN-4qdXsLcGTEUfW6udTcc2ebgQfcDYr5kYbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3lt1egtg%253D%253D&md5=90548393533c18587fec6e954a6530b5</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs40122-017-0086-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40122-017-0086-1%26sid%3Dliteratum%253Aachs%26aulast%3DCruccu%26aufirst%3DG.%26aulast%3DTruini%26aufirst%3DA.%26atitle%3DNeuropathic%2520pain%253A%2520the%2520scope%2520of%2520the%2520problem%26jtitle%3DPain%2520Ther.%26date%3D2017%26volume%3D6%26spage%3DS1%26epage%3DS3%26doi%3D10.1007%2Fs40122-017-0086-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrance, N.</span></span> <span> </span><span class="NLM_article-title">Epidemiology of neuropathic pain and its impact on quality of life</span>. <i>Curr. Pain Headache Rep.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1007/s11916-012-0256-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1007%2Fs11916-012-0256-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=22395856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADC%252BC38vls12jtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=191-198&author=B.+H.+Smithauthor=N.+Torrance&title=Epidemiology+of+neuropathic+pain+and+its+impact+on+quality+of+life&doi=10.1007%2Fs11916-012-0256-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology of neuropathic pain and its impact on quality of life</span></div><div class="casAuthors">Smith Blair H; Torrance Nicola</div><div class="citationInfo"><span class="NLM_cas:title">Current pain and headache reports</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epidemiology is an important clinical tool in designing and evaluating management and prevention strategies, and is particularly relevant to neuropathic pain.  However, there is a relative lack of accurate information available.  In one sense, neuropathic pain describes a symptom or a mechanism, rather than a specific disease; on the other hand, there are sufficient similarities in the effects and response to treatment between different causes to make it worthwhile to consider neuropathic pain as a distinct condition.  However, there are important specific disease-based factors that need to be considered separately.  Estimates of prevalence that are based on specific causes of neuropathic pain tend to be lower (1-2%) than those that are based on reports of the classic symptoms (6-8%), and further methodological research is needed.  All neuropathic pain is associated with poor general health, comparable with other severe chronic diseases.  The importance of newly proposed risk factors, including genetic factors, still needs to be assessed at a population level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_IOGgMJOMUGLFM_lbR1VmfW6udTcc2eYNIfDvVkXryrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vls12jtQ%253D%253D&md5=aa3551b70012e240d8a9d0959a8c95c3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs11916-012-0256-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11916-012-0256-0%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BH.%26aulast%3DTorrance%26aufirst%3DN.%26atitle%3DEpidemiology%2520of%2520neuropathic%2520pain%2520and%2520its%2520impact%2520on%2520quality%2520of%2520life%26jtitle%3DCurr.%2520Pain%2520Headache%2520Rep.%26date%3D2012%26volume%3D16%26spage%3D191%26epage%3D198%26doi%3D10.1007%2Fs11916-012-0256-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finnerup, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haroutounian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNicol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dworkin, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilron, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannpää, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamerman, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lund, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raja, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, A. S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowbotham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sena, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddall, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(14)70251-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2FS1474-4422%2814%2970251-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=25575710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovFygsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=162-173&author=N.+B.+Finnerupauthor=N.+Attalauthor=S.+Haroutounianauthor=E.+McNicolauthor=R.+Baronauthor=R.+H.+Dworkinauthor=I.+Gilronauthor=M.+Hannp%C3%A4%C3%A4author=P.+Hanssonauthor=T.+S.+Jensenauthor=P.+R.+Kamermanauthor=K.+Lundauthor=A.+Mooreauthor=S.+N.+Rajaauthor=A.+S.+C.+Riceauthor=M.+Rowbothamauthor=E.+Senaauthor=P.+Siddallauthor=B.+H.+Smithauthor=M.+Wallace&title=Pharmacotherapy+for+neuropathic+pain+in+adults%3A+a+systematic+review+and+meta-analysis&doi=10.1016%2FS1474-4422%2814%2970251-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis</span></div><div class="casAuthors">Finnerup, Nanna B.; Attal, Nadine; Haroutounian, Simon; McNicol, Ewan; Baron, Ralf; Dworkin, Robert H.; Gilron, Ian; Haanpaa, Maija; Hansson, Per; Jensen, Troels S.; Kamerman, Peter R.; Lund, Karen; Moore, Andrew; Raja, Srinivasa N.; Rice, Andrew S. C.; Rowbotham, Michael; Sena, Emily; Siddall, Philip; Smith, Blair H.; Wallace, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-173</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">New drug treatments, clin. trials, and stds. of quality for assessment of evidence justify an update of evidence-based recommendations for the pharmacol. treatment of neuropathic pain.  Using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE), we revised the Special Interest Group on Neuropathic Pain (NeuPSIG) recommendations for the pharmacotherapy of neuropathic pain based on the results of a systematic review and meta-anal.  Between Apr., 2013, and Jan., 2014, NeuPSIG of the International Assocn. for the Study of Pain did a systematic review and meta-anal. of randomised, double-blind studies of oral and topical pharmacotherapy for neuropathic pain, including studies published in peer-reviewed journals since Jan., 1966, and unpublished trials retrieved from ClinicalTrials.gov and websites of pharmaceutical companies.  We used no. needed to treat (NNT) for 50% pain relief as a primary measure and assessed publication bias; NNT was calcd. with the fixed-effects Mantel-Haenszel method.229 studies were included in the meta-anal.  Anal. of publication bias suggested a 10% overstatement of treatment effects.  Studies published in peer-reviewed journals reported greater effects than did unpublished studies (r2 9·3%, p=0·009).  Trial outcomes were generally modest: in particular, combined NNTs were 6·4 (95% CI 5·2-8·4) for serotonin-noradrenaline reuptake inhibitors, mainly including duloxetine (nine of 14 studies); 7·7 (6·5-9·4) for pregabalin; 7·2 (5·9-9·21) for gabapentin, including gabapentin extended release and enacarbil; and 10·6 (7·4-19·0) for capsaicin high-concn. patches.  NNTs were lower for tricyclic antidepressants, strong opioids, tramadol, and botulinum toxin A, and undetd. for lidocaine patches.  Based on GRADE, final quality of evidence was moderate or high for all treatments apart from lidocaine patches; tolerability and safety, and values and preferences were higher for topical drugs; and cost was lower for tricyclic antidepressants and tramadol.  These findings permitted a strong recommendation for use and proposal as first-line treatment in neuropathic pain for tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, pregabalin, and gabapentin; a weak recommendation for use and proposal as second line for lidocaine patches, capsaicin high-concn. patches, and tramadol; and a weak recommendation for use and proposal as third line for strong opioids and botulinum toxin A.  Topical agents and botulinum toxin A are recommended for peripheral neuropathic pain only.  Our results support a revision of the NeuPSIG recommendations for the pharmacotherapy of neuropathic pain.  Inadequate response to drug treatments constitutes a substantial unmet need in patients with neuropathic pain.  Modest efficacy, large placebo responses, heterogeneous diagnostic criteria, and poor phenotypic profiling probably account for moderate trial outcomes and should be taken into account in future studies.  NeuPSIG of the International Assocn. for the Study of Pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog3lY2ykFKHrVg90H21EOLACvtfcHk0ljWM9oHjnv6dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovFygsw%253D%253D&md5=aaae3dd82ea6896d3977412faedebffd</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2814%2970251-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252814%252970251-0%26sid%3Dliteratum%253Aachs%26aulast%3DFinnerup%26aufirst%3DN.%2BB.%26aulast%3DAttal%26aufirst%3DN.%26aulast%3DHaroutounian%26aufirst%3DS.%26aulast%3DMcNicol%26aufirst%3DE.%26aulast%3DBaron%26aufirst%3DR.%26aulast%3DDworkin%26aufirst%3DR.%2BH.%26aulast%3DGilron%26aufirst%3DI.%26aulast%3DHannp%25C3%25A4%25C3%25A4%26aufirst%3DM.%26aulast%3DHansson%26aufirst%3DP.%26aulast%3DJensen%26aufirst%3DT.%2BS.%26aulast%3DKamerman%26aufirst%3DP.%2BR.%26aulast%3DLund%26aufirst%3DK.%26aulast%3DMoore%26aufirst%3DA.%26aulast%3DRaja%26aufirst%3DS.%2BN.%26aulast%3DRice%26aufirst%3DA.%2BS.%2BC.%26aulast%3DRowbotham%26aufirst%3DM.%26aulast%3DSena%26aufirst%3DE.%26aulast%3DSiddall%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DB.%2BH.%26aulast%3DWallace%26aufirst%3DM.%26atitle%3DPharmacotherapy%2520for%2520neuropathic%2520pain%2520in%2520adults%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DLancet%2520Neurol.%26date%3D2015%26volume%3D14%26spage%3D162%26epage%3D173%26doi%3D10.1016%2FS1474-4422%2814%2970251-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finnerup, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sindrup, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, T. S.</span></span> <span> </span><span class="NLM_article-title">The evidence for pharmacological treatment of neuropathic pain</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1016/j.pain.2010.06.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2Fj.pain.2010.06.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=20705215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADC%252BC3cjmsVOisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2010&pages=573-581&author=N.+B.+Finnerupauthor=S.+H.+Sindrupauthor=T.+S.+Jensen&title=The+evidence+for+pharmacological+treatment+of+neuropathic+pain&doi=10.1016%2Fj.pain.2010.06.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The evidence for pharmacological treatment of neuropathic pain</span></div><div class="casAuthors">Finnerup Nanna Brix; Sindrup Soren Hein; Jensen Troels Staehelin</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">573-581</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Randomized, double-blind, placebo-controlled trials on neuropathic pain treatment are accumulating, so an updated review of the available evidence is needed.  Studies were identified using MEDLINE and EMBASE searches.  Numbers needed to treat (NNT) and numbers needed to harm (NNH) values were used to compare the efficacy and safety of different treatments for a number of neuropathic pain conditions.  One hundred and seventy-four studies were included, representing a 66% increase in published randomized, placebo-controlled trials in the last 5 years.  Painful poly-neuropathy (most often due to diabetes) was examined in 69 studies, postherpetic neuralgia in 23, while peripheral nerve injury, central pain, HIV neuropathy, and trigeminal neuralgia were less often studied.  Tricyclic antidepressants, serotonin noradrenaline reuptake inhibitors, the anticonvulsants gabapentin and pregabalin, and opioids are the drug classes for which there is the best evidence for a clinical relevant effect.  Despite a 66% increase in published trials only a limited improvement of neuropathic pain treatment has been obtained.  A large proportion of neuropathic pain patients are left with insufficient pain relief.  This fact calls for other treatment options to target chronic neuropathic pain.  Large-scale drug trials that aim to identify possible subgroups of patients who are likely to respond to specific drugs are needed to test the hypothesis that a mechanism-based classification may help improve treatment of the individual patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSGaQWHMjO4toUSrryheKE6fW6udTcc2eYNIfDvVkXryrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjmsVOisg%253D%253D&md5=d72cc434514579e6e8da7e06f8ea3fa9</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.pain.2010.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pain.2010.06.019%26sid%3Dliteratum%253Aachs%26aulast%3DFinnerup%26aufirst%3DN.%2BB.%26aulast%3DSindrup%26aufirst%3DS.%2BH.%26aulast%3DJensen%26aufirst%3DT.%2BS.%26atitle%3DThe%2520evidence%2520for%2520pharmacological%2520treatment%2520of%2520neuropathic%2520pain%26jtitle%3DPain%26date%3D2010%26volume%3D150%26spage%3D573%26epage%3D581%26doi%3D10.1016%2Fj.pain.2010.06.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fairbanks, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcox, G. L.</span></span> <span> </span><span class="NLM_article-title">Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2009.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2Fj.pharmthera.2009.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=19393691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFyhtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2009&pages=224-238&author=C.+A.+Fairbanksauthor=L.+S.+Stoneauthor=G.+L.+Wilcox&title=Pharmacological+profiles+of+alpha+2+adrenergic+receptor+agonists+identified+using+genetically+altered+mice+and+isobolographic+analysis&doi=10.1016%2Fj.pharmthera.2009.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis</span></div><div class="casAuthors">Fairbanks, Carolyn A.; Stone, Laura S.; Wilcox, George L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">224-238</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Endogenous, descending noradrenergic fibers impose analgesic control over spinal afferent circuitry mediating the rostrad transmission of pain signals.  These fibers target alpha 2 adrenergic receptors (α2ARs) on both primary afferent terminals and secondary neurons, and their activation mediates substantial inhibitory control over this transmission, rivaling that of opioid receptors which share a similar pattern of distribution.  The terminals of primary afferent nociceptive neurons and secondary spinal dorsal horn neurons express α2AAR and α2CAR subtypes, resp.  Spinal delivery of these agents serves to reduce their side effects, which are mediated largely at supraspinal sites, by concg. the drugs at the spinal level.  Targeting these spinal α2ARs with one of five selective therapeutic agonists, clonidine, dexmedetomidine, brimonidine, ST91 and moxonidine, produces significant antinociception that can work in concert with opioid agonists to yield synergistic antinociception.  Application of several genetically altered mouse lines had facilitated identification of the primary receptor subtypes that likely mediate the antinociceptive effects of these agents.  This review provides first an anatomical description of the localization of the three subtypes in the central nervous system, second a detailed account of the pharmacol. history of each of the six primary agonists, and finally a comprehensive report of the specific interactions of other GPCR agonists with each of the six principal α2AR agonists featured.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLBGBdc8kulrVg90H21EOLACvtfcHk0lgVh992Ch_mCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFyhtbg%253D&md5=6a358043378a8416816a2544daade0f1</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2009.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2009.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DFairbanks%26aufirst%3DC.%2BA.%26aulast%3DStone%26aufirst%3DL.%2BS.%26aulast%3DWilcox%26aufirst%3DG.%2BL.%26atitle%3DPharmacological%2520profiles%2520of%2520alpha%25202%2520adrenergic%2520receptor%2520agonists%2520identified%2520using%2520genetically%2520altered%2520mice%2520and%2520isobolographic%2520analysis%26jtitle%3DPharmacol.%2520Ther.%26date%3D2009%26volume%3D123%26spage%3D224%26epage%3D238%26doi%3D10.1016%2Fj.pharmthera.2009.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benarroch, E. E.</span></span> <span> </span><span class="NLM_article-title">Descending monoaminergic pain modulation: bidirectional control and clinical relevance</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1212/01.wnl.0000318225.51122.63</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1212%2F01.wnl.0000318225.51122.63" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=18625968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADC%252BD1cvltVWrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2008&pages=217-221&author=E.+E.+Benarroch&title=Descending+monoaminergic+pain+modulation%3A+bidirectional+control+and+clinical+relevance&doi=10.1212%2F01.wnl.0000318225.51122.63"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Descending monoaminergic pain modulation: bidirectional control and clinical relevance</span></div><div class="casAuthors">Benarroch Eduardo E</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAfJdaFxsZlZagfuraLLzSfW6udTcc2eaeEDCHLQOC-Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvltVWrtw%253D%253D&md5=fbbc75af607276ce8297591258c1ffc6</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1212%2F01.wnl.0000318225.51122.63&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252F01.wnl.0000318225.51122.63%26sid%3Dliteratum%253Aachs%26aulast%3DBenarroch%26aufirst%3DE.%2BE.%26atitle%3DDescending%2520monoaminergic%2520pain%2520modulation%253A%2520bidirectional%2520control%2520and%2520clinical%2520relevance%26jtitle%3DNeurology%26date%3D2008%26volume%3D71%26spage%3D217%26epage%3D221%26doi%3D10.1212%2F01.wnl.0000318225.51122.63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sills, G. J.</span></span> <span> </span><span class="NLM_article-title">The mechanisms of action of gabapentin and pregabalin</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">108</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2005.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2Fj.coph.2005.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=16376147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVyitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=108-113&author=G.+J.+Sills&title=The+mechanisms+of+action+of+gabapentin+and+pregabalin&doi=10.1016%2Fj.coph.2005.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanisms of action of Gabapentin and Pregabalin</span></div><div class="casAuthors">Sills, Graeme J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">108-113</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Gabapentin and Pregabalin are structurally related compds. with recognized efficacy in the treatment of both epilepsy and neuropathic pain.  The pharmacol. mechanisms by which these agents exert their clin. effects have, until recently, remained unclear.  The interaction of Gabapentin and Pregabalin with conventional antiepileptic and analgesic drug targets is likely to be modest, at best, and has been largely dismissed in favor of a selective inhibitory effect on voltage-gated calcium channels contg. the α2δ-1 subunit.  This mechanism is consistently obsd. in both rodent- and human-based exptl. paradigms and may be sufficiently robust to account for much of the clin. activity of these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVcGWT9vU4_7Vg90H21EOLACvtfcHk0lgVh992Ch_mCg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVyitQ%253D%253D&md5=f986039097362702cbf33f88deb50baf</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2005.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2005.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DSills%26aufirst%3DG.%2BJ.%26atitle%3DThe%2520mechanisms%2520of%2520action%2520of%2520gabapentin%2520and%2520pregabalin%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2006%26volume%3D6%26spage%3D108%26epage%3D113%26doi%3D10.1016%2Fj.coph.2005.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolphin, A. C.</span></span> <span> </span><span class="NLM_article-title">Calcium channel auxiliary α<sub>2</sub>δ and β subunits: trafficking and one step beyond</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1038/nrn3311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1038%2Fnrn3311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=22805911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVektLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=542-555&author=A.+C.+Dolphin&title=Calcium+channel+auxiliary+%CE%B12%CE%B4+and+%CE%B2+subunits%3A+trafficking+and+one+step+beyond&doi=10.1038%2Fnrn3311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium channel auxiliary α2δ and β subunits: trafficking and one step beyond</span></div><div class="casAuthors">Dolphin, Annette C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">542-555</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The voltage-gated calcium channel α2δ and β subunits are traditionally considered to be auxiliary subunits that enhance channel trafficking, increase the expression of functional calcium channels at the plasma membrane and influence the channels' biophys. properties.  Accumulating evidence indicates that these subunits may also have roles in the nervous system that are not directly linked to calcium channel function.  For example, β subunits may act as transcriptional regulators, and certain α2δ subunits may function in synaptogenesis.  The aim of this Review is to examine both the classic and novel roles for these auxiliary subunits in voltage-gated calcium channel function and beyond.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBOsgOAvtdaLVg90H21EOLACvtfcHk0ljWNK_1EUXVXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVektLbJ&md5=13e03e73e05f17579e7f1c63fb4fcc0d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrn3311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn3311%26sid%3Dliteratum%253Aachs%26aulast%3DDolphin%26aufirst%3DA.%2BC.%26atitle%3DCalcium%2520channel%2520auxiliary%2520%25CE%25B12%25CE%25B4%2520and%2520%25CE%25B2%2520subunits%253A%2520trafficking%2520and%2520one%2520step%2520beyond%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2012%26volume%3D13%26spage%3D542%26epage%3D555%26doi%3D10.1038%2Fnrn3311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorrell, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szklarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul Azeez, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Family-wide structural analysis of human numb-associated protein kinases</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.1016/j.str.2015.12.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2Fj.str.2015.12.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=26853940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=401-411&author=F.+J.+Sorrellauthor=M.+Szklarzauthor=K.+R.+Abdul+Azeezauthor=J.+M.+Elkinsauthor=S.+Knapp&title=Family-wide+structural+analysis+of+human+numb-associated+protein+kinases&doi=10.1016%2Fj.str.2015.12.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Family-wide Structural Analysis of Human Numb-Associated Protein Kinases</span></div><div class="casAuthors">Sorrell, Fiona J.; Szklarz, Marta; Abdul Azeez, Kamal R.; Elkins, Jon M.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">401-411</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The highly diverse Numb-assocd. kinase (NAK) family has been linked to broad cellular functions including receptor-mediated endocytosis, Notch pathway modulation, osteoblast differentiation, and dendrite morphogenesis.  Consequently, NAK kinases play a key role in a diverse range of diseases from Parkinson's and prostate cancer to HIV.  Due to the plasticity of this kinase family, NAK kinases are often inhibited by approved or investigational drugs and have been assocd. with side effects, but they are also potential drug targets.  The presence of cysteine residues in some NAK family members provides the possibility for selective targeting via covalent inhibition.  Here we report the first high-resoln. structures of kinases AAK1 and BIKE in complex with two drug candidates.  The presented data allow a comprehensive structural characterization of the NAK kinase family and provide the basis for rational design of selective NAK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryZi0QmT8YH7Vg90H21EOLACvtfcHk0ljWNK_1EUXVXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCktLY%253D&md5=6a353c993ec9f2b7152e459d72bab9d3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2015.12.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2015.12.015%26sid%3Dliteratum%253Aachs%26aulast%3DSorrell%26aufirst%3DF.%2BJ.%26aulast%3DSzklarz%26aufirst%3DM.%26aulast%3DAbdul%2BAzeez%26aufirst%3DK.%2BR.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DFamily-wide%2520structural%2520analysis%2520of%2520human%2520numb-associated%2520protein%2520kinases%26jtitle%3DStructure%26date%3D2016%26volume%3D24%26spage%3D401%26epage%3D411%26doi%3D10.1016%2Fj.str.2015.12.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conner, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, S. L.</span></span> <span> </span><span class="NLM_article-title">Identification of an adaptor-associated kinase, AAK1, as a regulator of clathrin-mediated endocytosis</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">929</span>, <span class="refDoi"> DOI: 10.1083/jcb.200108123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1083%2Fjcb.200108123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=11877461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD38XitVGmtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2002&pages=921-929&author=S.+D.+Connerauthor=S.+L.+Schmid&title=Identification+of+an+adaptor-associated+kinase%2C+AAK1%2C+as+a+regulator+of+clathrin-mediated+endocytosis&doi=10.1083%2Fjcb.200108123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an adaptor-associated kinase, AAK1, as a regulator of clathrin-mediated endocytosis</span></div><div class="casAuthors">Conner, Sean D.; Schmid, Sandra L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">921-929</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">The μ2 subunit of the AP2 complex is known to be phosphorylated in vitro by a copurifying kinase, and it has been demonstrated recently that μ2 phosphorylation is required for transferrin endocytosis.  However, the identity of the endogenous kinase responsible for this phosphorylation is unknown.  Here we identify and characterize a novel member of the Prk/Ark family of serine/threonine kinases, adaptor-assocd. kinase (AAK)1.  We find that AAK1 copurifies with adaptor protein (AP)2 and that it directly binds the ear domain of α-adaptin in vivo and in vitro.  In neuronal cells, AAK1 is enriched at presynaptic terminals, whereas in nonneuronal cells it colocalizes with clathrin and AP2 in clathrin-coated pits and at the leading edge of migrating cells.  AAK1 specifically phosphorylates the μ subunit in vitro, and stage-specific assays for endocytosis show that μ phosphorylation by AAK1 results in a decrease in AP2-stimulated transferrin internalization.  Together, these results provide strong evidence that AAK1 is the endogenous μ2 kinase and plays a regulatory role in clathrin-mediated endocytosis.  These results also lend support to the idea that clathrin-mediated endocytosis is controlled by cycles of phosphorylation/desphosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp62q8kuSqokbVg90H21EOLACvtfcHk0ljWNK_1EUXVXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitVGmtrg%253D&md5=0f9061fb428373240da331f7d25bb9bf</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200108123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200108123%26sid%3Dliteratum%253Aachs%26aulast%3DConner%26aufirst%3DS.%2BD.%26aulast%3DSchmid%26aufirst%3DS.%2BL.%26atitle%3DIdentification%2520of%2520an%2520adaptor-associated%2520kinase%252C%2520AAK1%252C%2520as%2520a%2520regulator%2520of%2520clathrin-mediated%2520endocytosis%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2002%26volume%3D156%26spage%3D921%26epage%3D929%26doi%3D10.1083%2Fjcb.200108123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conner, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schröter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, S. L.</span></span> <span> </span><span class="NLM_article-title">AAK1-mediated μ2 phosphorylation is stimulated by assembled clathrin</span>. <i>Traffic</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1046/j.1398-9219.2003.0142.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1046%2Fj.1398-9219.2003.0142.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=14617351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvVGhtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=885-890&author=S.+D.+Connerauthor=T.+Schr%C3%B6terauthor=S.+L.+Schmid&title=AAK1-mediated+%CE%BC2+phosphorylation+is+stimulated+by+assembled+clathrin&doi=10.1046%2Fj.1398-9219.2003.0142.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">AAK1-mediated μ2 phosphorylation is stimulated by assembled clathrin</span></div><div class="casAuthors">Conner, Sean D.; Schroeter, Thomas; Schmid, Sandra L.</div><div class="citationInfo"><span class="NLM_cas:title">Traffic (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">885-890</span>CODEN:
                <span class="NLM_cas:coden">TRAFFA</span>;
        ISSN:<span class="NLM_cas:issn">1398-9219</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">AAK1, the adaptor-assocd. kinase 1, phosphorylates the μ2 subunit of AP2 and regulates the recruitment of AP2 to tyrosine-based internalization motifs found on membrane-bound receptors.  AAK1 overexpression specifically inhibits the AP2-dependent internalization of transferrin receptor and LDL-receptor related protein by functionally sequestering AP2 (Conner and Schmid. J Cell Biol 2003; 162: 773).  However, while AAK1 stably assocs. with AP2 and specifically targets the μ2 subunit in vitro, μ2 phosphorylation in vivo was not altered by overexpression of either wild-type or kinase-inactive AAK1.  These results suggested that AAK1 might be tightly regulated in the cell.  Here, we report that AAK1 is an atypical kinase that is rate limited by its stable assocn. with AP2 and that clathrin stimulates μ2 phosphorylation by AAK1.  Efficient stimulation of AAK1 by clathrin involves multiple interactions between several domains on AAK1 and both heavy and light chains on clathrin.  Importantly, incubation of AAK1 with clathrin cages resulted in even greater stimulation when compared to that of unassembled clathrin triskelia.  Collectively, our observations indicate that clathrin function is not limited to structural and/or mech. roles in endocytic vesicle formation: the stimulatory effects of clathrin on AAK1 activity argue that it also plays a regulatory role by modulating the activity of AP2 complexes through activation of AAK1.  We suggest a model in which AAK1 is specifically activated in coated pits to enhance cargo recruitment and efficient internalization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_pbrwRqrFcLVg90H21EOLACvtfcHk0ljWNK_1EUXVXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvVGhtrw%253D&md5=1c9849cdd32f8682fbb4dc63ad2dabfc</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1046%2Fj.1398-9219.2003.0142.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1398-9219.2003.0142.x%26sid%3Dliteratum%253Aachs%26aulast%3DConner%26aufirst%3DS.%2BD.%26aulast%3DSchr%25C3%25B6ter%26aufirst%3DT.%26aulast%3DSchmid%26aufirst%3DS.%2BL.%26atitle%3DAAK1-mediated%2520%25CE%25BC2%2520phosphorylation%2520is%2520stimulated%2520by%2520assembled%2520clathrin%26jtitle%3DTraffic%26date%3D2003%26volume%3D4%26spage%3D885%26epage%3D890%26doi%3D10.1046%2Fj.1398-9219.2003.0142.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, M. S.</span>; <span class="NLM_string-name">Ball, C. L.</span>; <span class="NLM_string-name">Seaman, M. N. J.</span></span> <span> </span><span class="NLM_article-title">Adaptins and their Role in Clathrin-Mediated Vesicle Sorting</span>. In  <i>Molecular Mechanisms of Membrane Traffic</i>; <span class="NLM_series">NATO ASI Series (Series H: Cell Biology)</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morré, D. J.</span>; <span class="NLM_string-name">Howell, K. E.</span>; <span class="NLM_string-name">Bergeron, J. J. M.</span></span> Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Berlin, Heidelberg</span>, <span class="NLM_year">1993</span>, Vol.  <span class="NLM_volume">74</span>, pp.  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">236</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1007%2F978-3-662-02928-2_46" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1993&pages=229-236&author=M.+S.+Robinson&author=C.+L.+Ball&author=M.+N.+J.+Seamanauthor=D.+J.+Morr%C3%A9&author=K.+E.+Howell&author=J.+J.+M.+Bergeron&title=Molecular+Mechanisms+of+Membrane+Traffic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2F978-3-662-02928-2_46&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-662-02928-2_46%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DM.%2BS.%26atitle%3DAdaptins%2520and%2520their%2520Role%2520in%2520Clathrin-Mediated%2520Vesicle%2520Sorting%26btitle%3DMolecular%2520Mechanisms%2520of%2520Membrane%2520Traffic%26aulast%3DMorr%25C3%25A9%26aufirst%3DD.%2BJ.%26pub%3DSpringer%26date%3D1993%26volume%3D74%26spage%3D229%26epage%3D236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, M. S.</span></span> <span> </span><span class="NLM_article-title">Adaptable adaptors for coated vesicles</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1016/j.tcb.2004.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2Fj.tcb.2004.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=15066634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVGjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=167-174&author=M.+S.+Robinson&title=Adaptable+adaptors+for+coated+vesicles&doi=10.1016%2Fj.tcb.2004.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Adaptable adaptors for coated vesicles</span></div><div class="casAuthors">Robinson, Margaret S.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">167-174</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Adaptors select cargo for inclusion into coated vesicles in the late secretory and endocytic pathways.  Although originally there were thought to be just two adaptors, AP-1 and AP-2, it is now clear that there are many more: two addnl. adaptor complexes, AP-3 and AP-4, which might function independently of clathrin; a family of monomeric adaptors, the GGAs; and an ever-growing no. of cargo-specific adaptors.  The adaptors are targeted to the appropriate membrane at least in part by interacting with phosphoinositides, and, once on the membrane, they form interconnected networks to get different types of cargo into the same vesicle.  Adaptors participate in trafficking pathways shared by all cells, and they are also used to generate specialized organelles and to influence cell fate during development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZES4LlZkT97Vg90H21EOLACvtfcHk0ljxtcogI40UkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVGjt7w%253D&md5=5ffb2156af690a311059bf2a27f45419</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2004.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2004.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DM.%2BS.%26atitle%3DAdaptable%2520adaptors%2520for%2520coated%2520vesicles%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2004%26volume%3D14%26spage%3D167%26epage%3D174%26doi%3D10.1016%2Fj.tcb.2004.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirchhausen, T.</span></span> <span> </span><span class="NLM_article-title">Adaptors for clathrin-mediated traffic</span>. <i>Annu. Rev. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">705</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.1146/annurev.cellbio.15.1.705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1146%2Fannurev.cellbio.15.1.705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10611976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtVSnu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1999&pages=705-732&author=T.+Kirchhausen&title=Adaptors+for+clathrin-mediated+traffic&doi=10.1146%2Fannurev.cellbio.15.1.705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Adaptors for clathrin-mediated traffic</span></div><div class="casAuthors">Kirchhausen, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Cell and Developmental Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">705-732</span>CODEN:
                <span class="NLM_cas:coden">ARDBF8</span>;
        ISSN:<span class="NLM_cas:issn">1081-0706</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with approx. 150 refs.  Clathrin-based systems are responsible for a large portion of vesicular traffic originating from the plasma membrane and the trans-Golgi network that reaches the endosomal compartment.  The assembly of cytosolic clathrin forms the scaffold required for the local deformation of the membrane and for the formation of coated pits and vesicles.  In this process, clathrin interacts in a coordinated fashion with a large no. of protein partners.  A subset designated clathrin adaptors links integral membrane proteins to the clathrin coat, a process that results in the recruitment of specific cargo proteins to the budding vesicle.  This review focuses on the most recent advances dealing with the mol. basis for sorting by clathrin adaptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjj48TdSkDorVg90H21EOLACvtfcHk0ljxtcogI40UkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtVSnu7k%253D&md5=23b0bfbd0ccefa821f2ba5e00d38c3da</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1146%2Fannurev.cellbio.15.1.705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.cellbio.15.1.705%26sid%3Dliteratum%253Aachs%26aulast%3DKirchhausen%26aufirst%3DT.%26atitle%3DAdaptors%2520for%2520clathrin-mediated%2520traffic%26jtitle%3DAnnu.%2520Rev.%2520Cell%2520Dev.%2520Biol.%26date%3D1999%26volume%3D15%26spage%3D705%26epage%3D732%26doi%3D10.1146%2Fannurev.cellbio.15.1.705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournier, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosshart, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyatake, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallusser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchhausen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifacino, J. S.</span></span> <span> </span><span class="NLM_article-title">Interaction of tyrosine-based sorting signals with clathrin-associated proteins</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>269</i></span>,  <span class="NLM_fpage">1872</span>– <span class="NLM_lpage">1875</span>, <span class="refDoi"> DOI: 10.1126/science.7569928</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1126%2Fscience.7569928" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=7569928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADyaK2MXotlKqtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1995&pages=1872-1875&author=H.+Ohnoauthor=J.+Stewartauthor=M.+C.+Fournierauthor=H.+Bosshartauthor=I.+Rheeauthor=S.+Miyatakeauthor=T.+Saitoauthor=A.+Gallusserauthor=T.+Kirchhausenauthor=J.+S.+Bonifacino&title=Interaction+of+tyrosine-based+sorting+signals+with+clathrin-associated+proteins&doi=10.1126%2Fscience.7569928"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of tyrosine-based sorting signals with clathrin-associated proteins</span></div><div class="casAuthors">Ohno, Hiroshi; Stewart, Jay; Fournier, Marie-Christine; Bosshart, Herbert; Rhee, Ina; Miyatake, Shoichiro; Saito, Takashi; Gallusser, Andreas; Kirchhausen, Tomas; Bonifacino, Juan S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">5232</span>),
    <span class="NLM_cas:pages">1872-5</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Tyr-based signals within the cytoplasmic domain of integral membrane proteins mediate clathrin-dependent protein sorting in the endocytic and secretory pathways.  A yeast 2-hybrid system was used to identify proteins that bind to Tyr-based signals.  The medium chains (μ1 and μ2) of 2 clathrin-assocd. protein complexes (AP-1 and AP-2, resp.) specifically interacted with the Tyr-based signals of several integral membrane proteins (e.g., TGN38).  The interaction was confirmed by in vitro binding assays.  Thus, it is likely that the medium chains serve as signal-binding components of the clathrin-dependent sorting machinery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwelF8AB2bmbVg90H21EOLACvtfcHk0ljxtcogI40UkA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXotlKqtLc%253D&md5=7c354ca71c3065a1ab1abb6ab4751324</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1126%2Fscience.7569928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.7569928%26sid%3Dliteratum%253Aachs%26aulast%3DOhno%26aufirst%3DH.%26aulast%3DStewart%26aufirst%3DJ.%26aulast%3DFournier%26aufirst%3DM.%2BC.%26aulast%3DBosshart%26aufirst%3DH.%26aulast%3DRhee%26aufirst%3DI.%26aulast%3DMiyatake%26aufirst%3DS.%26aulast%3DSaito%26aufirst%3DT.%26aulast%3DGallusser%26aufirst%3DA.%26aulast%3DKirchhausen%26aufirst%3DT.%26aulast%3DBonifacino%26aufirst%3DJ.%2BS.%26atitle%3DInteraction%2520of%2520tyrosine-based%2520sorting%2520signals%2520with%2520clathrin-associated%2520proteins%26jtitle%3DScience%26date%3D1995%26volume%3D269%26spage%3D1872%26epage%3D1875%26doi%3D10.1126%2Fscience.7569928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shih, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallusser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchhausen, T.</span></span> <span> </span><span class="NLM_article-title">A clathrin-binding site in the hinge of the β2 chain of mammalian AP-2 complexes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">31083</span>– <span class="NLM_lpage">31090</span>, <span class="refDoi"> DOI: 10.1074/jbc.270.52.31083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1074%2Fjbc.270.52.31083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=8537368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADyaK28XivFSqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=31083-31090&author=W.+Shihauthor=A.+Gallusserauthor=T.+Kirchhausen&title=A+clathrin-binding+site+in+the+hinge+of+the+%CE%B22+chain+of+mammalian+AP-2+complexes&doi=10.1074%2Fjbc.270.52.31083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">A clathrin-binding site in the hinge of the β2 chain of mammalian AP-2 complexes</span></div><div class="casAuthors">Shih, William; Gallusser, Andreas; Kirchhausen, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">31083-90</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The assembly of cytosolic clathrin into the cytoplasmic face of coated pits and coated vesicles appears to be driven by the clathrin-assocd. protein (AP) complexes.  The authors have previously shown that one of the large chains of the AP complexes, the β chain, is sufficient to drive coat assembly in vitro.  This chain consists of two domains, the amino-terminal trunk and the carboxyl-terminal ear, linked by a "hinge.".  The authors report here that presence of the hinge in recombinant β trunk or in recombinant β ear fragments is essential for driving in vitro assembly of clathrin into coats.  The authors have also used nested deletion of hinge sequences to a 50-residue region in the center of the hinge.  This sequence is conserved in all known β sequences from multicellular organisms.  The interaction of a single β hinge with a clathrin triskelion is weak, and the authors propose that recruitment of cytosolic clathrin to a forming coated pit involves simultaneous contacts between the legs of single clathrin trimers and the β hinges of two or three membrane-bound AP complexes.  Uncoating is likely to require interruption of these contacts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkrXyU6OYwR7Vg90H21EOLACvtfcHk0liiLiXIrhRMGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XivFSqsQ%253D%253D&md5=95d1b57904b4da9cdf2e1b576ca48103</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.52.31083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.52.31083%26sid%3Dliteratum%253Aachs%26aulast%3DShih%26aufirst%3DW.%26aulast%3DGallusser%26aufirst%3DA.%26aulast%3DKirchhausen%26aufirst%3DT.%26atitle%3DA%2520clathrin-binding%2520site%2520in%2520the%2520hinge%2520of%2520the%2520%25CE%25B22%2520chain%2520of%2520mammalian%2520AP-2%2520complexes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D31083%26epage%3D31090%26doi%3D10.1074%2Fjbc.270.52.31083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifacino, J. S.</span></span> <span> </span><span class="NLM_article-title">Functional domain mapping of the clathrin-associated adaptor medium chains mu1 and mu2</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">27160</span>– <span class="NLM_lpage">27166</span>, <span class="refDoi"> DOI: 10.1074/jbc.272.43.27160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1074%2Fjbc.272.43.27160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=9341158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADyaK2sXmvFyrtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=27160-27166&author=R.+C.+Aguilarauthor=H.+Ohnoauthor=K.+W.+Rocheauthor=J.+S.+Bonifacino&title=Functional+domain+mapping+of+the+clathrin-associated+adaptor+medium+chains+mu1+and+mu2&doi=10.1074%2Fjbc.272.43.27160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Functional domain mapping of the clathrin-associated adaptor medium chains μ1 and μ2</span></div><div class="casAuthors">Aguilar, Ruben C.; Ohno, Hiroshi; Roche, Katherine W.; Bonifacino, Juan S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">27160-27166</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The clathrin-assocd. adaptors AP-1 and AP-2 are heterotetrameric complexes involved in the recognition of sorting signals present within the cytosolic domain of integral membrane proteins.  The medium chains of these complexes, μ1 and μ2, have been implicated in two types of interaction: assembly with the β1 and β2 chains of the corresponding complexes and recognition of tyrosine-based sorting signals.  In this study, we report the results of a structure-function anal. of the μ1 and μ2 chains aimed at identifying regions of the mols. that are responsible for each of the two interactions.  Analyses using the yeast two-hybrid system and proteolytic digestion expts. suggest that μ1 and μ2 have a bipartite structure, with the amino-terminal one-third (residues 1-145 of μ1 and μ2) being involved in assembly with the β chains and the carboxyl-terminal two-thirds (residues 147-423 of μ1 and 164-435 of μ2) binding tyrosine-based sorting signals.  These observations support a model in which the amino-terminal one-third of μ2 is embedded within the core of the AP-2 complex, while the carboxyl-terminal two-thirds of the protein are exposed to the medium, placing this region in a position to interact with tyrosine-based sorting signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0Xdqr1bWMZrVg90H21EOLACvtfcHk0liiLiXIrhRMGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmvFyrtrc%253D&md5=97e340bfa3f017f888351e28097cbe99</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.43.27160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.43.27160%26sid%3Dliteratum%253Aachs%26aulast%3DAguilar%26aufirst%3DR.%2BC.%26aulast%3DOhno%26aufirst%3DH.%26aulast%3DRoche%26aufirst%3DK.%2BW.%26aulast%3DBonifacino%26aufirst%3DJ.%2BS.%26atitle%3DFunctional%2520domain%2520mapping%2520of%2520the%2520clathrin-associated%2520adaptor%2520medium%2520chains%2520mu1%2520and%2520mu2%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D27160%26epage%3D27166%26doi%3D10.1074%2Fjbc.272.43.27160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Owen, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P. R.</span></span> <span> </span><span class="NLM_article-title">A structural explanation for the recognition of tyrosine-based endocytotic signals</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">1327</span>– <span class="NLM_lpage">1332</span>, <span class="refDoi"> DOI: 10.1126/science.282.5392.1327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1126%2Fscience.282.5392.1327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=9812899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADyaK1cXnsFenu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=1998&pages=1327-1332&author=D.+J.+Owenauthor=P.+R.+Evans&title=A+structural+explanation+for+the+recognition+of+tyrosine-based+endocytotic+signals&doi=10.1126%2Fscience.282.5392.1327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A structural explanation for the recognition of tyrosine-based endocytotic signals</span></div><div class="casAuthors">Owen, David J.; Evans, Philip R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">5392</span>),
    <span class="NLM_cas:pages">1327-1332</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Many cell surface proteins are marked for endocytosis by a cytoplasmic sequence motif, tyrosine-X-X-(hydrophobic residue), that is recognized by the μ2 subunit of AP2 adaptors.  Crystal structures of the internalization signal binding domain of μ2 complexed with the internalization signal peptides of epidermal growth factor receptor and the trans-Golgi network protein TGN38 have been detd. at 2.7 angstrom resoln.  The signal peptides adopted at extended conformation rather than the expected tight turn.  Specificity was conferred by hydrophobic pockets that bind the tyrosine and leucine in the peptide in the crystal, the protein forms dimers that could increase the strength and specificity of binding to dimeric receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyBnBGOl8LH7Vg90H21EOLACvtfcHk0liiLiXIrhRMGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnsFenu78%253D&md5=d3fb688f2b2788de8eba4a01d70b64f4</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1126%2Fscience.282.5392.1327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.282.5392.1327%26sid%3Dliteratum%253Aachs%26aulast%3DOwen%26aufirst%3DD.%2BJ.%26aulast%3DEvans%26aufirst%3DP.%2BR.%26atitle%3DA%2520structural%2520explanation%2520for%2520the%2520recognition%2520of%2520tyrosine-based%2520endocytotic%2520signals%26jtitle%3DScience%26date%3D1998%26volume%3D282%26spage%3D1327%26epage%3D1332%26doi%3D10.1126%2Fscience.282.5392.1327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fingerhut, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Figura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Höning, S.</span></span> <span> </span><span class="NLM_article-title">Binding of AP2 to sorting signals is modulated by AP2 phosphorylation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">5476</span>– <span class="NLM_lpage">5482</span>, <span class="refDoi"> DOI: 10.1074/jbc.M009516200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1074%2Fjbc.M009516200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=11044456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhs1Kms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=5476-5482&author=A.+Fingerhutauthor=K.+von+Figuraauthor=S.+H%C3%B6ning&title=Binding+of+AP2+to+sorting+signals+is+modulated+by+AP2+phosphorylation&doi=10.1074%2Fjbc.M009516200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Binding of AP2 to sorting signals is modulated by AP2 phosphorylation</span></div><div class="casAuthors">Fingerhut, Anja; Von Figura, Kurt; Honing, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">5476-5482</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The two clathrin-assocd. adaptor complexes AP1 and AP2 are known to participate in the formation of clathrin-coated vesicles at the trans-Golgi network and at the plasma membrane.  During this process adaptors are involved in the sequestration of vesicle cargo by binding to the sorting signals within the cytoplasmic domains of the cargo proteins and in the recruitment of the clathrin coat.  After budding of the clathrin-coated vesicles, the clathrin and adaptors dissoc. from the vesicles.  Here we show that in vitro binding of AP2 to sorting signals, which is one of the initial steps in receptor-mediated endocytosis, is modulated by adaptor phosphorylation.  AP2 was phosphorylated by incubating purified AP2 in the presence of ATP and dephosphorylated by incubation with alk. phosphatase.  Affinity for tyrosine-, leucine-based and noncanonical sorting motifs was 15-33 times higher for phosphorylated than for dephosphorylated AP2.  Also the binding of AP2 to membranes was regulated by adaptor phosphorylation/dephosphorylation and was about 8-fold higher for phosphorylated than for dephosphorylated AP2.  Moreover, AP2 isolated from cytosol is higher phosphorylated than membrane-extd. and exhibits a 5-fold higher binding affinity than AP2 extd. from membranes.  Taken together these data point to a cycle of phosphorylation/dephosphorylation as a mechanism for regulating the reversible assocn. of AP2 with membranes and sorting signals during the process of receptor-mediated endocytosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocki1UZ6U8u7Vg90H21EOLACvtfcHk0liiLiXIrhRMGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhs1Kms7s%253D&md5=765a830509af4acb2d140e17d878640a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M009516200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M009516200%26sid%3Dliteratum%253Aachs%26aulast%3DFingerhut%26aufirst%3DA.%26aulast%3Dvon%2BFigura%26aufirst%3DK.%26aulast%3DH%25C3%25B6ning%26aufirst%3DS.%26atitle%3DBinding%2520of%2520AP2%2520to%2520sorting%2520signals%2520is%2520modulated%2520by%2520AP2%2520phosphorylation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D5476%26epage%3D5482%26doi%3D10.1074%2Fjbc.M009516200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ricotta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Figura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Höning, S.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of the AP2 μ subunit by AAK1 mediates high affinity binding to the membrane protein sorting signals</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">795</span>, <span class="refDoi"> DOI: 10.1083/jcb.200111068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1083%2Fjcb.200111068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=11877457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD38XitVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2002&pages=791-795&author=D.+Ricottaauthor=S.+D.+Comerauthor=S.+L.+Schmidauthor=K.+von+Figuraauthor=S.+H%C3%B6ning&title=Phosphorylation+of+the+AP2+%CE%BC+subunit+by+AAK1+mediates+high+affinity+binding+to+the+membrane+protein+sorting+signals&doi=10.1083%2Fjcb.200111068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of the AP2 μ subunit by AAK1 mediates high affinity binding to membrane protein sorting signals</span></div><div class="casAuthors">Ricotta, Doris; Conner, Sean D.; Schmid, Sandra L.; Von Figura, Kurt; Honing, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">791-795</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">During receptor-mediated endocytosis, AP2 complexes act as a bridge between the cargo membrane proteins and the clathrin coat by binding to sorting signals via the μ2 subunit and to clathrin via the β subunit.  Here we show that binding of AP2 to sorting signals in vitro is regulated by phosphorylation of the μ2 subunit of AP2.  Phosphorylation of μ2 enhances the binding affinity of AP2 for sorting motifs as much as 25-fold compared with dephosphorylated AP2.  The recognition of sorting signals was not affected by the phosphorylation status of the α or β2 subunit, suggesting that phosphorylation of μ2 is crit. for regulation of AP2 binding to sorting signals.  Phosphorylation of μ2 occurs at a single threonine residue (Thr-156) and is mediated by the newly discovered adaptor-assocd. kinase, AAK1, which copurifies with AP2.  We propose that phosphorylation of the AP2 μ2 subunit by AAK1 ensures high affinity binding of AP2 to sorting signals of cargo membrane proteins during the initial steps of receptor-mediated endocytosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpo_Waay05sbVg90H21EOLACvtfcHk0lg-zPZmFjNytA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitVGmsbs%253D&md5=50e5a561308f7351a21ef8cc4eb7f35c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200111068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200111068%26sid%3Dliteratum%253Aachs%26aulast%3DRicotta%26aufirst%3DD.%26aulast%3DComer%26aufirst%3DS.%2BD.%26aulast%3DSchmid%26aufirst%3DS.%2BL.%26aulast%3Dvon%2BFigura%26aufirst%3DK.%26aulast%3DH%25C3%25B6ning%26aufirst%3DS.%26atitle%3DPhosphorylation%2520of%2520the%2520AP2%2520%25CE%25BC%2520subunit%2520by%2520AAK1%2520mediates%2520high%2520affinity%2520binding%2520to%2520the%2520membrane%2520protein%2520sorting%2520signals%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2002%26volume%3D156%26spage%3D791%26epage%3D795%26doi%3D10.1083%2Fjcb.200111068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olusanya, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swedlow, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smythe, E.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of threonine 156 of the μ2 subunit of the AP2 complex is essential for endocytosis in vitro and in vivo</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">896</span>– <span class="NLM_lpage">900</span>, <span class="refDoi"> DOI: 10.1016/S0960-9822(01)00240-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2FS0960-9822%2801%2900240-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=11516654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD3MXksVKjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=896-900&author=O.+Olusanyaauthor=P.+D.+Andrewsauthor=J.+R.+Swedlowauthor=E.+Smythe&title=Phosphorylation+of+threonine+156+of+the+%CE%BC2+subunit+of+the+AP2+complex+is+essential+for+endocytosis+in+vitro+and+in+vivo&doi=10.1016%2FS0960-9822%2801%2900240-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of threonine 156 of the μ2 subunit of the AP2 complex is essential for endocytosis in vitro and in vivo</span></div><div class="casAuthors">Olusanya, O.; Andrews, P. D.; Swedlow, J. R.; Smythe, E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">896-900</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The clathrin-coated pit is the major port of entry for many receptors and pathogens and is the paradigm for membrane-based sorting events in higher cells [1].  Recently, it has been possible to reconstitute in vitro the events leading to assembly, invagination, and budding off of clathrin-coated vesicles, allowing dissection of the machinery required for sequestration of receptors into these structures [2-6].  The AP2 adaptor complex is a key element of this machinery linking receptors to the coat lattice, and it has previously been reported that AP2 can be phosphorylated both in vitro and in vivo [7-10].  However, the physiol. significance of this has never been established.  Here, we show that phosphorylation of a single threonine residue (Thr156) of the μ2 subunit of the AP2 complex is essential for efficient endocytosis of transferrin both in an in vitro coated-pit budding assay and in living cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp42ua1wdmr2LVg90H21EOLACvtfcHk0lg-zPZmFjNytA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXksVKjs7s%253D&md5=67e1fafc2f12fbc68c42587e178ba8b4</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS0960-9822%2801%2900240-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-9822%252801%252900240-8%26sid%3Dliteratum%253Aachs%26aulast%3DOlusanya%26aufirst%3DO.%26aulast%3DAndrews%26aufirst%3DP.%2BD.%26aulast%3DSwedlow%26aufirst%3DJ.%2BR.%26aulast%3DSmythe%26aufirst%3DE.%26atitle%3DPhosphorylation%2520of%2520threonine%2520156%2520of%2520the%2520%25CE%25BC2%2520subunit%2520of%2520the%2520AP2%2520complex%2520is%2520essential%2520for%2520endocytosis%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DCurr.%2520Biol.%26date%3D2001%26volume%3D11%26spage%3D896%26epage%3D900%26doi%3D10.1016%2FS0960-9822%2801%2900240-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kostich, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naidu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dandapani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savelieva, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dokania, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elavazhagan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vattikundala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holenarsipur, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulianello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieschl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Malley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nouraldeen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanthorn, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balakrishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grace, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentz, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santone, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Main, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaffield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandlekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vikramadithyan, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nara, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzierba, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaczek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westphal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bristow, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambrowicz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albright, C. F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.235333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1124%2Fjpet.116.235333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=27411717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVyks7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2016&pages=371-386&author=W.+Kostichauthor=B.+D.+Hammanauthor=Y.-W.+Liauthor=S.+Naiduauthor=K.+Dandapaniauthor=J.+Fengauthor=A.+Eastonauthor=C.+Bourinauthor=K.+Bakerauthor=J.+Allenauthor=K.+Savelievaauthor=J.+V.+Louisauthor=M.+Dokaniaauthor=S.+Elavazhaganauthor=P.+Vattikundalaauthor=V.+Sharmaauthor=M.+L.+Dasauthor=G.+Shankarauthor=A.+Kumarauthor=V.+K.+Holenarsipurauthor=M.+Gulianelloauthor=T.+Molskiauthor=J.+M.+Brownauthor=M.+Lewisauthor=Y.+Huangauthor=Y.+Luauthor=R.+Pieschlauthor=K.+O%E2%80%99Malleyauthor=J.+Lippyauthor=A.+Nouraldeenauthor=T.+H.+Lanthornauthor=G.+Yeauthor=A.+Wilsonauthor=A.+Balakrishnanauthor=R.+Dentonauthor=J.+E.+Graceauthor=K.+A.+Lentzauthor=K.+S.+Santoneauthor=Y.+Biauthor=A.+Mainauthor=J.+Swaffieldauthor=K.+Carsonauthor=S.+Mandlekarauthor=R.+K.+Vikramadithyanauthor=S.+J.+Naraauthor=C.+Dzierbaauthor=J.+Bronsonauthor=J.+E.+Macorauthor=R.+Zaczekauthor=R.+Westphalauthor=L.+Kissauthor=L.+Bristowauthor=C.+M.+Conwayauthor=B.+Zambrowiczauthor=C.+F.+Albright&title=Inhibition+of+AAK1+kinase+as+a+novel+therapeutic+approach+to+treat+neuropathic+pain&doi=10.1124%2Fjpet.116.235333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain</span></div><div class="casAuthors">Kostich, Walter; Hamman, Brian D.; Li, Yu-Wen; Naidu, Sreenivasulu; Dandapani, Kumaran; Feng, Jianlin; Easton, Amy; Bourin, Clotilde; Baker, Kevin; Allen, Jason; Savelieva, Katerina; Louis, Justin V.; Dokania, Manoj; Elavazhagan, Saravanan; Vattikundala, Pradeep; Sharma, Vivek; Das, Manish Lal; Shankar, Ganesh; Kumar, Anoop; Holenarsipur, Vinay K.; Gulianello, Michael; Molski, Ted; Brown, Jeffrey M.; Lewis, Martin; Huang, Yanling; Lu, Yifeng; Pieschl, Rick; O'Malley, Kevin; Lippy, Jonathan; Nouraldeen, Amr; Lanthorn, Thomas H.; Ye, Guilan; Wilson, Alan; Balakrishnan, Anand; Denton, Rex; Grace, James E.; Lentz, Kimberley A.; Santone, Kenneth S.; Bi, Yingzhi; Main, Alan; Swaffield, Jon; Carson, Ken; Mandlekar, Sandhya; Vikramadithyan, Reeba K.; Nara, Susheel J.; Dzierba, Carolyn; Bronson, Joanne; Macor, John E.; Zaczek, Robert; Westphal, Ryan; Kiss, Laszlo; Bristow, Linda; Conway, Charles M.; Zambrowicz, Brian; Albright, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">371-386</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">To identify novel targets for neuropathic pain, 3097 mouse knockout lines were tested in acute and persistent pain behavior assays.  One of the lines from this screen, which contained a null allele of the adapter protein-2 assocd. kinase 1 (AAK1) gene, had a normal response in acute pain assays (hot plate, phase I formalin), but a markedly reduced response to persistent pain in phase II formalin.  AAK1 knockout mice also failed to develop tactile allodynia following the Chung procedure of spinal nerve ligation (SNL).  Based on these findings, potent, small-mol. inhibitors of AAK1 were identified.  Studies in mice showed that one such inhibitor, LP-935509, caused a reduced pain response in phase II formalin and reversed fully established pain behavior following the SNL procedure.  Further studies showed that the inhibitor also reduced evoked pain responses in the rat chronic constriction injury (CCI) model and the rat streptozotocin model of diabetic peripheral neuropathy.  Using a nonbrain-penetrant AAK1 inhibitor and local administration of an AAK1 inhibitor, the relevant pool of AAK1 for antineuropathic action was found to be in the spinal cord.  Consistent with these results, AAK1 inhibitors dose-dependently reduced the increased spontaneous neural activity in the spinal cord caused by CCI and blocked the development of windup induced by repeated elec. stimulation of the paw.  The mechanism of AAK1 antinociception was further investigated with inhibitors of α2 adrenergic and opioid receptors.  These studies showed that α2 adrenergic receptor inhibitors, but not opioid receptor inhibitors, not only prevented AAK1 inhibitor antineuropathic action in behavioral assays, but also blocked the AAK1 inhibitor-induced redn. in spinal neural activity in the rat CCI model.  Hence, AAK1 inhibitors are a novel therapeutic approach to neuropathic pain with activity in animal models that is mechanistically linked (behaviorally and electrophysiol.) to α2 adrenergic signaling, a pathway known to be antinociceptive in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5cJpGeOPjm7Vg90H21EOLACvtfcHk0lg-zPZmFjNytA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVyks7rI&md5=d4cec6b3681b63ba7d9119424e53ab61</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.235333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.235333%26sid%3Dliteratum%253Aachs%26aulast%3DKostich%26aufirst%3DW.%26aulast%3DHamman%26aufirst%3DB.%2BD.%26aulast%3DLi%26aufirst%3DY.-W.%26aulast%3DNaidu%26aufirst%3DS.%26aulast%3DDandapani%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DEaston%26aufirst%3DA.%26aulast%3DBourin%26aufirst%3DC.%26aulast%3DBaker%26aufirst%3DK.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DSavelieva%26aufirst%3DK.%26aulast%3DLouis%26aufirst%3DJ.%2BV.%26aulast%3DDokania%26aufirst%3DM.%26aulast%3DElavazhagan%26aufirst%3DS.%26aulast%3DVattikundala%26aufirst%3DP.%26aulast%3DSharma%26aufirst%3DV.%26aulast%3DDas%26aufirst%3DM.%2BL.%26aulast%3DShankar%26aufirst%3DG.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DHolenarsipur%26aufirst%3DV.%2BK.%26aulast%3DGulianello%26aufirst%3DM.%26aulast%3DMolski%26aufirst%3DT.%26aulast%3DBrown%26aufirst%3DJ.%2BM.%26aulast%3DLewis%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DPieschl%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DK.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DNouraldeen%26aufirst%3DA.%26aulast%3DLanthorn%26aufirst%3DT.%2BH.%26aulast%3DYe%26aufirst%3DG.%26aulast%3DWilson%26aufirst%3DA.%26aulast%3DBalakrishnan%26aufirst%3DA.%26aulast%3DDenton%26aufirst%3DR.%26aulast%3DGrace%26aufirst%3DJ.%2BE.%26aulast%3DLentz%26aufirst%3DK.%2BA.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DBi%26aufirst%3DY.%26aulast%3DMain%26aufirst%3DA.%26aulast%3DSwaffield%26aufirst%3DJ.%26aulast%3DCarson%26aufirst%3DK.%26aulast%3DMandlekar%26aufirst%3DS.%26aulast%3DVikramadithyan%26aufirst%3DR.%2BK.%26aulast%3DNara%26aufirst%3DS.%2BJ.%26aulast%3DDzierba%26aufirst%3DC.%26aulast%3DBronson%26aufirst%3DJ.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DZaczek%26aufirst%3DR.%26aulast%3DWestphal%26aufirst%3DR.%26aulast%3DKiss%26aufirst%3DL.%26aulast%3DBristow%26aufirst%3DL.%26aulast%3DConway%26aufirst%3DC.%2BM.%26aulast%3DZambrowicz%26aufirst%3DB.%26aulast%3DAlbright%26aufirst%3DC.%2BF.%26atitle%3DInhibition%2520of%2520AAK1%2520kinase%2520as%2520a%2520novel%2520therapeutic%2520approach%2520to%2520treat%2520neuropathic%2520pain%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D358%26spage%3D371%26epage%3D386%26doi%3D10.1124%2Fjpet.116.235333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubuisson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, S. G.</span></span> <span> </span><span class="NLM_article-title">The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1016/0304-3959(77)90130-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2F0304-3959%2877%2990130-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=564014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADyaE1cXhsVGrt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1977&pages=161-174&author=D.+Dubuissonauthor=S.+G.+Dennis&title=The+formalin+test%3A+a+quantitative+study+of+the+analgesic+effects+of+morphine%2C+meperidine%2C+and+brain+stem+stimulation+in+rats+and+cats&doi=10.1016%2F0304-3959%2877%2990130-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The formalin test:  a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats</span></div><div class="casAuthors">Dubuisson, David; Dennis, Stephen G.</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-74</span>CODEN:
                <span class="NLM_cas:coden">PAINDB</span>;
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    </div><div class="casAbstract">In a procedure to evaluate the analgesic strengths of morphine sulfate  [64-31-3] and meperidine-HCl  [50-13-5], cats or rats, which were pretreated with an appropriate analgesic dose of either drug, were injected with a soln. of formalin  [50-00-0] in the paws and the pain-related behavior was obsd. and compared with that obsd. in the control animals which received formalin but no analgesic.  Pretreatment with either of the 2 analgesics or brain stem stimulation significantly decreased the effect of the pain stimuli.  Morphine and brain stem stimulation provided similar and greater analgesia than meperidine.  The behavioral patterns of the animals seemed to be similar following morphine or the brain stem stimultion.  Thus, formalin injection can be used effectively to evaluate the potencies of analgesics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod0ErPKDkXGbVg90H21EOLACvtfcHk0lj6UL5mJAVvgA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXhsVGrt7s%253D&md5=bd26bbc3c46b9c964d0b3aa011580980</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2F0304-3959%2877%2990130-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3959%252877%252990130-0%26sid%3Dliteratum%253Aachs%26aulast%3DDubuisson%26aufirst%3DD.%26aulast%3DDennis%26aufirst%3DS.%2BG.%26atitle%3DThe%2520formalin%2520test%253A%2520a%2520quantitative%2520study%2520of%2520the%2520analgesic%2520effects%2520of%2520morphine%252C%2520meperidine%252C%2520and%2520brain%2520stem%2520stimulation%2520in%2520rats%2520and%2520cats%26jtitle%3DPain%26date%3D1977%26volume%3D4%26spage%3D161%26epage%3D174%26doi%3D10.1016%2F0304-3959%2877%2990130-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J. M.</span></span> <span> </span><span class="NLM_article-title">An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1016/0304-3959(92)90041-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2F0304-3959%2892%2990041-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1333581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADyaK3s%252FoslShtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1992&pages=355-363&author=S.+H.+Kimauthor=J.+M.+Chung&title=An+experimental+model+for+peripheral+neuropathy+produced+by+segmental+spinal+nerve+ligation+in+the+rat&doi=10.1016%2F0304-3959%2892%2990041-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat</span></div><div class="casAuthors">Kim S H; Chung J M</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">355-63</span>
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    </div><div class="casAbstract">We attempted to develop an experimental animal model for peripheral neuropathic pain.  Under sodium pentobarbital anesthesia, both the L5 and L6 spinal nerves (group 1) or the L5 spinal nerve alone (group 2) of one side of the rat were tightly ligated.  For comparison, a parallel study was conducted with another group of rats (group 3) which received a partial tight sciatic nerve ligation, a paradigm developed previously as a neuropathy model.  Withdrawal latencies to application of radiant heat to the foot were tested for the next 16 weeks in all 3 groups.  Sensitivity of the hind paw to mechanical stimulation was tested with von Frey filaments.  The general behavior of each rat was noted during the entire test period.  Results suggested that the surgical procedure in all 3 groups produced a long-lasting hyperalgesia to noxious heat (at least 5 weeks) and mechanical allodynia (at least 10 weeks) of the affected foot.  In addition, there were behavioral signs of the presence of spontaneous pain in the affected foot.  Therefore, we believe we have developed an experimental animal model for peripheral neuropathy using tight ligations of spinal nerves.  The model manifests the symptoms of human patients with causalgia and is compatible with a previously developed neuropathy model.  The present model has two unique features.  First, the surgical procedure is stereotyped.  Second, the levels of injured and intact spinal segments are completely separated, allowing independent experimental manipulations of the injured and intact spinal segments in future experiments to answer questions regarding mechanisms underlying causalgia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSEPstJUQcfvtj_Vg2vObihfW6udTcc2eZPNYLu7CZQSLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s%252FoslShtw%253D%253D&md5=13917a9997b26f37cd039fa54ee7eb36</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2F0304-3959%2892%2990041-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3959%252892%252990041-9%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DChung%26aufirst%3DJ.%2BM.%26atitle%3DAn%2520experimental%2520model%2520for%2520peripheral%2520neuropathy%2520produced%2520by%2520segmental%2520spinal%2520nerve%2520ligation%2520in%2520the%2520rat%26jtitle%3DPain%26date%3D1992%26volume%3D50%26spage%3D355%26epage%3D363%26doi%3D10.1016%2F0304-3959%2892%2990041-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savelieva, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanthorn, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajan, I.</span></span> <span> </span><span class="NLM_article-title">Ligation of mouse L4 and L5 spinal nerves produces robust allodynia without major motor function deficit</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2014.04.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2Fj.bbr.2014.04.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=24786331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADC%252BC2cnos1SqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2015&pages=99-110&author=G.+L.+Yeauthor=K.+V.+Savelievaauthor=P.+Vogelauthor=K.+B.+Bakerauthor=S.+Masonauthor=T.+H.+Lanthornauthor=I.+Rajan&title=Ligation+of+mouse+L4+and+L5+spinal+nerves+produces+robust+allodynia+without+major+motor+function+deficit&doi=10.1016%2Fj.bbr.2014.04.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Ligation of mouse L4 and L5 spinal nerves produces robust allodynia without major motor function deficit</span></div><div class="casAuthors">Ye Gui-Lan; Savelieva Katerina V; Vogel Peter; Baker Kevin B; Mason Sara; Lanthorn Thomas H; Rajan Indrani</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural brain research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">99-110</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Spinal nerve L5/L6 ligation (SNL) in rats has become the standard for mechanistic studies of peripheral neuropathy and screening for novel analgesics.  Conventional SNL in our hybrid mice resulted in a wide range of allodynia.  Anatomical evaluation indicated that a variable number of lumbar vertebrae existed, resulting in L4/L5 or L5/L6 being ligated.  Surprisingly, L4/L5 ligation did not result in ipsilateral hind limb paralysis and produced robust allodynia.  Following a recent report that the mouse L4 neural segment is homologous with rat L5 we generated L4, L5 or both L4 and L5 (L4/L5) ligations in C57 mice after establishing a modified set of surgical landmarks.  In contrast to rats, L4 ligation in these mice did not result in hind limb paralysis.  Robust allodynia was observed in all three ligation groups.  Nerve degeneration confirmed that L4 and L5, respectively, are primary contributors to the tibial and sural branches of the sciatic nerve in mice.  A larger von Frey sensitive area reflected the wider distribution of Wallerian degeneration in the hindlimb of L4- compared to L5-ligated mice.  Ligation of mouse L4 and L5 spinal nerves produces consistent, robust neuropathic pain behaviors and is suitable as a model for investigating mechanisms of neuropathic pain and for testing of novel analgesics.  Gabapentin, used as a validation drug in neuropathic pain models and as a reference compound for novel analgesics, significantly reduced allodynia in the mice tested (L4/L5 ligations).  Given the ease of surgery, robust allodynia, and larger von Frey sensitive area, we conclude that combined ligation of spinal nerves L4 and L5 optimizes the SNL model in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDf16bjaY9LIJKJbLTgsvCfW6udTcc2eZPNYLu7CZQSLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnos1SqsQ%253D%253D&md5=89dad62c7ec62b9c961e734280dd7265</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2014.04.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2014.04.039%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DG.%2BL.%26aulast%3DSavelieva%26aufirst%3DK.%2BV.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DBaker%26aufirst%3DK.%2BB.%26aulast%3DMason%26aufirst%3DS.%26aulast%3DLanthorn%26aufirst%3DT.%2BH.%26aulast%3DRajan%26aufirst%3DI.%26atitle%3DLigation%2520of%2520mouse%2520L4%2520and%2520L5%2520spinal%2520nerves%2520produces%2520robust%2520allodynia%2520without%2520major%2520motor%2520function%2520deficit%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2015%26volume%3D276%26spage%3D99%26epage%3D110%26doi%3D10.1016%2Fj.bbr.2014.04.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, W.</span></span> <span> </span><span class="NLM_article-title">Single-cell RNA expression profiling of ACE2, the putative receptor of SARS-CoV-2</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>202</i></span>,  <span class="NLM_fpage">756</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1164/rccm.202001-0179LE</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1164%2Frccm.202001-0179LE" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=32663409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitF2gs7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=2020&pages=756-759&author=Y.+Zhaoauthor=Z.+Zhaoauthor=Y.+Wangauthor=Y.+Zhouauthor=Y.+Maauthor=W.+Zuo&title=Single-cell+RNA+expression+profiling+of+ACE2%2C+the+putative+receptor+of+SARS-CoV-2&doi=10.1164%2Frccm.202001-0179LE"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2</span></div><div class="casAuthors">Zhao, Yu; Zhao, Zixian; Wang, Yujia; Zhou, Yueqing; Ma, Yu; Zuo, Wei</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">756-759</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">In this paper presents single-cell RNA expression profiling of ACE2, receptor of SARS-CoV-2.  We report the RNA expression profile of ACE2 in the human lung at single-cell resoln.  The tissue expression and distribution of the receptor decide the tropism of the virus infection, which has a major implication for understanding its pathogenesis and designing therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyOY88-7eNjLVg90H21EOLACvtfcHk0ljAY_gfO1uNYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitF2gs7fO&md5=34e7c584b254fa5c88e6ca0bc7058f2c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1164%2Frccm.202001-0179LE&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.202001-0179LE%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DZuo%26aufirst%3DW.%26atitle%3DSingle-cell%2520RNA%2520expression%2520profiling%2520of%2520ACE2%252C%2520the%2520putative%2520receptor%2520of%2520SARS-CoV-2%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2020%26volume%3D202%26spage%3D756%26epage%3D759%26doi%3D10.1164%2Frccm.202001-0179LE" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span> <span> </span><span class="NLM_article-title">Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">574</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(20)30251-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2FS0140-6736%2820%2930251-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=32007145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFOmsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=565-574&author=R.+Luauthor=X.+Zhaoauthor=J.+Liauthor=P.+Niuauthor=B.+Yangauthor=H.+Wuauthor=W.+Wangauthor=H.+Songauthor=B.+Huangauthor=N.+Zhuauthor=Y.+Biauthor=X.+Maauthor=F.+Zhanauthor=L.+Wangauthor=T.+Huauthor=H.+Zhouauthor=Z.+Huauthor=W.+Zhouauthor=L.+Zhaoauthor=J.+Chenauthor=Y.+Mengauthor=J.+Wangauthor=Y.+Linauthor=J.+Yuanauthor=Z.+Xieauthor=J.+Maauthor=W.+J.+Liuauthor=D.+Wangauthor=W.+Xuauthor=E.+C.+Holmesauthor=G.+F.+Gaoauthor=G.+Wuauthor=W.+Chenauthor=W.+Shiauthor=W.+Tan&title=Genomic+characterisation+and+epidemiology+of+2019+novel+coronavirus%3A+implications+for+virus+origins+and+receptor+binding&doi=10.1016%2FS0140-6736%2820%2930251-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</span></div><div class="casAuthors">Lu, Roujian; Zhao, Xiang; Li, Juan; Niu, Peihua; Yang, Bo; Wu, Honglong; Wang, Wenling; Song, Hao; Huang, Baoying; Zhu, Na; Bi, Yuhai; Ma, Xuejun; Zhan, Faxian; Wang, Liang; Hu, Tao; Zhou, Hong; Hu, Zhenhong; Zhou, Weimin; Zhao, Li; Chen, Jing; Meng, Yao; Wang, Ji; Lin, Yang; Yuan, Jianying; Xie, Zhihao; Ma, Jinmin; Liu, William J.; Wang, Dayan; Xu, Wenbo; Holmes, Edward C.; Gao, George F.; Wu, Guizhen; Chen, Weijun; Shi, Weifeng; Tan, Wenjie</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10224</span>),
    <span class="NLM_cas:pages">565-574</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In late Dec., 2019, patients presenting with viral pneumonia due to an unidentified microbial agent were reported in Wuhan, China.  A novel coronavirus was subsequently identified as the causative pathogen, provisionally named 2019 novel coronavirus (2019-nCoV).  As of Jan 26, 2020, more than 2000 cases of 2019-nCoV infection have been confirmed, most of which involved people living in or visiting Wuhan, and human-to-human transmission has been confirmed.  We did next-generation sequencing of samples from bronchoalveolar lavage fluid and cultured isolates from nine inpatients, eight of whom had visited the Huanan seafood market in Wuhan.  Complete and partial 2019-nCoV genome sequences were obtained from these individuals.  Viral contigs were connected using Sanger sequencing to obtain the full-length genomes, with the terminal regions detd. by rapid amplification of cDNA ends.  Phylogenetic anal. of these 2019-nCoV genomes and those of other coronaviruses was used to det. the evolutionary history of the virus and help infer its likely origin.  Homol. modeling was done to explore the likely receptor-binding properties of the virus.  The ten genome sequences of 2019-nCoV obtained from the nine patients were extremely similar, exhibiting more than 99·98% sequence identity.  Notably, 2019-nCoV was closely related (with 88% identity) to two bat-derived severe acute respiratory syndrome (SARS)-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21, collected in 2018 in Zhoushan, eastern China, but were more distant from SARS-CoV (about 79%) and MERS-CoV (about 50%).  Phylogenetic anal. revealed that 2019-nCoV fell within the subgenus Sarbecovirus of the genus Betacoronavirus, with a relatively long branch length to its closest relatives bat-SL-CoVZC45 and bat-SL-CoVZXC21, and was genetically distinct from SARS-CoV.  Notably, homol. modeling revealed that 2019-nCoV had a similar receptor-binding domain structure to that of SARS-CoV, despite amino acid variation at some key residues.2019-nCoV is sufficiently divergent from SARS-CoV to be considered a new human-infecting betacoronavirus.  Although our phylogenetic anal. suggests that bats might be the original host of this virus, an animal sold at the seafood market in Wuhan might represent an intermediate host facilitating the emergence of the virus in humans.  Importantly, structural anal. suggests that 2019-nCoV might be able to bind to the angiotensin-converting enzyme 2 receptor in humans.  The future evolution, adaptation, and spread of this virus warrant urgent investigation.  National Key Research and Development Program of China, National Major Project for Control and Prevention of Infectious Disease in China, Chinese Academy of Sciences, Shandong First Medical University.  These data have been deposited in the ChinaNational Microbiol. Data Center (accession no. NMDC10013002 and genome accession nos. NMDC60013002-01 to NMDC60013002-10) and the datafrom BGI have been deposited in the China National GeneBank (accession nos. CNA000733235).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNSLcS-1ejQbVg90H21EOLACvtfcHk0lijNFIMXf0Q8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFOmsLY%253D&md5=3a644f602ea1c68114e23b5f12625265</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930251-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930251-8%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNiu%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DN.%26aulast%3DBi%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DZhan%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DW.%2BJ.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DHolmes%26aufirst%3DE.%2BC.%26aulast%3DGao%26aufirst%3DG.%2BF.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DW.%26aulast%3DTan%26aufirst%3DW.%26atitle%3DGenomic%2520characterisation%2520and%2520epidemiology%2520of%25202019%2520novel%2520coronavirus%253A%2520implications%2520for%2520virus%2520origins%2520and%2520receptor%2520binding%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D565%26epage%3D574%26doi%3D10.1016%2FS0140-6736%2820%2930251-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pottoo, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abu-Izneid, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javed, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AlHajri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamrouni, A. M.</span></span> <span> </span><span class="NLM_article-title">Immune system response during viral infections: immunomodulators, cytokine storm (CS) and immunotherapeutics in COVID-19</span>. <i>Saudi Pharm. J.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1016/j.jsps.2020.12.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2Fj.jsps.2020.12.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=33519271" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2021&pages=173-187&author=F.+H.+Pottooauthor=T.+Abu-Izneidauthor=A.+M.+Ibrahimauthor=M.+N.+Javedauthor=N.+AlHajriauthor=A.+M.+Hamrouni&title=Immune+system+response+during+viral+infections%3A+immunomodulators%2C+cytokine+storm+%28CS%29+and+immunotherapeutics+in+COVID-19&doi=10.1016%2Fj.jsps.2020.12.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.jsps.2020.12.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsps.2020.12.018%26sid%3Dliteratum%253Aachs%26aulast%3DPottoo%26aufirst%3DF.%2BH.%26aulast%3DAbu-Izneid%26aufirst%3DT.%26aulast%3DIbrahim%26aufirst%3DA.%2BM.%26aulast%3DJaved%26aufirst%3DM.%2BN.%26aulast%3DAlHajri%26aufirst%3DN.%26aulast%3DHamrouni%26aufirst%3DA.%2BM.%26atitle%3DImmune%2520system%2520response%2520during%2520viral%2520infections%253A%2520immunomodulators%252C%2520cytokine%2520storm%2520%2528CS%2529%2520and%2520immunotherapeutics%2520in%2520COVID-19%26jtitle%3DSaudi%2520Pharm.%2520J.%26date%3D2021%26volume%3D29%26spage%3D173%26epage%3D187%26doi%3D10.1016%2Fj.jsps.2020.12.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span> <span> </span><span class="NLM_article-title">Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19</span>. <i>Int. J. Immunopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">106749</span>, <span class="refDoi"> DOI: 10.1016/j.intimp.2020.106749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2Fj.intimp.2020.106749" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2020&pages=106749&author=X.+Zhangauthor=Y.+Zhangauthor=W.+Qiaoauthor=J.+Zhangauthor=Z.+Qi&title=Baricitinib%2C+a+drug+with+potential+effect+to+prevent+SARS-COV-2+from+entering+target+cells+and+control+cytokine+storm+induced+by+COVID-19&doi=10.1016%2Fj.intimp.2020.106749"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2020.106749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2020.106749%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DQiao%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DZ.%26atitle%3DBaricitinib%252C%2520a%2520drug%2520with%2520potential%2520effect%2520to%2520prevent%2520SARS-COV-2%2520from%2520entering%2520target%2520cells%2520and%2520control%2520cytokine%2520storm%2520induced%2520by%2520COVID-19%26jtitle%3DInt.%2520J.%2520Immunopharmacol.%26date%3D2020%26volume%3D86%26spage%3D106749%26doi%3D10.1016%2Fj.intimp.2020.106749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covington, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favata, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeleswaram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">5298</span>– <span class="NLM_lpage">5307</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0902819</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.4049%2Fjimmunol.0902819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=20363976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=5298-5307&author=J.+S.+Fridmanauthor=P.+A.+Scherleauthor=R.+Collinsauthor=T.+C.+Burnauthor=Y.+Liauthor=J.+Liauthor=M.+B.+Covingtonauthor=B.+Thomasauthor=P.+Collierauthor=M.+F.+Favataauthor=X.+Wenauthor=J.+Shiauthor=R.+McGeeauthor=P.+J.+Haleyauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=S.+Yeleswaramauthor=G.+Hollisauthor=R.+C.+Newtonauthor=B.+Metcalfauthor=S.+M.+Friedmanauthor=K.+Vaddi&title=Selective+inhibition+of+JAK1+and+JAK2+is+efficacious+in+rodent+models+of+arthritis%3A+preclinical+characterization+of+INCB028050&doi=10.4049%2Fjimmunol.0902819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050</span></div><div class="casAuthors">Fridman, Jordan S.; Scherle, Peggy A.; Collins, Robert; Burn, Timothy C.; Li, Yanlong; Li, Jun; Covington, Maryanne B.; Thomas, Beth; Collier, Paul; Favata, Margaret F.; Wen, Xiaoming; Shi, Jack; McGee, Ryan; Haley, Patrick J.; Shepard, Stacey; Rodgers, James D.; Yeleswaram, Swamy; Hollis, Greg; Newton, Robert C.; Metcalf, Brian; Friedman, Steven M.; Vaddi, Kris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5298-5307</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Inhibiting signal transduction induced by inflammatory cytokines offers a new approach for the treatment of autoimmune diseases such as rheumatoid arthritis.  Kinase inhibitors have shown promising oral disease-modifying antirheumatic drug potential with efficacy similar to anti-TNF biologics.  Direct and indirect inhibition of the JAKs, with small mol. inhibitors like CP-690,550 and INCB018424 or neutralizing Abs, such as the anti-IL6 receptor Ab tocilizumab, have demonstrated rapid and sustained improvement in clin. measures of disease, consistent with their resp. preclin. expts.  Therefore, it is of interest to identify optimized JAK inhibitors with unique profiles to maximize therapeutic opportunities.  INCB028050 is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM).  INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concns. <50 nM.  Significant efficacy, as assessed by improvements in clin., histol. and radiog. signs of disease, was achieved in the rat adjuvant arthritis model with doses of INCB028050 providing partial and/or periodic inhibition of JAK1/JAK2 and no inhibition of JAK3.  Diminution of inflammatory Th1 and Th17 assocd. cytokine mRNA levels was obsd. in the draining lymph nodes of treated rats.  INCB028050 was also effective in multiple murine models of arthritis, with no evidence of suppression of humoral immunity or adverse hematol. effects.  These data suggest that fractional inhibition of JAK1 and JAK2 is sufficient for significant activity in autoimmune disease models.  Clin. evaluation of INCB028050 in RA is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4QiklQbX72bVg90H21EOLACvtfcHk0lijNFIMXf0Q8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D&md5=30b22f275eb2ba2dbca7fb7bec768bb9</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0902819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0902819%26sid%3Dliteratum%253Aachs%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%2BB.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DCollier%26aufirst%3DP.%26aulast%3DFavata%26aufirst%3DM.%2BF.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DMcGee%26aufirst%3DR.%26aulast%3DHaley%26aufirst%3DP.%2BJ.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DFriedman%26aufirst%3DS.%2BM.%26aulast%3DVaddi%26aufirst%3DK.%26atitle%3DSelective%2520inhibition%2520of%2520JAK1%2520and%2520JAK2%2520is%2520efficacious%2520in%2520rodent%2520models%2520of%2520arthritis%253A%2520preclinical%2520characterization%2520of%2520INCB028050%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D184%26spage%3D5298%26epage%3D5307%26doi%3D10.4049%2Fjimmunol.0902819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stebbing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaviani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casalini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauschke, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirazimi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youhanna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldanti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarasini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terres, J. A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickoloff, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgs, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlichting, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nirula, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbellino, M.</span></span>; <span class="NLM_contrib-group">the Sacco Baricitinib Study Group</span> <span> </span><span class="NLM_article-title">Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e12697</span> <span class="refDoi"> DOI: 10.15252/emmm.202012697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.15252%2Femmm.202012697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=32473600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1CmurbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&author=J.+Stebbingauthor=V.+Krishnanauthor=S.+de+Bonoauthor=S.+Ottavianiauthor=G.+Casaliniauthor=P.+J.+Richardsonauthor=V.+Monteilauthor=V.+M.+Lauschkeauthor=A.+Mirazimiauthor=S.+Youhannaauthor=Y.-J.+Tanauthor=F.+Baldantiauthor=A.+Sarasiniauthor=J.+A.+R.+Terresauthor=B.+J.+Nickoloffauthor=R.+E.+Higgsauthor=G.+Rochaauthor=N.+L.+Byersauthor=D.+E.+Schlichtingauthor=A.+Nirulaauthor=A.+Cardosoauthor=M.+Corbellinoauthor=the+Sacco+Baricitinib+Study+Group&title=Mechanism+of+baricitinib+supports+artificial+intelligence-predicted+testing+in+COVID-19+patients&doi=10.15252%2Femmm.202012697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients</span></div><div class="casAuthors">Stebbing, Justin; Krishnan, Venkatesh; de Bono, Stephanie; Ottaviani, Silvia; Casalini, Giacomo; Richardson, Peter J.; Monteil, Vanessa; Lauschke, Volker M.; Mirazimi, Ali; Youhanna, Sonia; Tan, Yee-Joo; Baldanti, Fausto; Sarasini, Antonella; Terres, Jorge A. Ross; Nickoloff, Brian J.; Higgs, Richard E.; Rocha, Guilherme; Byers, Nicole L.; Schlichting, Douglas E.; Nirula, Ajay; Cardoso, Anabela; Corbellino, Mario; the Sacco Baricitinib Study Group</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e12697</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved for the treatment of rheumatoid arthritis (RA) that was independently predicted, using artificial intelligence (AI) algorithms, to be useful for COVID-19 infection via proposed anti-cytokine effects and as an inhibitor of host cell viral propagation.  We evaluated the in vitro pharmacol. of baricitinib across relevant leukocyte subpopulations coupled to its in vivo pharmacokinetics and showed it inhibited signaling of cytokines implicated in COVID-19 infection.  We validated the AI-predicted biochem. inhibitory effects of baricitinib on human numb-assocd. kinase (hNAK) members measuring nanomolar affinities for AAK1, BIKE, and GAK.  Inhibition of NAKs led to reduced viral infectivity with baricitinib using human primary liver spheroids.  These effects occurred at exposure levels seen clin.  In a case series of patients with bilateral COVID-19 pneumonia, baricitinib treatment was assocd. with clin. and radiol. recovery, a rapid decline in SARS-CoV-2 viral load, inflammatory markers, and IL-6 levels.  Collectively, these data support further evaluation of the anti-cytokine and anti-viral activity of baricitinib and support its assessment in randomized trials in hospitalized COVID-19 patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiGmXcP_Gbz7Vg90H21EOLACvtfcHk0ljZnNAA6PYFmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1CmurbJ&md5=86d41fe8f3b03133c08acb5552266ef7</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.15252%2Femmm.202012697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Femmm.202012697%26sid%3Dliteratum%253Aachs%26aulast%3DStebbing%26aufirst%3DJ.%26aulast%3DKrishnan%26aufirst%3DV.%26aulast%3Dde%2BBono%26aufirst%3DS.%26aulast%3DOttaviani%26aufirst%3DS.%26aulast%3DCasalini%26aufirst%3DG.%26aulast%3DRichardson%26aufirst%3DP.%2BJ.%26aulast%3DMonteil%26aufirst%3DV.%26aulast%3DLauschke%26aufirst%3DV.%2BM.%26aulast%3DMirazimi%26aufirst%3DA.%26aulast%3DYouhanna%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DY.-J.%26aulast%3DBaldanti%26aufirst%3DF.%26aulast%3DSarasini%26aufirst%3DA.%26aulast%3DTerres%26aufirst%3DJ.%2BA.%2BR.%26aulast%3DNickoloff%26aufirst%3DB.%2BJ.%26aulast%3DHiggs%26aufirst%3DR.%2BE.%26aulast%3DRocha%26aufirst%3DG.%26aulast%3DByers%26aufirst%3DN.%2BL.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DNirula%26aufirst%3DA.%26aulast%3DCardoso%26aufirst%3DA.%26aulast%3DCorbellino%26aufirst%3DM.%26aulast%3D%26atitle%3DMechanism%2520of%2520baricitinib%2520supports%2520artificial%2520intelligence-predicted%2520testing%2520in%2520COVID-19%2520patients%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2020%26volume%3D12%26doi%3D10.15252%2Femmm.202012697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verdonck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrell, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froeyen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prugar, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorosky, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure–activity relationships of 3,5 disubstitutedpyrrolo[2,3-<i>b</i>]pyridines as inhibitors of adaptor-associated kinase 1 with antiviral activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5810</span>– <span class="NLM_lpage">5831</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00136</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00136" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVKgtr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5810-5831&author=S.+Verdonckauthor=S.-Y.+Puauthor=F.+J.+Sorrellauthor=J.+M.+Elkinsauthor=M.+Froeyenauthor=L.-J.+Gaoauthor=L.+I.+Prugarauthor=D.+E.+Doroskyauthor=J.+M.+Brannanauthor=R.+Barouch-Bentovauthor=S.+Knappauthor=J.+M.+Dyeauthor=P.+Herdewijnauthor=S.+Einavauthor=S.+De+Jonghe&title=Synthesis+and+structure%E2%80%93activity+relationships+of+3%2C5+disubstitutedpyrrolo%5B2%2C3-b%5Dpyridines+as+inhibitors+of+adaptor-associated+kinase+1+with+antiviral+activity&doi=10.1021%2Facs.jmedchem.9b00136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationships of 3,5-Disubstituted-pyrrolo[2,3-b]pyridines as Inhibitors of Adaptor-Associated Kinase 1 with Antiviral Activity</span></div><div class="casAuthors">Verdonck, Sven; Pu, Szu-Yuan; Sorrell, Fiona J.; Elkins, Jon M.; Froeyen, Mathy; Gao, Ling-Jie; Prugar, Laura I.; Dorosky, Danielle E.; Brannan, Jennifer M.; Barouch-Bentov, Rina; Knapp, Stefan; Dye, John M.; Herdewijn, Piet; Einav, Shirit; De Jonghe, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5810-5831</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There are currently no approved drugs for the treatment of emerging viral infections, such as dengue and Ebola.  Adaptor-assocd. kinase 1 (AAK1) is a cellular serine-threonine protein kinase that functions as a key regulator of the clathrin-assocd. host adaptor proteins and regulates the intracellular trafficking of multiple unrelated RNA viruses.  Moreover, AAK1 is overexpressed specifically in dengue virus-infected but not bystander cells.  Because AAK1 is a promising antiviral drug target, we have embarked on an optimization campaign of a previously identified 7-azaindole analog, yielding novel pyrrolo[2,3-b]pyridines with high AAK1 affinity.  The optimized compds. demonstrate improved activity against dengue virus both in vitro and in human primary dendritic cells and the unrelated Ebola virus.  These findings demonstrate that targeting cellular AAK1 may represent a promising broad-spectrum antiviral strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7SIdwEDKk_bVg90H21EOLACvtfcHk0ljZnNAA6PYFmg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVKgtr7P&md5=bdec475534dbe2ad18d1c377f8b4c67d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00136%26sid%3Dliteratum%253Aachs%26aulast%3DVerdonck%26aufirst%3DS.%26aulast%3DPu%26aufirst%3DS.-Y.%26aulast%3DSorrell%26aufirst%3DF.%2BJ.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DFroeyen%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DL.-J.%26aulast%3DPrugar%26aufirst%3DL.%2BI.%26aulast%3DDorosky%26aufirst%3DD.%2BE.%26aulast%3DBrannan%26aufirst%3DJ.%2BM.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DDye%26aufirst%3DJ.%2BM.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DEinav%26aufirst%3DS.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%25203%252C5%2520disubstitutedpyrrolo%255B2%252C3-b%255Dpyridines%2520as%2520inhibitors%2520of%2520adaptor-associated%2520kinase%25201%2520with%2520antiviral%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5810%26epage%3D5831%26doi%3D10.1021%2Facs.jmedchem.9b00136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couñago, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limas, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gileadi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapadia, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorente-Macias, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riemen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruela-de-Sousa, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zutshi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axtman, A. D.</span></span> <span> </span><span class="NLM_article-title">SGC-AAK1-1: a chemical probe targeting AAK1 and BMP2K</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">345</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00399</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00399" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitValtr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=340-345&author=C.+Wellsauthor=R.+M.+Cou%C3%B1agoauthor=J.+C.+Limasauthor=T.+L.+Almeidaauthor=J.+G.+Cookauthor=D.+H.+Drewryauthor=J.+M.+Elkinsauthor=O.+Gileadiauthor=N.+R.+Kapadiaauthor=A.+Lorente-Maciasauthor=J.+E.+Pickettauthor=A.+Riemenauthor=R.+R.+Ruela-de-Sousaauthor=T.+M.+Willsonauthor=C.+Zhangauthor=W.+J.+Zuercherauthor=R.+Zutshiauthor=A.+D.+Axtman&title=SGC-AAK1-1%3A+a+chemical+probe+targeting+AAK1+and+BMP2K&doi=10.1021%2Facsmedchemlett.9b00399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">SGC-AAK1-1: a chemical probe targeting AAK1 and BMP2K</span></div><div class="casAuthors">Wells, Carrow; Counago, Rafael M.; Limas, Juanita C.; Almeida, Tuanny L.; Cook, Jeanette Gowen; Drewry, David H.; Elkins, Jonathan M.; Gileadi, Opher; Kapadia, Nirav R.; Lorente-Macias, Alvaro; Pickett, Julie E.; Riemen, Alexander; Ruela-de-Sousa, Roberta R.; Willson, Timothy M.; Zhang, Cunyu; Zuercher, William J.; Zutshi, Reena; Axtman, Alison D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">340-345</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors based on a 3-acylaminoindazole scaffold were synthesized to yield potent dual AAK1/BMP2K inhibitors.  Optimization furnished a small mol. chem. probe (SGC-AAK1-1, 25 (I)) that is potent and selective for AAK1/BMP2K over other NAK family members, demonstrates narrow activity in a kinome-wide screen, and is functionally active in cells.  This inhibitor represents one of the best available small mol. tools to study the functions of AAK1 and BMP2K.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOSOYD5xWr1LVg90H21EOLACvtfcHk0ljY4WNXJ2dBcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitValtr3K&md5=d525d20f1ba1282697684e6ac1d09693</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00399%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DC.%26aulast%3DCou%25C3%25B1ago%26aufirst%3DR.%2BM.%26aulast%3DLimas%26aufirst%3DJ.%2BC.%26aulast%3DAlmeida%26aufirst%3DT.%2BL.%26aulast%3DCook%26aufirst%3DJ.%2BG.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DGileadi%26aufirst%3DO.%26aulast%3DKapadia%26aufirst%3DN.%2BR.%26aulast%3DLorente-Macias%26aufirst%3DA.%26aulast%3DPickett%26aufirst%3DJ.%2BE.%26aulast%3DRiemen%26aufirst%3DA.%26aulast%3DRuela-de-Sousa%26aufirst%3DR.%2BR.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26aulast%3DZutshi%26aufirst%3DR.%26aulast%3DAxtman%26aufirst%3DA.%2BD.%26atitle%3DSGC-AAK1-1%253A%2520a%2520chemical%2520probe%2520targeting%2520AAK1%2520and%2520BMP2K%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D340%26epage%3D345%26doi%3D10.1021%2Facsmedchemlett.9b00399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziv-Av, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e1002845</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1002845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1371%2Fjournal.ppat.1002845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=22916011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Cns7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&author=G.+Neveuauthor=R.+Barouch-Bentovauthor=A.+Ziv-Avauthor=D.+Gerberauthor=Y.+Jacobauthor=S.+Einav&title=Identification+and+targeting+of+an+interaction+between+a+tyrosine+motif+within+hepatitis+C+virus+core+protein+and+AP2M1+essential+for+viral+assembly&doi=10.1371%2Fjournal.ppat.1002845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly</span></div><div class="casAuthors">Neveu, Gregory; Barouch-Bentov, Rina; Ziv-Av, Amotz; Gerber, Doron; Jacob, Yves; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e1002845</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Novel therapies are urgently needed against hepatitis C virus infection (HCV), a major global health problem.  The current model of infectious virus prodn. suggests that HCV virions are assembled on or near the surface of lipid droplets, acquire their envelope at the ER, and egress through the secretory pathway.  The mechanisms of HCV assembly and particularly the role of viral-host protein-protein interactions in mediating this process are, however, poorly understood.  We identified a conserved heretofore unrecognized YXXΦ motif (Φ is a bulky hydrophobic residue) within the core protein.  This motif is homologous to sorting signals within host cargo proteins known to mediate binding of AP2M1, the μ subunit of clathrin adaptor protein complex 2 (AP-2), and intracellular trafficking.  Using microfluidics affinity anal., protein-fragment complementation assays, and co-immunopptns. in infected cells, we show that this motif mediates core binding to AP2M1.  YXXΦ mutations, silencing AP2M1 expression or overexpressing a dominant neg. AP2M1 mutant had no effect on HCV RNA replication, however, they dramatically inhibited intra- and extra-cellular infectivity, consistent with a defect in viral assembly.  Quant. confocal immunofluorescence anal. revealed that core's YXXΦ motif mediates recruitment of AP2M1 to lipid droplets and that the obsd. defect in HCV assembly following disruption of core-AP2M1 binding correlates with accumulation of core on lipid droplets, reduced core colocalization with E2 and reduced core localization to trans-Golgi network (TGN), the presumed site of viral particles maturation.  Furthermore, AAK1 and GAK, serine/threonine kinases known to stimulate binding of AP2M1 to host cargo proteins, regulate core-AP2M1 binding and are essential for HCV assembly.  Last, approved anti-cancer drugs that inhibit AAK1 or GAK not only disrupt core-AP2M1 binding, but also significantly inhibit HCV assembly and infectious virus prodn.  These results validate viral-host interactions essential for HCV assembly and yield compds. for pharmaceutical development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjKaGJVLP2vLVg90H21EOLACvtfcHk0ljY4WNXJ2dBcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Cns7bF&md5=811c0818d4b2500b1b788076ac4abc5d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1002845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1002845%26sid%3Dliteratum%253Aachs%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DZiv-Av%26aufirst%3DA.%26aulast%3DGerber%26aufirst%3DD.%26aulast%3DJacob%26aufirst%3DY.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DIdentification%2520and%2520targeting%2520of%2520an%2520interaction%2520between%2520a%2520tyrosine%2520motif%2520within%2520hepatitis%2520C%2520virus%2520core%2520protein%2520and%2520AP2M1%2520essential%2520for%2520viral%2520assembly%26jtitle%3DPLoS%2520Pathog.%26date%3D2012%26volume%3D8%26doi%3D10.1371%2Fjournal.ppat.1002845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Dysfunction of endocytic kinase AAK1 in ALS</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">22918</span>– <span class="NLM_lpage">22932</span>, <span class="refDoi"> DOI: 10.3390/ijms151222918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.3390%2Fijms151222918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=25514244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVGitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=22918-22932&author=B.+Shiauthor=S.+Connerauthor=J.+Liu&title=Dysfunction+of+endocytic+kinase+AAK1+in+ALS&doi=10.3390%2Fijms151222918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Dysfunction of endocytic kinase AAK1 in ALS</span></div><div class="casAuthors">Shi, Bingxing; Conner, Sean D.; Liu, Jian</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">22918-22932</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Mechanisms of human mutant superoxide dismutase 1 (SOD1)-induced toxicity in causing the familial form of amyotrophic lateral sclerosis (ALS) remain elusive.  Identification of new proteins that can selectively interact with mutant SOD1s and investigation of their potential roles in ALS are important to discover new pathways that are involved in disease pathol.  Using the yeast two-hybrid system, we identified the adaptor-assocd. kinase 1 (AAK1), a regulatory protein in clathrin-coated vesicle endocytic pathway that selectively interacted with the mutant but not the wild-type SOD1.  Using both transgenic mouse and rat SOD1-linked familial ALS (FALS) models, we found that AAK1 was partially colocalized with the endosomal and presynaptic protein markers under the normal physiol. condition, but was mislocated into aggregates that contained mutant SOD1s and the neurofilament proteins in rodent models of ALS in disease.  AAK1 protein levels were also decreased in ALS patients.  These results suggest that dysfunction of a component in the endosomal and synaptic vesicle recycling pathway is involved in ALS pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbYe9fs11Hh7Vg90H21EOLACvtfcHk0ljY4WNXJ2dBcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVGitA%253D%253D&md5=1363032909ce960012c43902e9d9c418</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.3390%2Fijms151222918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms151222918%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DB.%26aulast%3DConner%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DDysfunction%2520of%2520endocytic%2520kinase%2520AAK1%2520in%2520ALS%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2014%26volume%3D15%26spage%3D22918%26epage%3D22932%26doi%3D10.3390%2Fijms151222918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta-Rossi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortica, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meas-Yedid, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moretti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivo-Marin, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Israël, A.</span></span> <span> </span><span class="NLM_article-title">The adaptor-associated kinase 1, AAK1, is a positive regulator of the Notch pathway</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">18720</span>– <span class="NLM_lpage">18730</span>, <span class="refDoi"> DOI: 10.1074/jbc.M110.190769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1074%2Fjbc.M110.190769" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=21464124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtlGltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=18720-18730&author=N.+Gupta-Rossiauthor=S.+Orticaauthor=V.+Meas-Yedidauthor=S.+Heussauthor=J.+Morettiauthor=J.-C.+Olivo-Marinauthor=A.+Isra%C3%ABl&title=The+adaptor-associated+kinase+1%2C+AAK1%2C+is+a+positive+regulator+of+the+Notch+pathway&doi=10.1074%2Fjbc.M110.190769"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The adaptor-associated Kinase 1, AAK1, is a positive regulator of the Notch pathway</span></div><div class="casAuthors">Gupta-Rossi, Neetu; Ortica, Sara; Meas-Yedid, Vannary; Heuss, Sara; Moretti, Julien; Olivo-Marin, Jean-Christophe; Israel, Alain</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">18720-18730</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The Notch pathway is involved in cell-cell signaling during development and adulthood from invertebrates to higher eukaryotes.  The activation of the Notch receptor by its ligands relies on multi-step processing.  The extracellular part of the receptor is removed by a metalloprotease of the ADAM family and the remaining fragment is cleaved within its transmembrane domain by a presenilin-dependent γ-secretase activity.  The γ-secretase processing of Notch has previously been shown to depend upon monoubiquitination as well as clathrin-mediated endocytosis (CME).  Here, the authors show that AAK1 kinase directly interacts with the membrane-tethered active form of Notch released by metalloprotease cleavage.  Active AAK1 acted upstream of the γ-secretase cleavage by stabilizing both the membrane-tethered activated form of Notch and its monoubiquitinated counterpart.  The authors propose that AAK1 acts as an adaptor for Notch interaction with components of the clathrin-mediated pathway such as Eps15b.  Moreover, transfected AAK1 increased the localization of activated Notch to Rab5-pos. endocytic vesicles, while AAK1 depletion or overexpression of Numb, an inhibitor of the pathway, interfered with this localization.  These results suggest that after ligand-induced activation of Notch, the membrane-tethered form can be directed to different endocytic pathways leading to distinct fates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr47uq9qZR_4rVg90H21EOLACvtfcHk0lgtm4ojeuciUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtlGltL4%253D&md5=48d7a335adef0bae7f31db2a853def37</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.190769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.190769%26sid%3Dliteratum%253Aachs%26aulast%3DGupta-Rossi%26aufirst%3DN.%26aulast%3DOrtica%26aufirst%3DS.%26aulast%3DMeas-Yedid%26aufirst%3DV.%26aulast%3DHeuss%26aufirst%3DS.%26aulast%3DMoretti%26aufirst%3DJ.%26aulast%3DOlivo-Marin%26aufirst%3DJ.-C.%26aulast%3DIsra%25C3%25ABl%26aufirst%3DA.%26atitle%3DThe%2520adaptor-associated%2520kinase%25201%252C%2520AAK1%252C%2520is%2520a%2520positive%2520regulator%2520of%2520the%2520Notch%2520pathway%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D18720%26epage%3D18730%26doi%3D10.1074%2Fjbc.M110.190769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Gualda, B.</span>; <span class="NLM_string-name">Schols, D.</span>; <span class="NLM_string-name">De Jonghe, S.</span></span> <span> </span><span class="NLM_article-title">A patent review of adaptor associated kinase 1 (AAK1) inhibitors (2013-present)</span>.  <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>, (in press), <span class="refDoi"> DOI: 10.1080/13543776.2021.1928637</span> ,  <span class="NLM_fpage">1</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1080%2F13543776.2021.1928637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=33971786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADC%252BB2c%252Fis1yjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2021&pages=1&author=B.+Martinez-Gualda&author=D.+Schols&author=S.+De+Jonghe&title=A+patent+review+of+adaptor+associated+kinase+1+%28AAK1%29+inhibitors+%282013-present%29&doi=10.1080%2F13543776.2021.1928637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A patent review of adaptor associated kinase 1 (AAK1) inhibitors (2013-present)</span></div><div class="casAuthors">Martinez-Gualda Belen; Martinez-Gualda Belen; Schols Dominique; De Jonghe Steven</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on therapeutic patents</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Adaptor-associated kinase 1 (AAK1) has been proposed as being a promising drug target for the treatment of a variety of neurological and psychiatric disorders, such as schizophrenia, cognitive deficits in schizophrenia, Parkinson's disease, bipolar disorder, Alzheimer's disease and neuropathic pain.  More recently, AAK1 was shown to be an essential cellular factor for viral replication and therefore has been pursued as a host target for the development of broad-spectrum antiviral agents.  AREAS COVERED:  This review provides an overview of the patented AAK1 inhibitors from 2013 to present.  EXPERT OPINION:  The promise of AAK1 as drug target for the treatment of neuropathic pain stimulated the search for AAK1 inhibitors.  However, only two companies (i.e.  Lexicon Pharmaceuticals and Bristol Myers Squibb) seemed to be active in this field and filed patent applications in the last few years.  The most promising congeners showed promising in vitro activity in a variety of AAK1-related assays.  Moreover, selected compounds were also endowed with in vivo activity in various preclinical animal models for neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTkcDcukcrmC0bxh97K6Vt6fW6udTcc2ebnyFGAZfNLwbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB2c%252Fis1yjsQ%253D%253D&md5=e323682fd82ee6e702c9f0ef8905a846</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1080%2F13543776.2021.1928637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2021.1928637%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez-Gualda%26aufirst%3DB.%26atitle%3DA%2520patent%2520review%2520of%2520adaptor%2520associated%2520kinase%25201%2520%2528AAK1%2529%2520inhibitors%2520%25282013-present%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2021%26doi%3D10.1080%2F13543776.2021.1928637%26spage%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span> <i>The
PyMOL Molecular Graphics
System, Version 2.3.4</i>; <span class="NLM_publisher-name">Schrödinger
LLC</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+The%0APyMOL+Molecular+Graphics%0ASystem%2C+Version+2.3.4%3B+Schr%C3%B6dinger%0ALLC."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%250APyMOL%2520Molecular%2520Graphics%250ASystem%252C%2520Version%25202.3.4%26pub%3DSchr%25C3%25B6dinger%250ALLC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hitchcock, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span> <span> </span><span class="NLM_article-title">Structure–brain exposure relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">7559</span>– <span class="NLM_lpage">7583</span>, <span class="refDoi"> DOI: 10.1021/jm060642i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060642i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1yrtrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=7559-7583&author=S.+A.+Hitchcockauthor=L.+D.+Pennington&title=Structure%E2%80%93brain+exposure+relationships&doi=10.1021%2Fjm060642i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-brain exposure relationships</span></div><div class="casAuthors">Hitchcock, Stephen A.; Pennington, Lewis D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7559-7583</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on the use of structure modification to influence blood-brain barrier penetration by modulating either passive diffusion or active transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3V-TERRGy07Vg90H21EOLACvtfcHk0lgtm4ojeuciUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1yrtrnK&md5=97dff583ffae6d0ef66512ffbee38c34</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm060642i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060642i%26sid%3Dliteratum%253Aachs%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26atitle%3DStructure%25E2%2580%2593brain%2520exposure%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D7559%26epage%3D7583%26doi%3D10.1021%2Fjm060642i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span> <span> </span><span class="NLM_article-title">Strategies to optimize brian penetration in drug discovery</span>. <i>Curr. Opin. Drug Discovery Dev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">512</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=16022187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvFCgtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2005&pages=505-512&author=X.+Liuauthor=C.+Chen&title=Strategies+to+optimize+brian+penetration+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to optimize brain penetration in drug discovery</span></div><div class="casAuthors">Liu, Xingrong; Chen, Cuiping</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">505-512</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  The kinetics of brain penetration has two components, extent and rate.  Achieving a high extent of brain penetration is an important focus for central nervous system (CNS) drug discovery.  Optimal brain penetration can be achieved by reducing efflux transport at the blood-brain barrier (BBB), and it is crit. to ensure that a high total brain/plasma ratio (the most commonly used parameter for measuring brain penetration) is due to efflux transport activity at the BBB and not related to high non-specific brain tissue binding or low plasma binding.  Rapid brain penetration is essential for those drugs that require fast onset of action in the CNS.  This can be achieved by increasing passive permeability and reducing brain tissue binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI4i1b3bPJ5rVg90H21EOLACvtfcHk0lgtm4ojeuciUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvFCgtLo%253D&md5=004d6f5f8fc110aab7ca1f0eaf3a0ec7</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DC.%26atitle%3DStrategies%2520to%2520optimize%2520brian%2520penetration%2520in%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2005%26volume%3D8%26spage%3D505%26epage%3D512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, G. T.</span></span> <span> </span><span class="NLM_article-title">Strategies to assess blood–brain barrier penetration</span>. <i>Expert. Opin. Drug Discov.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">687</span>, <span class="refDoi"> DOI: 10.1517/17460441.3.6.677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1517%2F17460441.3.6.677" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=23506148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotVyrtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=677-687&author=L.+Diauthor=E.+H.+Kernsauthor=G.+T.+Carter&title=Strategies+to+assess+blood%E2%80%93brain+barrier+penetration&doi=10.1517%2F17460441.3.6.677"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to assess blood-brain barrier penetration</span></div><div class="casAuthors">Di, Li; Kerns, Edward H.; Carter, Guy T.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">677-687</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: The principles and screening strategies for brain penetration in drug discovery are important in identifying drug candidates with desirable CNS properties.  Objective: Define key variables and assays that are essential for detg. brain penetration.  Methods: This review covers issues, methods, and strategies for assessing brain penetration of small mols. in drug discovery.  Results/conclusion: Brain penetration is assessed using both initial rate and extent at steady-state.  Unbound drug is the active species that exerts pharmacol. effects.  Low brain penetration can be due to low blood-brain barrier (BBB) permeability, P-glycoprotein (Pgp) efflux, or high plasma protein binding.  Successful methods include: parallel artificial membrane permeability assay (PAMPA)-BBB permeability, MDR1-MDCKII for Pgp efflux, B-P dialysis for fraction unbound, and in vivo B/P ratio to extrapolate unbound brain drug concn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOHHdHc1xH7LVg90H21EOLACvtfcHk0lgfopSArQ3VmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotVyrtL0%253D&md5=8186d3a972120691aebb3dba4810f7f8</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1517%2F17460441.3.6.677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.3.6.677%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26aulast%3DCarter%26aufirst%3DG.%2BT.%26atitle%3DStrategies%2520to%2520assess%2520blood%25E2%2580%2593brain%2520barrier%2520penetration%26jtitle%3DExpert.%2520Opin.%2520Drug%2520Discov.%26date%3D2008%26volume%3D3%26spage%3D677%26epage%3D687%26doi%3D10.1517%2F17460441.3.6.677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span> <span> </span><span class="NLM_article-title">Demystifying brain penetration in central nervous system drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1021/jm301297f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301297f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFamtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2-12&author=L.+Diauthor=H.+Rongauthor=B.+Feng&title=Demystifying+brain+penetration+in+central+nervous+system+drug+discovery&doi=10.1021%2Fjm301297f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Demystifying Brain Penetration in Central Nervous System Drug Discovery</span></div><div class="casAuthors">Di, Li; Rong, Haojing; Feng, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-12</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This Perspective provides important concepts about the blood-brain barrier (BBB) in drug discovery and how they should be applied effectively in designing successful CNS drugs.  Key parameters for brain penetration are discussed, including unbound brain concn., unbound brain-to-plasma ratio, BBB permeability, fraction unbound in brain and plasma, and transporters.  Results from a retrospective anal. of 32 Pfizer CNS clin. drug candidates are described.  Frequently encountered misconceptions about brain penetration in drug discovery programs are clarified.  Strategies and guidance are provided to enhance or minimize brain exposure for CNS or peripheral targets, resp.  Recommendations for screening methodologies and a cascade in assessing brain penetration potential are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmurs7cfju37Vg90H21EOLACvtfcHk0lgfopSArQ3VmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFamtrrJ&md5=8b88e2044bf41898ab40c45e18f2a20d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm301297f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301297f%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DFeng%26aufirst%3DB.%26atitle%3DDemystifying%2520brain%2520penetration%2520in%2520central%2520nervous%2520system%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2%26epage%3D12%26doi%3D10.1021%2Fjm301297f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBartolo, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tess, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. O.</span></span> <span> </span><span class="NLM_article-title">Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1124/dmd.104.001222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1124%2Fdmd.104.001222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=15502010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlentA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=175-181&author=T.+S.+Maurerauthor=D.+B.+DeBartoloauthor=D.+A.+Tessauthor=D.+O.+Scott&title=Relationship+between+exposure+and+nonspecific+binding+of+thirty-three+central+nervous+system+drugs+in+mice&doi=10.1124%2Fdmd.104.001222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice</span></div><div class="casAuthors">Maurer, Tristan S.; DeBartolo, Demetria B.; Tess, David A.; Scott, Dennis O.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">175-181</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Unbound fractions in mouse brain and plasma were detd. for 31 structurally diverse central nervous system (CNS) drugs and two active metabolites.  Three comparisons were made between in vitro binding and in vivo exposure data, namely: (1) mouse brain-to-plasma exposure vs. unbound plasma-to-unbound brain fraction ratio (fuplasma/fubrain), (2) cerebrospinal fluid-to-brain exposure vs. unbound brain fraction (fubrain), and (3) cerebrospinal fluid-to-plasma exposure vs. unbound plasma fraction (fuplasma).  Unbound fraction data were within 3-fold of in vivo exposure ratios for the majority of the drugs examd. (i.e., 22 of 33), indicating a predominately free equil. across the blood-brain and blood-CSF barriers.  Some degree of distributional impairment at either the blood-CSF or the blood-brain barrier was indicated for 8 of the 11 remaining drugs (i.e., carbamazepine, midazolam, phenytoin, sulpiride, thiopental, risperidone, 9-hydroxyrisperidone, and zolpidem).  In several cases, the indicated distributional impairment is consistent with other independent literature reports for these drugs.  Through the use of this approach, it appears that most CNS-active agents freely equilibrate across the blood-brain and blood-CSF barriers such that unbound drug concns. in brain approx. those in the plasma.  However, these results also support the intuitive concept that distributional impairment does not necessarily preclude CNS activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH6imduXukj7Vg90H21EOLACvtfcHk0lgfopSArQ3VmQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlentA%253D%253D&md5=27e70989846ff3eeb4fa4a7d8c6e73b5</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1124%2Fdmd.104.001222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.104.001222%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDeBartolo%26aufirst%3DD.%2BB.%26aulast%3DTess%26aufirst%3DD.%2BA.%26aulast%3DScott%26aufirst%3DD.%2BO.%26atitle%3DRelationship%2520between%2520exposure%2520and%2520nonspecific%2520binding%2520of%2520thirty-three%2520central%2520nervous%2520system%2520drugs%2520in%2520mice%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D175%26epage%3D181%26doi%3D10.1124%2Fdmd.104.001222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E. H.</span></span> <span> </span><span class="NLM_article-title">The effect of plasma protein binding on <i>in vivo</i> efficacy: misconceptions in drug discovery</span>. <i>Nat. Rev. Drug Discov.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">929</span>– <span class="NLM_lpage">939</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1038%2Fnrd3287" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=929-939&author=D.+A.+Smithauthor=L.+Diauthor=E.+H.+Kerns&title=The+effect+of+plasma+protein+binding+on+in+vivo+efficacy%3A+misconceptions+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnrd3287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3287%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26atitle%3DThe%2520effect%2520of%2520plasma%2520protein%2520binding%2520on%2520in%2520vivo%2520efficacy%253A%2520misconceptions%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discov.%26date%3D2010%26volume%3D12%26spage%3D929%26epage%3D939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0ljBFllmFrGZoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tjølsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berge, O. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunskaar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosland, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hole, K.</span></span> <span> </span><span class="NLM_article-title">The formalin test: an evaluation of the method</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1016/0304-3959(92)90003-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2F0304-3959%2892%2990003-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1454405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADyaK3s%252FoslSnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1992&pages=5-17&author=A.+Tj%C3%B8lsenauthor=O.+G.+Bergeauthor=S.+Hunskaarauthor=J.+H.+Roslandauthor=K.+Hole&title=The+formalin+test%3A+an+evaluation+of+the+method&doi=10.1016%2F0304-3959%2892%2990003-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The formalin test: an evaluation of the method</span></div><div class="casAuthors">Tjolsen Arne; Berge Odd-Geir; Hunskaar Steinar; Rosland Jan Henrik; Hole Kjell</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-17</span>
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    </div><div class="casAbstract">The formalin test for nociception, which is predominantly used with rats and mice, involves moderate, continuous pain generated by injured tissue.  In this way it differs from most traditional tests of nociception which rely upon brief stimuli of threshold intensity.  In this article we describe the main features of the formalin test, including the characteristics of the stimulus and how changes in nociceptive behaviour may be measured and interpreted.  The response to formalin shows an early and a late phase.  The early phase seems to be caused predominantly by C-fibre activation due to the peripheral stimulus, while the late phase appears to be dependent on the combination of an inflammatory reaction in the peripheral tissue and functional changes in the dorsal horn of the spinal cord.  These functional changes seem to be initiated by the C-fibre barrage during the early phase.  In mice, the behavioural response in the late phase depends on the ambient temperature.  We argue that the peripheral tissue temperature as well as other factors influencing the peripheral inflammation may affect the response, possibly confounding the results obtained with the test.  Furthermore, we discuss the methods of recording the response and the value of observing more than one aspect of behaviour.  Scoring of several behavioural variables provides a means of assessing motor or sensorimotor function as possible causes for changes in behaviour.  In conclusion, the formalin test is a valuable addition to the battery of methods available to study nociception.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSEPstJUQcfvkEksK8CslK8fW6udTcc2eY8oIZEXrDpvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s%252FoslSnsA%253D%253D&md5=d56dc5eb88d109dd30d319dcf580c781</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2F0304-3959%2892%2990003-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3959%252892%252990003-T%26sid%3Dliteratum%253Aachs%26aulast%3DTj%25C3%25B8lsen%26aufirst%3DA.%26aulast%3DBerge%26aufirst%3DO.%2BG.%26aulast%3DHunskaar%26aufirst%3DS.%26aulast%3DRosland%26aufirst%3DJ.%2BH.%26aulast%3DHole%26aufirst%3DK.%26atitle%3DThe%2520formalin%2520test%253A%2520an%2520evaluation%2520of%2520the%2520method%26jtitle%3DPain%26date%3D1992%26volume%3D51%26spage%3D5%26epage%3D17%26doi%3D10.1016%2F0304-3959%2892%2990003-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y. K.</span></span> <span> </span><span class="NLM_article-title">A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1016/0304-3959(88)90209-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2F0304-3959%2888%2990209-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=2837713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADyaL1c3kslGhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1988&pages=87-107&author=G.+J.+Bennettauthor=Y.+K.+Xie&title=A+peripheral+mononeuropathy+in+rat+that+produces+disorders+of+pain+sensation+like+those+seen+in+man&doi=10.1016%2F0304-3959%2888%2990209-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man</span></div><div class="casAuthors">Bennett Gary J; Xie Y-K</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-107</span>
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    </div><div class="casAbstract">A peripheral mononeuropathy was produced in adult rats by placing loosely constrictive ligatures around the common sciatic nerve.  The postoperative behavior of these rats indicated that hyperalgesia, allodynia and, possibly, spontaneous pain (or dysesthesia) were produced.  Hyperalgesic responses to noxious radiant heat were evident on the second postoperative day and lasted for over 2 months.  Hyperalgesic responses to chemogenic pain were also present.  The presence of allodynia was inferred from the nocifensive responses evoked by standing on an innocuous, chilled metal floor or by innocuous mechanical stimulation, and by the rats' persistence in holding the hind paw in a guarded position.  The presence of spontaneous pain was suggested by a suppression of appetite and by the frequent occurrence of apparently spontaneous nocifensive responses.  The affected hind paw was abnormally warm or cool in about one-third of the rats.  About one-half of the rats developed grossly overgrown claws on the affected side.  Experiments with this animal model may advance our understanding of the neural mechanisms of neuropathic pain disorders in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSvFbgQgoOLbwWRJ3OJdH_qfW6udTcc2eY8oIZEXrDpvbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1c3kslGhsw%253D%253D&md5=b65eee81b7058ce686a014eee46ead80</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2F0304-3959%2888%2990209-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3959%252888%252990209-6%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DG.%2BJ.%26aulast%3DXie%26aufirst%3DY.%2BK.%26atitle%3DA%2520peripheral%2520mononeuropathy%2520in%2520rat%2520that%2520produces%2520disorders%2520of%2520pain%2520sensation%2520like%2520those%2520seen%2520in%2520man%26jtitle%3DPain%26date%3D1988%26volume%3D33%26spage%3D87%26epage%3D107%26doi%3D10.1016%2F0304-3959%2888%2990209-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandel-Brehm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bautista, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deranian, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julius, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanger, C. M.</span></span> <span> </span><span class="NLM_article-title">TRPA1 mediates formalin-induced pain</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">13525</span>– <span class="NLM_lpage">13530</span>, <span class="refDoi"> DOI: 10.1073/pnas.0705924104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1073%2Fpnas.0705924104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=17686976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD2sXps1eqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=13525-13530&author=C.+R.+McNamaraauthor=J.+Mandel-Brehmauthor=D.+M.+Bautistaauthor=J.+Siemensauthor=K.+L.+Deranianauthor=M.+Zhaoauthor=N.+J.+Haywardauthor=J.+A.+Chongauthor=D.+Juliusauthor=M.+M.+Moranauthor=C.+M.+Fanger&title=TRPA1+mediates+formalin-induced+pain&doi=10.1073%2Fpnas.0705924104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">TRPA1 mediates formalin-induced pain</span></div><div class="casAuthors">McNamara, Colleen R.; Mandel-Brehm, Josh; Bautista, Diana M.; Siemens, Jan; Deranian, Kari L.; Zhao, Michael; Hayward, Neil J.; Chong, Jayhong A.; Julius, David; Moran, Magdalene M.; Fanger, Christopher M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">13525-13530</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The formalin model is widely used for evaluating the effects of analgesic compds. in lab. animals.  Injection of formalin into the hind paw induces a biphasic pain response; the first phase is thought to result from direct activation of primary afferent sensory neurons, whereas the second phase has been proposed to reflect the combined effects of afferent input and central sensitization in the dorsal horn.  Here we show that formalin excites sensory neurons by directly activating transient receptor potential ion channel TRPA1, a cation channel that plays an important role in inflammatory pain.  Formalin induced robust calcium influx in cells expressing cloned or native TRPA1 channels, and these responses were attenuated by a previously undescribed TRPA1-selective antagonist.  Moreover, sensory neurons from TRPA1-deficient mice lacked formalin sensitivity.  At the behavioral level, pharmacol. blockade or genetic ablation of TRPA1 produced marked attenuation of the characteristic flinching, licking, and lifting responses resulting from intraplantar injection of formalin.  Our results show that TRPA1 is the principal site of formalin's pain-producing action in vivo, and that activation of this excitatory channel underlies the physiol. and behavioral responses assocd. with this model of pain hypersensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgRKOZy2rNILVg90H21EOLACvtfcHk0lgzpRaY9-4NUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXps1eqsL8%253D&md5=2482d7b071a4eb6c3131d3d95ea05ae2</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0705924104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0705924104%26sid%3Dliteratum%253Aachs%26aulast%3DMcNamara%26aufirst%3DC.%2BR.%26aulast%3DMandel-Brehm%26aufirst%3DJ.%26aulast%3DBautista%26aufirst%3DD.%2BM.%26aulast%3DSiemens%26aufirst%3DJ.%26aulast%3DDeranian%26aufirst%3DK.%2BL.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DHayward%26aufirst%3DN.%2BJ.%26aulast%3DChong%26aufirst%3DJ.%2BA.%26aulast%3DJulius%26aufirst%3DD.%26aulast%3DMoran%26aufirst%3DM.%2BM.%26aulast%3DFanger%26aufirst%3DC.%2BM.%26atitle%3DTRPA1%2520mediates%2520formalin-induced%2520pain%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D13525%26epage%3D13530%26doi%3D10.1073%2Fpnas.0705924104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorkin, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaksh, T. L.</span></span> <span> </span><span class="NLM_article-title">Behavioral models of pain states evoked by physical injury to the peripheral nerve</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1016/j.nurt.2009.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2Fj.nurt.2009.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=19789066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADC%252BD1Mnls1CqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=609-619&author=L.+S.+Sorkinauthor=T.+L.+Yaksh&title=Behavioral+models+of+pain+states+evoked+by+physical+injury+to+the+peripheral+nerve&doi=10.1016%2Fj.nurt.2009.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioral models of pain states evoked by physical injury to the peripheral nerve</span></div><div class="casAuthors">Sorkin Linda S; Yaksh Tony L</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">609-19</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Physical injury or compression of the root, dorsal root ganglion, or peripheral sensory axon leads to well-defined changes in biology and function.  Behaviorally, humans report ongoing painful dysesthesias and aberrations in function, such that an otherwise innocuous stimulus will yield a pain report.  These behavioral reports are believed to reflect the underlying changes in nerve function after injury, wherein increased spontaneous activity arises from the neuroma and dorsal root ganglion and spinal changes increase the response of spinal projection neurons.  These pain states are distinct from those associated with tissue injury and pose particular problems in management.  To provide for developing an understanding of the underlying mechanisms of these pain states and to promote development of therapeutic agents, preclinical models involving section, compression, and constriction of the peripheral nerve or compression of the dorsal root ganglion have been developed.  These models give rise to behaviors, which parallel those observed in the human after nerve injury.  The present review considers these models and their application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRqq0bHyJy-BDEwO064Z95rfW6udTcc2eakjU3Y7LFS2bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mnls1CqtQ%253D%253D&md5=c4b93e93e54333934195ab6b98fbee32</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.nurt.2009.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nurt.2009.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DSorkin%26aufirst%3DL.%2BS.%26aulast%3DYaksh%26aufirst%3DT.%2BL.%26atitle%3DBehavioral%2520models%2520of%2520pain%2520states%2520evoked%2520by%2520physical%2520injury%2520to%2520the%2520peripheral%2520nerve%26jtitle%3DNeurotherapeutics%26date%3D2009%26volume%3D6%26spage%3D609%26epage%3D619%26doi%3D10.1016%2Fj.nurt.2009.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flores, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joris, J.</span></span> <span> </span><span class="NLM_article-title">A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1016/0304-3959(88)90026-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2F0304-3959%2888%2990026-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=3340425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADyaL1c7itlOntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1988&pages=77-88&author=K.+Hargreavesauthor=R.+Dubnerauthor=F.+Brownauthor=C.+Floresauthor=J.+Joris&title=A+new+and+sensitive+method+for+measuring+thermal+nociception+in+cutaneous+hyperalgesia&doi=10.1016%2F0304-3959%2888%2990026-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia</span></div><div class="casAuthors">Hargreaves K; Dubner R; Brown F; Flores C; Joris J</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-88</span>
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    </div><div class="casAbstract">A method to measure cutaneous hyperalgesia to thermal stimulation in unrestrained animals is described.  The testing paradigm uses an automated detection of the behavioral end-point; repeated testing does not contribute to the development of the observed hyperalgesia.  Carrageenan-induced inflammation resulted in significantly shorter paw withdrawal latencies as compared to saline-treated paws and these latency changes corresponded to a decreased thermal nociceptive threshold.  Both the thermal method and the Randall-Selitto mechanical method detected dose-related hyperalgesia and its blockade by either morphine or indomethacin.  However, the thermal method showed greater bioassay sensitivity and allowed for the measurement of other behavioral parameters in addition to the nociceptive threshold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcMP0T_8qqvqcY7HFp97qMfW6udTcc2eakjU3Y7LFS2bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1c7itlOntw%253D%253D&md5=6a8e191b520661ba76ebc947f0b0b1b1</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2F0304-3959%2888%2990026-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3959%252888%252990026-7%26sid%3Dliteratum%253Aachs%26aulast%3DHargreaves%26aufirst%3DK.%26aulast%3DDubner%26aufirst%3DR.%26aulast%3DBrown%26aufirst%3DF.%26aulast%3DFlores%26aufirst%3DC.%26aulast%3DJoris%26aufirst%3DJ.%26atitle%3DA%2520new%2520and%2520sensitive%2520method%2520for%2520measuring%2520thermal%2520nociception%2520in%2520cutaneous%2520hyperalgesia%26jtitle%3DPain%26date%3D1988%26volume%3D32%26spage%3D77%26epage%3D88%26doi%3D10.1016%2F0304-3959%2888%2990026-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Randall, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selitto, J. J.</span></span> <span> </span><span class="NLM_article-title">A method for measurement of analgesic activity on inflamed tissue</span>. <i>Arch. Int. Pharmacodyn. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1957</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">409</span>– <span class="NLM_lpage">419</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=13471093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADyaG1cXis1Gnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=1957&pages=409-419&author=L.+O.+Randallauthor=J.+J.+Selitto&title=A+method+for+measurement+of+analgesic+activity+on+inflamed+tissue"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A method for measurement of analgesic activity on inflamed tissue</span></div><div class="casAuthors">Randall, Lowell O.; Selitto, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Archives Internationales de Pharmacodynamie et de Therapie</span>
        (<span class="NLM_cas:date">1957</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">409-19</span>CODEN:
                <span class="NLM_cas:coden">AIPTAK</span>;
        ISSN:<span class="NLM_cas:issn">0003-9780</span>.
    </div><div class="casAbstract">The inflamed feet of the rat were twice as sensitive to pressure as were normal feet.  Salicylate, phenylbutazone, and Ro 2-5383 raise the pain threshold of inflamed but not of normal feet, and aminopyrine and narcotic analgesics raise it in both.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWxvjwjaEQurVg90H21EOLACvtfcHk0lisoIpJzhjNcQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG1cXis1Gnug%253D%253D&md5=b4ddc4f843cb6b8963315e1e7c69edeb</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRandall%26aufirst%3DL.%2BO.%26aulast%3DSelitto%26aufirst%3DJ.%2BJ.%26atitle%3DA%2520method%2520for%2520measurement%2520of%2520analgesic%2520activity%2520on%2520inflamed%2520tissue%26jtitle%3DArch.%2520Int.%2520Pharmacodyn.%2520Ther.%26date%3D1957%26volume%3D111%26spage%3D409%26epage%3D419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos-Nogueira, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancuso, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, X.</span></span> <span> </span><span class="NLM_article-title">Randall-Selitto test: a new approach for the detection of neuropathic pain after spinal cord injury</span>. <i>J. Neurotrauma.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">898</span>– <span class="NLM_lpage">904</span>, <span class="refDoi"> DOI: 10.1089/neu.2010.1700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1089%2Fneu.2010.1700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=21682605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADC%252BC38zgtlansA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=898-904&author=E.+Santos-Nogueiraauthor=E.+R.+Castroauthor=R.+Mancusoauthor=X.+Navarro&title=Randall-Selitto+test%3A+a+new+approach+for+the+detection+of+neuropathic+pain+after+spinal+cord+injury&doi=10.1089%2Fneu.2010.1700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Randall-Selitto test: a new approach for the detection of neuropathic pain after spinal cord injury</span></div><div class="casAuthors">Santos-Nogueira Eva; Redondo Castro Elena; Mancuso Renzo; Navarro Xavier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurotrauma</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">898-904</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In this work we assess the usefulness of the Randall-Selitto test as a method to detect and quantify neuropathic pain responses in rats subjected to different spinal cord injuries.  The mechanical nociceptive thresholds were significantly reduced during follow-up after spinal cord contusion or transection.  Our results demonstrate that the Randall-Selitto test allows the detection of neuropathic pain both in forepaws and hindpaws, as well as in dorsal and plantar surfaces.  Moreover, it does not require weight support capacity, so it can be used at early time points after the injury.  This is the first time that this method has been used to describe the changes in nociceptive thresholds that take place after spinal cord injuries of different severities over time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSoAYwXaNmlky-bLEOO4dYpfW6udTcc2ear_Cbe3nNmrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zgtlansA%253D%253D&md5=44e3b270a8d85952c3f1798ddaace3f7</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1089%2Fneu.2010.1700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fneu.2010.1700%26sid%3Dliteratum%253Aachs%26aulast%3DSantos-Nogueira%26aufirst%3DE.%26aulast%3DCastro%26aufirst%3DE.%2BR.%26aulast%3DMancuso%26aufirst%3DR.%26aulast%3DNavarro%26aufirst%3DX.%26atitle%3DRandall-Selitto%2520test%253A%2520a%2520new%2520approach%2520for%2520the%2520detection%2520of%2520neuropathic%2520pain%2520after%2520spinal%2520cord%2520injury%26jtitle%3DJ.%2520Neurotrauma.%26date%3D2012%26volume%3D29%26spage%3D898%26epage%3D904%26doi%3D10.1089%2Fneu.2010.1700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanimoto-Mori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakazato-Imasato, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toide, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kita, Y.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic investigation of the mechanism underlying cold allodynia using a new cold plate procedure in rats with chronic constriction injuries</span>. <i>Behav. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1097/FBP.0b013e3282f3d0a3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1097%2FFBP.0b013e3282f3d0a3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=18195599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FktFamtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=85-90&author=S.+Tanimoto-Moriauthor=E.+Nakazato-Imasatoauthor=K.+Toideauthor=Y.+Kita&title=Pharmacologic+investigation+of+the+mechanism+underlying+cold+allodynia+using+a+new+cold+plate+procedure+in+rats+with+chronic+constriction+injuries&doi=10.1097%2FFBP.0b013e3282f3d0a3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic investigation of the mechanism underlying cold allodynia using a new cold plate procedure in rats with chronic constriction injuries</span></div><div class="casAuthors">Tanimoto-Mori Sachi; Nakazato-Imasato Etsuko; Toide Katsuo; Kita Yasuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-90</span>
        ISSN:<span class="NLM_cas:issn">0955-8810</span>.
    </div><div class="casAbstract">Cold allodynia is a frequent clinical symptom of patients with neuropathic pain.  Despite numerous studies of cold allodynia, using animal models of neuropathic pain, little is known about its underlying mechanisms.  This study was performed to establish a method for the pharmacologic evaluation of cold allodynia using several analgesics in a chronic constriction injury (CCI) rat model of neuropathic pain.  Compared with the results obtained before the CCI operation, the CCI rats placed on a cork plate at 20 degrees C exhibited a slight change in the paw withdrawal latency because of the mechanical stimulus mediated by the injured paw touching the plate.  By contrast, there was a significant reduction in the paw withdrawal latency on a cold metal plate compared with that on the cork plate after the CCI surgery, with the maximum decrease occurring on postoperative day 7.  This reduction is thought to specifically reflect cold-induced pain behavior.  In addition, both naive and CCI rats showed behavioral changes at 5 and 0 degrees C, but not at 10 degrees C or higher.  Interestingly, a subcutaneous morphine dose of 6 mg/kg completely inhibited cold allodynia induced at 10 degrees C on postoperative day 7.  Under this condition, both the sodium channel blocker mexiletine (10 and 30 mg/kg, subcutaneously) and the calcium channel alpha2delta subunit blocker pregabalin (30 and 100 mg/kg, orally) significantly suppressed cold allodynia.  Additionally, both resiniferatoxin (0.3 mg/kg, subcutaneously), an ultrapotent analog of capsaicin that desensitizes C fibers, and the VR1 channel antagonist N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl) tetrahydropyrazine-1(2H)-carboxamide (10 and 30 mg/kg, orally) significantly prolonged the paw withdrawal latency.  In conclusion, our data suggest that the activation of C fibers mediates cold allodynia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTEIX4hFO5fykwlCcfExbvbfW6udTcc2ear_Cbe3nNmrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FktFamtg%253D%253D&md5=003742ed1772c4767dffcec6d4004753</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1097%2FFBP.0b013e3282f3d0a3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFBP.0b013e3282f3d0a3%26sid%3Dliteratum%253Aachs%26aulast%3DTanimoto-Mori%26aufirst%3DS.%26aulast%3DNakazato-Imasato%26aufirst%3DE.%26aulast%3DToide%26aufirst%3DK.%26aulast%3DKita%26aufirst%3DY.%26atitle%3DPharmacologic%2520investigation%2520of%2520the%2520mechanism%2520underlying%2520cold%2520allodynia%2520using%2520a%2520new%2520cold%2520plate%2520procedure%2520in%2520rats%2520with%2520chronic%2520constriction%2520injuries%26jtitle%3DBehav.%2520Pharmacol.%26date%3D2008%26volume%3D19%26spage%3D85%26epage%3D90%26doi%3D10.1097%2FFBP.0b013e3282f3d0a3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haranishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sata, T.</span></span> <span> </span><span class="NLM_article-title">Antinociceptive effect of intrathecal administration of taurine in rat models of neuropathic pain</span>. <i>Can. J. Anesth.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">630</span>– <span class="NLM_lpage">637</span>, <span class="refDoi"> DOI: 10.1007/s12630-011-9504-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1007%2Fs12630-011-9504-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=21512835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADC%252BC3MjltF2jsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2011&pages=630-637&author=T.+Teradaauthor=K.+Haraauthor=Y.+Haranishiauthor=T.+Sata&title=Antinociceptive+effect+of+intrathecal+administration+of+taurine+in+rat+models+of+neuropathic+pain&doi=10.1007%2Fs12630-011-9504-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Antinociceptive effect of intrathecal administration of taurine in rat models of neuropathic pain</span></div><div class="casAuthors">Terada Tadanori; Hara Koji; Haranishi Yasunori; Sata Takeyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Canadian journal of anaesthesia = Journal canadien d'anesthesie</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">630-637</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Taurine is the most abundant amino acid in many tissues.  Although taurine has been shown to be antinociceptive, in this report, our focus is to elucidate the mechanism and action site on neuropathic pain.  This study used behavioural assessments to determine whether taurine attenuates neuropathic pain in the spinal cord.  METHODS:  Chronic constriction injury (CCI) to the sciatic nerve and streptozotocin-induced diabetic neuropathy were introduced to male Sprague-Dawley rats.  We then assessed the antinociceptive effect of spinal injections of taurine (100, 200, 400, or 800 μg) using electronic von Frey, paw pressure, and plantar tests.  To explore the effect of taurine on motor function, a rotarod test was performed, and in order to determine which neurotransmitter pathway is involved in taurine's action, we examined how several antagonists of spinal pain processing receptors altered the effect of taurine 400 μg in a paw pressure test.  RESULTS:  Taurine alleviated mechanical allodynia, mechanical hyperalgesia, and thermal hyperalgesia in CCI rats and suppressed mechanical allodynia and hyperalgesia in diabetic rats.  Significant effects were observed at 200 μg in both models.  On the other hand, taurine dose-dependently affected motor performance, and a significant effect was seen at 400 μg.  The antinociceptive effects were reversed completely by pretreatment with an intrathecal injection of strychnine, a glycine receptor antagonist.  CONCLUSION:  The present study demonstrated that intrathecal administration of taurine attenuates different models of neuropathic pain, and these effects seem to be mediated by the activation of glycinergic neurotransmission.  These findings suggest that taurine may be a candidate remedy for neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRT_t63j72197FU0A1HOshhfW6udTcc2ear_Cbe3nNmrbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjltF2jsg%253D%253D&md5=2d56d55d412698026048aad5abb44359</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1007%2Fs12630-011-9504-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12630-011-9504-8%26sid%3Dliteratum%253Aachs%26aulast%3DTerada%26aufirst%3DT.%26aulast%3DHara%26aufirst%3DK.%26aulast%3DHaranishi%26aufirst%3DY.%26aulast%3DSata%26aufirst%3DT.%26atitle%3DAntinociceptive%2520effect%2520of%2520intrathecal%2520administration%2520of%2520taurine%2520in%2520rat%2520models%2520of%2520neuropathic%2520pain%26jtitle%3DCan.%2520J.%2520Anesth.%26date%3D2011%26volume%3D58%26spage%3D630%26epage%3D637%26doi%3D10.1007%2Fs12630-011-9504-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umland, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troutman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liston, T. E.</span></span> <span> </span><span class="NLM_article-title">Species independence in brain tissue binding using brain homogenates</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1270</span>– <span class="NLM_lpage">1277</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.038778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1124%2Fdmd.111.038778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=21474681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFWktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1270-1277&author=L.+Diauthor=J.+P.+Umlandauthor=G.+Changauthor=Y.+Huangauthor=Z.+Linauthor=D.+O.+Scottauthor=M.+D.+Troutmanauthor=T.+E.+Liston&title=Species+independence+in+brain+tissue+binding+using+brain+homogenates&doi=10.1124%2Fdmd.111.038778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Species independence in brain tissue binding using brain homogenates</span></div><div class="casAuthors">Di, Li; Umland, John P.; Chang, George; Huang, Youping; Lin, Zhen; Scott, Dennis O.; Troutman, Matthew D.; Liston, Theodore E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1270-1277</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Species independence of brain tissue binding was assessed with a large no. of structurally diverse compds. using equil. dialysis with brain homogenates of seven species and strains (Wistar Han rat, Sprague-Dawley rat, CD-1 mouse, Hartley guinea pig, beagle dog, cynomolgus monkey, and human).  The results showed that the fractions unbound of the seven species and strains were strongly correlated with correlation coeffs. ranging from 0.93 to 0.99.  The cross-species/strain correlations were not significantly different from the interassay correlation with the same species.  The linear correlation between Wistar Han and other species had a slope close to 1 and an intercept near 0.  Based on orthogonal statistical anal., no correction is needed for extrapolation of fraction unbound from Wistar Han rat to the other species or strains.  Hence, brain tissue binding of Wistar Han rat can be used to obtain binding of other species and strains in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoub4FiLWkAFrVg90H21EOLACvtfcHk0lgtJ5YHotDjqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFWktrg%253D&md5=93a51addedb22de4648e6e5ee39c6c81</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.038778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.038778%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DUmland%26aufirst%3DJ.%2BP.%26aulast%3DChang%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DScott%26aufirst%3DD.%2BO.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26aulast%3DListon%26aufirst%3DT.%2BE.%26atitle%3DSpecies%2520independence%2520in%2520brain%2520tissue%2520binding%2520using%2520brain%2520homogenates%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1270%26epage%3D1277%26doi%3D10.1124%2Fdmd.111.038778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span> <span> </span><span class="NLM_article-title">Brain regional pharmacokinetics of <i>p</i>-aminosalicylic acid and its <i>N</i>-acetylated metabolite: effectiveness in chelating brain manganese</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1904</span>– <span class="NLM_lpage">1909</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.040915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1124%2Fdmd.111.040915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=21768272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ekurbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1904-1909&author=L.+Hongauthor=W.+Jiangauthor=H.+Panauthor=Y.+Jiangauthor=S.+Zengauthor=W.+Zheng&title=Brain+regional+pharmacokinetics+of+p-aminosalicylic+acid+and+its+N-acetylated+metabolite%3A+effectiveness+in+chelating+brain+manganese&doi=10.1124%2Fdmd.111.040915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Brain regional pharmacokinetics of p-aminosalicylic acid and its N-acetylated metabolite: effectiveness in chelating brain manganese</span></div><div class="casAuthors">Hong, Lan; Jiang, Wendy; Pan, Hao; Jiang, Yueming; Zeng, Su; Zheng, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1904-1909</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Para-Aminosalicylic acid (PAS; 4-amino-2-hydroxybenzoic acid), an antituberculosis drug in use since the 1950s, has recently been suggested to be an effective agent for treatment of manganese-induced parkinsonian disorders.  However, the neuropharmacokinetics of PAS and its metabolite N-acetyl-para-aminosalicylic acid (AcPAS; N-acetyl-4-amino-2-hydroxybenzoic acid) are unknown.  This study was designed to investigate the pharmacokinetics of PAS and its distribution in brain to help better design the dosing regimen for clin. trials.  Male Sprague-Dawley rats received single femoral artery injections of PAS (200 mg/kg).  Plasma, cerebrospinal fluid, and brain tissues were collected, and PAS and AcPAS concns. were quantified by high-performance liq. chromatog.  After administration, the concns. of PAS declined rapidly in plasma with an elimination t1/2 of 34 min; the metabolite AcPAS was detected in plasma and eliminated with a t1/2 of 147 min.  PAS and AcPAS were detected in brain tissues; AcPAS had a much higher tissue concn. and a longer t1/2 than the parent PAS in most tissues examd.  Although both were present in blood or tissues as free, unbound mols., AcPAS appeared to have a higher tissue affinity than PAS.  Taken together, our results suggest that a dosing regimen with continuous i.v. infusion of PAS is necessary to achieve therapeutic levels in targeted brain regions.  Furthermore, PAS and AcPAS seem to be effective in reducing manganese levels in brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwuBKpN5kMorVg90H21EOLACvtfcHk0lgtJ5YHotDjqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ekurbJ&md5=ed26d7985eca98970902ae8812815f8e</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.040915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.040915%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DPan%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DW.%26atitle%3DBrain%2520regional%2520pharmacokinetics%2520of%2520p-aminosalicylic%2520acid%2520and%2520its%2520N-acetylated%2520metabolite%253A%2520effectiveness%2520in%2520chelating%2520brain%2520manganese%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1904%26epage%3D1909%26doi%3D10.1124%2Fdmd.111.040915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pabst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hörsten, S.</span></span> <span> </span><span class="NLM_article-title">Behavioral phenotyping of mice in pharmacological and toxicological research</span>. <i>Exp. Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1078/0940-2993-00301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1078%2F0940-2993-00301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=12940631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADC%252BD3svgtF2jtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2003&pages=69-83&author=T.+Karlauthor=R.+Pabstauthor=S.+van+H%C3%B6rsten&title=Behavioral+phenotyping+of+mice+in+pharmacological+and+toxicological+research&doi=10.1078%2F0940-2993-00301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioral phenotyping of mice in pharmacological and toxicological research</span></div><div class="casAuthors">Karl Tim; Pabst Reinhard; von Horsten Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-83</span>
        ISSN:<span class="NLM_cas:issn">0940-2993</span>.
    </div><div class="casAbstract">The evaluation of behavioral effects is an important component for the in vivo screening of drugs or potentially toxic compounds in mice.  Ideally, such screening should be composed of monitoring general health, sensory functions, and motor abilities, right before specific behavioral domains are tested.  A rational strategy in the design and procedure of testing as well as an effective composition of different well-established and reproducible behavioral tests can minimize the risk of false positive and false negative results in drug screening.  In the present review we describe such basic considerations in planning experiments, selecting strains of mice, and propose groups of behavioral tasks suitable for a reliable detection of differences in specific behavioral domains in mice.  Screening of general health and neurophysiologic functions (reflexes, sensory abilities) and motor function (pole test, wire hang test, beam walking, rotarod, accelerod, and footprint) as well as specific hypothesis-guided testing in the behavioral domains of learning and memory (water maze, radial maze, conditioned fear, and avoidance tasks), emotionality (open field, hole board, elevated plus maze, and object exploration), nociception (tail flick, hot plate), psychiatric-like conditions (porsolt swim test, acoustic startle response, and prepulse inhibition), and aggression (isolation-induced aggression, spontaneous aggression, and territorial aggression) are described in further detail.  This review is designed to describe a general approach, which increases reliability of behavioral screening.  Furthermore, it provides an overview on a selection of specific procedures suitable for but not limited to behavioral screening in pharmacology and toxicology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRS5l4UT704azEwO064Z95rfW6udTcc2eaZ8AOQ2piei7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svgtF2jtw%253D%253D&md5=90cc625f983720eb940c43660245af3c</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1078%2F0940-2993-00301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1078%252F0940-2993-00301%26sid%3Dliteratum%253Aachs%26aulast%3DKarl%26aufirst%3DT.%26aulast%3DPabst%26aufirst%3DR.%26aulast%3Dvan%2BH%25C3%25B6rsten%26aufirst%3DS.%26atitle%3DBehavioral%2520phenotyping%2520of%2520mice%2520in%2520pharmacological%2520and%2520toxicological%2520research%26jtitle%3DExp.%2520Toxicol.%2520Pathol.%26date%3D2003%26volume%3D55%26spage%3D69%26epage%3D83%26doi%3D10.1078%2F0940-2993-00301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shuman, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omstein, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paschal, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gesellchen, P. D.</span></span> <span> </span><span class="NLM_article-title">An improved synthesis of homoproline and derivatives</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">738</span>– <span class="NLM_lpage">741</span>, <span class="refDoi"> DOI: 10.1021/jo00289a058</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00289a058" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADyaK3cXls1eqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1990&pages=738-741&author=R.+T.+Shumanauthor=P.+L.+Omsteinauthor=J.+W.+Paschalauthor=P.+D.+Gesellchen&title=An+improved+synthesis+of+homoproline+and+derivatives&doi=10.1021%2Fjo00289a058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">An improved synthesis of homoproline and derivatives</span></div><div class="casAuthors">Shuman, Robert T.; Ornstein, Paul L.; Paschal, Jonathan W.; Gesellchen, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">738-41</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">Homoproline derivs. I (R = 3-Me, 4-Me, 6-Me, 4-Et, 4-OMe, 4-CMe3) were prepd. from the corresponding pyridines II in 4 steps.  A key step was the treatment of N-oxides III (R = same) with Me3SiCN and Me2NCOCl in CH2Cl2 to give nitriles IV (R = same).  5,6-Benzohomoprolines V (R1 = H, Me) were also prepd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC2ygcm4nNZrVg90H21EOLACvtfcHk0lha5ECBS602VQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXls1eqtg%253D%253D&md5=0a4c88f7f1c4a3c1e98f033e5df6a7bd</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjo00289a058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00289a058%26sid%3Dliteratum%253Aachs%26aulast%3DShuman%26aufirst%3DR.%2BT.%26aulast%3DOmstein%26aufirst%3DP.%2BL.%26aulast%3DPaschal%26aufirst%3DJ.%2BW.%26aulast%3DGesellchen%26aufirst%3DP.%2BD.%26atitle%3DAn%2520improved%2520synthesis%2520of%2520homoproline%2520and%2520derivatives%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1990%26volume%3D55%26spage%3D738%26epage%3D741%26doi%3D10.1021%2Fjo00289a058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">and references cited therein</p></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sreedhar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiva Kumar, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubrahmanyam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkanna, G. T.</span></span> <span> </span><span class="NLM_article-title">CuI/L-histidine catalyzed <i>N</i>-arylation of heterocycles</span>. <i>J. Mol. Catal. A: Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>265</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1016/j.molcata.2006.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2Fj.molcata.2006.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis1Oqu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=2007&pages=183-185&author=B.+Sreedharauthor=K.+B.+Shiva+Kumarauthor=P.+Srinivasauthor=V.+Balasubrahmanyamauthor=G.+T.+Venkanna&title=CuI%2FL-histidine+catalyzed+N-arylation+of+heterocycles&doi=10.1016%2Fj.molcata.2006.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">CuI/L-histidine catalyzed N-arylation of heterocycles</span></div><div class="casAuthors">Sreedhar, B.; Shiva Kumar, K. B.; Srinivas, P.; Balasubrahmanyam, V.; Venkanna, G. T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Catalysis A: Chemical</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">265</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">183-185</span>CODEN:
                <span class="NLM_cas:coden">JMCCF2</span>;
        ISSN:<span class="NLM_cas:issn">1381-1169</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">CuI/L-histidine is an effective catalyst for N-arylation of heterocycles, using K2CO3 as base in DMSO solvent.  N-Arylated products were isolated in good to excellent yields, demonstrating the versatility of the reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtKByHHZyCkbVg90H21EOLACvtfcHk0lha5ECBS602VQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis1Oqu7g%253D&md5=aca04bbec7c03e4824c363f335d948ea</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.molcata.2006.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcata.2006.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DSreedhar%26aufirst%3DB.%26aulast%3DShiva%2BKumar%26aufirst%3DK.%2BB.%26aulast%3DSrinivas%26aufirst%3DP.%26aulast%3DBalasubrahmanyam%26aufirst%3DV.%26aulast%3DVenkanna%26aufirst%3DG.%2BT.%26atitle%3DCuI%252FL-histidine%2520catalyzed%2520N-arylation%2520of%2520heterocycles%26jtitle%3DJ.%2520Mol.%2520Catal.%2520A%253A%2520Chem.%26date%3D2007%26volume%3D265%26spage%3D183%26epage%3D185%26doi%3D10.1016%2Fj.molcata.2006.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="note"><p class="first last">Compound <b>85</b> was prepared according to the method described in:</p></div><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paone, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginnetti, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreher, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgey, C. S.</span></span> <span> </span><span class="NLM_article-title">Copper-facilitated Suzuki reactions: application to 2-heterocyclic boronates</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">347</span>, <span class="refDoi"> DOI: 10.1021/ol802556f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol802556f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFWqsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=345-347&author=J.+Z.+Dengauthor=D.+V.+Paoneauthor=A.+T.+Ginnettiauthor=H.+Kuriharaauthor=S.+D.+Dreherauthor=S.+A.+Weissmanauthor=S.+R.+Staufferauthor=C.+S.+Burgey&title=Copper-facilitated+Suzuki+reactions%3A+application+to+2-heterocyclic+boronates&doi=10.1021%2Fol802556f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Copper-Facilitated Suzuki Reactions: Application to 2-Heterocyclic Boronates</span></div><div class="casAuthors">Deng, James Z.; Paone, Daniel V.; Ginnetti, Anthony T.; Kurihara, Hideki; Dreher, Spencer D.; Weissman, Steven A.; Stauffer, Shaun R.; Burgey, Christopher S.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">345-347</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The palladium-catalyzed Suzuki-Miyaura reaction has been utilized as one of the most powerful methods for C-C bond formation.  However, Suzuki reactions of electron-deficient 2-heterocyclic boronates generally give low conversions and remain challenging.  The successful copper(I) facilitated Suzuki coupling of 2-heterocyclic boronates that is broad in scope is reported.  Use of this methodol. affords greatly enhanced yields of these notoriously difficult couplings.  E.g., reaction of 2-heterocyclic boronate I and 4-IC6H4Ph in presence of Pd(OAc)2, dppf, and CuCl gave 89% pyridine deriv. II.  Furthermore, mechanistic investigations suggest a possible role of copper in the catalytic cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo10K3bNpyQq7Vg90H21EOLACvtfcHk0lha5ECBS602VQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFWqsrvI&md5=da568b6dd09940f183fe8c331db88734</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fol802556f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol802556f%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DJ.%2BZ.%26aulast%3DPaone%26aufirst%3DD.%2BV.%26aulast%3DGinnetti%26aufirst%3DA.%2BT.%26aulast%3DKurihara%26aufirst%3DH.%26aulast%3DDreher%26aufirst%3DS.%2BD.%26aulast%3DWeissman%26aufirst%3DS.%2BA.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26aulast%3DBurgey%26aufirst%3DC.%2BS.%26atitle%3DCopper-facilitated%2520Suzuki%2520reactions%253A%2520application%2520to%25202-heterocyclic%2520boronates%26jtitle%3DOrg.%2520Lett.%26date%3D2009%26volume%3D11%26spage%3D345%26epage%3D347%26doi%3D10.1021%2Fol802556f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwanowicz, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murali
Dhar, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleener, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouleau, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheney, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenbaugh, D. L.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of inosine monophosphate dehydrogenase: SARs about the <i>N</i>-3-methoxy-4-(5-oxazolyl)phenyl moiety</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2059</span>– <span class="NLM_lpage">2063</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(03)00258-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2FS0960-894X%2803%2900258-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=12781195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktVGqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=2059-2063&author=E.+J.+Iwanowiczauthor=S.+H.+Wattersonauthor=J.+Guoauthor=W.+J.+Pittsauthor=T.+G.+Murali%0ADharauthor=Z.+Shenauthor=P.+Chenauthor=H.+H.+Guauthor=C.+A.+Fleenerauthor=K.+A.+Rouleauauthor=D.+L.+Cheneyauthor=R.+M.+Townsendauthor=D.+L.+Hollenbaugh&title=Inhibitors+of+inosine+monophosphate+dehydrogenase%3A+SARs+about+the+N-3-methoxy-4-%285-oxazolyl%29phenyl+moiety&doi=10.1016%2FS0960-894X%2803%2900258-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of inosine monophosphate dehydrogenase: SARs about the N-[3-Methoxy-4-(5-oxazolyl)phenyl] moiety</span></div><div class="casAuthors">Iwanowicz, Edwin J.; Watterson, Scott H.; Guo, Junqing; Pitts, William J.; Murali Dhar, T. G.; Shen, Zhongqi; Chen, Ping; Gu, Henry H.; Fleener, Catherine A.; Rouleau, Katherine A.; Cheney, Daniel L.; Townsend, Robert M.; Hollenbaugh, Diane L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2059-2063</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The first reported structure-activity relationships (SARs) about the N-[3-methoxy-4-(5-oxazolyl)phenyl] moiety for a series of recently disclosed inosine monophosphate dehydrogenase (IMPDH) inhibitors are described.  The syntheses and in vitro inhibitory values for IMPDH II, and T-cell proliferation (for select analogs) are given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR1qsIn2bQ5rVg90H21EOLACvtfcHk0liqNK-tXGa3Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktVGqtrc%253D&md5=7ac330eb05076313669d1a6ba866d19c</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2803%2900258-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252803%252900258-0%26sid%3Dliteratum%253Aachs%26aulast%3DIwanowicz%26aufirst%3DE.%2BJ.%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26aulast%3DMurali%2BDhar%26aufirst%3DT.%2BG.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DGu%26aufirst%3DH.%2BH.%26aulast%3DFleener%26aufirst%3DC.%2BA.%26aulast%3DRouleau%26aufirst%3DK.%2BA.%26aulast%3DCheney%26aufirst%3DD.%2BL.%26aulast%3DTownsend%26aufirst%3DR.%2BM.%26aulast%3DHollenbaugh%26aufirst%3DD.%2BL.%26atitle%3DInhibitors%2520of%2520inosine%2520monophosphate%2520dehydrogenase%253A%2520SARs%2520about%2520the%2520N-3-methoxy-4-%25285-oxazolyl%2529phenyl%2520moiety%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D2059%26epage%3D2063%26doi%3D10.1016%2FS0960-894X%2803%2900258-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, R.</span></span> <span> </span><span class="NLM_article-title"><i>p</i>-Nitrobenzaldehyde</span>. <i>Org. Syn. Collect.</i> <span class="NLM_year" style="font-weight: bold;">1943</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">443</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1943&pages=441-443&author=S.+V.+Liebermanauthor=R.+Connor&title=p-Nitrobenzaldehyde"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLieberman%26aufirst%3DS.%2BV.%26aulast%3DConnor%26aufirst%3DR.%26atitle%3Dp-Nitrobenzaldehyde%26jtitle%3DOrg.%2520Syn.%2520Collect.%26date%3D1943%26volume%3D2%26spage%3D441%26epage%3D443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cassayre, J. Y.</span>; <span class="NLM_string-name">Pitterna, T.</span>; <span class="NLM_string-name">Corsi, C.</span>; <span class="NLM_string-name">Maienfisch, P.</span></span> <span> </span><span class="NLM_article-title">Insecticidal compounds</span>. World Patent Appl. <span class="NLM_patent">WO 2011/3684 A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+Y.+Cassayre&author=T.+Pitterna&author=C.+Corsi&author=P.+Maienfisch&title=Insecticidal+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCassayre%26aufirst%3DJ.%2BY.%26atitle%3DInsecticidal%2520compounds%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="note"><p class="first last">See reference <a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Supporting Information for additional in vitro assay details.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kieltyka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vath, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baglieri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvyaga, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drexler, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shou, W. Z.</span></span> <span> </span><span class="NLM_article-title">A high throughput bioanalytical platform using automated infusion for tandem mass spectrometric method optimization and its application in a metabolic stability screen</span>. <i>Rapid Commun. Mass Spectrom.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1579</span>– <span class="NLM_lpage">1591</span>, <span class="refDoi"> DOI: 10.1002/rcm.4037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1002%2Frcm.4037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=19399765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVKmt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=1579-1591&author=K.+Kieltykaauthor=J.+Zhangauthor=S.+Liauthor=M.+Vathauthor=C.+Baglieriauthor=C.+Ferraroauthor=T.+A.+Zvyagaauthor=D.+M.+Drexlerauthor=H.+N.+Wellerauthor=W.+Z.+Shou&title=A+high+throughput+bioanalytical+platform+using+automated+infusion+for+tandem+mass+spectrometric+method+optimization+and+its+application+in+a+metabolic+stability+screen&doi=10.1002%2Frcm.4037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">A high-throughput bioanalytical platform using automated infusion for tandem mass spectrometric method optimization and its application in a metabolic stability screen</span></div><div class="casAuthors">Kieltyka, Kasia; Zhang, Jun; Li, Shu; Vath, Marianne; Baglieri, Chris; Ferraro, Cheryl; Zvyaga, Tatyana A.; Drexler, Dieter M.; Weller, Harold N.; Shou, Wilson Z.</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1579-1591</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Liq. chromatog./tandem mass spectrometry (LC/MS/MS) is the bioanal. method of choice to support plate-based, in vitro early ADME (Absorption, Distribution, Metab. and Excretion) screens such as metabolic stability (Metstab) assessment.  MS/MS method optimization has historically been the bottleneck in this environment, where samples from thousands of discrete compds. are analyzed on a monthly basis, mainly due to the lack of a high-quality com. available platform to handle the necessary MS/MS method optimization steps for sample anal. by selected reaction monitoring (SRM) on triple quadrupole mass spectrometers.  To address this challenge, we recently developed a highly automated bioanal. platform by successfully integrating QuickQuan 2.0, a unique high-throughput soln. featuring MS/MS method optimization by automated infusion, with a customized inhouse software tool in support of a Metstab screen.  In this platform, a dual-column setup running parallel chromatog. was also implemented to reduce the bioanal. cycle time for LC/MS/MS sample anal.  A set of 45 validation compds. was used to demonstrate the speed, quality and reproducibility of MS/MS method optimization, sample anal., and data processing using this automated platform.  Metstab results for the validation compds. in microsomes from multiple species (human, rat, mouse) showed good consistency within each batch, and also between batches conducted on different days.  We have achieved and maintained a monthly throughput of 1300 compd. assays representing 500 discrete compds. per instrument per mo on this platform, and it has been used to generate metabolic stability data for more than 25 000 compds. to date with an overall success rate of more than 95%.  Copyright © 2009 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8W1PNTqYnALVg90H21EOLACvtfcHk0liqNK-tXGa3Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVKmt70%253D&md5=57977322942dc41955c1d9cf015e5b05</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1002%2Frcm.4037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.4037%26sid%3Dliteratum%253Aachs%26aulast%3DKieltyka%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DVath%26aufirst%3DM.%26aulast%3DBaglieri%26aufirst%3DC.%26aulast%3DFerraro%26aufirst%3DC.%26aulast%3DZvyaga%26aufirst%3DT.%2BA.%26aulast%3DDrexler%26aufirst%3DD.%2BM.%26aulast%3DWeller%26aufirst%3DH.%2BN.%26aulast%3DShou%26aufirst%3DW.%2BZ.%26atitle%3DA%2520high%2520throughput%2520bioanalytical%2520platform%2520using%2520automated%2520infusion%2520for%2520tandem%2520mass%2520spectrometric%2520method%2520optimization%2520and%2520its%2520application%2520in%2520a%2520metabolic%2520stability%2520screen%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2009%26volume%3D23%26spage%3D1579%26epage%3D1591%26doi%3D10.1002%2Frcm.4037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paiva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, H.</span></span> <span> </span><span class="NLM_article-title">Addition of optimized bovine serum albumin level in a high-throughput Caco-2 assay enabled accurate permeability assessment for lipophilic compounds</span>. <i>SLAS Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">738</span>– <span class="NLM_lpage">744</span>, <span class="refDoi"> DOI: 10.1177/2472555219848483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1177%2F2472555219848483" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=31076010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFams7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=738-744&author=X.+Caiauthor=S.+Madariauthor=A.+Walkerauthor=A.+Paivaauthor=Y.+Liauthor=J.+Herbstauthor=W.+Shouauthor=H.+Weller&title=Addition+of+optimized+bovine+serum+albumin+level+in+a+high-throughput+Caco-2+assay+enabled+accurate+permeability+assessment+for+lipophilic+compounds&doi=10.1177%2F2472555219848483"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Addition of Optimized Bovine Serum Albumin Level in a High-Throughput Caco-2 Assay Enabled Accurate Permeability Assessment for Lipophilic Compounds</span></div><div class="casAuthors">Cai, Xianmei; Madari, Shilpa; Walker, Aaron; Paiva, Anthony; Li, Ying; Herbst, John; Shou, Wilson; Weller, Harold</div><div class="citationInfo"><span class="NLM_cas:title">SLAS Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">738-744</span>CODEN:
                <span class="NLM_cas:coden">SDLIBT</span>;
        ISSN:<span class="NLM_cas:issn">2472-5560</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The Caco-2 permeability assay is a well-accepted in vitro model to evaluate compds.' potential for oral absorption at early discovery.  However, for many lipophilic compds., no meaningful Caco-2 data could be generated due to their low soly. in assay buffer and/or poor recovery from the assay.  In our previous study, we reported an org. catch approach to improve compd. recovery.  To further reduce compd. loss and increase soly. in aq. buffer, we explored the addn. of bovine serum albumin (BSA).  However, in contrast to the commonly used BSA level at 4%, a lower level of BSA was selected in an effort to minimize the potential risk of missing the identification of efflux substrates, and to avoid the extensive sample cleanup needed for 4% BSA.  Through a systematic evaluation, it was found that 0.5% BSA was effective in enhancing compd. soly. and reducing nonspecific binding, which allowed reliable assessment of the permeability and efflux potential for lipophilic compds.  Also, with an optimized sample handling process, no extra sample cleanup was required before liq. chromatog.-mass spectrometry (LC-MS) anal.  The implementation of this assay has enabled accurate permeability assessment for compds. that had poor soly. and/or poor mass balance under the non-BSA assay conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWB9jtL5enBrVg90H21EOLACvtfcHk0liqNK-tXGa3Rg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFams7rJ&md5=f5cad97c5d624a513f88887eaefb2b73</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1177%2F2472555219848483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2472555219848483%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DMadari%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DA.%26aulast%3DPaiva%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHerbst%26aufirst%3DJ.%26aulast%3DShou%26aufirst%3DW.%26aulast%3DWeller%26aufirst%3DH.%26atitle%3DAddition%2520of%2520optimized%2520bovine%2520serum%2520albumin%2520level%2520in%2520a%2520high-throughput%2520Caco-2%2520assay%2520enabled%2520accurate%2520permeability%2520assessment%2520for%2520lipophilic%2520compounds%26jtitle%3DSLAS%2520Discovery%26date%3D2019%26volume%3D24%26spage%3D738%26epage%3D744%26doi%3D10.1177%2F2472555219848483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paiva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, H.</span></span> <span> </span><span class="NLM_article-title">Approach to improve compound recovery in a high-throughput Caco-2 permeability assay supported by liquid chromatography–tandem mass spectrometry</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">2755</span>– <span class="NLM_lpage">2762</span>, <span class="refDoi"> DOI: 10.1002/jps.23194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1002%2Fjps.23194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=22611052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1Cgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2012&pages=2755-2762&author=X.+Caiauthor=A.+Walkerauthor=C.+Chengauthor=A.+Paivaauthor=Y.+Liauthor=J.+Kolbauthor=J.+Herbstauthor=W.+Shouauthor=H.+Weller&title=Approach+to+improve+compound+recovery+in+a+high-throughput+Caco-2+permeability+assay+supported+by+liquid+chromatography%E2%80%93tandem+mass+spectrometry&doi=10.1002%2Fjps.23194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Approach to improve compound recovery in a high-throughput Caco-2 permeability assay supported by liquid chromatography-tandem mass spectrometry</span></div><div class="casAuthors">Cai, Xianmei; Walker, Aaron; Cheng, Charles; Paiva, Anthony; Li, Ying; Kolb, Janet; Herbst, John; Shou, Wilson; Weller, Harold</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2755-2762</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The Caco-2 cell culture system is widely employed as an in vitro model for prediction of intestinal absorption of test compds. in early drug discovery.  Poor recovery is a commonly encountered issue in Caco-2 assay, which can lead to difficulty in data interpretation and underestimation of the apparent permeability of affected compds.  In this study, we systematically investigated the potential sources of compd. loss in our automated, high-throughput Caco-2 assay, sample storage, and anal. processes, and as a result found the nonspecific binding to various plastic surfaces to be the major cause of poor compd. recovery.  To minimize the nonspecific binding, we implemented a simple and practical approach in our assay automation by preloading collection plates with org. solvent contg. internal std. prior to transferring incubations samples.  The implementation of this new method has been shown to significantly increase recovery in many compds. previously identified as having poor recovery in the Caco-2 permeability assay.  With improved recovery, permeability results were obtained for many compds. that were previously not detected in the basolateral samples.  In addn. to recovery improvement, this new approach also simplified sample prepn. for liq. chromatog.-tandem mass spectrometric anal. and therefore achieved time and cost savings for the bioanalyst. © 2012 Wiley Periodicals, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3d7jZyPfxPLVg90H21EOLACvtfcHk0liL3MBzZX26VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1Cgu70%253D&md5=16cfacab071344c98a95dc8c6f4483af</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1002%2Fjps.23194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.23194%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DWalker%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DPaiva%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DKolb%26aufirst%3DJ.%26aulast%3DHerbst%26aufirst%3DJ.%26aulast%3DShou%26aufirst%3DW.%26aulast%3DWeller%26aufirst%3DH.%26atitle%3DApproach%2520to%2520improve%2520compound%2520recovery%2520in%2520a%2520high-throughput%2520Caco-2%2520permeability%2520assay%2520supported%2520by%2520liquid%2520chromatography%25E2%2580%2593tandem%2520mass%2520spectrometry%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2012%26volume%3D101%26spage%3D2755%26epage%3D2762%26doi%3D10.1002%2Fjps.23194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duke, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newitt, J. A.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">705</span>– <span class="NLM_lpage">710</span>, <span class="refDoi"> DOI: 10.1107/S0907444908010032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1107%2FS0907444908010032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntlCrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2008&pages=705-710&author=J.+S.+Sackauthor=K.+F.+Kishauthor=M.+Pokrossauthor=D.+Xieauthor=G.+J.+Dukeauthor=J.+A.+Tredupauthor=S.+E.+Kieferauthor=J.+A.+Newitt&title=Structural+basis+for+the+high-affinity+binding+of+pyrrolotriazine+inhibitors+of+p38+MAP+kinase&doi=10.1107%2FS0907444908010032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase</span></div><div class="casAuthors">Sack, John S.; Kish, Kevin F.; Pokross, Matthew; Xie, Dianlin; Duke, Gerald J.; Tredup, Jeffrey A.; Kiefer, Susan E.; Newitt, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">705-710, S705/1</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The crystal structure of unphosphorylated p38α MAP kinase complexed with a representative pyrrolotriazine-based inhibitor led to the elucidation of the high-affinity binding mode of this class of compds. at the ATP-binding site.  The ligand binds in an extended conformation, with one end interacting with the adenine-pocket hinge region, including a hydrogen bond from the carboxyl O atom of Met-109.  The other end of the ligand interacts with the hydrophobic pocket of the binding site and with the backbone N atom of Asp-168 in the DFG activation loop.  Addn. of an extended benzylmorpholine group forces the DFG loop to flip out of position and allows the ligand to make addnl. interactions with the protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA3XUI3FjZC7Vg90H21EOLACvtfcHk0liL3MBzZX26VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntlCrsLg%253D&md5=a3d643539a2c89187e9bf4faf842f3c2</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1107%2FS0907444908010032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444908010032%26sid%3Dliteratum%253Aachs%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DKish%26aufirst%3DK.%2BF.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DDuke%26aufirst%3DG.%2BJ.%26aulast%3DTredup%26aufirst%3DJ.%2BA.%26aulast%3DKiefer%26aufirst%3DS.%2BE.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26atitle%3DStructural%2520basis%2520for%2520the%2520high-affinity%2520binding%2520of%2520pyrrolotriazine%2520inhibitors%2520of%2520p38%2520MAP%2520kinase%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2008%26volume%3D64%26spage%3D705%26epage%3D710%26doi%3D10.1107%2FS0907444908010032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="note"><p class="first last">Compound <b>112</b> is Example 9 in</p></div><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dzierba, C. D.</span>; <span class="NLM_string-name">Dasgupta, B.</span>; <span class="NLM_string-name">Macor, J. E.</span>; <span class="NLM_string-name">Bronson, J.</span>; <span class="NLM_string-name">Rajamani, R.</span>; <span class="NLM_string-name">Karageorge, G. N.</span></span> <span> </span><span class="NLM_article-title">Pyrrolotriazine kinase inhibitors</span>. World Patent Appl. <span class="NLM_patent">WO 2015/054358 A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=C.+D.+Dzierba&author=B.+Dasgupta&author=J.+E.+Macor&author=J.+Bronson&author=R.+Rajamani&author=G.+N.+Karageorge&title=Pyrrolotriazine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDzierba%26aufirst%3DC.%2BD.%26atitle%3DPyrrolotriazine%2520kinase%2520inhibitors%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storoni, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span> <span> </span><span class="NLM_article-title">Phaser crystallographic software</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0liL3MBzZX26VA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="note"><p class="first last">The compound used as an internal standard was Example 6a in</p></div><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vrudhula, V. M.</span>; <span class="NLM_string-name">Pan, Senliang</span>; <span class="NLM_string-name">Rajamani, R.</span>; <span class="NLM_string-name">Macor, J. E.</span>; <span class="NLM_string-name">Bronson, J. J.</span>; <span class="NLM_string-name">Dzierba, C. D.</span>; <span class="NLM_string-name">Nara, S. J.</span>; <span class="NLM_string-name">Karatholuvhu, M. S.</span></span> <span> </span><span class="NLM_article-title">Aryl ether-base kinase inhibitors</span>. World Patent Appl. <span class="NLM_patent">WO 2013/134036 A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=V.+M.+Vrudhula&author=Senliang+Pan&author=R.+Rajamani&author=J.+E.+Macor&author=J.+J.+Bronson&author=C.+D.+Dzierba&author=S.+J.+Nara&author=M.+S.+Karatholuvhu&title=Aryl+ether-base+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVrudhula%26aufirst%3DV.%2BM.%26atitle%3DAryl%2520ether-base%2520kinase%2520inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler-Aceto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, A.</span></span> <span> </span><span class="NLM_article-title">Standardization of the rat paw formalin test for the evaluation of analgesics</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1007/BF02244551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1007%2FBF02244551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1882002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADyaK3MXkt1Wms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1991&pages=35-44&author=H.+Wheeler-Acetoauthor=A.+Cowan&title=Standardization+of+the+rat+paw+formalin+test+for+the+evaluation+of+analgesics&doi=10.1007%2FBF02244551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Standardization of the rat paw formalin test for the evaluation of analgesics</span></div><div class="casAuthors">Wheeler-Aceto, Helen; Cowan, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-44</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    </div><div class="casAbstract">Administration of 5% formalin into the rat or guinea pig hind paw evokes two spontaneous responses: flinching/shaking and licking/biting of the injected paw.  The temporal and behavioral characteristics of these objective endpoints are described.  Addnl., several practical suggestions aimed at standardizing this test for the evaluation of analgesics are presented.  The early/acute and late/tonic (0-10 and 20-35 min post-formalin, resp.) phases of flinching were used to quantitate antinociception in the rat.  PD 117302, the kappa selective agonist, was three times more potent than morphine against tonic flinching after s.c. administration.  Formalin may therefore be a noxious stimulus of choice in the evaluation of kappa agonists.  Morphine was only twice as potent against tonic flinching as against acute flinching or the tail-dip reflex to water (50°).  In contrast, PD 117302 was 27 times less potent on early phase and was inactive in the tail-dip test.  Thus, while morphine is essentially equipotent across tests, PD 117302 shows a spectrum of activity with impressive potency and efficacy being obtained against tonic pain.  Kappa receptors may therefore be prominently involved in tonic pain states.  Aspirin given orally was not consistently antinociceptive in either phase of the formalin test.  Spinal transection completely abolished late phase responding but only partly attenuated flinching in the early phase.  This suggests that the relative involvement of spinal (as opposed to supraspinal) processing of noxious inputs may, at least in part, be a function of stimulus intensity and underlie the differences in antinociceptive potency obsd. in this work.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqddB-QBhf6z7Vg90H21EOLACvtfcHk0lgnfo4z7CD3JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXkt1Wms7Y%253D&md5=8516037add46a95f4b55c733b7f0db48</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1007%2FBF02244551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02244551%26sid%3Dliteratum%253Aachs%26aulast%3DWheeler-Aceto%26aufirst%3DH.%26aulast%3DCowan%26aufirst%3DA.%26atitle%3DStandardization%2520of%2520the%2520rat%2520paw%2520formalin%2520test%2520for%2520the%2520evaluation%2520of%2520analgesics%26jtitle%3DPsychopharmacology%26date%3D1991%26volume%3D104%26spage%3D35%26epage%3D44%26doi%3D10.1007%2FBF02244551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimoyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorman, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inturrisi, C. E.</span></span> <span> </span><span class="NLM_article-title">Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite, norketamine</span>. <i>Pain.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/S0304-3959(98)00269-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2FS0304-3959%2898%2900269-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10353496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADyaK1MXjtFajsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1999&pages=85-93&author=M.+Shimoyamaauthor=N.+Shimoyamaauthor=L.+A.+Gormanauthor=K.+J.+Elliottauthor=C.+E.+Inturrisi&title=Oral+ketamine+is+antinociceptive+in+the+rat+formalin+test%3A+role+of+the+metabolite%2C+norketamine&doi=10.1016%2FS0304-3959%2898%2900269-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite, norketamine</span></div><div class="casAuthors">Shimoyama, Megumi; Shimoyama, Naohito; Gorman, A. Laurel; Elliott, Kathryn J.; Inturrisi, Charles E.</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">85-93</span>CODEN:
                <span class="NLM_cas:coden">PAINDB</span>;
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The present study was designed to evaluate the oral efficacy and bioavailability of ketamine.  Antinociceptive efficacy was detd. with the rat formalin test and oral bioavailability by the measurement of plasma and brain concns. of ketamine and its major metabolite, norketamine.  Oral ketamine in a dose range from 30 to 180 mg/kg or saline was given prior to intraplantar formalin and the flinching behavior was measured.  Oral ketamine dose-dependently reduced the flinching during phase 2, while flinching during phase 1 was reduced only with the highest dose given.  Following oral ketamine at 100 mg/kg, blood and brain samples were obtained and plasma and brain ketamine and norketamine levels were measured using high-performance liq. chromatog. (HPLC).  The av. concn. ratio of norketamine/ketamine, as expressed by the area under the curve (AUC) value, was 6.4 for plasma and 2.9 for brain.  These results demonstrate that a significant amt. of norketamine is formed by first pass biotransformation of ketamine and is distributed to the brain.  Competition binding assays for the [3H]MK-801-labeled non-competitive site of the N-methyl-d-aspartate receptor (NMDA) receptor revealed that both norketamine and ketamine displaced [3H]MK-801 at low micromolar concns. with Ki values of 2.5 and 0.3 mM in the forebrain, and 4.2 and 1.0 mM in the spinal cord, resp.  Spinal norketamine was approx. equipotent to ketamine in producing antinociceptive effects during phase 2 of the formalin test.  Thus, norketamine appears to contribute to the antinociceptive effects of oral ketamine through its NMDA receptor antagonist activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol23fCP1OXFrVg90H21EOLACvtfcHk0lgnfo4z7CD3JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjtFajsr0%253D&md5=5779f585c19a90c10d191133d0d7cea3</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2FS0304-3959%2898%2900269-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0304-3959%252898%252900269-3%26sid%3Dliteratum%253Aachs%26aulast%3DShimoyama%26aufirst%3DM.%26aulast%3DShimoyama%26aufirst%3DN.%26aulast%3DGorman%26aufirst%3DL.%2BA.%26aulast%3DElliott%26aufirst%3DK.%2BJ.%26aulast%3DInturrisi%26aufirst%3DC.%2BE.%26atitle%3DOral%2520ketamine%2520is%2520antinociceptive%2520in%2520the%2520rat%2520formalin%2520test%253A%2520role%2520of%2520the%2520metabolite%252C%2520norketamine%26jtitle%3DPain.%26date%3D1999%26volume%3D81%26spage%3D85%26epage%3D93%26doi%3D10.1016%2FS0304-3959%2898%2900269-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munro, G.</span></span> <span> </span><span class="NLM_article-title">Pharmacological assessment of the rat formalin test utilizing the clinically used analgesic drugs gabapentin, lamotrigine, morphine, duloxetine, tramadol and ibuprofen: influence of low and high formalin concentrations</span>. <i>Eur. J. Pharmcol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>605</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">102</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2009.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2Fj.ejphar.2009.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=19168051" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=605&publication_year=2009&pages=95-102&author=G.+Munro&title=Pharmacological+assessment+of+the+rat+formalin+test+utilizing+the+clinically+used+analgesic+drugs+gabapentin%2C+lamotrigine%2C+morphine%2C+duloxetine%2C+tramadol+and+ibuprofen%3A+influence+of+low+and+high+formalin+concentrations&doi=10.1016%2Fj.ejphar.2009.01.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2009.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2009.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DMunro%26aufirst%3DG.%26atitle%3DPharmacological%2520assessment%2520of%2520the%2520rat%2520formalin%2520test%2520utilizing%2520the%2520clinically%2520used%2520analgesic%2520drugs%2520gabapentin%252C%2520lamotrigine%252C%2520morphine%252C%2520duloxetine%252C%2520tramadol%2520and%2520ibuprofen%253A%2520influence%2520of%2520low%2520and%2520high%2520formalin%2520concentrations%26jtitle%3DEur.%2520J.%2520Pharmcol.%26date%3D2009%26volume%3D605%26spage%3D95%26epage%3D102%26doi%3D10.1016%2Fj.ejphar.2009.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':[],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article has not yet been cited by other publications.</p></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0035.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0035.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Structures of duloxetine (<b>1</b>), γ-aminobutyric acid (GABA) (<b>2</b>), gabapentin (<b>3</b>), and pregabalin (<b>4</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of AAK1 inhibitors <b>5</b>–<b>10</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Structure of compound <b>11</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray crystal structure of AAK1 in complex with compound <b>19</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LVH">7LVH</a>). Compound <b>19</b> is rendered as a stick model with orange carbon atoms. Hydrogen bonds are shown as black dashed lines. (A) Final refined 2Fo-Fc electron density map is shown contoured at 1σ around compound <b>19</b>. (B) Compound <b>19</b> bound to the ATP binding site of AAK1 with the P-loop shown. (C, D) A surface representation of protein with <b>19</b> bound to the ATP-binding site of AAK1 showing the close proximity of the isopropyl group to a small hydrophobic pocket on the underside of the P-loop (shown from two orientations). Figures were made with PyMol.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. X-ray crystal structure of AAK1 in complex with compound <b>19</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LVH">7LVH</a>). Compound <b>19</b> is rendered as a space filling model with green carbon atoms. The methoxy group packs up against Leu52 and Ala53 on the P-loop above and Leu183 below, resulting in hydrophobic interactions. The figure was made with PyMol.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. X-ray crystal structure of AAK1 in complex with compound <b>(<i>R</i>,<i>R</i>)-40</b> (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LVI">7LVI</a>). Compound <b>(<i>R</i>,<i>R</i>)-40</b> is rendered as a stick model with green carbon atoms. Hydrogen bonds are shown as black dashed lines. (A) Final refined 2Fo-Fc electron density map is shown contoured (1σ) around compound <b>(<i>R</i>,<i>R</i>)-40</b>. Two conformations of Cys193 were observed in the X-ray co-crystal structure. (B) A surface representation of the protein with <b>(<i>R</i>,<i>R</i>)-40</b> superimposed onto <b>19</b> (orange) bound to the ATP-binding site of AAK1. Figures were made with PyMol.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Ambit radial graph depicting the kinase selectivity profile of compound <b>59</b>. Each line represents the remaining activity of a single kinase in the presence of 1 μM of the test compound. Individual kinases are grouped into families represented by differing line colors. Starting from the center, the circles indicate 83, 33, and 0% of control binding remaining. AAK1 is shown in dark green (other).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Mice were treated with <b>59</b> (60 mg/kg, sc) or vehicle and euthanized 1 h post-treatment (<i>n</i> = 5). For comparison, brain lysate was collected from AAK1 knockout mice and nontreated wild-type mice that were euthanized by focused beam microwave irradiation. Western blot analysis was used to measure the level of μ2 phosphorylation. Columns represent the mean change (±1 SD) in phospho-μ2 protein relative to control. * indicates <i>P</i> < 0.05 relative to control tissue (Student’s <i>t</i> test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. (A) Mice were treated with increasing doses of compound <b>59</b> or vehicle and euthanized 30 min postdose (<i>n</i> = 5). Western blot analysis was used to measure the level of μ2 phosphorylation. Columns represent the mean change (±1 SD) in phospho-μ2 protein relative to control. * indicates <i>P</i> < 0.05 relative to control tissue (one-way ANOVA with Dunnett’s post hoc analysis). (B) Mice were treated with compound <b>59</b> (30 mg/kg, sc) and euthanized by microwave irradiation 15–120 min postdose (<i>n</i> = 6). Closed symbols represent phospho-μ2 levels as determined by Western blot analysis. Open symbols represent the plasma exposure of <b>59</b> as determined from satellite animals (<i>n</i> = 4). (C) EC<sub>50</sub> of compound <b>59</b> for in vivo inhibition of μ2 phosphorylation (top = 85.00, LogEC<sub>50</sub> = −5.078, hill slope = 1.112, and EC<sub>50</sub> = 8.3 μM).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0011.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Compound <b>59</b> reduces phase II formalin nociceptive behaviors in rats. Rats were treated with vehicle (sc), compound <b>59</b> (30 mg/kg, sc), or duloxetine (10 mg/kg, sc) 60 min prior to formalin injection. Results are presented as the mean ± SEM (A) number of hind paw flinches or (B) hind paw licking/biting duration determined 11–40 min after formalin injection (<i>n</i> = 6–8/group). Data were analyzed by ANOVA followed by Dunnett’s post hoc test; **<i>P</i> < 0.01 and ***<i>P</i> < 0.001 compared to vehicle.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0012.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Compound <b>59</b> reduces thermal hyperalgesia and mechanical hyperalgesia in CCI rats. Subjects were treated with vehicle (sc), compound <b>59</b> (60 mg/kg, sc), or gabapentin (100 mg/kg, po) and then tested for (A) thermal hyperalgesia (Hargreaves test) or (B) mechanical hyperalgesia (Randall–Selitto test). Results are presented as the mean ± SEM paw withdrawal latency or nociceptive threshold (<i>n</i> = 10–12/treatment) and were analyzed by two-way repeated measures ANOVA followed by Dunnett’s post hoc test; *<i>P</i> < 0.05, **<i>P</i> < 0.01, and ***<i>P</i> < 0.001 compared to CCI/vehicle-treated subjects.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig12" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 12</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0013.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 12. Compound <b>59</b> reduces cold allodynia and mechanical allodynia in CCI rats. Subjects were treated with vehicle (sc), compound <b>59</b> (60 mg/kg, sc), or gabapentin (100 mg/kg, po) and then tested for (A) cold allodynia (10 °C cold plate) or (B) mechanical allodynia (electronic von Frey test). Results are presented as the mean ± SEM latency (<i>n</i> = 6–12/treatment) or force (<i>n</i> = 7–10/treatment) required to elicit a paw withdrawal response. Data were analyzed by two-way repeated measures ANOVA followed by Dunnett’s post hoc test; *<i>P</i> < 0.05, **<i>P</i> < 0.01, and ***<i>P</i> < 0.001 compared to CCI/vehicle-treated subjects.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig12"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig13" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 13</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0014.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 13. Compound <b>59</b> dose-dependently reduces thermal hyperalgesia in CCI rats. Subjects were treated with vehicle (sc), compound <b>59</b> (1–30 mg/kg, sc), or gabapentin (100 mg/kg, po) and tested for thermal hyperalgesia. Results are presented as the mean ± SEM latency to paw withdrawal (<i>n</i> = 8–9/treatment) and were analyzed by two-way repeated measures ANOVA followed by Dunnett’s post hoc test; ***<i>P</i> < 0.01 compared to CCI/vehicle-treated subjects.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig13"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig14" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 14</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0015.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 14. Compound <b>59</b> does not impair rotarod performance in rats. Subjects were treated with vehicle (sc), compound <b>59</b> (10–60 mg/kg, sc), or gabapentin (100 mg/kg, po), and rotarod performance was determined 30, 90, or 180 min later. Results are presented as the mean ± SEM riding time determined in a 5 min test session (<i>n</i> = 8–10/group). Data were analyzed by two-way repeated measures ANOVA followed by Dunnett’s post hoc test; **<i>P</i> < 0.01 and ***<i>P</i> < 0.001 compared to vehicle-treated subjects.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=fig14"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0016.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0016.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthetic Route for the Preparation of Amide Analogs<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TosMIC, K<sub>2</sub>CO<sub>3</sub>, MeOH, 86%; (b) H<sub>2</sub>, Pd/C, EtOH, 40 psi, 82%; (c) Boc, Fmoc, or Cbz-protected amino acid, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 29–100%; (d) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 40–100%, for all analogs except the following: <b>21</b> (piperidine, CH<sub>2</sub>Cl<sub>2</sub>, 87%), <b>24</b> (H<sub>2</sub>, 10% Pd/C, NH<sub>4</sub>OH, MeOH, 46%), and <b>33</b> and <b>34</b> ((i) H<sub>2</sub>, 10% Pd/C, MeOH, 40–58%; (ii) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 43–99%); (e) Boc-<span class="smallcaps smallerCapital">d</span>-leucine, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 66%; (f) Ba(OH)<sub>2</sub>, MeI, DMF, H<sub>2</sub>O, 97%; and (g) carboxylic acids, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 40–67%.</p></p></figure><figure data-id="sch2" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0017.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0017.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthetic Route for the Preparation of <b>(<i>R</i>,<i>R</i>)-40</b> and <b>(<i>S</i>,<i>S</i>)-40</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Xphos precatalyst, K<sub>3</sub>PO<sub>4</sub>, THF/H<sub>2</sub>O, 70 °C, 55%; (b) H<sub>2</sub>, PtO<sub>2</sub>, EtOH, 4 N HCl in 1,4-dioxane; (c) (Boc)<sub>2</sub>O, Na<sub>2</sub>CO<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>/H<sub>2</sub>O, 67% over two steps; (d) LiOH, H<sub>2</sub>O, THF/MeOH, 98%; (e) <b>67</b>, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 40 °C, 91%; (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 91–97%; and (g) the enantiomers of <b>(<i>rac</i>)-74</b> were separated by chiral HPLC (Chiralcel OD column), 28% for <b>(<i>R</i>,<i>R</i>)-74</b>; 35% for <b>(<i>S</i>,<i>S</i>)-74</b>.</p></p></figure><figure data-id="sch3" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0018.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Compounds <b>41</b>, <b>44</b>, <b>47</b>, <b>50</b>, and <b>54</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc-<span class="smallcaps smallerCapital">d</span>-leucine, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 85%; (b) RB(OH)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, toluene/EtOH/H<sub>2</sub>O or DME/H<sub>2</sub>O, 18–76%; (c) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 16–74%; (d) bis(pinacolato)diboron, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, KOAc, 1,4-dioxane, 28%; and (e) 5-bromothiazole, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, K<sub>3</sub>PO<sub>4</sub>, 1,4-dioxane, 65%.</p></p></figure><figure data-id="sch4" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0019.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Compounds <b>42</b>, <b>43</b>, <b>45</b>, <b>46</b>, <b>48</b>, <b>49</b>, <b>51</b>, and <b>53</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) ethynyltrimethylsilane, CuI, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, reflux, 85%; (b) TBAF, THF, 55%; (c) azidotrimethylsilane, 125 °C, 51%; (d) (1<i>H</i>-pyrazol-4-yl)boronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, DME, 62%; (e) NaH, MeI, DMF, 88%; (f) 1<i>H</i>-imidazole, CuI, <span class="smallcaps smallerCapital">l</span>-histidine, K<sub>2</sub>CO<sub>3</sub> DMSO 100 °C, 97% (for <b>82</b>); (g) 1<i>H</i>-1,2,4-triazole, CuI, <span class="smallcaps smallerCapital">l</span>-histidine, K<sub>2</sub>CO<sub>3</sub> DMSO 100 °C, 25% (for <b>83</b>); (h) bis(pinacolato)diboron, PdCl<sub>2</sub>(dppf)·CH<sub>2</sub>Cl<sub>2</sub>, KOAc, 1,4-dioxane, 70%; (i) 4-bromopyridazine, Pd(OAc)<sub>2</sub>, dppf, CuCl, Cs<sub>2</sub>CO<sub>3</sub>, DMF, 27% (for <b>85</b>); (j) 4-chloropyrimidine, XPhos precatalyst, K<sub>3</sub>PO<sub>4</sub>, THF/water, 99% (for <b>86</b>); (k) 4-chloropyridin-2-amine, Pd(OAc)<sub>2</sub>, SPhos, K<sub>3</sub>PO<sub>4</sub>, <i>n</i>-BuOH, 63% (for <b>87</b>); (l) 3-pyridylboronic acid, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub>, toluene/EtOH/H<sub>2</sub>O, 76% (for <b>88</b>); (m) H<sub>2</sub>, 10% Pd/C, EtOH/CHCl<sub>3</sub>, 40 psi, 70–100% (for <b>89a</b>–<b>89e</b>, <b>89h</b>); (n) Zn, NH<sub>4</sub>Cl, EtOH, 61% (for <b>89f</b>); (o) SnCl<sub>2</sub>·H<sub>2</sub>O, EtOH, 93% (for <b>89g</b>); (p) Boc-<span class="smallcaps smallerCapital">d</span>-leucine, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 29–100%; and (q) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 17–96%.</p></p></figure><figure data-id="sch5" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0020.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of Compound <b>52</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (2-chloropyridin-4-yl)boronic acid, Pd(PPh<sub>3</sub>)<sub>2</sub>Cl<sub>2</sub>, Na<sub>2</sub>CO<sub>3</sub>, THF/H<sub>2</sub>O, 28%; (b) <i>N</i>,<i>N</i>-methylbenzylamine, Pd(OAc)<sub>2</sub>, dppp, <i>t</i>-BuOH, toluene, 35%; (c) SnCl<sub>2</sub>·2H<sub>2</sub>O, EtOH/EtOAc, 51%; (d) Boc-<span class="smallcaps smallerCapital">d</span>-leucine, TBTU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 88%; (e) ammonium formate, 10% Pd/C, EtOH, 66%; and (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 40%.</p></p></figure><figure data-id="sch6" data-index="20" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0021.jpeg" id="rightTab-gr20" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Compounds <b>56</b> and <b>57</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) TosMIC, K<sub>2</sub>CO<sub>3</sub>, MeOH, 86%; (b) SnCl<sub>2</sub>·2H<sub>2</sub>O, EtOH, quantitative; (c) Boc-<span class="smallcaps smallerCapital">d</span>-leucine, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 93%; (d) MeB(OH)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub> (aq), toluene/MeOH, 87%; (e) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 71–95%; (f) vinylboronic anhydride pyridine complex, Pd(PPh<sub>3</sub>)<sub>4</sub>, Na<sub>2</sub>CO<sub>3</sub> (aq), toluene/MeOH, 62%; (g) TosMIC, K<sub>2</sub>CO<sub>3</sub>, MeOH, 16%; (h) H<sub>2</sub>, 10% Pd/C, EtOH, 40 psi; and (i) Boc-<span class="smallcaps smallerCapital">d</span>-leucine, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 49% over two steps.</p></p></figure><figure data-id="sch7" data-index="21" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0022.jpeg" id="rightTab-gr21" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of Compounds <b>58</b> and <b>59</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BBr<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, 80 °C, 51%; (b) EtI, K<sub>2</sub>CO<sub>3</sub>, DMF, 96% (for <b>99</b>); (c) K<sub>2</sub>CO<sub>3</sub>, methyl 2-chloro-2,2-difluoroacetate, DMF, 90 °C, 80% (for <b>100</b>); (d) H<sub>2</sub>, 10% Pd/C, EtOH/CHCl<sub>3</sub>, 40 psi, 65–99%; (e) Boc-<span class="smallcaps smallerCapital">d</span>-leucine, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 52–90%; and (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 43–95%.</p></p></figure><figure data-id="sch8" data-index="22" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0023.jpeg" id="rightTab-gr22" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Compound <b>60</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc-<span class="smallcaps smallerCapital">d</span>-leucine, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 77%; (b) tributyl(vinyl)stannane, Pd(PPh<sub>3</sub>)<sub>4</sub>, toluene, 61%; (c) OsO<sub>4</sub>. NaIO<sub>4</sub>, 2,6-lutidine, 1,4-dioxane/H<sub>2</sub>O, 68%; (d) TosMIC, K<sub>2</sub>CO<sub>3</sub>, MeOH, 60%; and (e) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 81%.</p></p></figure><figure data-id="sch9" data-index="23" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0024.jpeg" id="rightTab-gr23" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of Compound <b>61</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) BH<sub>3</sub>·THF, THF, 94%; (b) (COCl)<sub>2</sub>, DMSO, Et<sub>3</sub>N, CH<sub>2</sub>Cl<sub>2</sub>, 97%; (c) TosMIC, K<sub>2</sub>CO<sub>3</sub>, MeOH, 68%; (d) H<sub>2</sub>, 10% Pd/C, EtOH/CHCl<sub>3</sub>, 40 psi, 97%; (e) Boc-<span class="smallcaps smallerCapital">d</span>-leucine, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 55%; and (f) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 76%.</p></p></figure><figure data-id="sch10" data-index="24" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0025.jpeg" id="rightTab-gr24" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of Compound <b>62</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) KCN, Bu<sub>3</sub>SnCl, Pd(PPh<sub>3</sub>)<sub>4</sub>, MeCN, 95 °C, 52%; (b) H<sub>2</sub>, Pd(OAc)<sub>2</sub>, KF (aq), PMHS, THF, 83%; (c) Boc-<span class="smallcaps smallerCapital">d</span>-leucine, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>; and (d) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 50%, over two steps.</p></p></figure><figure data-id="sch11" data-index="25" class="article__inlineFigure"><h2 class="fig-label">Scheme 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/medium/jm1c00472_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0026.jpeg" id="rightTab-gr25" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 11. Synthesis of Compounds <b>63</b> and <b>64</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/0/jmcmar.ahead-of-print/acs.jmedchem.1c00472/20210716/images/large/jm1c00472_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.1c00472&amp;id=sch11"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) Boc-<span class="smallcaps smallerCapital">d</span>-leucine, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 100%; (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>, 50–73%; and (c) <b>73</b>, HATU, <i>i</i>-Pr<sub>2</sub>NEt, CH<sub>2</sub>Cl<sub>2</sub>, 40 °C, 81%.</p></p></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i187">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13066" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13066" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 75 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Costigan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scholz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woolf, C. J.</span></span> <span> </span><span class="NLM_article-title">Neuropathic pain: a maladaptive response of the nervous system to damage</span>. <i>Annu. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">32</span>, <span class="refDoi"> DOI: 10.1146/annurev.neuro.051508.135531</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1146%2Fannurev.neuro.051508.135531" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=19400724" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpsV2nur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2009&pages=1-32&author=M.+Costiganauthor=J.+Scholzauthor=C.+J.+Woolf&title=Neuropathic+pain%3A+a+maladaptive+response+of+the+nervous+system+to+damage&doi=10.1146%2Fannurev.neuro.051508.135531"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Neuropathic pain: a maladaptive response of the nervous system to damage</span></div><div class="casAuthors">Costigan, Michael; Scholz, Joachim; Woolf, Clifford J.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Neuroscience</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-32</span>CODEN:
                <span class="NLM_cas:coden">ARNSD5</span>;
        ISSN:<span class="NLM_cas:issn">0147-006X</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Neuropathic pain is triggered by lesions to the somatosensory nervous system that alter its structure and function so that pain occurs spontaneously and responses to noxious and innocuous stimuli are pathol. amplified.  The pain is an expression of maladaptive plasticity within the nociceptive system, a series of changes that constitute a neural disease state.  Multiple alterations distributed widely across the nervous system contribute to complex pain phenotypes.  These alterations include ectopic generation of action potentials, facilitation and disinhibition of synaptic transmission, loss of synaptic connectivity and formation of new synaptic circuits, and neuroimmune interactions.  Although neural lesions are necessary, they are not sufficient to generate neuropathic pain; genetic polymorphisms, gender, and age all influence the risk of developing persistent pain.  Treatment needs to move from merely suppressing symptoms to a disease-modifying strategy aimed at both preventing maladaptive plasticity and reducing intrinsic risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodJvh-ROUpD7Vg90H21EOLACvtfcHk0ljJFcF4xKPeLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpsV2nur8%253D&md5=7869abfea9d20587dd6894eba3669cd2</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1146%2Fannurev.neuro.051508.135531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.neuro.051508.135531%26sid%3Dliteratum%253Aachs%26aulast%3DCostigan%26aufirst%3DM.%26aulast%3DScholz%26aufirst%3DJ.%26aulast%3DWoolf%26aufirst%3DC.%2BJ.%26atitle%3DNeuropathic%2520pain%253A%2520a%2520maladaptive%2520response%2520of%2520the%2520nervous%2520system%2520to%2520damage%26jtitle%3DAnnu.%2520Rev.%2520Neurosci.%26date%3D2009%26volume%3D32%26spage%3D1%26epage%3D32%26doi%3D10.1146%2Fannurev.neuro.051508.135531" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cruccu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truini, A.</span></span> <span> </span><span class="NLM_article-title">Neuropathic pain: the scope of the problem</span>. <i>Pain Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">S1</span>– <span class="NLM_lpage">S3</span>, <span class="refDoi"> DOI: 10.1007/s40122-017-0086-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1007%2Fs40122-017-0086-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=29178038" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADC%252BC1M3lt1egtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&pages=S1-S3&author=G.+Cruccuauthor=A.+Truini&title=Neuropathic+pain%3A+the+scope+of+the+problem&doi=10.1007%2Fs40122-017-0086-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Neuropathic Pain: The Scope of the Problem</span></div><div class="casAuthors">Cruccu Giorgio; Truini Andrea</div><div class="citationInfo"><span class="NLM_cas:title">Pain and therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">Suppl 1</span>),
    <span class="NLM_cas:pages">1-3</span>
        ISSN:<span class="NLM_cas:issn">2193-8237</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRyTuLMvUnN-4qdXsLcGTEUfW6udTcc2eZbHxqlpU5A0bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M3lt1egtg%253D%253D&md5=90548393533c18587fec6e954a6530b5</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs40122-017-0086-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40122-017-0086-1%26sid%3Dliteratum%253Aachs%26aulast%3DCruccu%26aufirst%3DG.%26aulast%3DTruini%26aufirst%3DA.%26atitle%3DNeuropathic%2520pain%253A%2520the%2520scope%2520of%2520the%2520problem%26jtitle%3DPain%2520Ther.%26date%3D2017%26volume%3D6%26spage%3DS1%26epage%3DS3%26doi%3D10.1007%2Fs40122-017-0086-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torrance, N.</span></span> <span> </span><span class="NLM_article-title">Epidemiology of neuropathic pain and its impact on quality of life</span>. <i>Curr. Pain Headache Rep.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">191</span>– <span class="NLM_lpage">198</span>, <span class="refDoi"> DOI: 10.1007/s11916-012-0256-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1007%2Fs11916-012-0256-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=22395856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADC%252BC38vls12jtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2012&pages=191-198&author=B.+H.+Smithauthor=N.+Torrance&title=Epidemiology+of+neuropathic+pain+and+its+impact+on+quality+of+life&doi=10.1007%2Fs11916-012-0256-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Epidemiology of neuropathic pain and its impact on quality of life</span></div><div class="casAuthors">Smith Blair H; Torrance Nicola</div><div class="citationInfo"><span class="NLM_cas:title">Current pain and headache reports</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">191-8</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epidemiology is an important clinical tool in designing and evaluating management and prevention strategies, and is particularly relevant to neuropathic pain.  However, there is a relative lack of accurate information available.  In one sense, neuropathic pain describes a symptom or a mechanism, rather than a specific disease; on the other hand, there are sufficient similarities in the effects and response to treatment between different causes to make it worthwhile to consider neuropathic pain as a distinct condition.  However, there are important specific disease-based factors that need to be considered separately.  Estimates of prevalence that are based on specific causes of neuropathic pain tend to be lower (1-2%) than those that are based on reports of the classic symptoms (6-8%), and further methodological research is needed.  All neuropathic pain is associated with poor general health, comparable with other severe chronic diseases.  The importance of newly proposed risk factors, including genetic factors, still needs to be assessed at a population level.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT_IOGgMJOMUGLFM_lbR1VmfW6udTcc2eZbHxqlpU5A0bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vls12jtQ%253D%253D&md5=aa3551b70012e240d8a9d0959a8c95c3</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1007%2Fs11916-012-0256-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11916-012-0256-0%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DB.%2BH.%26aulast%3DTorrance%26aufirst%3DN.%26atitle%3DEpidemiology%2520of%2520neuropathic%2520pain%2520and%2520its%2520impact%2520on%2520quality%2520of%2520life%26jtitle%3DCurr.%2520Pain%2520Headache%2520Rep.%26date%3D2012%26volume%3D16%26spage%3D191%26epage%3D198%26doi%3D10.1007%2Fs11916-012-0256-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finnerup, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Attal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haroutounian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNicol, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dworkin, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilron, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannpää, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansson, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamerman, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lund, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raja, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rice, A. S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowbotham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sena, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddall, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, B. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, M.</span></span> <span> </span><span class="NLM_article-title">Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis</span>. <i>Lancet Neurol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">162</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1016/S1474-4422(14)70251-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2FS1474-4422%2814%2970251-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=25575710" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXovFygsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=162-173&author=N.+B.+Finnerupauthor=N.+Attalauthor=S.+Haroutounianauthor=E.+McNicolauthor=R.+Baronauthor=R.+H.+Dworkinauthor=I.+Gilronauthor=M.+Hannp%C3%A4%C3%A4author=P.+Hanssonauthor=T.+S.+Jensenauthor=P.+R.+Kamermanauthor=K.+Lundauthor=A.+Mooreauthor=S.+N.+Rajaauthor=A.+S.+C.+Riceauthor=M.+Rowbothamauthor=E.+Senaauthor=P.+Siddallauthor=B.+H.+Smithauthor=M.+Wallace&title=Pharmacotherapy+for+neuropathic+pain+in+adults%3A+a+systematic+review+and+meta-analysis&doi=10.1016%2FS1474-4422%2814%2970251-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis</span></div><div class="casAuthors">Finnerup, Nanna B.; Attal, Nadine; Haroutounian, Simon; McNicol, Ewan; Baron, Ralf; Dworkin, Robert H.; Gilron, Ian; Haanpaa, Maija; Hansson, Per; Jensen, Troels S.; Kamerman, Peter R.; Lund, Karen; Moore, Andrew; Raja, Srinivasa N.; Rice, Andrew S. C.; Rowbotham, Michael; Sena, Emily; Siddall, Philip; Smith, Blair H.; Wallace, Mark</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Neurology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">162-173</span>CODEN:
                <span class="NLM_cas:coden">LNAEAM</span>;
        ISSN:<span class="NLM_cas:issn">1474-4422</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">New drug treatments, clin. trials, and stds. of quality for assessment of evidence justify an update of evidence-based recommendations for the pharmacol. treatment of neuropathic pain.  Using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE), we revised the Special Interest Group on Neuropathic Pain (NeuPSIG) recommendations for the pharmacotherapy of neuropathic pain based on the results of a systematic review and meta-anal.  Between Apr., 2013, and Jan., 2014, NeuPSIG of the International Assocn. for the Study of Pain did a systematic review and meta-anal. of randomised, double-blind studies of oral and topical pharmacotherapy for neuropathic pain, including studies published in peer-reviewed journals since Jan., 1966, and unpublished trials retrieved from ClinicalTrials.gov and websites of pharmaceutical companies.  We used no. needed to treat (NNT) for 50% pain relief as a primary measure and assessed publication bias; NNT was calcd. with the fixed-effects Mantel-Haenszel method.229 studies were included in the meta-anal.  Anal. of publication bias suggested a 10% overstatement of treatment effects.  Studies published in peer-reviewed journals reported greater effects than did unpublished studies (r2 9·3%, p=0·009).  Trial outcomes were generally modest: in particular, combined NNTs were 6·4 (95% CI 5·2-8·4) for serotonin-noradrenaline reuptake inhibitors, mainly including duloxetine (nine of 14 studies); 7·7 (6·5-9·4) for pregabalin; 7·2 (5·9-9·21) for gabapentin, including gabapentin extended release and enacarbil; and 10·6 (7·4-19·0) for capsaicin high-concn. patches.  NNTs were lower for tricyclic antidepressants, strong opioids, tramadol, and botulinum toxin A, and undetd. for lidocaine patches.  Based on GRADE, final quality of evidence was moderate or high for all treatments apart from lidocaine patches; tolerability and safety, and values and preferences were higher for topical drugs; and cost was lower for tricyclic antidepressants and tramadol.  These findings permitted a strong recommendation for use and proposal as first-line treatment in neuropathic pain for tricyclic antidepressants, serotonin-noradrenaline reuptake inhibitors, pregabalin, and gabapentin; a weak recommendation for use and proposal as second line for lidocaine patches, capsaicin high-concn. patches, and tramadol; and a weak recommendation for use and proposal as third line for strong opioids and botulinum toxin A.  Topical agents and botulinum toxin A are recommended for peripheral neuropathic pain only.  Our results support a revision of the NeuPSIG recommendations for the pharmacotherapy of neuropathic pain.  Inadequate response to drug treatments constitutes a substantial unmet need in patients with neuropathic pain.  Modest efficacy, large placebo responses, heterogeneous diagnostic criteria, and poor phenotypic profiling probably account for moderate trial outcomes and should be taken into account in future studies.  NeuPSIG of the International Assocn. for the Study of Pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGog3lY2ykFKHrVg90H21EOLACvtfcHk0lgvkiCOcQ-aBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXovFygsw%253D%253D&md5=aaae3dd82ea6896d3977412faedebffd</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1016%2FS1474-4422%2814%2970251-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1474-4422%252814%252970251-0%26sid%3Dliteratum%253Aachs%26aulast%3DFinnerup%26aufirst%3DN.%2BB.%26aulast%3DAttal%26aufirst%3DN.%26aulast%3DHaroutounian%26aufirst%3DS.%26aulast%3DMcNicol%26aufirst%3DE.%26aulast%3DBaron%26aufirst%3DR.%26aulast%3DDworkin%26aufirst%3DR.%2BH.%26aulast%3DGilron%26aufirst%3DI.%26aulast%3DHannp%25C3%25A4%25C3%25A4%26aufirst%3DM.%26aulast%3DHansson%26aufirst%3DP.%26aulast%3DJensen%26aufirst%3DT.%2BS.%26aulast%3DKamerman%26aufirst%3DP.%2BR.%26aulast%3DLund%26aufirst%3DK.%26aulast%3DMoore%26aufirst%3DA.%26aulast%3DRaja%26aufirst%3DS.%2BN.%26aulast%3DRice%26aufirst%3DA.%2BS.%2BC.%26aulast%3DRowbotham%26aufirst%3DM.%26aulast%3DSena%26aufirst%3DE.%26aulast%3DSiddall%26aufirst%3DP.%26aulast%3DSmith%26aufirst%3DB.%2BH.%26aulast%3DWallace%26aufirst%3DM.%26atitle%3DPharmacotherapy%2520for%2520neuropathic%2520pain%2520in%2520adults%253A%2520a%2520systematic%2520review%2520and%2520meta-analysis%26jtitle%3DLancet%2520Neurol.%26date%3D2015%26volume%3D14%26spage%3D162%26epage%3D173%26doi%3D10.1016%2FS1474-4422%2814%2970251-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finnerup, N. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sindrup, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jensen, T. S.</span></span> <span> </span><span class="NLM_article-title">The evidence for pharmacological treatment of neuropathic pain</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>150</i></span>,  <span class="NLM_fpage">573</span>– <span class="NLM_lpage">581</span>, <span class="refDoi"> DOI: 10.1016/j.pain.2010.06.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2Fj.pain.2010.06.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=20705215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADC%252BC3cjmsVOisg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=150&publication_year=2010&pages=573-581&author=N.+B.+Finnerupauthor=S.+H.+Sindrupauthor=T.+S.+Jensen&title=The+evidence+for+pharmacological+treatment+of+neuropathic+pain&doi=10.1016%2Fj.pain.2010.06.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The evidence for pharmacological treatment of neuropathic pain</span></div><div class="casAuthors">Finnerup Nanna Brix; Sindrup Soren Hein; Jensen Troels Staehelin</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">150</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">573-581</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Randomized, double-blind, placebo-controlled trials on neuropathic pain treatment are accumulating, so an updated review of the available evidence is needed.  Studies were identified using MEDLINE and EMBASE searches.  Numbers needed to treat (NNT) and numbers needed to harm (NNH) values were used to compare the efficacy and safety of different treatments for a number of neuropathic pain conditions.  One hundred and seventy-four studies were included, representing a 66% increase in published randomized, placebo-controlled trials in the last 5 years.  Painful poly-neuropathy (most often due to diabetes) was examined in 69 studies, postherpetic neuralgia in 23, while peripheral nerve injury, central pain, HIV neuropathy, and trigeminal neuralgia were less often studied.  Tricyclic antidepressants, serotonin noradrenaline reuptake inhibitors, the anticonvulsants gabapentin and pregabalin, and opioids are the drug classes for which there is the best evidence for a clinical relevant effect.  Despite a 66% increase in published trials only a limited improvement of neuropathic pain treatment has been obtained.  A large proportion of neuropathic pain patients are left with insufficient pain relief.  This fact calls for other treatment options to target chronic neuropathic pain.  Large-scale drug trials that aim to identify possible subgroups of patients who are likely to respond to specific drugs are needed to test the hypothesis that a mechanism-based classification may help improve treatment of the individual patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSGaQWHMjO4toUSrryheKE6fW6udTcc2ebQ09His-qHfLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3cjmsVOisg%253D%253D&md5=d72cc434514579e6e8da7e06f8ea3fa9</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.pain.2010.06.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pain.2010.06.019%26sid%3Dliteratum%253Aachs%26aulast%3DFinnerup%26aufirst%3DN.%2BB.%26aulast%3DSindrup%26aufirst%3DS.%2BH.%26aulast%3DJensen%26aufirst%3DT.%2BS.%26atitle%3DThe%2520evidence%2520for%2520pharmacological%2520treatment%2520of%2520neuropathic%2520pain%26jtitle%3DPain%26date%3D2010%26volume%3D150%26spage%3D573%26epage%3D581%26doi%3D10.1016%2Fj.pain.2010.06.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fairbanks, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stone, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilcox, G. L.</span></span> <span> </span><span class="NLM_article-title">Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>123</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2009.04.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2Fj.pharmthera.2009.04.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=19393691" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXnsFyhtbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2009&pages=224-238&author=C.+A.+Fairbanksauthor=L.+S.+Stoneauthor=G.+L.+Wilcox&title=Pharmacological+profiles+of+alpha+2+adrenergic+receptor+agonists+identified+using+genetically+altered+mice+and+isobolographic+analysis&doi=10.1016%2Fj.pharmthera.2009.04.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological profiles of alpha 2 adrenergic receptor agonists identified using genetically altered mice and isobolographic analysis</span></div><div class="casAuthors">Fairbanks, Carolyn A.; Stone, Laura S.; Wilcox, George L.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">123</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">224-238</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review.  Endogenous, descending noradrenergic fibers impose analgesic control over spinal afferent circuitry mediating the rostrad transmission of pain signals.  These fibers target alpha 2 adrenergic receptors (α2ARs) on both primary afferent terminals and secondary neurons, and their activation mediates substantial inhibitory control over this transmission, rivaling that of opioid receptors which share a similar pattern of distribution.  The terminals of primary afferent nociceptive neurons and secondary spinal dorsal horn neurons express α2AAR and α2CAR subtypes, resp.  Spinal delivery of these agents serves to reduce their side effects, which are mediated largely at supraspinal sites, by concg. the drugs at the spinal level.  Targeting these spinal α2ARs with one of five selective therapeutic agonists, clonidine, dexmedetomidine, brimonidine, ST91 and moxonidine, produces significant antinociception that can work in concert with opioid agonists to yield synergistic antinociception.  Application of several genetically altered mouse lines had facilitated identification of the primary receptor subtypes that likely mediate the antinociceptive effects of these agents.  This review provides first an anatomical description of the localization of the three subtypes in the central nervous system, second a detailed account of the pharmacol. history of each of the six primary agonists, and finally a comprehensive report of the specific interactions of other GPCR agonists with each of the six principal α2AR agonists featured.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLBGBdc8kulrVg90H21EOLACvtfcHk0lgvkiCOcQ-aBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXnsFyhtbg%253D&md5=6a358043378a8416816a2544daade0f1</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2009.04.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2009.04.001%26sid%3Dliteratum%253Aachs%26aulast%3DFairbanks%26aufirst%3DC.%2BA.%26aulast%3DStone%26aufirst%3DL.%2BS.%26aulast%3DWilcox%26aufirst%3DG.%2BL.%26atitle%3DPharmacological%2520profiles%2520of%2520alpha%25202%2520adrenergic%2520receptor%2520agonists%2520identified%2520using%2520genetically%2520altered%2520mice%2520and%2520isobolographic%2520analysis%26jtitle%3DPharmacol.%2520Ther.%26date%3D2009%26volume%3D123%26spage%3D224%26epage%3D238%26doi%3D10.1016%2Fj.pharmthera.2009.04.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benarroch, E. E.</span></span> <span> </span><span class="NLM_article-title">Descending monoaminergic pain modulation: bidirectional control and clinical relevance</span>. <i>Neurology</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1212/01.wnl.0000318225.51122.63</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1212%2F01.wnl.0000318225.51122.63" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=18625968" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADC%252BD1cvltVWrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=2008&pages=217-221&author=E.+E.+Benarroch&title=Descending+monoaminergic+pain+modulation%3A+bidirectional+control+and+clinical+relevance&doi=10.1212%2F01.wnl.0000318225.51122.63"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Descending monoaminergic pain modulation: bidirectional control and clinical relevance</span></div><div class="casAuthors">Benarroch Eduardo E</div><div class="citationInfo"><span class="NLM_cas:title">Neurology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQAfJdaFxsZlZagfuraLLzSfW6udTcc2ebQ09His-qHfLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1cvltVWrtw%253D%253D&md5=fbbc75af607276ce8297591258c1ffc6</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1212%2F01.wnl.0000318225.51122.63&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1212%252F01.wnl.0000318225.51122.63%26sid%3Dliteratum%253Aachs%26aulast%3DBenarroch%26aufirst%3DE.%2BE.%26atitle%3DDescending%2520monoaminergic%2520pain%2520modulation%253A%2520bidirectional%2520control%2520and%2520clinical%2520relevance%26jtitle%3DNeurology%26date%3D2008%26volume%3D71%26spage%3D217%26epage%3D221%26doi%3D10.1212%2F01.wnl.0000318225.51122.63" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sills, G. J.</span></span> <span> </span><span class="NLM_article-title">The mechanisms of action of gabapentin and pregabalin</span>. <i>Curr. Opin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">108</span>– <span class="NLM_lpage">113</span>, <span class="refDoi"> DOI: 10.1016/j.coph.2005.11.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2Fj.coph.2005.11.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=16376147" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVyitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2006&pages=108-113&author=G.+J.+Sills&title=The+mechanisms+of+action+of+gabapentin+and+pregabalin&doi=10.1016%2Fj.coph.2005.11.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The mechanisms of action of Gabapentin and Pregabalin</span></div><div class="casAuthors">Sills, Graeme J.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">108-113</span>CODEN:
                <span class="NLM_cas:coden">COPUBK</span>;
        ISSN:<span class="NLM_cas:issn">1471-4892</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Gabapentin and Pregabalin are structurally related compds. with recognized efficacy in the treatment of both epilepsy and neuropathic pain.  The pharmacol. mechanisms by which these agents exert their clin. effects have, until recently, remained unclear.  The interaction of Gabapentin and Pregabalin with conventional antiepileptic and analgesic drug targets is likely to be modest, at best, and has been largely dismissed in favor of a selective inhibitory effect on voltage-gated calcium channels contg. the α2δ-1 subunit.  This mechanism is consistently obsd. in both rodent- and human-based exptl. paradigms and may be sufficiently robust to account for much of the clin. activity of these compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVcGWT9vU4_7Vg90H21EOLACvtfcHk0lgBFyJT9xrogQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVyitQ%253D%253D&md5=f986039097362702cbf33f88deb50baf</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1016%2Fj.coph.2005.11.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.coph.2005.11.003%26sid%3Dliteratum%253Aachs%26aulast%3DSills%26aufirst%3DG.%2BJ.%26atitle%3DThe%2520mechanisms%2520of%2520action%2520of%2520gabapentin%2520and%2520pregabalin%26jtitle%3DCurr.%2520Opin.%2520Pharmacol.%26date%3D2006%26volume%3D6%26spage%3D108%26epage%3D113%26doi%3D10.1016%2Fj.coph.2005.11.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolphin, A. C.</span></span> <span> </span><span class="NLM_article-title">Calcium channel auxiliary α<sub>2</sub>δ and β subunits: trafficking and one step beyond</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">542</span>– <span class="NLM_lpage">555</span>, <span class="refDoi"> DOI: 10.1038/nrn3311</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1038%2Fnrn3311" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=22805911" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVektLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=542-555&author=A.+C.+Dolphin&title=Calcium+channel+auxiliary+%CE%B12%CE%B4+and+%CE%B2+subunits%3A+trafficking+and+one+step+beyond&doi=10.1038%2Fnrn3311"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium channel auxiliary α2δ and β subunits: trafficking and one step beyond</span></div><div class="casAuthors">Dolphin, Annette C.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">542-555</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The voltage-gated calcium channel α2δ and β subunits are traditionally considered to be auxiliary subunits that enhance channel trafficking, increase the expression of functional calcium channels at the plasma membrane and influence the channels' biophys. properties.  Accumulating evidence indicates that these subunits may also have roles in the nervous system that are not directly linked to calcium channel function.  For example, β subunits may act as transcriptional regulators, and certain α2δ subunits may function in synaptogenesis.  The aim of this Review is to examine both the classic and novel roles for these auxiliary subunits in voltage-gated calcium channel function and beyond.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBOsgOAvtdaLVg90H21EOLACvtfcHk0lgBFyJT9xrogQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVektLbJ&md5=13e03e73e05f17579e7f1c63fb4fcc0d</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1038%2Fnrn3311&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn3311%26sid%3Dliteratum%253Aachs%26aulast%3DDolphin%26aufirst%3DA.%2BC.%26atitle%3DCalcium%2520channel%2520auxiliary%2520%25CE%25B12%25CE%25B4%2520and%2520%25CE%25B2%2520subunits%253A%2520trafficking%2520and%2520one%2520step%2520beyond%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2012%26volume%3D13%26spage%3D542%26epage%3D555%26doi%3D10.1038%2Fnrn3311" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorrell, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szklarz, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abdul Azeez, K. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span> <span> </span><span class="NLM_article-title">Family-wide structural analysis of human numb-associated protein kinases</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">401</span>– <span class="NLM_lpage">411</span>, <span class="refDoi"> DOI: 10.1016/j.str.2015.12.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2Fj.str.2015.12.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=26853940" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC28XitFCktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=401-411&author=F.+J.+Sorrellauthor=M.+Szklarzauthor=K.+R.+Abdul+Azeezauthor=J.+M.+Elkinsauthor=S.+Knapp&title=Family-wide+structural+analysis+of+human+numb-associated+protein+kinases&doi=10.1016%2Fj.str.2015.12.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Family-wide Structural Analysis of Human Numb-Associated Protein Kinases</span></div><div class="casAuthors">Sorrell, Fiona J.; Szklarz, Marta; Abdul Azeez, Kamal R.; Elkins, Jon M.; Knapp, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">401-411</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The highly diverse Numb-assocd. kinase (NAK) family has been linked to broad cellular functions including receptor-mediated endocytosis, Notch pathway modulation, osteoblast differentiation, and dendrite morphogenesis.  Consequently, NAK kinases play a key role in a diverse range of diseases from Parkinson's and prostate cancer to HIV.  Due to the plasticity of this kinase family, NAK kinases are often inhibited by approved or investigational drugs and have been assocd. with side effects, but they are also potential drug targets.  The presence of cysteine residues in some NAK family members provides the possibility for selective targeting via covalent inhibition.  Here we report the first high-resoln. structures of kinases AAK1 and BIKE in complex with two drug candidates.  The presented data allow a comprehensive structural characterization of the NAK kinase family and provide the basis for rational design of selective NAK inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGryZi0QmT8YH7Vg90H21EOLACvtfcHk0lgBFyJT9xrogQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitFCktLY%253D&md5=6a353c993ec9f2b7152e459d72bab9d3</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2015.12.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2015.12.015%26sid%3Dliteratum%253Aachs%26aulast%3DSorrell%26aufirst%3DF.%2BJ.%26aulast%3DSzklarz%26aufirst%3DM.%26aulast%3DAbdul%2BAzeez%26aufirst%3DK.%2BR.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DKnapp%26aufirst%3DS.%26atitle%3DFamily-wide%2520structural%2520analysis%2520of%2520human%2520numb-associated%2520protein%2520kinases%26jtitle%3DStructure%26date%3D2016%26volume%3D24%26spage%3D401%26epage%3D411%26doi%3D10.1016%2Fj.str.2015.12.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conner, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, S. L.</span></span> <span> </span><span class="NLM_article-title">Identification of an adaptor-associated kinase, AAK1, as a regulator of clathrin-mediated endocytosis</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">921</span>– <span class="NLM_lpage">929</span>, <span class="refDoi"> DOI: 10.1083/jcb.200108123</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1083%2Fjcb.200108123" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=11877461" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD38XitVGmtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2002&pages=921-929&author=S.+D.+Connerauthor=S.+L.+Schmid&title=Identification+of+an+adaptor-associated+kinase%2C+AAK1%2C+as+a+regulator+of+clathrin-mediated+endocytosis&doi=10.1083%2Fjcb.200108123"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Identification of an adaptor-associated kinase, AAK1, as a regulator of clathrin-mediated endocytosis</span></div><div class="casAuthors">Conner, Sean D.; Schmid, Sandra L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">921-929</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">The μ2 subunit of the AP2 complex is known to be phosphorylated in vitro by a copurifying kinase, and it has been demonstrated recently that μ2 phosphorylation is required for transferrin endocytosis.  However, the identity of the endogenous kinase responsible for this phosphorylation is unknown.  Here we identify and characterize a novel member of the Prk/Ark family of serine/threonine kinases, adaptor-assocd. kinase (AAK)1.  We find that AAK1 copurifies with adaptor protein (AP)2 and that it directly binds the ear domain of α-adaptin in vivo and in vitro.  In neuronal cells, AAK1 is enriched at presynaptic terminals, whereas in nonneuronal cells it colocalizes with clathrin and AP2 in clathrin-coated pits and at the leading edge of migrating cells.  AAK1 specifically phosphorylates the μ subunit in vitro, and stage-specific assays for endocytosis show that μ phosphorylation by AAK1 results in a decrease in AP2-stimulated transferrin internalization.  Together, these results provide strong evidence that AAK1 is the endogenous μ2 kinase and plays a regulatory role in clathrin-mediated endocytosis.  These results also lend support to the idea that clathrin-mediated endocytosis is controlled by cycles of phosphorylation/desphosphorylation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp62q8kuSqokbVg90H21EOLACvtfcHk0lhmeMvVmWHmVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitVGmtrg%253D&md5=0f9061fb428373240da331f7d25bb9bf</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200108123&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200108123%26sid%3Dliteratum%253Aachs%26aulast%3DConner%26aufirst%3DS.%2BD.%26aulast%3DSchmid%26aufirst%3DS.%2BL.%26atitle%3DIdentification%2520of%2520an%2520adaptor-associated%2520kinase%252C%2520AAK1%252C%2520as%2520a%2520regulator%2520of%2520clathrin-mediated%2520endocytosis%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2002%26volume%3D156%26spage%3D921%26epage%3D929%26doi%3D10.1083%2Fjcb.200108123" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Conner, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schröter, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, S. L.</span></span> <span> </span><span class="NLM_article-title">AAK1-mediated μ2 phosphorylation is stimulated by assembled clathrin</span>. <i>Traffic</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1046/j.1398-9219.2003.0142.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1046%2Fj.1398-9219.2003.0142.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=14617351" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvVGhtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=885-890&author=S.+D.+Connerauthor=T.+Schr%C3%B6terauthor=S.+L.+Schmid&title=AAK1-mediated+%CE%BC2+phosphorylation+is+stimulated+by+assembled+clathrin&doi=10.1046%2Fj.1398-9219.2003.0142.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">AAK1-mediated μ2 phosphorylation is stimulated by assembled clathrin</span></div><div class="casAuthors">Conner, Sean D.; Schroeter, Thomas; Schmid, Sandra L.</div><div class="citationInfo"><span class="NLM_cas:title">Traffic (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">885-890</span>CODEN:
                <span class="NLM_cas:coden">TRAFFA</span>;
        ISSN:<span class="NLM_cas:issn">1398-9219</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">AAK1, the adaptor-assocd. kinase 1, phosphorylates the μ2 subunit of AP2 and regulates the recruitment of AP2 to tyrosine-based internalization motifs found on membrane-bound receptors.  AAK1 overexpression specifically inhibits the AP2-dependent internalization of transferrin receptor and LDL-receptor related protein by functionally sequestering AP2 (Conner and Schmid. J Cell Biol 2003; 162: 773).  However, while AAK1 stably assocs. with AP2 and specifically targets the μ2 subunit in vitro, μ2 phosphorylation in vivo was not altered by overexpression of either wild-type or kinase-inactive AAK1.  These results suggested that AAK1 might be tightly regulated in the cell.  Here, we report that AAK1 is an atypical kinase that is rate limited by its stable assocn. with AP2 and that clathrin stimulates μ2 phosphorylation by AAK1.  Efficient stimulation of AAK1 by clathrin involves multiple interactions between several domains on AAK1 and both heavy and light chains on clathrin.  Importantly, incubation of AAK1 with clathrin cages resulted in even greater stimulation when compared to that of unassembled clathrin triskelia.  Collectively, our observations indicate that clathrin function is not limited to structural and/or mech. roles in endocytic vesicle formation: the stimulatory effects of clathrin on AAK1 activity argue that it also plays a regulatory role by modulating the activity of AP2 complexes through activation of AAK1.  We suggest a model in which AAK1 is specifically activated in coated pits to enhance cargo recruitment and efficient internalization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_pbrwRqrFcLVg90H21EOLACvtfcHk0lhmeMvVmWHmVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvVGhtrw%253D&md5=1c9849cdd32f8682fbb4dc63ad2dabfc</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1046%2Fj.1398-9219.2003.0142.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1398-9219.2003.0142.x%26sid%3Dliteratum%253Aachs%26aulast%3DConner%26aufirst%3DS.%2BD.%26aulast%3DSchr%25C3%25B6ter%26aufirst%3DT.%26aulast%3DSchmid%26aufirst%3DS.%2BL.%26atitle%3DAAK1-mediated%2520%25CE%25BC2%2520phosphorylation%2520is%2520stimulated%2520by%2520assembled%2520clathrin%26jtitle%3DTraffic%26date%3D2003%26volume%3D4%26spage%3D885%26epage%3D890%26doi%3D10.1046%2Fj.1398-9219.2003.0142.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, M. S.</span>; <span class="NLM_string-name">Ball, C. L.</span>; <span class="NLM_string-name">Seaman, M. N. J.</span></span> <span> </span><span class="NLM_article-title">Adaptins and their Role in Clathrin-Mediated Vesicle Sorting</span>. In  <i>Molecular Mechanisms of Membrane Traffic</i>; <span class="NLM_series">NATO ASI Series (Series H: Cell Biology)</span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morré, D. J.</span>; <span class="NLM_string-name">Howell, K. E.</span>; <span class="NLM_string-name">Bergeron, J. J. M.</span></span> Eds.; <span class="NLM_publisher-name">Springer</span>: <span class="NLM_publisher-loc">Berlin, Heidelberg</span>, <span class="NLM_year">1993</span>, Vol.  <span class="NLM_volume">74</span>, pp.  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">236</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1007%2F978-3-662-02928-2_46" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1993&pages=229-236&author=M.+S.+Robinson&author=C.+L.+Ball&author=M.+N.+J.+Seamanauthor=D.+J.+Morr%C3%A9&author=K.+E.+Howell&author=J.+J.+M.+Bergeron&title=Molecular+Mechanisms+of+Membrane+Traffic"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2F978-3-662-02928-2_46&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1007%252F978-3-662-02928-2_46%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DM.%2BS.%26atitle%3DAdaptins%2520and%2520their%2520Role%2520in%2520Clathrin-Mediated%2520Vesicle%2520Sorting%26btitle%3DMolecular%2520Mechanisms%2520of%2520Membrane%2520Traffic%26aulast%3DMorr%25C3%25A9%26aufirst%3DD.%2BJ.%26pub%3DSpringer%26date%3D1993%26volume%3D74%26spage%3D229%26epage%3D236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robinson, M. S.</span></span> <span> </span><span class="NLM_article-title">Adaptable adaptors for coated vesicles</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>14</i></span>,  <span class="NLM_fpage">167</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1016/j.tcb.2004.02.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2Fj.tcb.2004.02.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=15066634" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVGjt7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2004&pages=167-174&author=M.+S.+Robinson&title=Adaptable+adaptors+for+coated+vesicles&doi=10.1016%2Fj.tcb.2004.02.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Adaptable adaptors for coated vesicles</span></div><div class="casAuthors">Robinson, Margaret S.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">167-174</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Adaptors select cargo for inclusion into coated vesicles in the late secretory and endocytic pathways.  Although originally there were thought to be just two adaptors, AP-1 and AP-2, it is now clear that there are many more: two addnl. adaptor complexes, AP-3 and AP-4, which might function independently of clathrin; a family of monomeric adaptors, the GGAs; and an ever-growing no. of cargo-specific adaptors.  The adaptors are targeted to the appropriate membrane at least in part by interacting with phosphoinositides, and, once on the membrane, they form interconnected networks to get different types of cargo into the same vesicle.  Adaptors participate in trafficking pathways shared by all cells, and they are also used to generate specialized organelles and to influence cell fate during development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZES4LlZkT97Vg90H21EOLACvtfcHk0lhmeMvVmWHmVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVGjt7w%253D&md5=5ffb2156af690a311059bf2a27f45419</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2004.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2004.02.002%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DM.%2BS.%26atitle%3DAdaptable%2520adaptors%2520for%2520coated%2520vesicles%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2004%26volume%3D14%26spage%3D167%26epage%3D174%26doi%3D10.1016%2Fj.tcb.2004.02.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirchhausen, T.</span></span> <span> </span><span class="NLM_article-title">Adaptors for clathrin-mediated traffic</span>. <i>Annu. Rev. Cell Dev. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">705</span>– <span class="NLM_lpage">732</span>, <span class="refDoi"> DOI: 10.1146/annurev.cellbio.15.1.705</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1146%2Fannurev.cellbio.15.1.705" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10611976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD3cXhtVSnu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1999&pages=705-732&author=T.+Kirchhausen&title=Adaptors+for+clathrin-mediated+traffic&doi=10.1146%2Fannurev.cellbio.15.1.705"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Adaptors for clathrin-mediated traffic</span></div><div class="casAuthors">Kirchhausen, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Cell and Developmental Biology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">705-732</span>CODEN:
                <span class="NLM_cas:coden">ARDBF8</span>;
        ISSN:<span class="NLM_cas:issn">1081-0706</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review with approx. 150 refs.  Clathrin-based systems are responsible for a large portion of vesicular traffic originating from the plasma membrane and the trans-Golgi network that reaches the endosomal compartment.  The assembly of cytosolic clathrin forms the scaffold required for the local deformation of the membrane and for the formation of coated pits and vesicles.  In this process, clathrin interacts in a coordinated fashion with a large no. of protein partners.  A subset designated clathrin adaptors links integral membrane proteins to the clathrin coat, a process that results in the recruitment of specific cargo proteins to the budding vesicle.  This review focuses on the most recent advances dealing with the mol. basis for sorting by clathrin adaptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjj48TdSkDorVg90H21EOLACvtfcHk0lhmeMvVmWHmVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXhtVSnu7k%253D&md5=23b0bfbd0ccefa821f2ba5e00d38c3da</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1146%2Fannurev.cellbio.15.1.705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.cellbio.15.1.705%26sid%3Dliteratum%253Aachs%26aulast%3DKirchhausen%26aufirst%3DT.%26atitle%3DAdaptors%2520for%2520clathrin-mediated%2520traffic%26jtitle%3DAnnu.%2520Rev.%2520Cell%2520Dev.%2520Biol.%26date%3D1999%26volume%3D15%26spage%3D705%26epage%3D732%26doi%3D10.1146%2Fannurev.cellbio.15.1.705" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fournier, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bosshart, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyatake, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saito, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallusser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchhausen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifacino, J. S.</span></span> <span> </span><span class="NLM_article-title">Interaction of tyrosine-based sorting signals with clathrin-associated proteins</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>269</i></span>,  <span class="NLM_fpage">1872</span>– <span class="NLM_lpage">1875</span>, <span class="refDoi"> DOI: 10.1126/science.7569928</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1126%2Fscience.7569928" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=7569928" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADyaK2MXotlKqtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=269&publication_year=1995&pages=1872-1875&author=H.+Ohnoauthor=J.+Stewartauthor=M.+C.+Fournierauthor=H.+Bosshartauthor=I.+Rheeauthor=S.+Miyatakeauthor=T.+Saitoauthor=A.+Gallusserauthor=T.+Kirchhausenauthor=J.+S.+Bonifacino&title=Interaction+of+tyrosine-based+sorting+signals+with+clathrin-associated+proteins&doi=10.1126%2Fscience.7569928"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction of tyrosine-based sorting signals with clathrin-associated proteins</span></div><div class="casAuthors">Ohno, Hiroshi; Stewart, Jay; Fournier, Marie-Christine; Bosshart, Herbert; Rhee, Ina; Miyatake, Shoichiro; Saito, Takashi; Gallusser, Andreas; Kirchhausen, Tomas; Bonifacino, Juan S.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">269</span>
        (<span class="NLM_cas:issue">5232</span>),
    <span class="NLM_cas:pages">1872-5</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Tyr-based signals within the cytoplasmic domain of integral membrane proteins mediate clathrin-dependent protein sorting in the endocytic and secretory pathways.  A yeast 2-hybrid system was used to identify proteins that bind to Tyr-based signals.  The medium chains (μ1 and μ2) of 2 clathrin-assocd. protein complexes (AP-1 and AP-2, resp.) specifically interacted with the Tyr-based signals of several integral membrane proteins (e.g., TGN38).  The interaction was confirmed by in vitro binding assays.  Thus, it is likely that the medium chains serve as signal-binding components of the clathrin-dependent sorting machinery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwelF8AB2bmbVg90H21EOLACvtfcHk0lgNxU8gnrl90g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXotlKqtLc%253D&md5=7c354ca71c3065a1ab1abb6ab4751324</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1126%2Fscience.7569928&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.7569928%26sid%3Dliteratum%253Aachs%26aulast%3DOhno%26aufirst%3DH.%26aulast%3DStewart%26aufirst%3DJ.%26aulast%3DFournier%26aufirst%3DM.%2BC.%26aulast%3DBosshart%26aufirst%3DH.%26aulast%3DRhee%26aufirst%3DI.%26aulast%3DMiyatake%26aufirst%3DS.%26aulast%3DSaito%26aufirst%3DT.%26aulast%3DGallusser%26aufirst%3DA.%26aulast%3DKirchhausen%26aufirst%3DT.%26aulast%3DBonifacino%26aufirst%3DJ.%2BS.%26atitle%3DInteraction%2520of%2520tyrosine-based%2520sorting%2520signals%2520with%2520clathrin-associated%2520proteins%26jtitle%3DScience%26date%3D1995%26volume%3D269%26spage%3D1872%26epage%3D1875%26doi%3D10.1126%2Fscience.7569928" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shih, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallusser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirchhausen, T.</span></span> <span> </span><span class="NLM_article-title">A clathrin-binding site in the hinge of the β2 chain of mammalian AP-2 complexes</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>270</i></span>,  <span class="NLM_fpage">31083</span>– <span class="NLM_lpage">31090</span>, <span class="refDoi"> DOI: 10.1074/jbc.270.52.31083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1074%2Fjbc.270.52.31083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=8537368" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADyaK28XivFSqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=270&publication_year=1995&pages=31083-31090&author=W.+Shihauthor=A.+Gallusserauthor=T.+Kirchhausen&title=A+clathrin-binding+site+in+the+hinge+of+the+%CE%B22+chain+of+mammalian+AP-2+complexes&doi=10.1074%2Fjbc.270.52.31083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">A clathrin-binding site in the hinge of the β2 chain of mammalian AP-2 complexes</span></div><div class="casAuthors">Shih, William; Gallusser, Andreas; Kirchhausen, Tomas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">270</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">31083-90</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The assembly of cytosolic clathrin into the cytoplasmic face of coated pits and coated vesicles appears to be driven by the clathrin-assocd. protein (AP) complexes.  The authors have previously shown that one of the large chains of the AP complexes, the β chain, is sufficient to drive coat assembly in vitro.  This chain consists of two domains, the amino-terminal trunk and the carboxyl-terminal ear, linked by a "hinge.".  The authors report here that presence of the hinge in recombinant β trunk or in recombinant β ear fragments is essential for driving in vitro assembly of clathrin into coats.  The authors have also used nested deletion of hinge sequences to a 50-residue region in the center of the hinge.  This sequence is conserved in all known β sequences from multicellular organisms.  The interaction of a single β hinge with a clathrin triskelion is weak, and the authors propose that recruitment of cytosolic clathrin to a forming coated pit involves simultaneous contacts between the legs of single clathrin trimers and the β hinges of two or three membrane-bound AP complexes.  Uncoating is likely to require interruption of these contacts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkrXyU6OYwR7Vg90H21EOLACvtfcHk0lgNxU8gnrl90g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28XivFSqsQ%253D%253D&md5=95d1b57904b4da9cdf2e1b576ca48103</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1074%2Fjbc.270.52.31083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.270.52.31083%26sid%3Dliteratum%253Aachs%26aulast%3DShih%26aufirst%3DW.%26aulast%3DGallusser%26aufirst%3DA.%26aulast%3DKirchhausen%26aufirst%3DT.%26atitle%3DA%2520clathrin-binding%2520site%2520in%2520the%2520hinge%2520of%2520the%2520%25CE%25B22%2520chain%2520of%2520mammalian%2520AP-2%2520complexes%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1995%26volume%3D270%26spage%3D31083%26epage%3D31090%26doi%3D10.1074%2Fjbc.270.52.31083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aguilar, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roche, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonifacino, J. S.</span></span> <span> </span><span class="NLM_article-title">Functional domain mapping of the clathrin-associated adaptor medium chains mu1 and mu2</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">27160</span>– <span class="NLM_lpage">27166</span>, <span class="refDoi"> DOI: 10.1074/jbc.272.43.27160</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1074%2Fjbc.272.43.27160" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=9341158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADyaK2sXmvFyrtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=27160-27166&author=R.+C.+Aguilarauthor=H.+Ohnoauthor=K.+W.+Rocheauthor=J.+S.+Bonifacino&title=Functional+domain+mapping+of+the+clathrin-associated+adaptor+medium+chains+mu1+and+mu2&doi=10.1074%2Fjbc.272.43.27160"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Functional domain mapping of the clathrin-associated adaptor medium chains μ1 and μ2</span></div><div class="casAuthors">Aguilar, Ruben C.; Ohno, Hiroshi; Roche, Katherine W.; Bonifacino, Juan S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">43</span>),
    <span class="NLM_cas:pages">27160-27166</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The clathrin-assocd. adaptors AP-1 and AP-2 are heterotetrameric complexes involved in the recognition of sorting signals present within the cytosolic domain of integral membrane proteins.  The medium chains of these complexes, μ1 and μ2, have been implicated in two types of interaction: assembly with the β1 and β2 chains of the corresponding complexes and recognition of tyrosine-based sorting signals.  In this study, we report the results of a structure-function anal. of the μ1 and μ2 chains aimed at identifying regions of the mols. that are responsible for each of the two interactions.  Analyses using the yeast two-hybrid system and proteolytic digestion expts. suggest that μ1 and μ2 have a bipartite structure, with the amino-terminal one-third (residues 1-145 of μ1 and μ2) being involved in assembly with the β chains and the carboxyl-terminal two-thirds (residues 147-423 of μ1 and 164-435 of μ2) binding tyrosine-based sorting signals.  These observations support a model in which the amino-terminal one-third of μ2 is embedded within the core of the AP-2 complex, while the carboxyl-terminal two-thirds of the protein are exposed to the medium, placing this region in a position to interact with tyrosine-based sorting signals.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0Xdqr1bWMZrVg90H21EOLACvtfcHk0lgNxU8gnrl90g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXmvFyrtrc%253D&md5=97e340bfa3f017f888351e28097cbe99</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.43.27160&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.43.27160%26sid%3Dliteratum%253Aachs%26aulast%3DAguilar%26aufirst%3DR.%2BC.%26aulast%3DOhno%26aufirst%3DH.%26aulast%3DRoche%26aufirst%3DK.%2BW.%26aulast%3DBonifacino%26aufirst%3DJ.%2BS.%26atitle%3DFunctional%2520domain%2520mapping%2520of%2520the%2520clathrin-associated%2520adaptor%2520medium%2520chains%2520mu1%2520and%2520mu2%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D27160%26epage%3D27166%26doi%3D10.1074%2Fjbc.272.43.27160" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Owen, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evans, P. R.</span></span> <span> </span><span class="NLM_article-title">A structural explanation for the recognition of tyrosine-based endocytotic signals</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>282</i></span>,  <span class="NLM_fpage">1327</span>– <span class="NLM_lpage">1332</span>, <span class="refDoi"> DOI: 10.1126/science.282.5392.1327</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1126%2Fscience.282.5392.1327" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=9812899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADyaK1cXnsFenu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=1998&pages=1327-1332&author=D.+J.+Owenauthor=P.+R.+Evans&title=A+structural+explanation+for+the+recognition+of+tyrosine-based+endocytotic+signals&doi=10.1126%2Fscience.282.5392.1327"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">A structural explanation for the recognition of tyrosine-based endocytotic signals</span></div><div class="casAuthors">Owen, David J.; Evans, Philip R.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">282</span>
        (<span class="NLM_cas:issue">5392</span>),
    <span class="NLM_cas:pages">1327-1332</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Many cell surface proteins are marked for endocytosis by a cytoplasmic sequence motif, tyrosine-X-X-(hydrophobic residue), that is recognized by the μ2 subunit of AP2 adaptors.  Crystal structures of the internalization signal binding domain of μ2 complexed with the internalization signal peptides of epidermal growth factor receptor and the trans-Golgi network protein TGN38 have been detd. at 2.7 angstrom resoln.  The signal peptides adopted at extended conformation rather than the expected tight turn.  Specificity was conferred by hydrophobic pockets that bind the tyrosine and leucine in the peptide in the crystal, the protein forms dimers that could increase the strength and specificity of binding to dimeric receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyBnBGOl8LH7Vg90H21EOLACvtfcHk0li-PO4P0nydig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXnsFenu78%253D&md5=d3fb688f2b2788de8eba4a01d70b64f4</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1126%2Fscience.282.5392.1327&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.282.5392.1327%26sid%3Dliteratum%253Aachs%26aulast%3DOwen%26aufirst%3DD.%2BJ.%26aulast%3DEvans%26aufirst%3DP.%2BR.%26atitle%3DA%2520structural%2520explanation%2520for%2520the%2520recognition%2520of%2520tyrosine-based%2520endocytotic%2520signals%26jtitle%3DScience%26date%3D1998%26volume%3D282%26spage%3D1327%26epage%3D1332%26doi%3D10.1126%2Fscience.282.5392.1327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fingerhut, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Figura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Höning, S.</span></span> <span> </span><span class="NLM_article-title">Binding of AP2 to sorting signals is modulated by AP2 phosphorylation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">5476</span>– <span class="NLM_lpage">5482</span>, <span class="refDoi"> DOI: 10.1074/jbc.M009516200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1074%2Fjbc.M009516200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=11044456" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhs1Kms7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2001&pages=5476-5482&author=A.+Fingerhutauthor=K.+von+Figuraauthor=S.+H%C3%B6ning&title=Binding+of+AP2+to+sorting+signals+is+modulated+by+AP2+phosphorylation&doi=10.1074%2Fjbc.M009516200"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Binding of AP2 to sorting signals is modulated by AP2 phosphorylation</span></div><div class="casAuthors">Fingerhut, Anja; Von Figura, Kurt; Honing, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">5476-5482</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The two clathrin-assocd. adaptor complexes AP1 and AP2 are known to participate in the formation of clathrin-coated vesicles at the trans-Golgi network and at the plasma membrane.  During this process adaptors are involved in the sequestration of vesicle cargo by binding to the sorting signals within the cytoplasmic domains of the cargo proteins and in the recruitment of the clathrin coat.  After budding of the clathrin-coated vesicles, the clathrin and adaptors dissoc. from the vesicles.  Here we show that in vitro binding of AP2 to sorting signals, which is one of the initial steps in receptor-mediated endocytosis, is modulated by adaptor phosphorylation.  AP2 was phosphorylated by incubating purified AP2 in the presence of ATP and dephosphorylated by incubation with alk. phosphatase.  Affinity for tyrosine-, leucine-based and noncanonical sorting motifs was 15-33 times higher for phosphorylated than for dephosphorylated AP2.  Also the binding of AP2 to membranes was regulated by adaptor phosphorylation/dephosphorylation and was about 8-fold higher for phosphorylated than for dephosphorylated AP2.  Moreover, AP2 isolated from cytosol is higher phosphorylated than membrane-extd. and exhibits a 5-fold higher binding affinity than AP2 extd. from membranes.  Taken together these data point to a cycle of phosphorylation/dephosphorylation as a mechanism for regulating the reversible assocn. of AP2 with membranes and sorting signals during the process of receptor-mediated endocytosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocki1UZ6U8u7Vg90H21EOLACvtfcHk0li-PO4P0nydig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhs1Kms7s%253D&md5=765a830509af4acb2d140e17d878640a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M009516200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M009516200%26sid%3Dliteratum%253Aachs%26aulast%3DFingerhut%26aufirst%3DA.%26aulast%3Dvon%2BFigura%26aufirst%3DK.%26aulast%3DH%25C3%25B6ning%26aufirst%3DS.%26atitle%3DBinding%2520of%2520AP2%2520to%2520sorting%2520signals%2520is%2520modulated%2520by%2520AP2%2520phosphorylation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2001%26volume%3D276%26spage%3D5476%26epage%3D5482%26doi%3D10.1074%2Fjbc.M009516200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ricotta, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Comer, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmid, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">von Figura, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Höning, S.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of the AP2 μ subunit by AAK1 mediates high affinity binding to the membrane protein sorting signals</span>. <i>J. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>156</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">795</span>, <span class="refDoi"> DOI: 10.1083/jcb.200111068</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1083%2Fjcb.200111068" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=11877457" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD38XitVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=156&publication_year=2002&pages=791-795&author=D.+Ricottaauthor=S.+D.+Comerauthor=S.+L.+Schmidauthor=K.+von+Figuraauthor=S.+H%C3%B6ning&title=Phosphorylation+of+the+AP2+%CE%BC+subunit+by+AAK1+mediates+high+affinity+binding+to+the+membrane+protein+sorting+signals&doi=10.1083%2Fjcb.200111068"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of the AP2 μ subunit by AAK1 mediates high affinity binding to membrane protein sorting signals</span></div><div class="casAuthors">Ricotta, Doris; Conner, Sean D.; Schmid, Sandra L.; Von Figura, Kurt; Honing, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Biology</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">156</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">791-795</span>CODEN:
                <span class="NLM_cas:coden">JCLBA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9525</span>.
    
            (<span class="NLM_cas:orgname">Rockefeller University Press</span>)
        </div><div class="casAbstract">During receptor-mediated endocytosis, AP2 complexes act as a bridge between the cargo membrane proteins and the clathrin coat by binding to sorting signals via the μ2 subunit and to clathrin via the β subunit.  Here we show that binding of AP2 to sorting signals in vitro is regulated by phosphorylation of the μ2 subunit of AP2.  Phosphorylation of μ2 enhances the binding affinity of AP2 for sorting motifs as much as 25-fold compared with dephosphorylated AP2.  The recognition of sorting signals was not affected by the phosphorylation status of the α or β2 subunit, suggesting that phosphorylation of μ2 is crit. for regulation of AP2 binding to sorting signals.  Phosphorylation of μ2 occurs at a single threonine residue (Thr-156) and is mediated by the newly discovered adaptor-assocd. kinase, AAK1, which copurifies with AP2.  We propose that phosphorylation of the AP2 μ2 subunit by AAK1 ensures high affinity binding of AP2 to sorting signals of cargo membrane proteins during the initial steps of receptor-mediated endocytosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpo_Waay05sbVg90H21EOLACvtfcHk0li-PO4P0nydig"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitVGmsbs%253D&md5=50e5a561308f7351a21ef8cc4eb7f35c</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1083%2Fjcb.200111068&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1083%252Fjcb.200111068%26sid%3Dliteratum%253Aachs%26aulast%3DRicotta%26aufirst%3DD.%26aulast%3DComer%26aufirst%3DS.%2BD.%26aulast%3DSchmid%26aufirst%3DS.%2BL.%26aulast%3Dvon%2BFigura%26aufirst%3DK.%26aulast%3DH%25C3%25B6ning%26aufirst%3DS.%26atitle%3DPhosphorylation%2520of%2520the%2520AP2%2520%25CE%25BC%2520subunit%2520by%2520AAK1%2520mediates%2520high%2520affinity%2520binding%2520to%2520the%2520membrane%2520protein%2520sorting%2520signals%26jtitle%3DJ.%2520Cell%2520Biol.%26date%3D2002%26volume%3D156%26spage%3D791%26epage%3D795%26doi%3D10.1083%2Fjcb.200111068" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olusanya, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrews, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swedlow, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smythe, E.</span></span> <span> </span><span class="NLM_article-title">Phosphorylation of threonine 156 of the μ2 subunit of the AP2 complex is essential for endocytosis in vitro and in vivo</span>. <i>Curr. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">896</span>– <span class="NLM_lpage">900</span>, <span class="refDoi"> DOI: 10.1016/S0960-9822(01)00240-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2FS0960-9822%2801%2900240-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=11516654" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD3MXksVKjs7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=896-900&author=O.+Olusanyaauthor=P.+D.+Andrewsauthor=J.+R.+Swedlowauthor=E.+Smythe&title=Phosphorylation+of+threonine+156+of+the+%CE%BC2+subunit+of+the+AP2+complex+is+essential+for+endocytosis+in+vitro+and+in+vivo&doi=10.1016%2FS0960-9822%2801%2900240-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphorylation of threonine 156 of the μ2 subunit of the AP2 complex is essential for endocytosis in vitro and in vivo</span></div><div class="casAuthors">Olusanya, O.; Andrews, P. D.; Swedlow, J. R.; Smythe, E.</div><div class="citationInfo"><span class="NLM_cas:title">Current Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">896-900</span>CODEN:
                <span class="NLM_cas:coden">CUBLE2</span>;
        ISSN:<span class="NLM_cas:issn">0960-9822</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The clathrin-coated pit is the major port of entry for many receptors and pathogens and is the paradigm for membrane-based sorting events in higher cells [1].  Recently, it has been possible to reconstitute in vitro the events leading to assembly, invagination, and budding off of clathrin-coated vesicles, allowing dissection of the machinery required for sequestration of receptors into these structures [2-6].  The AP2 adaptor complex is a key element of this machinery linking receptors to the coat lattice, and it has previously been reported that AP2 can be phosphorylated both in vitro and in vivo [7-10].  However, the physiol. significance of this has never been established.  Here, we show that phosphorylation of a single threonine residue (Thr156) of the μ2 subunit of the AP2 complex is essential for efficient endocytosis of transferrin both in an in vitro coated-pit budding assay and in living cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp42ua1wdmr2LVg90H21EOLACvtfcHk0lg3C1PNYUQ_lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXksVKjs7s%253D&md5=67e1fafc2f12fbc68c42587e178ba8b4</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1016%2FS0960-9822%2801%2900240-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-9822%252801%252900240-8%26sid%3Dliteratum%253Aachs%26aulast%3DOlusanya%26aufirst%3DO.%26aulast%3DAndrews%26aufirst%3DP.%2BD.%26aulast%3DSwedlow%26aufirst%3DJ.%2BR.%26aulast%3DSmythe%26aufirst%3DE.%26atitle%3DPhosphorylation%2520of%2520threonine%2520156%2520of%2520the%2520%25CE%25BC2%2520subunit%2520of%2520the%2520AP2%2520complex%2520is%2520essential%2520for%2520endocytosis%2520in%2520vitro%2520and%2520in%2520vivo%26jtitle%3DCurr.%2520Biol.%26date%3D2001%26volume%3D11%26spage%3D896%26epage%3D900%26doi%3D10.1016%2FS0960-9822%2801%2900240-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kostich, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naidu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dandapani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Easton, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bourin, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savelieva, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Louis, J. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dokania, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elavazhagan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vattikundala, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shankar, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holenarsipur, V. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gulianello, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molski, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pieschl, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Malley, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lippy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nouraldeen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanthorn, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balakrishnan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denton, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grace, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lentz, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santone, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Main, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swaffield, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandlekar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vikramadithyan, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nara, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dzierba, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bronson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaczek, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westphal, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiss, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bristow, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conway, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zambrowicz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albright, C. F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>358</i></span>,  <span class="NLM_fpage">371</span>– <span class="NLM_lpage">386</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.235333</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1124%2Fjpet.116.235333" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=27411717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC28XhvVyks7rI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=358&publication_year=2016&pages=371-386&author=W.+Kostichauthor=B.+D.+Hammanauthor=Y.-W.+Liauthor=S.+Naiduauthor=K.+Dandapaniauthor=J.+Fengauthor=A.+Eastonauthor=C.+Bourinauthor=K.+Bakerauthor=J.+Allenauthor=K.+Savelievaauthor=J.+V.+Louisauthor=M.+Dokaniaauthor=S.+Elavazhaganauthor=P.+Vattikundalaauthor=V.+Sharmaauthor=M.+L.+Dasauthor=G.+Shankarauthor=A.+Kumarauthor=V.+K.+Holenarsipurauthor=M.+Gulianelloauthor=T.+Molskiauthor=J.+M.+Brownauthor=M.+Lewisauthor=Y.+Huangauthor=Y.+Luauthor=R.+Pieschlauthor=K.+O%E2%80%99Malleyauthor=J.+Lippyauthor=A.+Nouraldeenauthor=T.+H.+Lanthornauthor=G.+Yeauthor=A.+Wilsonauthor=A.+Balakrishnanauthor=R.+Dentonauthor=J.+E.+Graceauthor=K.+A.+Lentzauthor=K.+S.+Santoneauthor=Y.+Biauthor=A.+Mainauthor=J.+Swaffieldauthor=K.+Carsonauthor=S.+Mandlekarauthor=R.+K.+Vikramadithyanauthor=S.+J.+Naraauthor=C.+Dzierbaauthor=J.+Bronsonauthor=J.+E.+Macorauthor=R.+Zaczekauthor=R.+Westphalauthor=L.+Kissauthor=L.+Bristowauthor=C.+M.+Conwayauthor=B.+Zambrowiczauthor=C.+F.+Albright&title=Inhibition+of+AAK1+kinase+as+a+novel+therapeutic+approach+to+treat+neuropathic+pain&doi=10.1124%2Fjpet.116.235333"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain</span></div><div class="casAuthors">Kostich, Walter; Hamman, Brian D.; Li, Yu-Wen; Naidu, Sreenivasulu; Dandapani, Kumaran; Feng, Jianlin; Easton, Amy; Bourin, Clotilde; Baker, Kevin; Allen, Jason; Savelieva, Katerina; Louis, Justin V.; Dokania, Manoj; Elavazhagan, Saravanan; Vattikundala, Pradeep; Sharma, Vivek; Das, Manish Lal; Shankar, Ganesh; Kumar, Anoop; Holenarsipur, Vinay K.; Gulianello, Michael; Molski, Ted; Brown, Jeffrey M.; Lewis, Martin; Huang, Yanling; Lu, Yifeng; Pieschl, Rick; O'Malley, Kevin; Lippy, Jonathan; Nouraldeen, Amr; Lanthorn, Thomas H.; Ye, Guilan; Wilson, Alan; Balakrishnan, Anand; Denton, Rex; Grace, James E.; Lentz, Kimberley A.; Santone, Kenneth S.; Bi, Yingzhi; Main, Alan; Swaffield, Jon; Carson, Ken; Mandlekar, Sandhya; Vikramadithyan, Reeba K.; Nara, Susheel J.; Dzierba, Carolyn; Bronson, Joanne; Macor, John E.; Zaczek, Robert; Westphal, Ryan; Kiss, Laszlo; Bristow, Linda; Conway, Charles M.; Zambrowicz, Brian; Albright, Charles F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">358</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">371-386</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">To identify novel targets for neuropathic pain, 3097 mouse knockout lines were tested in acute and persistent pain behavior assays.  One of the lines from this screen, which contained a null allele of the adapter protein-2 assocd. kinase 1 (AAK1) gene, had a normal response in acute pain assays (hot plate, phase I formalin), but a markedly reduced response to persistent pain in phase II formalin.  AAK1 knockout mice also failed to develop tactile allodynia following the Chung procedure of spinal nerve ligation (SNL).  Based on these findings, potent, small-mol. inhibitors of AAK1 were identified.  Studies in mice showed that one such inhibitor, LP-935509, caused a reduced pain response in phase II formalin and reversed fully established pain behavior following the SNL procedure.  Further studies showed that the inhibitor also reduced evoked pain responses in the rat chronic constriction injury (CCI) model and the rat streptozotocin model of diabetic peripheral neuropathy.  Using a nonbrain-penetrant AAK1 inhibitor and local administration of an AAK1 inhibitor, the relevant pool of AAK1 for antineuropathic action was found to be in the spinal cord.  Consistent with these results, AAK1 inhibitors dose-dependently reduced the increased spontaneous neural activity in the spinal cord caused by CCI and blocked the development of windup induced by repeated elec. stimulation of the paw.  The mechanism of AAK1 antinociception was further investigated with inhibitors of α2 adrenergic and opioid receptors.  These studies showed that α2 adrenergic receptor inhibitors, but not opioid receptor inhibitors, not only prevented AAK1 inhibitor antineuropathic action in behavioral assays, but also blocked the AAK1 inhibitor-induced redn. in spinal neural activity in the rat CCI model.  Hence, AAK1 inhibitors are a novel therapeutic approach to neuropathic pain with activity in animal models that is mechanistically linked (behaviorally and electrophysiol.) to α2 adrenergic signaling, a pathway known to be antinociceptive in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5cJpGeOPjm7Vg90H21EOLACvtfcHk0lg3C1PNYUQ_lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhvVyks7rI&md5=d4cec6b3681b63ba7d9119424e53ab61</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.235333&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.235333%26sid%3Dliteratum%253Aachs%26aulast%3DKostich%26aufirst%3DW.%26aulast%3DHamman%26aufirst%3DB.%2BD.%26aulast%3DLi%26aufirst%3DY.-W.%26aulast%3DNaidu%26aufirst%3DS.%26aulast%3DDandapani%26aufirst%3DK.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DEaston%26aufirst%3DA.%26aulast%3DBourin%26aufirst%3DC.%26aulast%3DBaker%26aufirst%3DK.%26aulast%3DAllen%26aufirst%3DJ.%26aulast%3DSavelieva%26aufirst%3DK.%26aulast%3DLouis%26aufirst%3DJ.%2BV.%26aulast%3DDokania%26aufirst%3DM.%26aulast%3DElavazhagan%26aufirst%3DS.%26aulast%3DVattikundala%26aufirst%3DP.%26aulast%3DSharma%26aufirst%3DV.%26aulast%3DDas%26aufirst%3DM.%2BL.%26aulast%3DShankar%26aufirst%3DG.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DHolenarsipur%26aufirst%3DV.%2BK.%26aulast%3DGulianello%26aufirst%3DM.%26aulast%3DMolski%26aufirst%3DT.%26aulast%3DBrown%26aufirst%3DJ.%2BM.%26aulast%3DLewis%26aufirst%3DM.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DPieschl%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Malley%26aufirst%3DK.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DNouraldeen%26aufirst%3DA.%26aulast%3DLanthorn%26aufirst%3DT.%2BH.%26aulast%3DYe%26aufirst%3DG.%26aulast%3DWilson%26aufirst%3DA.%26aulast%3DBalakrishnan%26aufirst%3DA.%26aulast%3DDenton%26aufirst%3DR.%26aulast%3DGrace%26aufirst%3DJ.%2BE.%26aulast%3DLentz%26aufirst%3DK.%2BA.%26aulast%3DSantone%26aufirst%3DK.%2BS.%26aulast%3DBi%26aufirst%3DY.%26aulast%3DMain%26aufirst%3DA.%26aulast%3DSwaffield%26aufirst%3DJ.%26aulast%3DCarson%26aufirst%3DK.%26aulast%3DMandlekar%26aufirst%3DS.%26aulast%3DVikramadithyan%26aufirst%3DR.%2BK.%26aulast%3DNara%26aufirst%3DS.%2BJ.%26aulast%3DDzierba%26aufirst%3DC.%26aulast%3DBronson%26aufirst%3DJ.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DZaczek%26aufirst%3DR.%26aulast%3DWestphal%26aufirst%3DR.%26aulast%3DKiss%26aufirst%3DL.%26aulast%3DBristow%26aufirst%3DL.%26aulast%3DConway%26aufirst%3DC.%2BM.%26aulast%3DZambrowicz%26aufirst%3DB.%26aulast%3DAlbright%26aufirst%3DC.%2BF.%26atitle%3DInhibition%2520of%2520AAK1%2520kinase%2520as%2520a%2520novel%2520therapeutic%2520approach%2520to%2520treat%2520neuropathic%2520pain%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2016%26volume%3D358%26spage%3D371%26epage%3D386%26doi%3D10.1124%2Fjpet.116.235333" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dubuisson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dennis, S. G.</span></span> <span> </span><span class="NLM_article-title">The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">174</span>, <span class="refDoi"> DOI: 10.1016/0304-3959(77)90130-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2F0304-3959%2877%2990130-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=564014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADyaE1cXhsVGrt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=1977&pages=161-174&author=D.+Dubuissonauthor=S.+G.+Dennis&title=The+formalin+test%3A+a+quantitative+study+of+the+analgesic+effects+of+morphine%2C+meperidine%2C+and+brain+stem+stimulation+in+rats+and+cats&doi=10.1016%2F0304-3959%2877%2990130-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">The formalin test:  a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats</span></div><div class="casAuthors">Dubuisson, David; Dennis, Stephen G.</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-74</span>CODEN:
                <span class="NLM_cas:coden">PAINDB</span>;
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    </div><div class="casAbstract">In a procedure to evaluate the analgesic strengths of morphine sulfate  [64-31-3] and meperidine-HCl  [50-13-5], cats or rats, which were pretreated with an appropriate analgesic dose of either drug, were injected with a soln. of formalin  [50-00-0] in the paws and the pain-related behavior was obsd. and compared with that obsd. in the control animals which received formalin but no analgesic.  Pretreatment with either of the 2 analgesics or brain stem stimulation significantly decreased the effect of the pain stimuli.  Morphine and brain stem stimulation provided similar and greater analgesia than meperidine.  The behavioral patterns of the animals seemed to be similar following morphine or the brain stem stimultion.  Thus, formalin injection can be used effectively to evaluate the potencies of analgesics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod0ErPKDkXGbVg90H21EOLACvtfcHk0lg3C1PNYUQ_lQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE1cXhsVGrt7s%253D&md5=bd26bbc3c46b9c964d0b3aa011580980</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2F0304-3959%2877%2990130-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3959%252877%252990130-0%26sid%3Dliteratum%253Aachs%26aulast%3DDubuisson%26aufirst%3DD.%26aulast%3DDennis%26aufirst%3DS.%2BG.%26atitle%3DThe%2520formalin%2520test%253A%2520a%2520quantitative%2520study%2520of%2520the%2520analgesic%2520effects%2520of%2520morphine%252C%2520meperidine%252C%2520and%2520brain%2520stem%2520stimulation%2520in%2520rats%2520and%2520cats%26jtitle%3DPain%26date%3D1977%26volume%3D4%26spage%3D161%26epage%3D174%26doi%3D10.1016%2F0304-3959%2877%2990130-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chung, J. M.</span></span> <span> </span><span class="NLM_article-title">An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>50</i></span>,  <span class="NLM_fpage">355</span>– <span class="NLM_lpage">363</span>, <span class="refDoi"> DOI: 10.1016/0304-3959(92)90041-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2F0304-3959%2892%2990041-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1333581" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADyaK3s%252FoslShtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=1992&pages=355-363&author=S.+H.+Kimauthor=J.+M.+Chung&title=An+experimental+model+for+peripheral+neuropathy+produced+by+segmental+spinal+nerve+ligation+in+the+rat&doi=10.1016%2F0304-3959%2892%2990041-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat</span></div><div class="casAuthors">Kim S H; Chung J M</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">355-63</span>
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    </div><div class="casAbstract">We attempted to develop an experimental animal model for peripheral neuropathic pain.  Under sodium pentobarbital anesthesia, both the L5 and L6 spinal nerves (group 1) or the L5 spinal nerve alone (group 2) of one side of the rat were tightly ligated.  For comparison, a parallel study was conducted with another group of rats (group 3) which received a partial tight sciatic nerve ligation, a paradigm developed previously as a neuropathy model.  Withdrawal latencies to application of radiant heat to the foot were tested for the next 16 weeks in all 3 groups.  Sensitivity of the hind paw to mechanical stimulation was tested with von Frey filaments.  The general behavior of each rat was noted during the entire test period.  Results suggested that the surgical procedure in all 3 groups produced a long-lasting hyperalgesia to noxious heat (at least 5 weeks) and mechanical allodynia (at least 10 weeks) of the affected foot.  In addition, there were behavioral signs of the presence of spontaneous pain in the affected foot.  Therefore, we believe we have developed an experimental animal model for peripheral neuropathy using tight ligations of spinal nerves.  The model manifests the symptoms of human patients with causalgia and is compatible with a previously developed neuropathy model.  The present model has two unique features.  First, the surgical procedure is stereotyped.  Second, the levels of injured and intact spinal segments are completely separated, allowing independent experimental manipulations of the injured and intact spinal segments in future experiments to answer questions regarding mechanisms underlying causalgia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSEPstJUQcfvtj_Vg2vObihfW6udTcc2ea_TfrXUZfHKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s%252FoslShtw%253D%253D&md5=13917a9997b26f37cd039fa54ee7eb36</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2F0304-3959%2892%2990041-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3959%252892%252990041-9%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DChung%26aufirst%3DJ.%2BM.%26atitle%3DAn%2520experimental%2520model%2520for%2520peripheral%2520neuropathy%2520produced%2520by%2520segmental%2520spinal%2520nerve%2520ligation%2520in%2520the%2520rat%26jtitle%3DPain%26date%3D1992%26volume%3D50%26spage%3D355%26epage%3D363%26doi%3D10.1016%2F0304-3959%2892%2990041-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ye, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savelieva, K. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lanthorn, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajan, I.</span></span> <span> </span><span class="NLM_article-title">Ligation of mouse L4 and L5 spinal nerves produces robust allodynia without major motor function deficit</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>276</i></span>,  <span class="NLM_fpage">99</span>– <span class="NLM_lpage">110</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2014.04.039</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2Fj.bbr.2014.04.039" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=24786331" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADC%252BC2cnos1SqsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=276&publication_year=2015&pages=99-110&author=G.+L.+Yeauthor=K.+V.+Savelievaauthor=P.+Vogelauthor=K.+B.+Bakerauthor=S.+Masonauthor=T.+H.+Lanthornauthor=I.+Rajan&title=Ligation+of+mouse+L4+and+L5+spinal+nerves+produces+robust+allodynia+without+major+motor+function+deficit&doi=10.1016%2Fj.bbr.2014.04.039"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Ligation of mouse L4 and L5 spinal nerves produces robust allodynia without major motor function deficit</span></div><div class="casAuthors">Ye Gui-Lan; Savelieva Katerina V; Vogel Peter; Baker Kevin B; Mason Sara; Lanthorn Thomas H; Rajan Indrani</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural brain research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">276</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">99-110</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Spinal nerve L5/L6 ligation (SNL) in rats has become the standard for mechanistic studies of peripheral neuropathy and screening for novel analgesics.  Conventional SNL in our hybrid mice resulted in a wide range of allodynia.  Anatomical evaluation indicated that a variable number of lumbar vertebrae existed, resulting in L4/L5 or L5/L6 being ligated.  Surprisingly, L4/L5 ligation did not result in ipsilateral hind limb paralysis and produced robust allodynia.  Following a recent report that the mouse L4 neural segment is homologous with rat L5 we generated L4, L5 or both L4 and L5 (L4/L5) ligations in C57 mice after establishing a modified set of surgical landmarks.  In contrast to rats, L4 ligation in these mice did not result in hind limb paralysis.  Robust allodynia was observed in all three ligation groups.  Nerve degeneration confirmed that L4 and L5, respectively, are primary contributors to the tibial and sural branches of the sciatic nerve in mice.  A larger von Frey sensitive area reflected the wider distribution of Wallerian degeneration in the hindlimb of L4- compared to L5-ligated mice.  Ligation of mouse L4 and L5 spinal nerves produces consistent, robust neuropathic pain behaviors and is suitable as a model for investigating mechanisms of neuropathic pain and for testing of novel analgesics.  Gabapentin, used as a validation drug in neuropathic pain models and as a reference compound for novel analgesics, significantly reduced allodynia in the mice tested (L4/L5 ligations).  Given the ease of surgery, robust allodynia, and larger von Frey sensitive area, we conclude that combined ligation of spinal nerves L4 and L5 optimizes the SNL model in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDf16bjaY9LIJKJbLTgsvCfW6udTcc2ea_TfrXUZfHKrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cnos1SqsQ%253D%253D&md5=89dad62c7ec62b9c961e734280dd7265</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2014.04.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2014.04.039%26sid%3Dliteratum%253Aachs%26aulast%3DYe%26aufirst%3DG.%2BL.%26aulast%3DSavelieva%26aufirst%3DK.%2BV.%26aulast%3DVogel%26aufirst%3DP.%26aulast%3DBaker%26aufirst%3DK.%2BB.%26aulast%3DMason%26aufirst%3DS.%26aulast%3DLanthorn%26aufirst%3DT.%2BH.%26aulast%3DRajan%26aufirst%3DI.%26atitle%3DLigation%2520of%2520mouse%2520L4%2520and%2520L5%2520spinal%2520nerves%2520produces%2520robust%2520allodynia%2520without%2520major%2520motor%2520function%2520deficit%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2015%26volume%3D276%26spage%3D99%26epage%3D110%26doi%3D10.1016%2Fj.bbr.2014.04.039" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, W.</span></span> <span> </span><span class="NLM_article-title">Single-cell RNA expression profiling of ACE2, the putative receptor of SARS-CoV-2</span>. <i>Am. J. Respir. Crit. Care Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>202</i></span>,  <span class="NLM_fpage">756</span>– <span class="NLM_lpage">759</span>, <span class="refDoi"> DOI: 10.1164/rccm.202001-0179LE</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1164%2Frccm.202001-0179LE" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=32663409" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BB3cXitF2gs7fO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=2020&pages=756-759&author=Y.+Zhaoauthor=Z.+Zhaoauthor=Y.+Wangauthor=Y.+Zhouauthor=Y.+Maauthor=W.+Zuo&title=Single-cell+RNA+expression+profiling+of+ACE2%2C+the+putative+receptor+of+SARS-CoV-2&doi=10.1164%2Frccm.202001-0179LE"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Single-cell RNA expression profiling of ACE2, the receptor of SARS-CoV-2</span></div><div class="casAuthors">Zhao, Yu; Zhao, Zixian; Wang, Yujia; Zhou, Yueqing; Ma, Yu; Zuo, Wei</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Respiratory and Critical Care Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">756-759</span>CODEN:
                <span class="NLM_cas:coden">AJCMED</span>;
        ISSN:<span class="NLM_cas:issn">1073-449X</span>.
    
            (<span class="NLM_cas:orgname">American Thoracic Society</span>)
        </div><div class="casAbstract">In this paper presents single-cell RNA expression profiling of ACE2, receptor of SARS-CoV-2.  We report the RNA expression profile of ACE2 in the human lung at single-cell resoln.  The tissue expression and distribution of the receptor decide the tropism of the virus infection, which has a major implication for understanding its pathogenesis and designing therapeutic strategies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoyOY88-7eNjLVg90H21EOLACvtfcHk0lhL-AM_g8NAAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXitF2gs7fO&md5=34e7c584b254fa5c88e6ca0bc7058f2c</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1164%2Frccm.202001-0179LE&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1164%252Frccm.202001-0179LE%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DY.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DY.%26aulast%3DZuo%26aufirst%3DW.%26atitle%3DSingle-cell%2520RNA%2520expression%2520profiling%2520of%2520ACE2%252C%2520the%2520putative%2520receptor%2520of%2520SARS-CoV-2%26jtitle%3DAm.%2520J.%2520Respir.%2520Crit.%2520Care%2520Med.%26date%3D2020%26volume%3D202%26spage%3D756%26epage%3D759%26doi%3D10.1164%2Frccm.202001-0179LE" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holmes, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, G. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, W.</span></span> <span> </span><span class="NLM_article-title">Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>395</i></span>,  <span class="NLM_fpage">565</span>– <span class="NLM_lpage">574</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(20)30251-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2FS0140-6736%2820%2930251-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=32007145" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhvFOmsLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=395&publication_year=2020&pages=565-574&author=R.+Luauthor=X.+Zhaoauthor=J.+Liauthor=P.+Niuauthor=B.+Yangauthor=H.+Wuauthor=W.+Wangauthor=H.+Songauthor=B.+Huangauthor=N.+Zhuauthor=Y.+Biauthor=X.+Maauthor=F.+Zhanauthor=L.+Wangauthor=T.+Huauthor=H.+Zhouauthor=Z.+Huauthor=W.+Zhouauthor=L.+Zhaoauthor=J.+Chenauthor=Y.+Mengauthor=J.+Wangauthor=Y.+Linauthor=J.+Yuanauthor=Z.+Xieauthor=J.+Maauthor=W.+J.+Liuauthor=D.+Wangauthor=W.+Xuauthor=E.+C.+Holmesauthor=G.+F.+Gaoauthor=G.+Wuauthor=W.+Chenauthor=W.+Shiauthor=W.+Tan&title=Genomic+characterisation+and+epidemiology+of+2019+novel+coronavirus%3A+implications+for+virus+origins+and+receptor+binding&doi=10.1016%2FS0140-6736%2820%2930251-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding</span></div><div class="casAuthors">Lu, Roujian; Zhao, Xiang; Li, Juan; Niu, Peihua; Yang, Bo; Wu, Honglong; Wang, Wenling; Song, Hao; Huang, Baoying; Zhu, Na; Bi, Yuhai; Ma, Xuejun; Zhan, Faxian; Wang, Liang; Hu, Tao; Zhou, Hong; Hu, Zhenhong; Zhou, Weimin; Zhao, Li; Chen, Jing; Meng, Yao; Wang, Ji; Lin, Yang; Yuan, Jianying; Xie, Zhihao; Ma, Jinmin; Liu, William J.; Wang, Dayan; Xu, Wenbo; Holmes, Edward C.; Gao, George F.; Wu, Guizhen; Chen, Weijun; Shi, Weifeng; Tan, Wenjie</div><div class="citationInfo"><span class="NLM_cas:title">Lancet</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">395</span>
        (<span class="NLM_cas:issue">10224</span>),
    <span class="NLM_cas:pages">565-574</span>CODEN:
                <span class="NLM_cas:coden">LANCAO</span>;
        ISSN:<span class="NLM_cas:issn">0140-6736</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">In late Dec., 2019, patients presenting with viral pneumonia due to an unidentified microbial agent were reported in Wuhan, China.  A novel coronavirus was subsequently identified as the causative pathogen, provisionally named 2019 novel coronavirus (2019-nCoV).  As of Jan 26, 2020, more than 2000 cases of 2019-nCoV infection have been confirmed, most of which involved people living in or visiting Wuhan, and human-to-human transmission has been confirmed.  We did next-generation sequencing of samples from bronchoalveolar lavage fluid and cultured isolates from nine inpatients, eight of whom had visited the Huanan seafood market in Wuhan.  Complete and partial 2019-nCoV genome sequences were obtained from these individuals.  Viral contigs were connected using Sanger sequencing to obtain the full-length genomes, with the terminal regions detd. by rapid amplification of cDNA ends.  Phylogenetic anal. of these 2019-nCoV genomes and those of other coronaviruses was used to det. the evolutionary history of the virus and help infer its likely origin.  Homol. modeling was done to explore the likely receptor-binding properties of the virus.  The ten genome sequences of 2019-nCoV obtained from the nine patients were extremely similar, exhibiting more than 99·98% sequence identity.  Notably, 2019-nCoV was closely related (with 88% identity) to two bat-derived severe acute respiratory syndrome (SARS)-like coronaviruses, bat-SL-CoVZC45 and bat-SL-CoVZXC21, collected in 2018 in Zhoushan, eastern China, but were more distant from SARS-CoV (about 79%) and MERS-CoV (about 50%).  Phylogenetic anal. revealed that 2019-nCoV fell within the subgenus Sarbecovirus of the genus Betacoronavirus, with a relatively long branch length to its closest relatives bat-SL-CoVZC45 and bat-SL-CoVZXC21, and was genetically distinct from SARS-CoV.  Notably, homol. modeling revealed that 2019-nCoV had a similar receptor-binding domain structure to that of SARS-CoV, despite amino acid variation at some key residues.2019-nCoV is sufficiently divergent from SARS-CoV to be considered a new human-infecting betacoronavirus.  Although our phylogenetic anal. suggests that bats might be the original host of this virus, an animal sold at the seafood market in Wuhan might represent an intermediate host facilitating the emergence of the virus in humans.  Importantly, structural anal. suggests that 2019-nCoV might be able to bind to the angiotensin-converting enzyme 2 receptor in humans.  The future evolution, adaptation, and spread of this virus warrant urgent investigation.  National Key Research and Development Program of China, National Major Project for Control and Prevention of Infectious Disease in China, Chinese Academy of Sciences, Shandong First Medical University.  These data have been deposited in the ChinaNational Microbiol. Data Center (accession no. NMDC10013002 and genome accession nos. NMDC60013002-01 to NMDC60013002-10) and the datafrom BGI have been deposited in the China National GeneBank (accession nos. CNA000733235).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNSLcS-1ejQbVg90H21EOLACvtfcHk0li5LduRoLWfBw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhvFOmsLY%253D&md5=3a644f602ea1c68114e23b5f12625265</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2820%2930251-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252820%252930251-8%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DR.%26aulast%3DZhao%26aufirst%3DX.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNiu%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DB.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DN.%26aulast%3DBi%26aufirst%3DY.%26aulast%3DMa%26aufirst%3DX.%26aulast%3DZhan%26aufirst%3DF.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DHu%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DH.%26aulast%3DHu%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DMeng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLin%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DXie%26aufirst%3DZ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DW.%2BJ.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DHolmes%26aufirst%3DE.%2BC.%26aulast%3DGao%26aufirst%3DG.%2BF.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DShi%26aufirst%3DW.%26aulast%3DTan%26aufirst%3DW.%26atitle%3DGenomic%2520characterisation%2520and%2520epidemiology%2520of%25202019%2520novel%2520coronavirus%253A%2520implications%2520for%2520virus%2520origins%2520and%2520receptor%2520binding%26jtitle%3DLancet%26date%3D2020%26volume%3D395%26spage%3D565%26epage%3D574%26doi%3D10.1016%2FS0140-6736%2820%2930251-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pottoo, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abu-Izneid, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ibrahim, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Javed, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">AlHajri, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamrouni, A. M.</span></span> <span> </span><span class="NLM_article-title">Immune system response during viral infections: immunomodulators, cytokine storm (CS) and immunotherapeutics in COVID-19</span>. <i>Saudi Pharm. J.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">173</span>– <span class="NLM_lpage">187</span>, <span class="refDoi"> DOI: 10.1016/j.jsps.2020.12.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2Fj.jsps.2020.12.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=33519271" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2021&pages=173-187&author=F.+H.+Pottooauthor=T.+Abu-Izneidauthor=A.+M.+Ibrahimauthor=M.+N.+Javedauthor=N.+AlHajriauthor=A.+M.+Hamrouni&title=Immune+system+response+during+viral+infections%3A+immunomodulators%2C+cytokine+storm+%28CS%29+and+immunotherapeutics+in+COVID-19&doi=10.1016%2Fj.jsps.2020.12.018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.jsps.2020.12.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsps.2020.12.018%26sid%3Dliteratum%253Aachs%26aulast%3DPottoo%26aufirst%3DF.%2BH.%26aulast%3DAbu-Izneid%26aufirst%3DT.%26aulast%3DIbrahim%26aufirst%3DA.%2BM.%26aulast%3DJaved%26aufirst%3DM.%2BN.%26aulast%3DAlHajri%26aufirst%3DN.%26aulast%3DHamrouni%26aufirst%3DA.%2BM.%26atitle%3DImmune%2520system%2520response%2520during%2520viral%2520infections%253A%2520immunomodulators%252C%2520cytokine%2520storm%2520%2528CS%2529%2520and%2520immunotherapeutics%2520in%2520COVID-19%26jtitle%3DSaudi%2520Pharm.%2520J.%26date%3D2021%26volume%3D29%26spage%3D173%26epage%3D187%26doi%3D10.1016%2Fj.jsps.2020.12.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, Z.</span></span> <span> </span><span class="NLM_article-title">Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19</span>. <i>Int. J. Immunopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>86</i></span>,  <span class="NLM_fpage">106749</span>, <span class="refDoi"> DOI: 10.1016/j.intimp.2020.106749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2Fj.intimp.2020.106749" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=86&publication_year=2020&pages=106749&author=X.+Zhangauthor=Y.+Zhangauthor=W.+Qiaoauthor=J.+Zhangauthor=Z.+Qi&title=Baricitinib%2C+a+drug+with+potential+effect+to+prevent+SARS-COV-2+from+entering+target+cells+and+control+cytokine+storm+induced+by+COVID-19&doi=10.1016%2Fj.intimp.2020.106749"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.intimp.2020.106749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.intimp.2020.106749%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DQiao%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DQi%26aufirst%3DZ.%26atitle%3DBaricitinib%252C%2520a%2520drug%2520with%2520potential%2520effect%2520to%2520prevent%2520SARS-COV-2%2520from%2520entering%2520target%2520cells%2520and%2520control%2520cytokine%2520storm%2520induced%2520by%2520COVID-19%26jtitle%3DInt.%2520J.%2520Immunopharmacol.%26date%3D2020%26volume%3D86%26spage%3D106749%26doi%3D10.1016%2Fj.intimp.2020.106749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fridman, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scherle, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burn, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Covington, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collier, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Favata, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGee, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haley, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shepard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodgers, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeleswaram, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollis, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newton, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Metcalf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaddi, K.</span></span> <span> </span><span class="NLM_article-title">Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>184</i></span>,  <span class="NLM_fpage">5298</span>– <span class="NLM_lpage">5307</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.0902819</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.4049%2Fjimmunol.0902819" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=20363976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=184&publication_year=2010&pages=5298-5307&author=J.+S.+Fridmanauthor=P.+A.+Scherleauthor=R.+Collinsauthor=T.+C.+Burnauthor=Y.+Liauthor=J.+Liauthor=M.+B.+Covingtonauthor=B.+Thomasauthor=P.+Collierauthor=M.+F.+Favataauthor=X.+Wenauthor=J.+Shiauthor=R.+McGeeauthor=P.+J.+Haleyauthor=S.+Shepardauthor=J.+D.+Rodgersauthor=S.+Yeleswaramauthor=G.+Hollisauthor=R.+C.+Newtonauthor=B.+Metcalfauthor=S.+M.+Friedmanauthor=K.+Vaddi&title=Selective+inhibition+of+JAK1+and+JAK2+is+efficacious+in+rodent+models+of+arthritis%3A+preclinical+characterization+of+INCB028050&doi=10.4049%2Fjimmunol.0902819"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050</span></div><div class="casAuthors">Fridman, Jordan S.; Scherle, Peggy A.; Collins, Robert; Burn, Timothy C.; Li, Yanlong; Li, Jun; Covington, Maryanne B.; Thomas, Beth; Collier, Paul; Favata, Margaret F.; Wen, Xiaoming; Shi, Jack; McGee, Ryan; Haley, Patrick J.; Shepard, Stacey; Rodgers, James D.; Yeleswaram, Swamy; Hollis, Greg; Newton, Robert C.; Metcalf, Brian; Friedman, Steven M.; Vaddi, Kris</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">184</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">5298-5307</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Inhibiting signal transduction induced by inflammatory cytokines offers a new approach for the treatment of autoimmune diseases such as rheumatoid arthritis.  Kinase inhibitors have shown promising oral disease-modifying antirheumatic drug potential with efficacy similar to anti-TNF biologics.  Direct and indirect inhibition of the JAKs, with small mol. inhibitors like CP-690,550 and INCB018424 or neutralizing Abs, such as the anti-IL6 receptor Ab tocilizumab, have demonstrated rapid and sustained improvement in clin. measures of disease, consistent with their resp. preclin. expts.  Therefore, it is of interest to identify optimized JAK inhibitors with unique profiles to maximize therapeutic opportunities.  INCB028050 is a selective orally bioavailable JAK1/JAK2 inhibitor with nanomolar potency against JAK1 (5.9 nM) and JAK2 (5.7 nM).  INCB028050 inhibits intracellular signaling of multiple proinflammatory cytokines including IL-6 and IL-23 at concns. <50 nM.  Significant efficacy, as assessed by improvements in clin., histol. and radiog. signs of disease, was achieved in the rat adjuvant arthritis model with doses of INCB028050 providing partial and/or periodic inhibition of JAK1/JAK2 and no inhibition of JAK3.  Diminution of inflammatory Th1 and Th17 assocd. cytokine mRNA levels was obsd. in the draining lymph nodes of treated rats.  INCB028050 was also effective in multiple murine models of arthritis, with no evidence of suppression of humoral immunity or adverse hematol. effects.  These data suggest that fractional inhibition of JAK1 and JAK2 is sufficient for significant activity in autoimmune disease models.  Clin. evaluation of INCB028050 in RA is ongoing.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp4QiklQbX72bVg90H21EOLACvtfcHk0liKZww_p2kV2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXltVGht70%253D&md5=30b22f275eb2ba2dbca7fb7bec768bb9</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.0902819&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.0902819%26sid%3Dliteratum%253Aachs%26aulast%3DFridman%26aufirst%3DJ.%2BS.%26aulast%3DScherle%26aufirst%3DP.%2BA.%26aulast%3DCollins%26aufirst%3DR.%26aulast%3DBurn%26aufirst%3DT.%2BC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DCovington%26aufirst%3DM.%2BB.%26aulast%3DThomas%26aufirst%3DB.%26aulast%3DCollier%26aufirst%3DP.%26aulast%3DFavata%26aufirst%3DM.%2BF.%26aulast%3DWen%26aufirst%3DX.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DMcGee%26aufirst%3DR.%26aulast%3DHaley%26aufirst%3DP.%2BJ.%26aulast%3DShepard%26aufirst%3DS.%26aulast%3DRodgers%26aufirst%3DJ.%2BD.%26aulast%3DYeleswaram%26aufirst%3DS.%26aulast%3DHollis%26aufirst%3DG.%26aulast%3DNewton%26aufirst%3DR.%2BC.%26aulast%3DMetcalf%26aufirst%3DB.%26aulast%3DFriedman%26aufirst%3DS.%2BM.%26aulast%3DVaddi%26aufirst%3DK.%26atitle%3DSelective%2520inhibition%2520of%2520JAK1%2520and%2520JAK2%2520is%2520efficacious%2520in%2520rodent%2520models%2520of%2520arthritis%253A%2520preclinical%2520characterization%2520of%2520INCB028050%26jtitle%3DJ.%2520Immunol.%26date%3D2010%26volume%3D184%26spage%3D5298%26epage%3D5307%26doi%3D10.4049%2Fjimmunol.0902819" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Stebbing, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnan, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Bono, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaviani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casalini, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monteil, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lauschke, V. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mirazimi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Youhanna, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baldanti, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarasini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terres, J. A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nickoloff, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higgs, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rocha, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byers, N. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlichting, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nirula, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cardoso, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Corbellino, M.</span></span>; <span class="NLM_contrib-group">the Sacco Baricitinib Study Group</span> <span> </span><span class="NLM_article-title">Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients</span>. <i>EMBO Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>12</i></span>, <span class="NLM_elocation-id">e12697</span> <span class="refDoi"> DOI: 10.15252/emmm.202012697</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.15252%2Femmm.202012697" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=32473600" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BB3cXht1CmurbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2020&author=J.+Stebbingauthor=V.+Krishnanauthor=S.+de+Bonoauthor=S.+Ottavianiauthor=G.+Casaliniauthor=P.+J.+Richardsonauthor=V.+Monteilauthor=V.+M.+Lauschkeauthor=A.+Mirazimiauthor=S.+Youhannaauthor=Y.-J.+Tanauthor=F.+Baldantiauthor=A.+Sarasiniauthor=J.+A.+R.+Terresauthor=B.+J.+Nickoloffauthor=R.+E.+Higgsauthor=G.+Rochaauthor=N.+L.+Byersauthor=D.+E.+Schlichtingauthor=A.+Nirulaauthor=A.+Cardosoauthor=M.+Corbellinoauthor=the+Sacco+Baricitinib+Study+Group&title=Mechanism+of+baricitinib+supports+artificial+intelligence-predicted+testing+in+COVID-19+patients&doi=10.15252%2Femmm.202012697"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients</span></div><div class="casAuthors">Stebbing, Justin; Krishnan, Venkatesh; de Bono, Stephanie; Ottaviani, Silvia; Casalini, Giacomo; Richardson, Peter J.; Monteil, Vanessa; Lauschke, Volker M.; Mirazimi, Ali; Youhanna, Sonia; Tan, Yee-Joo; Baldanti, Fausto; Sarasini, Antonella; Terres, Jorge A. Ross; Nickoloff, Brian J.; Higgs, Richard E.; Rocha, Guilherme; Byers, Nicole L.; Schlichting, Douglas E.; Nirula, Ajay; Cardoso, Anabela; Corbellino, Mario; the Sacco Baricitinib Study Group</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Molecular Medicine</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e12697</span>CODEN:
                <span class="NLM_cas:coden">EMMMAM</span>;
        ISSN:<span class="NLM_cas:issn">1757-4684</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Baricitinib is an oral Janus kinase (JAK)1/JAK2 inhibitor approved for the treatment of rheumatoid arthritis (RA) that was independently predicted, using artificial intelligence (AI) algorithms, to be useful for COVID-19 infection via proposed anti-cytokine effects and as an inhibitor of host cell viral propagation.  We evaluated the in vitro pharmacol. of baricitinib across relevant leukocyte subpopulations coupled to its in vivo pharmacokinetics and showed it inhibited signaling of cytokines implicated in COVID-19 infection.  We validated the AI-predicted biochem. inhibitory effects of baricitinib on human numb-assocd. kinase (hNAK) members measuring nanomolar affinities for AAK1, BIKE, and GAK.  Inhibition of NAKs led to reduced viral infectivity with baricitinib using human primary liver spheroids.  These effects occurred at exposure levels seen clin.  In a case series of patients with bilateral COVID-19 pneumonia, baricitinib treatment was assocd. with clin. and radiol. recovery, a rapid decline in SARS-CoV-2 viral load, inflammatory markers, and IL-6 levels.  Collectively, these data support further evaluation of the anti-cytokine and anti-viral activity of baricitinib and support its assessment in randomized trials in hospitalized COVID-19 patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoiGmXcP_Gbz7Vg90H21EOLACvtfcHk0liKZww_p2kV2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXht1CmurbJ&md5=86d41fe8f3b03133c08acb5552266ef7</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.15252%2Femmm.202012697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.15252%252Femmm.202012697%26sid%3Dliteratum%253Aachs%26aulast%3DStebbing%26aufirst%3DJ.%26aulast%3DKrishnan%26aufirst%3DV.%26aulast%3Dde%2BBono%26aufirst%3DS.%26aulast%3DOttaviani%26aufirst%3DS.%26aulast%3DCasalini%26aufirst%3DG.%26aulast%3DRichardson%26aufirst%3DP.%2BJ.%26aulast%3DMonteil%26aufirst%3DV.%26aulast%3DLauschke%26aufirst%3DV.%2BM.%26aulast%3DMirazimi%26aufirst%3DA.%26aulast%3DYouhanna%26aufirst%3DS.%26aulast%3DTan%26aufirst%3DY.-J.%26aulast%3DBaldanti%26aufirst%3DF.%26aulast%3DSarasini%26aufirst%3DA.%26aulast%3DTerres%26aufirst%3DJ.%2BA.%2BR.%26aulast%3DNickoloff%26aufirst%3DB.%2BJ.%26aulast%3DHiggs%26aufirst%3DR.%2BE.%26aulast%3DRocha%26aufirst%3DG.%26aulast%3DByers%26aufirst%3DN.%2BL.%26aulast%3DSchlichting%26aufirst%3DD.%2BE.%26aulast%3DNirula%26aufirst%3DA.%26aulast%3DCardoso%26aufirst%3DA.%26aulast%3DCorbellino%26aufirst%3DM.%26aulast%3D%26atitle%3DMechanism%2520of%2520baricitinib%2520supports%2520artificial%2520intelligence-predicted%2520testing%2520in%2520COVID-19%2520patients%26jtitle%3DEMBO%2520Mol.%2520Med.%26date%3D2020%26volume%3D12%26doi%3D10.15252%2Femmm.202012697" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Verdonck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pu, S.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorrell, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Froeyen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prugar, L. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorosky, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brannan, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dye, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herdewijn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Jonghe, S.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure–activity relationships of 3,5 disubstitutedpyrrolo[2,3-<i>b</i>]pyridines as inhibitors of adaptor-associated kinase 1 with antiviral activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5810</span>– <span class="NLM_lpage">5831</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00136</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00136" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVKgtr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=5810-5831&author=S.+Verdonckauthor=S.-Y.+Puauthor=F.+J.+Sorrellauthor=J.+M.+Elkinsauthor=M.+Froeyenauthor=L.-J.+Gaoauthor=L.+I.+Prugarauthor=D.+E.+Doroskyauthor=J.+M.+Brannanauthor=R.+Barouch-Bentovauthor=S.+Knappauthor=J.+M.+Dyeauthor=P.+Herdewijnauthor=S.+Einavauthor=S.+De+Jonghe&title=Synthesis+and+structure%E2%80%93activity+relationships+of+3%2C5+disubstitutedpyrrolo%5B2%2C3-b%5Dpyridines+as+inhibitors+of+adaptor-associated+kinase+1+with+antiviral+activity&doi=10.1021%2Facs.jmedchem.9b00136"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationships of 3,5-Disubstituted-pyrrolo[2,3-b]pyridines as Inhibitors of Adaptor-Associated Kinase 1 with Antiviral Activity</span></div><div class="casAuthors">Verdonck, Sven; Pu, Szu-Yuan; Sorrell, Fiona J.; Elkins, Jon M.; Froeyen, Mathy; Gao, Ling-Jie; Prugar, Laura I.; Dorosky, Danielle E.; Brannan, Jennifer M.; Barouch-Bentov, Rina; Knapp, Stefan; Dye, John M.; Herdewijn, Piet; Einav, Shirit; De Jonghe, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5810-5831</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">There are currently no approved drugs for the treatment of emerging viral infections, such as dengue and Ebola.  Adaptor-assocd. kinase 1 (AAK1) is a cellular serine-threonine protein kinase that functions as a key regulator of the clathrin-assocd. host adaptor proteins and regulates the intracellular trafficking of multiple unrelated RNA viruses.  Moreover, AAK1 is overexpressed specifically in dengue virus-infected but not bystander cells.  Because AAK1 is a promising antiviral drug target, we have embarked on an optimization campaign of a previously identified 7-azaindole analog, yielding novel pyrrolo[2,3-b]pyridines with high AAK1 affinity.  The optimized compds. demonstrate improved activity against dengue virus both in vitro and in human primary dendritic cells and the unrelated Ebola virus.  These findings demonstrate that targeting cellular AAK1 may represent a promising broad-spectrum antiviral strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7SIdwEDKk_bVg90H21EOLACvtfcHk0liKZww_p2kV2A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVKgtr7P&md5=bdec475534dbe2ad18d1c377f8b4c67d</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00136&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00136%26sid%3Dliteratum%253Aachs%26aulast%3DVerdonck%26aufirst%3DS.%26aulast%3DPu%26aufirst%3DS.-Y.%26aulast%3DSorrell%26aufirst%3DF.%2BJ.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DFroeyen%26aufirst%3DM.%26aulast%3DGao%26aufirst%3DL.-J.%26aulast%3DPrugar%26aufirst%3DL.%2BI.%26aulast%3DDorosky%26aufirst%3DD.%2BE.%26aulast%3DBrannan%26aufirst%3DJ.%2BM.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DDye%26aufirst%3DJ.%2BM.%26aulast%3DHerdewijn%26aufirst%3DP.%26aulast%3DEinav%26aufirst%3DS.%26aulast%3DDe%2BJonghe%26aufirst%3DS.%26atitle%3DSynthesis%2520and%2520structure%25E2%2580%2593activity%2520relationships%2520of%25203%252C5%2520disubstitutedpyrrolo%255B2%252C3-b%255Dpyridines%2520as%2520inhibitors%2520of%2520adaptor-associated%2520kinase%25201%2520with%2520antiviral%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D5810%26epage%3D5831%26doi%3D10.1021%2Facs.jmedchem.9b00136" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wells, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Couñago, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Limas, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Almeida, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cook, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drewry, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gileadi, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapadia, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lorente-Macias, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pickett, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riemen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruela-de-Sousa, R. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willson, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuercher, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zutshi, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Axtman, A. D.</span></span> <span> </span><span class="NLM_article-title">SGC-AAK1-1: a chemical probe targeting AAK1 and BMP2K</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">340</span>– <span class="NLM_lpage">345</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.9b00399</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.9b00399" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitValtr3K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2020&pages=340-345&author=C.+Wellsauthor=R.+M.+Cou%C3%B1agoauthor=J.+C.+Limasauthor=T.+L.+Almeidaauthor=J.+G.+Cookauthor=D.+H.+Drewryauthor=J.+M.+Elkinsauthor=O.+Gileadiauthor=N.+R.+Kapadiaauthor=A.+Lorente-Maciasauthor=J.+E.+Pickettauthor=A.+Riemenauthor=R.+R.+Ruela-de-Sousaauthor=T.+M.+Willsonauthor=C.+Zhangauthor=W.+J.+Zuercherauthor=R.+Zutshiauthor=A.+D.+Axtman&title=SGC-AAK1-1%3A+a+chemical+probe+targeting+AAK1+and+BMP2K&doi=10.1021%2Facsmedchemlett.9b00399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">SGC-AAK1-1: a chemical probe targeting AAK1 and BMP2K</span></div><div class="casAuthors">Wells, Carrow; Counago, Rafael M.; Limas, Juanita C.; Almeida, Tuanny L.; Cook, Jeanette Gowen; Drewry, David H.; Elkins, Jonathan M.; Gileadi, Opher; Kapadia, Nirav R.; Lorente-Macias, Alvaro; Pickett, Julie E.; Riemen, Alexander; Ruela-de-Sousa, Roberta R.; Willson, Timothy M.; Zhang, Cunyu; Zuercher, William J.; Zutshi, Reena; Axtman, Alison D.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">340-345</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Inhibitors based on a 3-acylaminoindazole scaffold were synthesized to yield potent dual AAK1/BMP2K inhibitors.  Optimization furnished a small mol. chem. probe (SGC-AAK1-1, 25 (I)) that is potent and selective for AAK1/BMP2K over other NAK family members, demonstrates narrow activity in a kinome-wide screen, and is functionally active in cells.  This inhibitor represents one of the best available small mol. tools to study the functions of AAK1 and BMP2K.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOSOYD5xWr1LVg90H21EOLACvtfcHk0lgzuneTdPzBiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitValtr3K&md5=d525d20f1ba1282697684e6ac1d09693</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.9b00399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.9b00399%26sid%3Dliteratum%253Aachs%26aulast%3DWells%26aufirst%3DC.%26aulast%3DCou%25C3%25B1ago%26aufirst%3DR.%2BM.%26aulast%3DLimas%26aufirst%3DJ.%2BC.%26aulast%3DAlmeida%26aufirst%3DT.%2BL.%26aulast%3DCook%26aufirst%3DJ.%2BG.%26aulast%3DDrewry%26aufirst%3DD.%2BH.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DGileadi%26aufirst%3DO.%26aulast%3DKapadia%26aufirst%3DN.%2BR.%26aulast%3DLorente-Macias%26aufirst%3DA.%26aulast%3DPickett%26aufirst%3DJ.%2BE.%26aulast%3DRiemen%26aufirst%3DA.%26aulast%3DRuela-de-Sousa%26aufirst%3DR.%2BR.%26aulast%3DWillson%26aufirst%3DT.%2BM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZuercher%26aufirst%3DW.%2BJ.%26aulast%3DZutshi%26aufirst%3DR.%26aulast%3DAxtman%26aufirst%3DA.%2BD.%26atitle%3DSGC-AAK1-1%253A%2520a%2520chemical%2520probe%2520targeting%2520AAK1%2520and%2520BMP2K%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2020%26volume%3D11%26spage%3D340%26epage%3D345%26doi%3D10.1021%2Facsmedchemlett.9b00399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barouch-Bentov, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ziv-Av, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerber, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacob, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Einav, S.</span></span> <span> </span><span class="NLM_article-title">Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly</span>. <i>PLoS Pathog.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>8</i></span>, <span class="NLM_elocation-id">e1002845</span> <span class="refDoi"> DOI: 10.1371/journal.ppat.1002845</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1371%2Fjournal.ppat.1002845" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=22916011" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1Cns7bF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&author=G.+Neveuauthor=R.+Barouch-Bentovauthor=A.+Ziv-Avauthor=D.+Gerberauthor=Y.+Jacobauthor=S.+Einav&title=Identification+and+targeting+of+an+interaction+between+a+tyrosine+motif+within+hepatitis+C+virus+core+protein+and+AP2M1+essential+for+viral+assembly&doi=10.1371%2Fjournal.ppat.1002845"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and targeting of an interaction between a tyrosine motif within hepatitis C virus core protein and AP2M1 essential for viral assembly</span></div><div class="casAuthors">Neveu, Gregory; Barouch-Bentov, Rina; Ziv-Av, Amotz; Gerber, Doron; Jacob, Yves; Einav, Shirit</div><div class="citationInfo"><span class="NLM_cas:title">PLoS Pathogens</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">e1002845</span>CODEN:
                <span class="NLM_cas:coden">PPLACN</span>;
        ISSN:<span class="NLM_cas:issn">1553-7374</span>.
    
            (<span class="NLM_cas:orgname">Public Library of Science</span>)
        </div><div class="casAbstract">Novel therapies are urgently needed against hepatitis C virus infection (HCV), a major global health problem.  The current model of infectious virus prodn. suggests that HCV virions are assembled on or near the surface of lipid droplets, acquire their envelope at the ER, and egress through the secretory pathway.  The mechanisms of HCV assembly and particularly the role of viral-host protein-protein interactions in mediating this process are, however, poorly understood.  We identified a conserved heretofore unrecognized YXXΦ motif (Φ is a bulky hydrophobic residue) within the core protein.  This motif is homologous to sorting signals within host cargo proteins known to mediate binding of AP2M1, the μ subunit of clathrin adaptor protein complex 2 (AP-2), and intracellular trafficking.  Using microfluidics affinity anal., protein-fragment complementation assays, and co-immunopptns. in infected cells, we show that this motif mediates core binding to AP2M1.  YXXΦ mutations, silencing AP2M1 expression or overexpressing a dominant neg. AP2M1 mutant had no effect on HCV RNA replication, however, they dramatically inhibited intra- and extra-cellular infectivity, consistent with a defect in viral assembly.  Quant. confocal immunofluorescence anal. revealed that core's YXXΦ motif mediates recruitment of AP2M1 to lipid droplets and that the obsd. defect in HCV assembly following disruption of core-AP2M1 binding correlates with accumulation of core on lipid droplets, reduced core colocalization with E2 and reduced core localization to trans-Golgi network (TGN), the presumed site of viral particles maturation.  Furthermore, AAK1 and GAK, serine/threonine kinases known to stimulate binding of AP2M1 to host cargo proteins, regulate core-AP2M1 binding and are essential for HCV assembly.  Last, approved anti-cancer drugs that inhibit AAK1 or GAK not only disrupt core-AP2M1 binding, but also significantly inhibit HCV assembly and infectious virus prodn.  These results validate viral-host interactions essential for HCV assembly and yield compds. for pharmaceutical development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpjKaGJVLP2vLVg90H21EOLACvtfcHk0lgzuneTdPzBiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1Cns7bF&md5=811c0818d4b2500b1b788076ac4abc5d</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1371%2Fjournal.ppat.1002845&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.ppat.1002845%26sid%3Dliteratum%253Aachs%26aulast%3DNeveu%26aufirst%3DG.%26aulast%3DBarouch-Bentov%26aufirst%3DR.%26aulast%3DZiv-Av%26aufirst%3DA.%26aulast%3DGerber%26aufirst%3DD.%26aulast%3DJacob%26aufirst%3DY.%26aulast%3DEinav%26aufirst%3DS.%26atitle%3DIdentification%2520and%2520targeting%2520of%2520an%2520interaction%2520between%2520a%2520tyrosine%2520motif%2520within%2520hepatitis%2520C%2520virus%2520core%2520protein%2520and%2520AP2M1%2520essential%2520for%2520viral%2520assembly%26jtitle%3DPLoS%2520Pathog.%26date%3D2012%26volume%3D8%26doi%3D10.1371%2Fjournal.ppat.1002845" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shi, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span> <span> </span><span class="NLM_article-title">Dysfunction of endocytic kinase AAK1 in ALS</span>. <i>Int. J. Mol. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">22918</span>– <span class="NLM_lpage">22932</span>, <span class="refDoi"> DOI: 10.3390/ijms151222918</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.3390%2Fijms151222918" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=25514244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC2MXisVGitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2014&pages=22918-22932&author=B.+Shiauthor=S.+Connerauthor=J.+Liu&title=Dysfunction+of+endocytic+kinase+AAK1+in+ALS&doi=10.3390%2Fijms151222918"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Dysfunction of endocytic kinase AAK1 in ALS</span></div><div class="casAuthors">Shi, Bingxing; Conner, Sean D.; Liu, Jian</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Molecular Sciences</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">22918-22932</span>CODEN:
                <span class="NLM_cas:coden">IJMCFK</span>;
        ISSN:<span class="NLM_cas:issn">1422-0067</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Mechanisms of human mutant superoxide dismutase 1 (SOD1)-induced toxicity in causing the familial form of amyotrophic lateral sclerosis (ALS) remain elusive.  Identification of new proteins that can selectively interact with mutant SOD1s and investigation of their potential roles in ALS are important to discover new pathways that are involved in disease pathol.  Using the yeast two-hybrid system, we identified the adaptor-assocd. kinase 1 (AAK1), a regulatory protein in clathrin-coated vesicle endocytic pathway that selectively interacted with the mutant but not the wild-type SOD1.  Using both transgenic mouse and rat SOD1-linked familial ALS (FALS) models, we found that AAK1 was partially colocalized with the endosomal and presynaptic protein markers under the normal physiol. condition, but was mislocated into aggregates that contained mutant SOD1s and the neurofilament proteins in rodent models of ALS in disease.  AAK1 protein levels were also decreased in ALS patients.  These results suggest that dysfunction of a component in the endosomal and synaptic vesicle recycling pathway is involved in ALS pathol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbYe9fs11Hh7Vg90H21EOLACvtfcHk0lgzuneTdPzBiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXisVGitA%253D%253D&md5=1363032909ce960012c43902e9d9c418</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.3390%2Fijms151222918&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fijms151222918%26sid%3Dliteratum%253Aachs%26aulast%3DShi%26aufirst%3DB.%26aulast%3DConner%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DJ.%26atitle%3DDysfunction%2520of%2520endocytic%2520kinase%2520AAK1%2520in%2520ALS%26jtitle%3DInt.%2520J.%2520Mol.%2520Sci.%26date%3D2014%26volume%3D15%26spage%3D22918%26epage%3D22932%26doi%3D10.3390%2Fijms151222918" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gupta-Rossi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortica, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meas-Yedid, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuss, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moretti, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olivo-Marin, J.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Israël, A.</span></span> <span> </span><span class="NLM_article-title">The adaptor-associated kinase 1, AAK1, is a positive regulator of the Notch pathway</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">18720</span>– <span class="NLM_lpage">18730</span>, <span class="refDoi"> DOI: 10.1074/jbc.M110.190769</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1074%2Fjbc.M110.190769" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=21464124" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtlGltL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=18720-18730&author=N.+Gupta-Rossiauthor=S.+Orticaauthor=V.+Meas-Yedidauthor=S.+Heussauthor=J.+Morettiauthor=J.-C.+Olivo-Marinauthor=A.+Isra%C3%ABl&title=The+adaptor-associated+kinase+1%2C+AAK1%2C+is+a+positive+regulator+of+the+Notch+pathway&doi=10.1074%2Fjbc.M110.190769"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The adaptor-associated Kinase 1, AAK1, is a positive regulator of the Notch pathway</span></div><div class="casAuthors">Gupta-Rossi, Neetu; Ortica, Sara; Meas-Yedid, Vannary; Heuss, Sara; Moretti, Julien; Olivo-Marin, Jean-Christophe; Israel, Alain</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">18720-18730</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The Notch pathway is involved in cell-cell signaling during development and adulthood from invertebrates to higher eukaryotes.  The activation of the Notch receptor by its ligands relies on multi-step processing.  The extracellular part of the receptor is removed by a metalloprotease of the ADAM family and the remaining fragment is cleaved within its transmembrane domain by a presenilin-dependent γ-secretase activity.  The γ-secretase processing of Notch has previously been shown to depend upon monoubiquitination as well as clathrin-mediated endocytosis (CME).  Here, the authors show that AAK1 kinase directly interacts with the membrane-tethered active form of Notch released by metalloprotease cleavage.  Active AAK1 acted upstream of the γ-secretase cleavage by stabilizing both the membrane-tethered activated form of Notch and its monoubiquitinated counterpart.  The authors propose that AAK1 acts as an adaptor for Notch interaction with components of the clathrin-mediated pathway such as Eps15b.  Moreover, transfected AAK1 increased the localization of activated Notch to Rab5-pos. endocytic vesicles, while AAK1 depletion or overexpression of Numb, an inhibitor of the pathway, interfered with this localization.  These results suggest that after ligand-induced activation of Notch, the membrane-tethered form can be directed to different endocytic pathways leading to distinct fates.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr47uq9qZR_4rVg90H21EOLACvtfcHk0lgBBh6cZo_NlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtlGltL4%253D&md5=48d7a335adef0bae7f31db2a853def37</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.190769&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.190769%26sid%3Dliteratum%253Aachs%26aulast%3DGupta-Rossi%26aufirst%3DN.%26aulast%3DOrtica%26aufirst%3DS.%26aulast%3DMeas-Yedid%26aufirst%3DV.%26aulast%3DHeuss%26aufirst%3DS.%26aulast%3DMoretti%26aufirst%3DJ.%26aulast%3DOlivo-Marin%26aufirst%3DJ.-C.%26aulast%3DIsra%25C3%25ABl%26aufirst%3DA.%26atitle%3DThe%2520adaptor-associated%2520kinase%25201%252C%2520AAK1%252C%2520is%2520a%2520positive%2520regulator%2520of%2520the%2520Notch%2520pathway%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D18720%26epage%3D18730%26doi%3D10.1074%2Fjbc.M110.190769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martinez-Gualda, B.</span>; <span class="NLM_string-name">Schols, D.</span>; <span class="NLM_string-name">De Jonghe, S.</span></span> <span> </span><span class="NLM_article-title">A patent review of adaptor associated kinase 1 (AAK1) inhibitors (2013-present)</span>.  <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2021</span>, (in press), <span class="refDoi"> DOI: 10.1080/13543776.2021.1928637</span> ,  <span class="NLM_fpage">1</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1080%2F13543776.2021.1928637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=33971786" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADC%252BB2c%252Fis1yjsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2021&pages=1&author=B.+Martinez-Gualda&author=D.+Schols&author=S.+De+Jonghe&title=A+patent+review+of+adaptor+associated+kinase+1+%28AAK1%29+inhibitors+%282013-present%29&doi=10.1080%2F13543776.2021.1928637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">A patent review of adaptor associated kinase 1 (AAK1) inhibitors (2013-present)</span></div><div class="casAuthors">Martinez-Gualda Belen; Martinez-Gualda Belen; Schols Dominique; De Jonghe Steven</div><div class="citationInfo"><span class="NLM_cas:title">Expert opinion on therapeutic patents</span>
        (<span class="NLM_cas:date">2021</span>),
    <span class="NLM_cas:volume"></span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">INTRODUCTION:  Adaptor-associated kinase 1 (AAK1) has been proposed as being a promising drug target for the treatment of a variety of neurological and psychiatric disorders, such as schizophrenia, cognitive deficits in schizophrenia, Parkinson's disease, bipolar disorder, Alzheimer's disease and neuropathic pain.  More recently, AAK1 was shown to be an essential cellular factor for viral replication and therefore has been pursued as a host target for the development of broad-spectrum antiviral agents.  AREAS COVERED:  This review provides an overview of the patented AAK1 inhibitors from 2013 to present.  EXPERT OPINION:  The promise of AAK1 as drug target for the treatment of neuropathic pain stimulated the search for AAK1 inhibitors.  However, only two companies (i.e.  Lexicon Pharmaceuticals and Bristol Myers Squibb) seemed to be active in this field and filed patent applications in the last few years.  The most promising congeners showed promising in vitro activity in a variety of AAK1-related assays.  Moreover, selected compounds were also endowed with in vivo activity in various preclinical animal models for neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTkcDcukcrmC0bxh97K6Vt6fW6udTcc2eZ0A2ItREqHcLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB2c%252Fis1yjsQ%253D%253D&md5=e323682fd82ee6e702c9f0ef8905a846</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1080%2F13543776.2021.1928637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2021.1928637%26sid%3Dliteratum%253Aachs%26aulast%3DMartinez-Gualda%26aufirst%3DB.%26atitle%3DA%2520patent%2520review%2520of%2520adaptor%2520associated%2520kinase%25201%2520%2528AAK1%2529%2520inhibitors%2520%25282013-present%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2021%26doi%3D10.1080%2F13543776.2021.1928637%26spage%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span> <i>The
PyMOL Molecular Graphics
System, Version 2.3.4</i>; <span class="NLM_publisher-name">Schrödinger
LLC</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=+The%0APyMOL+Molecular+Graphics%0ASystem%2C+Version+2.3.4%3B+Schr%C3%B6dinger%0ALLC."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%250APyMOL%2520Molecular%2520Graphics%250ASystem%252C%2520Version%25202.3.4%26pub%3DSchr%25C3%25B6dinger%250ALLC" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hitchcock, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennington, L. D.</span></span> <span> </span><span class="NLM_article-title">Structure–brain exposure relationships</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">7559</span>– <span class="NLM_lpage">7583</span>, <span class="refDoi"> DOI: 10.1021/jm060642i</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm060642i" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1yrtrnK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=7559-7583&author=S.+A.+Hitchcockauthor=L.+D.+Pennington&title=Structure%E2%80%93brain+exposure+relationships&doi=10.1021%2Fjm060642i"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-brain exposure relationships</span></div><div class="casAuthors">Hitchcock, Stephen A.; Pennington, Lewis D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">7559-7583</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review on the use of structure modification to influence blood-brain barrier penetration by modulating either passive diffusion or active transport.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp3V-TERRGy07Vg90H21EOLACvtfcHk0lgBBh6cZo_NlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1yrtrnK&md5=97dff583ffae6d0ef66512ffbee38c34</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1021%2Fjm060642i&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm060642i%26sid%3Dliteratum%253Aachs%26aulast%3DHitchcock%26aufirst%3DS.%2BA.%26aulast%3DPennington%26aufirst%3DL.%2BD.%26atitle%3DStructure%25E2%2580%2593brain%2520exposure%2520relationships%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D7559%26epage%3D7583%26doi%3D10.1021%2Fjm060642i" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, C.</span></span> <span> </span><span class="NLM_article-title">Strategies to optimize brian penetration in drug discovery</span>. <i>Curr. Opin. Drug Discovery Dev.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">505</span>– <span class="NLM_lpage">512</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=16022187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD2MXlvFCgtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2005&pages=505-512&author=X.+Liuauthor=C.+Chen&title=Strategies+to+optimize+brian+penetration+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to optimize brain penetration in drug discovery</span></div><div class="casAuthors">Liu, Xingrong; Chen, Cuiping</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Drug Discovery & Development</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">505-512</span>CODEN:
                <span class="NLM_cas:coden">CODDFF</span>;
        ISSN:<span class="NLM_cas:issn">1367-6733</span>.
    
            (<span class="NLM_cas:orgname">Thomson Scientific</span>)
        </div><div class="casAbstract">A review.  The kinetics of brain penetration has two components, extent and rate.  Achieving a high extent of brain penetration is an important focus for central nervous system (CNS) drug discovery.  Optimal brain penetration can be achieved by reducing efflux transport at the blood-brain barrier (BBB), and it is crit. to ensure that a high total brain/plasma ratio (the most commonly used parameter for measuring brain penetration) is due to efflux transport activity at the BBB and not related to high non-specific brain tissue binding or low plasma binding.  Rapid brain penetration is essential for those drugs that require fast onset of action in the CNS.  This can be achieved by increasing passive permeability and reducing brain tissue binding.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI4i1b3bPJ5rVg90H21EOLACvtfcHk0lgBBh6cZo_NlQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXlvFCgtLo%253D&md5=004d6f5f8fc110aab7ca1f0eaf3a0ec7</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DC.%26atitle%3DStrategies%2520to%2520optimize%2520brian%2520penetration%2520in%2520drug%2520discovery%26jtitle%3DCurr.%2520Opin.%2520Drug%2520Discovery%2520Dev.%26date%3D2005%26volume%3D8%26spage%3D505%26epage%3D512" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, G. T.</span></span> <span> </span><span class="NLM_article-title">Strategies to assess blood–brain barrier penetration</span>. <i>Expert. Opin. Drug Discov.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">677</span>– <span class="NLM_lpage">687</span>, <span class="refDoi"> DOI: 10.1517/17460441.3.6.677</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1517%2F17460441.3.6.677" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=23506148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXotVyrtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=677-687&author=L.+Diauthor=E.+H.+Kernsauthor=G.+T.+Carter&title=Strategies+to+assess+blood%E2%80%93brain+barrier+penetration&doi=10.1517%2F17460441.3.6.677"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies to assess blood-brain barrier penetration</span></div><div class="casAuthors">Di, Li; Kerns, Edward H.; Carter, Guy T.</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Discovery</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">677-687</span>CODEN:
                <span class="NLM_cas:coden">EODDBX</span>;
        ISSN:<span class="NLM_cas:issn">1746-0441</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Background: The principles and screening strategies for brain penetration in drug discovery are important in identifying drug candidates with desirable CNS properties.  Objective: Define key variables and assays that are essential for detg. brain penetration.  Methods: This review covers issues, methods, and strategies for assessing brain penetration of small mols. in drug discovery.  Results/conclusion: Brain penetration is assessed using both initial rate and extent at steady-state.  Unbound drug is the active species that exerts pharmacol. effects.  Low brain penetration can be due to low blood-brain barrier (BBB) permeability, P-glycoprotein (Pgp) efflux, or high plasma protein binding.  Successful methods include: parallel artificial membrane permeability assay (PAMPA)-BBB permeability, MDR1-MDCKII for Pgp efflux, B-P dialysis for fraction unbound, and in vivo B/P ratio to extrapolate unbound brain drug concn.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOHHdHc1xH7LVg90H21EOLACvtfcHk0lgt4PtQuMsM7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXotVyrtL0%253D&md5=8186d3a972120691aebb3dba4810f7f8</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1517%2F17460441.3.6.677&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F17460441.3.6.677%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26aulast%3DCarter%26aufirst%3DG.%2BT.%26atitle%3DStrategies%2520to%2520assess%2520blood%25E2%2580%2593brain%2520barrier%2520penetration%26jtitle%3DExpert.%2520Opin.%2520Drug%2520Discov.%26date%3D2008%26volume%3D3%26spage%3D677%26epage%3D687%26doi%3D10.1517%2F17460441.3.6.677" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, B.</span></span> <span> </span><span class="NLM_article-title">Demystifying brain penetration in central nervous system drug discovery</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">12</span>, <span class="refDoi"> DOI: 10.1021/jm301297f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301297f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsFamtrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=2-12&author=L.+Diauthor=H.+Rongauthor=B.+Feng&title=Demystifying+brain+penetration+in+central+nervous+system+drug+discovery&doi=10.1021%2Fjm301297f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Demystifying Brain Penetration in Central Nervous System Drug Discovery</span></div><div class="casAuthors">Di, Li; Rong, Haojing; Feng, Bo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-12</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  This Perspective provides important concepts about the blood-brain barrier (BBB) in drug discovery and how they should be applied effectively in designing successful CNS drugs.  Key parameters for brain penetration are discussed, including unbound brain concn., unbound brain-to-plasma ratio, BBB permeability, fraction unbound in brain and plasma, and transporters.  Results from a retrospective anal. of 32 Pfizer CNS clin. drug candidates are described.  Frequently encountered misconceptions about brain penetration in drug discovery programs are clarified.  Strategies and guidance are provided to enhance or minimize brain exposure for CNS or peripheral targets, resp.  Recommendations for screening methodologies and a cascade in assessing brain penetration potential are presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmurs7cfju37Vg90H21EOLACvtfcHk0lgt4PtQuMsM7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsFamtrrJ&md5=8b88e2044bf41898ab40c45e18f2a20d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjm301297f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301297f%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DFeng%26aufirst%3DB.%26atitle%3DDemystifying%2520brain%2520penetration%2520in%2520central%2520nervous%2520system%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D2%26epage%3D12%26doi%3D10.1021%2Fjm301297f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurer, T. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeBartolo, D. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tess, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. O.</span></span> <span> </span><span class="NLM_article-title">Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">175</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1124/dmd.104.001222</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1124%2Fdmd.104.001222" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=15502010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD2MXltlentA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2005&pages=175-181&author=T.+S.+Maurerauthor=D.+B.+DeBartoloauthor=D.+A.+Tessauthor=D.+O.+Scott&title=Relationship+between+exposure+and+nonspecific+binding+of+thirty-three+central+nervous+system+drugs+in+mice&doi=10.1124%2Fdmd.104.001222"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Relationship between exposure and nonspecific binding of thirty-three central nervous system drugs in mice</span></div><div class="casAuthors">Maurer, Tristan S.; DeBartolo, Demetria B.; Tess, David A.; Scott, Dennis O.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">175-181</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Unbound fractions in mouse brain and plasma were detd. for 31 structurally diverse central nervous system (CNS) drugs and two active metabolites.  Three comparisons were made between in vitro binding and in vivo exposure data, namely: (1) mouse brain-to-plasma exposure vs. unbound plasma-to-unbound brain fraction ratio (fuplasma/fubrain), (2) cerebrospinal fluid-to-brain exposure vs. unbound brain fraction (fubrain), and (3) cerebrospinal fluid-to-plasma exposure vs. unbound plasma fraction (fuplasma).  Unbound fraction data were within 3-fold of in vivo exposure ratios for the majority of the drugs examd. (i.e., 22 of 33), indicating a predominately free equil. across the blood-brain and blood-CSF barriers.  Some degree of distributional impairment at either the blood-CSF or the blood-brain barrier was indicated for 8 of the 11 remaining drugs (i.e., carbamazepine, midazolam, phenytoin, sulpiride, thiopental, risperidone, 9-hydroxyrisperidone, and zolpidem).  In several cases, the indicated distributional impairment is consistent with other independent literature reports for these drugs.  Through the use of this approach, it appears that most CNS-active agents freely equilibrate across the blood-brain and blood-CSF barriers such that unbound drug concns. in brain approx. those in the plasma.  However, these results also support the intuitive concept that distributional impairment does not necessarily preclude CNS activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqH6imduXukj7Vg90H21EOLACvtfcHk0lgt4PtQuMsM7Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXltlentA%253D%253D&md5=27e70989846ff3eeb4fa4a7d8c6e73b5</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1124%2Fdmd.104.001222&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.104.001222%26sid%3Dliteratum%253Aachs%26aulast%3DMaurer%26aufirst%3DT.%2BS.%26aulast%3DDeBartolo%26aufirst%3DD.%2BB.%26aulast%3DTess%26aufirst%3DD.%2BA.%26aulast%3DScott%26aufirst%3DD.%2BO.%26atitle%3DRelationship%2520between%2520exposure%2520and%2520nonspecific%2520binding%2520of%2520thirty-three%2520central%2520nervous%2520system%2520drugs%2520in%2520mice%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2005%26volume%3D33%26spage%3D175%26epage%3D181%26doi%3D10.1124%2Fdmd.104.001222" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kerns, E. H.</span></span> <span> </span><span class="NLM_article-title">The effect of plasma protein binding on <i>in vivo</i> efficacy: misconceptions in drug discovery</span>. <i>Nat. Rev. Drug Discov.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">929</span>– <span class="NLM_lpage">939</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1038%2Fnrd3287" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2010&pages=929-939&author=D.+A.+Smithauthor=L.+Diauthor=E.+H.+Kerns&title=The+effect+of+plasma+protein+binding+on+in+vivo+efficacy%3A+misconceptions+in+drug+discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fnrd3287&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3287%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DD.%2BA.%26aulast%3DDi%26aufirst%3DL.%26aulast%3DKerns%26aufirst%3DE.%2BH.%26atitle%3DThe%2520effect%2520of%2520plasma%2520protein%2520binding%2520on%2520in%2520vivo%2520efficacy%253A%2520misconceptions%2520in%2520drug%2520discovery%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discov.%26date%3D2010%26volume%3D12%26spage%3D929%26epage%3D939" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0ljyu7gJkgRlXQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tjølsen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berge, O. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunskaar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosland, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hole, K.</span></span> <span> </span><span class="NLM_article-title">The formalin test: an evaluation of the method</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">5</span>– <span class="NLM_lpage">17</span>, <span class="refDoi"> DOI: 10.1016/0304-3959(92)90003-T</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2F0304-3959%2892%2990003-T" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1454405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADyaK3s%252FoslSnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=1992&pages=5-17&author=A.+Tj%C3%B8lsenauthor=O.+G.+Bergeauthor=S.+Hunskaarauthor=J.+H.+Roslandauthor=K.+Hole&title=The+formalin+test%3A+an+evaluation+of+the+method&doi=10.1016%2F0304-3959%2892%2990003-T"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The formalin test: an evaluation of the method</span></div><div class="casAuthors">Tjolsen Arne; Berge Odd-Geir; Hunskaar Steinar; Rosland Jan Henrik; Hole Kjell</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-17</span>
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    </div><div class="casAbstract">The formalin test for nociception, which is predominantly used with rats and mice, involves moderate, continuous pain generated by injured tissue.  In this way it differs from most traditional tests of nociception which rely upon brief stimuli of threshold intensity.  In this article we describe the main features of the formalin test, including the characteristics of the stimulus and how changes in nociceptive behaviour may be measured and interpreted.  The response to formalin shows an early and a late phase.  The early phase seems to be caused predominantly by C-fibre activation due to the peripheral stimulus, while the late phase appears to be dependent on the combination of an inflammatory reaction in the peripheral tissue and functional changes in the dorsal horn of the spinal cord.  These functional changes seem to be initiated by the C-fibre barrage during the early phase.  In mice, the behavioural response in the late phase depends on the ambient temperature.  We argue that the peripheral tissue temperature as well as other factors influencing the peripheral inflammation may affect the response, possibly confounding the results obtained with the test.  Furthermore, we discuss the methods of recording the response and the value of observing more than one aspect of behaviour.  Scoring of several behavioural variables provides a means of assessing motor or sensorimotor function as possible causes for changes in behaviour.  In conclusion, the formalin test is a valuable addition to the battery of methods available to study nociception.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSEPstJUQcfvkEksK8CslK8fW6udTcc2eYe2GXo5tu12bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3s%252FoslSnsA%253D%253D&md5=d56dc5eb88d109dd30d319dcf580c781</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2F0304-3959%2892%2990003-T&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3959%252892%252990003-T%26sid%3Dliteratum%253Aachs%26aulast%3DTj%25C3%25B8lsen%26aufirst%3DA.%26aulast%3DBerge%26aufirst%3DO.%2BG.%26aulast%3DHunskaar%26aufirst%3DS.%26aulast%3DRosland%26aufirst%3DJ.%2BH.%26aulast%3DHole%26aufirst%3DK.%26atitle%3DThe%2520formalin%2520test%253A%2520an%2520evaluation%2520of%2520the%2520method%26jtitle%3DPain%26date%3D1992%26volume%3D51%26spage%3D5%26epage%3D17%26doi%3D10.1016%2F0304-3959%2892%2990003-T" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bennett, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, Y. K.</span></span> <span> </span><span class="NLM_article-title">A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>33</i></span>,  <span class="NLM_fpage">87</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1016/0304-3959(88)90209-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2F0304-3959%2888%2990209-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=2837713" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADyaL1c3kslGhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=1988&pages=87-107&author=G.+J.+Bennettauthor=Y.+K.+Xie&title=A+peripheral+mononeuropathy+in+rat+that+produces+disorders+of+pain+sensation+like+those+seen+in+man&doi=10.1016%2F0304-3959%2888%2990209-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man</span></div><div class="casAuthors">Bennett Gary J; Xie Y-K</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-107</span>
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    </div><div class="casAbstract">A peripheral mononeuropathy was produced in adult rats by placing loosely constrictive ligatures around the common sciatic nerve.  The postoperative behavior of these rats indicated that hyperalgesia, allodynia and, possibly, spontaneous pain (or dysesthesia) were produced.  Hyperalgesic responses to noxious radiant heat were evident on the second postoperative day and lasted for over 2 months.  Hyperalgesic responses to chemogenic pain were also present.  The presence of allodynia was inferred from the nocifensive responses evoked by standing on an innocuous, chilled metal floor or by innocuous mechanical stimulation, and by the rats' persistence in holding the hind paw in a guarded position.  The presence of spontaneous pain was suggested by a suppression of appetite and by the frequent occurrence of apparently spontaneous nocifensive responses.  The affected hind paw was abnormally warm or cool in about one-third of the rats.  About one-half of the rats developed grossly overgrown claws on the affected side.  Experiments with this animal model may advance our understanding of the neural mechanisms of neuropathic pain disorders in humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSvFbgQgoOLbwWRJ3OJdH_qfW6udTcc2eYe2GXo5tu12bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1c3kslGhsw%253D%253D&md5=b65eee81b7058ce686a014eee46ead80</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2F0304-3959%2888%2990209-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3959%252888%252990209-6%26sid%3Dliteratum%253Aachs%26aulast%3DBennett%26aufirst%3DG.%2BJ.%26aulast%3DXie%26aufirst%3DY.%2BK.%26atitle%3DA%2520peripheral%2520mononeuropathy%2520in%2520rat%2520that%2520produces%2520disorders%2520of%2520pain%2520sensation%2520like%2520those%2520seen%2520in%2520man%26jtitle%3DPain%26date%3D1988%26volume%3D33%26spage%3D87%26epage%3D107%26doi%3D10.1016%2F0304-3959%2888%2990209-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, C. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mandel-Brehm, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bautista, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siemens, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deranian, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hayward, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chong, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Julius, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanger, C. M.</span></span> <span> </span><span class="NLM_article-title">TRPA1 mediates formalin-induced pain</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">13525</span>– <span class="NLM_lpage">13530</span>, <span class="refDoi"> DOI: 10.1073/pnas.0705924104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1073%2Fpnas.0705924104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=17686976" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD2sXps1eqsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=13525-13530&author=C.+R.+McNamaraauthor=J.+Mandel-Brehmauthor=D.+M.+Bautistaauthor=J.+Siemensauthor=K.+L.+Deranianauthor=M.+Zhaoauthor=N.+J.+Haywardauthor=J.+A.+Chongauthor=D.+Juliusauthor=M.+M.+Moranauthor=C.+M.+Fanger&title=TRPA1+mediates+formalin-induced+pain&doi=10.1073%2Fpnas.0705924104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">TRPA1 mediates formalin-induced pain</span></div><div class="casAuthors">McNamara, Colleen R.; Mandel-Brehm, Josh; Bautista, Diana M.; Siemens, Jan; Deranian, Kari L.; Zhao, Michael; Hayward, Neil J.; Chong, Jayhong A.; Julius, David; Moran, Magdalene M.; Fanger, Christopher M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">13525-13530</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The formalin model is widely used for evaluating the effects of analgesic compds. in lab. animals.  Injection of formalin into the hind paw induces a biphasic pain response; the first phase is thought to result from direct activation of primary afferent sensory neurons, whereas the second phase has been proposed to reflect the combined effects of afferent input and central sensitization in the dorsal horn.  Here we show that formalin excites sensory neurons by directly activating transient receptor potential ion channel TRPA1, a cation channel that plays an important role in inflammatory pain.  Formalin induced robust calcium influx in cells expressing cloned or native TRPA1 channels, and these responses were attenuated by a previously undescribed TRPA1-selective antagonist.  Moreover, sensory neurons from TRPA1-deficient mice lacked formalin sensitivity.  At the behavioral level, pharmacol. blockade or genetic ablation of TRPA1 produced marked attenuation of the characteristic flinching, licking, and lifting responses resulting from intraplantar injection of formalin.  Our results show that TRPA1 is the principal site of formalin's pain-producing action in vivo, and that activation of this excitatory channel underlies the physiol. and behavioral responses assocd. with this model of pain hypersensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgRKOZy2rNILVg90H21EOLACvtfcHk0li8Qvsm9Kuv3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXps1eqsL8%253D&md5=2482d7b071a4eb6c3131d3d95ea05ae2</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0705924104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0705924104%26sid%3Dliteratum%253Aachs%26aulast%3DMcNamara%26aufirst%3DC.%2BR.%26aulast%3DMandel-Brehm%26aufirst%3DJ.%26aulast%3DBautista%26aufirst%3DD.%2BM.%26aulast%3DSiemens%26aufirst%3DJ.%26aulast%3DDeranian%26aufirst%3DK.%2BL.%26aulast%3DZhao%26aufirst%3DM.%26aulast%3DHayward%26aufirst%3DN.%2BJ.%26aulast%3DChong%26aufirst%3DJ.%2BA.%26aulast%3DJulius%26aufirst%3DD.%26aulast%3DMoran%26aufirst%3DM.%2BM.%26aulast%3DFanger%26aufirst%3DC.%2BM.%26atitle%3DTRPA1%2520mediates%2520formalin-induced%2520pain%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26spage%3D13525%26epage%3D13530%26doi%3D10.1073%2Fpnas.0705924104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sorkin, L. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yaksh, T. L.</span></span> <span> </span><span class="NLM_article-title">Behavioral models of pain states evoked by physical injury to the peripheral nerve</span>. <i>Neurotherapeutics</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">609</span>– <span class="NLM_lpage">619</span>, <span class="refDoi"> DOI: 10.1016/j.nurt.2009.07.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2Fj.nurt.2009.07.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=19789066" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADC%252BD1Mnls1CqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2009&pages=609-619&author=L.+S.+Sorkinauthor=T.+L.+Yaksh&title=Behavioral+models+of+pain+states+evoked+by+physical+injury+to+the+peripheral+nerve&doi=10.1016%2Fj.nurt.2009.07.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioral models of pain states evoked by physical injury to the peripheral nerve</span></div><div class="casAuthors">Sorkin Linda S; Yaksh Tony L</div><div class="citationInfo"><span class="NLM_cas:title">Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">609-19</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Physical injury or compression of the root, dorsal root ganglion, or peripheral sensory axon leads to well-defined changes in biology and function.  Behaviorally, humans report ongoing painful dysesthesias and aberrations in function, such that an otherwise innocuous stimulus will yield a pain report.  These behavioral reports are believed to reflect the underlying changes in nerve function after injury, wherein increased spontaneous activity arises from the neuroma and dorsal root ganglion and spinal changes increase the response of spinal projection neurons.  These pain states are distinct from those associated with tissue injury and pose particular problems in management.  To provide for developing an understanding of the underlying mechanisms of these pain states and to promote development of therapeutic agents, preclinical models involving section, compression, and constriction of the peripheral nerve or compression of the dorsal root ganglion have been developed.  These models give rise to behaviors, which parallel those observed in the human after nerve injury.  The present review considers these models and their application.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRqq0bHyJy-BDEwO064Z95rfW6udTcc2eaYVHQNqM4qwbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mnls1CqtQ%253D%253D&md5=c4b93e93e54333934195ab6b98fbee32</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.nurt.2009.07.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nurt.2009.07.007%26sid%3Dliteratum%253Aachs%26aulast%3DSorkin%26aufirst%3DL.%2BS.%26aulast%3DYaksh%26aufirst%3DT.%2BL.%26atitle%3DBehavioral%2520models%2520of%2520pain%2520states%2520evoked%2520by%2520physical%2520injury%2520to%2520the%2520peripheral%2520nerve%26jtitle%3DNeurotherapeutics%26date%3D2009%26volume%3D6%26spage%3D609%26epage%3D619%26doi%3D10.1016%2Fj.nurt.2009.07.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hargreaves, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flores, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joris, J.</span></span> <span> </span><span class="NLM_article-title">A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia</span>. <i>Pain</i> <span class="NLM_year" style="font-weight: bold;">1988</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">77</span>– <span class="NLM_lpage">88</span>, <span class="refDoi"> DOI: 10.1016/0304-3959(88)90026-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2F0304-3959%2888%2990026-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=3340425" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADyaL1c7itlOntw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=1988&pages=77-88&author=K.+Hargreavesauthor=R.+Dubnerauthor=F.+Brownauthor=C.+Floresauthor=J.+Joris&title=A+new+and+sensitive+method+for+measuring+thermal+nociception+in+cutaneous+hyperalgesia&doi=10.1016%2F0304-3959%2888%2990026-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia</span></div><div class="casAuthors">Hargreaves K; Dubner R; Brown F; Flores C; Joris J</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">1988</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">77-88</span>
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    </div><div class="casAbstract">A method to measure cutaneous hyperalgesia to thermal stimulation in unrestrained animals is described.  The testing paradigm uses an automated detection of the behavioral end-point; repeated testing does not contribute to the development of the observed hyperalgesia.  Carrageenan-induced inflammation resulted in significantly shorter paw withdrawal latencies as compared to saline-treated paws and these latency changes corresponded to a decreased thermal nociceptive threshold.  Both the thermal method and the Randall-Selitto mechanical method detected dose-related hyperalgesia and its blockade by either morphine or indomethacin.  However, the thermal method showed greater bioassay sensitivity and allowed for the measurement of other behavioral parameters in addition to the nociceptive threshold.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQcMP0T_8qqvqcY7HFp97qMfW6udTcc2eaYVHQNqM4qwbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL1c7itlOntw%253D%253D&md5=6a8e191b520661ba76ebc947f0b0b1b1</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2F0304-3959%2888%2990026-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0304-3959%252888%252990026-7%26sid%3Dliteratum%253Aachs%26aulast%3DHargreaves%26aufirst%3DK.%26aulast%3DDubner%26aufirst%3DR.%26aulast%3DBrown%26aufirst%3DF.%26aulast%3DFlores%26aufirst%3DC.%26aulast%3DJoris%26aufirst%3DJ.%26atitle%3DA%2520new%2520and%2520sensitive%2520method%2520for%2520measuring%2520thermal%2520nociception%2520in%2520cutaneous%2520hyperalgesia%26jtitle%3DPain%26date%3D1988%26volume%3D32%26spage%3D77%26epage%3D88%26doi%3D10.1016%2F0304-3959%2888%2990026-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Randall, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Selitto, J. J.</span></span> <span> </span><span class="NLM_article-title">A method for measurement of analgesic activity on inflamed tissue</span>. <i>Arch. Int. Pharmacodyn. Ther.</i> <span class="NLM_year" style="font-weight: bold;">1957</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">409</span>– <span class="NLM_lpage">419</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=13471093" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADyaG1cXis1Gnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=1957&pages=409-419&author=L.+O.+Randallauthor=J.+J.+Selitto&title=A+method+for+measurement+of+analgesic+activity+on+inflamed+tissue"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">A method for measurement of analgesic activity on inflamed tissue</span></div><div class="casAuthors">Randall, Lowell O.; Selitto, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Archives Internationales de Pharmacodynamie et de Therapie</span>
        (<span class="NLM_cas:date">1957</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">409-19</span>CODEN:
                <span class="NLM_cas:coden">AIPTAK</span>;
        ISSN:<span class="NLM_cas:issn">0003-9780</span>.
    </div><div class="casAbstract">The inflamed feet of the rat were twice as sensitive to pressure as were normal feet.  Salicylate, phenylbutazone, and Ro 2-5383 raise the pain threshold of inflamed but not of normal feet, and aminopyrine and narcotic analgesics raise it in both.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWxvjwjaEQurVg90H21EOLACvtfcHk0lgsCpsoy1PBwg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaG1cXis1Gnug%253D%253D&md5=b4ddc4f843cb6b8963315e1e7c69edeb</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DRandall%26aufirst%3DL.%2BO.%26aulast%3DSelitto%26aufirst%3DJ.%2BJ.%26atitle%3DA%2520method%2520for%2520measurement%2520of%2520analgesic%2520activity%2520on%2520inflamed%2520tissue%26jtitle%3DArch.%2520Int.%2520Pharmacodyn.%2520Ther.%26date%3D1957%26volume%3D111%26spage%3D409%26epage%3D419" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Santos-Nogueira, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castro, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mancuso, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Navarro, X.</span></span> <span> </span><span class="NLM_article-title">Randall-Selitto test: a new approach for the detection of neuropathic pain after spinal cord injury</span>. <i>J. Neurotrauma.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">898</span>– <span class="NLM_lpage">904</span>, <span class="refDoi"> DOI: 10.1089/neu.2010.1700</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1089%2Fneu.2010.1700" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=21682605" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADC%252BC38zgtlansA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2012&pages=898-904&author=E.+Santos-Nogueiraauthor=E.+R.+Castroauthor=R.+Mancusoauthor=X.+Navarro&title=Randall-Selitto+test%3A+a+new+approach+for+the+detection+of+neuropathic+pain+after+spinal+cord+injury&doi=10.1089%2Fneu.2010.1700"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Randall-Selitto test: a new approach for the detection of neuropathic pain after spinal cord injury</span></div><div class="casAuthors">Santos-Nogueira Eva; Redondo Castro Elena; Mancuso Renzo; Navarro Xavier</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neurotrauma</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">898-904</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">In this work we assess the usefulness of the Randall-Selitto test as a method to detect and quantify neuropathic pain responses in rats subjected to different spinal cord injuries.  The mechanical nociceptive thresholds were significantly reduced during follow-up after spinal cord contusion or transection.  Our results demonstrate that the Randall-Selitto test allows the detection of neuropathic pain both in forepaws and hindpaws, as well as in dorsal and plantar surfaces.  Moreover, it does not require weight support capacity, so it can be used at early time points after the injury.  This is the first time that this method has been used to describe the changes in nociceptive thresholds that take place after spinal cord injuries of different severities over time.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSoAYwXaNmlky-bLEOO4dYpfW6udTcc2eYdp5oObHtx9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38zgtlansA%253D%253D&md5=44e3b270a8d85952c3f1798ddaace3f7</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1089%2Fneu.2010.1700&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1089%252Fneu.2010.1700%26sid%3Dliteratum%253Aachs%26aulast%3DSantos-Nogueira%26aufirst%3DE.%26aulast%3DCastro%26aufirst%3DE.%2BR.%26aulast%3DMancuso%26aufirst%3DR.%26aulast%3DNavarro%26aufirst%3DX.%26atitle%3DRandall-Selitto%2520test%253A%2520a%2520new%2520approach%2520for%2520the%2520detection%2520of%2520neuropathic%2520pain%2520after%2520spinal%2520cord%2520injury%26jtitle%3DJ.%2520Neurotrauma.%26date%3D2012%26volume%3D29%26spage%3D898%26epage%3D904%26doi%3D10.1089%2Fneu.2010.1700" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanimoto-Mori, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakazato-Imasato, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toide, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kita, Y.</span></span> <span> </span><span class="NLM_article-title">Pharmacologic investigation of the mechanism underlying cold allodynia using a new cold plate procedure in rats with chronic constriction injuries</span>. <i>Behav. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">90</span>, <span class="refDoi"> DOI: 10.1097/FBP.0b013e3282f3d0a3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1097%2FFBP.0b013e3282f3d0a3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=18195599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252FktFamtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2008&pages=85-90&author=S.+Tanimoto-Moriauthor=E.+Nakazato-Imasatoauthor=K.+Toideauthor=Y.+Kita&title=Pharmacologic+investigation+of+the+mechanism+underlying+cold+allodynia+using+a+new+cold+plate+procedure+in+rats+with+chronic+constriction+injuries&doi=10.1097%2FFBP.0b013e3282f3d0a3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacologic investigation of the mechanism underlying cold allodynia using a new cold plate procedure in rats with chronic constriction injuries</span></div><div class="casAuthors">Tanimoto-Mori Sachi; Nakazato-Imasato Etsuko; Toide Katsuo; Kita Yasuhiro</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">85-90</span>
        ISSN:<span class="NLM_cas:issn">0955-8810</span>.
    </div><div class="casAbstract">Cold allodynia is a frequent clinical symptom of patients with neuropathic pain.  Despite numerous studies of cold allodynia, using animal models of neuropathic pain, little is known about its underlying mechanisms.  This study was performed to establish a method for the pharmacologic evaluation of cold allodynia using several analgesics in a chronic constriction injury (CCI) rat model of neuropathic pain.  Compared with the results obtained before the CCI operation, the CCI rats placed on a cork plate at 20 degrees C exhibited a slight change in the paw withdrawal latency because of the mechanical stimulus mediated by the injured paw touching the plate.  By contrast, there was a significant reduction in the paw withdrawal latency on a cold metal plate compared with that on the cork plate after the CCI surgery, with the maximum decrease occurring on postoperative day 7.  This reduction is thought to specifically reflect cold-induced pain behavior.  In addition, both naive and CCI rats showed behavioral changes at 5 and 0 degrees C, but not at 10 degrees C or higher.  Interestingly, a subcutaneous morphine dose of 6 mg/kg completely inhibited cold allodynia induced at 10 degrees C on postoperative day 7.  Under this condition, both the sodium channel blocker mexiletine (10 and 30 mg/kg, subcutaneously) and the calcium channel alpha2delta subunit blocker pregabalin (30 and 100 mg/kg, orally) significantly suppressed cold allodynia.  Additionally, both resiniferatoxin (0.3 mg/kg, subcutaneously), an ultrapotent analog of capsaicin that desensitizes C fibers, and the VR1 channel antagonist N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl) tetrahydropyrazine-1(2H)-carboxamide (10 and 30 mg/kg, orally) significantly prolonged the paw withdrawal latency.  In conclusion, our data suggest that the activation of C fibers mediates cold allodynia.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTEIX4hFO5fykwlCcfExbvbfW6udTcc2eYdp5oObHtx9bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252FktFamtg%253D%253D&md5=003742ed1772c4767dffcec6d4004753</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1097%2FFBP.0b013e3282f3d0a3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FFBP.0b013e3282f3d0a3%26sid%3Dliteratum%253Aachs%26aulast%3DTanimoto-Mori%26aufirst%3DS.%26aulast%3DNakazato-Imasato%26aufirst%3DE.%26aulast%3DToide%26aufirst%3DK.%26aulast%3DKita%26aufirst%3DY.%26atitle%3DPharmacologic%2520investigation%2520of%2520the%2520mechanism%2520underlying%2520cold%2520allodynia%2520using%2520a%2520new%2520cold%2520plate%2520procedure%2520in%2520rats%2520with%2520chronic%2520constriction%2520injuries%26jtitle%3DBehav.%2520Pharmacol.%26date%3D2008%26volume%3D19%26spage%3D85%26epage%3D90%26doi%3D10.1097%2FFBP.0b013e3282f3d0a3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Terada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hara, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haranishi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sata, T.</span></span> <span> </span><span class="NLM_article-title">Antinociceptive effect of intrathecal administration of taurine in rat models of neuropathic pain</span>. <i>Can. J. Anesth.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">630</span>– <span class="NLM_lpage">637</span>, <span class="refDoi"> DOI: 10.1007/s12630-011-9504-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1007%2Fs12630-011-9504-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=21512835" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADC%252BC3MjltF2jsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2011&pages=630-637&author=T.+Teradaauthor=K.+Haraauthor=Y.+Haranishiauthor=T.+Sata&title=Antinociceptive+effect+of+intrathecal+administration+of+taurine+in+rat+models+of+neuropathic+pain&doi=10.1007%2Fs12630-011-9504-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Antinociceptive effect of intrathecal administration of taurine in rat models of neuropathic pain</span></div><div class="casAuthors">Terada Tadanori; Hara Koji; Haranishi Yasunori; Sata Takeyoshi</div><div class="citationInfo"><span class="NLM_cas:title">Canadian journal of anaesthesia = Journal canadien d'anesthesie</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">630-637</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">PURPOSE:  Taurine is the most abundant amino acid in many tissues.  Although taurine has been shown to be antinociceptive, in this report, our focus is to elucidate the mechanism and action site on neuropathic pain.  This study used behavioural assessments to determine whether taurine attenuates neuropathic pain in the spinal cord.  METHODS:  Chronic constriction injury (CCI) to the sciatic nerve and streptozotocin-induced diabetic neuropathy were introduced to male Sprague-Dawley rats.  We then assessed the antinociceptive effect of spinal injections of taurine (100, 200, 400, or 800 μg) using electronic von Frey, paw pressure, and plantar tests.  To explore the effect of taurine on motor function, a rotarod test was performed, and in order to determine which neurotransmitter pathway is involved in taurine's action, we examined how several antagonists of spinal pain processing receptors altered the effect of taurine 400 μg in a paw pressure test.  RESULTS:  Taurine alleviated mechanical allodynia, mechanical hyperalgesia, and thermal hyperalgesia in CCI rats and suppressed mechanical allodynia and hyperalgesia in diabetic rats.  Significant effects were observed at 200 μg in both models.  On the other hand, taurine dose-dependently affected motor performance, and a significant effect was seen at 400 μg.  The antinociceptive effects were reversed completely by pretreatment with an intrathecal injection of strychnine, a glycine receptor antagonist.  CONCLUSION:  The present study demonstrated that intrathecal administration of taurine attenuates different models of neuropathic pain, and these effects seem to be mediated by the activation of glycinergic neurotransmission.  These findings suggest that taurine may be a candidate remedy for neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRT_t63j72197FU0A1HOshhfW6udTcc2ea2c5PxQk14u7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3MjltF2jsg%253D%253D&md5=2d56d55d412698026048aad5abb44359</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1007%2Fs12630-011-9504-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs12630-011-9504-8%26sid%3Dliteratum%253Aachs%26aulast%3DTerada%26aufirst%3DT.%26aulast%3DHara%26aufirst%3DK.%26aulast%3DHaranishi%26aufirst%3DY.%26aulast%3DSata%26aufirst%3DT.%26atitle%3DAntinociceptive%2520effect%2520of%2520intrathecal%2520administration%2520of%2520taurine%2520in%2520rat%2520models%2520of%2520neuropathic%2520pain%26jtitle%3DCan.%2520J.%2520Anesth.%26date%3D2011%26volume%3D58%26spage%3D630%26epage%3D637%26doi%3D10.1007%2Fs12630-011-9504-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Umland, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Troutman, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liston, T. E.</span></span> <span> </span><span class="NLM_article-title">Species independence in brain tissue binding using brain homogenates</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1270</span>– <span class="NLM_lpage">1277</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.038778</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1124%2Fdmd.111.038778" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=21474681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFWktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1270-1277&author=L.+Diauthor=J.+P.+Umlandauthor=G.+Changauthor=Y.+Huangauthor=Z.+Linauthor=D.+O.+Scottauthor=M.+D.+Troutmanauthor=T.+E.+Liston&title=Species+independence+in+brain+tissue+binding+using+brain+homogenates&doi=10.1124%2Fdmd.111.038778"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Species independence in brain tissue binding using brain homogenates</span></div><div class="casAuthors">Di, Li; Umland, John P.; Chang, George; Huang, Youping; Lin, Zhen; Scott, Dennis O.; Troutman, Matthew D.; Liston, Theodore E.</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1270-1277</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Species independence of brain tissue binding was assessed with a large no. of structurally diverse compds. using equil. dialysis with brain homogenates of seven species and strains (Wistar Han rat, Sprague-Dawley rat, CD-1 mouse, Hartley guinea pig, beagle dog, cynomolgus monkey, and human).  The results showed that the fractions unbound of the seven species and strains were strongly correlated with correlation coeffs. ranging from 0.93 to 0.99.  The cross-species/strain correlations were not significantly different from the interassay correlation with the same species.  The linear correlation between Wistar Han and other species had a slope close to 1 and an intercept near 0.  Based on orthogonal statistical anal., no correction is needed for extrapolation of fraction unbound from Wistar Han rat to the other species or strains.  Hence, brain tissue binding of Wistar Han rat can be used to obtain binding of other species and strains in drug discovery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoub4FiLWkAFrVg90H21EOLACvtfcHk0lgp1oIQGnurUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFWktrg%253D&md5=93a51addedb22de4648e6e5ee39c6c81</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.038778&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.038778%26sid%3Dliteratum%253Aachs%26aulast%3DDi%26aufirst%3DL.%26aulast%3DUmland%26aufirst%3DJ.%2BP.%26aulast%3DChang%26aufirst%3DG.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DScott%26aufirst%3DD.%2BO.%26aulast%3DTroutman%26aufirst%3DM.%2BD.%26aulast%3DListon%26aufirst%3DT.%2BE.%26atitle%3DSpecies%2520independence%2520in%2520brain%2520tissue%2520binding%2520using%2520brain%2520homogenates%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1270%26epage%3D1277%26doi%3D10.1124%2Fdmd.111.038778" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, W.</span></span> <span> </span><span class="NLM_article-title">Brain regional pharmacokinetics of <i>p</i>-aminosalicylic acid and its <i>N</i>-acetylated metabolite: effectiveness in chelating brain manganese</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1904</span>– <span class="NLM_lpage">1909</span>, <span class="refDoi"> DOI: 10.1124/dmd.111.040915</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1124%2Fdmd.111.040915" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=21768272" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ekurbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2011&pages=1904-1909&author=L.+Hongauthor=W.+Jiangauthor=H.+Panauthor=Y.+Jiangauthor=S.+Zengauthor=W.+Zheng&title=Brain+regional+pharmacokinetics+of+p-aminosalicylic+acid+and+its+N-acetylated+metabolite%3A+effectiveness+in+chelating+brain+manganese&doi=10.1124%2Fdmd.111.040915"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Brain regional pharmacokinetics of p-aminosalicylic acid and its N-acetylated metabolite: effectiveness in chelating brain manganese</span></div><div class="casAuthors">Hong, Lan; Jiang, Wendy; Pan, Hao; Jiang, Yueming; Zeng, Su; Zheng, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1904-1909</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Para-Aminosalicylic acid (PAS; 4-amino-2-hydroxybenzoic acid), an antituberculosis drug in use since the 1950s, has recently been suggested to be an effective agent for treatment of manganese-induced parkinsonian disorders.  However, the neuropharmacokinetics of PAS and its metabolite N-acetyl-para-aminosalicylic acid (AcPAS; N-acetyl-4-amino-2-hydroxybenzoic acid) are unknown.  This study was designed to investigate the pharmacokinetics of PAS and its distribution in brain to help better design the dosing regimen for clin. trials.  Male Sprague-Dawley rats received single femoral artery injections of PAS (200 mg/kg).  Plasma, cerebrospinal fluid, and brain tissues were collected, and PAS and AcPAS concns. were quantified by high-performance liq. chromatog.  After administration, the concns. of PAS declined rapidly in plasma with an elimination t1/2 of 34 min; the metabolite AcPAS was detected in plasma and eliminated with a t1/2 of 147 min.  PAS and AcPAS were detected in brain tissues; AcPAS had a much higher tissue concn. and a longer t1/2 than the parent PAS in most tissues examd.  Although both were present in blood or tissues as free, unbound mols., AcPAS appeared to have a higher tissue affinity than PAS.  Taken together, our results suggest that a dosing regimen with continuous i.v. infusion of PAS is necessary to achieve therapeutic levels in targeted brain regions.  Furthermore, PAS and AcPAS seem to be effective in reducing manganese levels in brain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwuBKpN5kMorVg90H21EOLACvtfcHk0lgp1oIQGnurUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ekurbJ&md5=ed26d7985eca98970902ae8812815f8e</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1124%2Fdmd.111.040915&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fdmd.111.040915%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DW.%26aulast%3DPan%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DZeng%26aufirst%3DS.%26aulast%3DZheng%26aufirst%3DW.%26atitle%3DBrain%2520regional%2520pharmacokinetics%2520of%2520p-aminosalicylic%2520acid%2520and%2520its%2520N-acetylated%2520metabolite%253A%2520effectiveness%2520in%2520chelating%2520brain%2520manganese%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2011%26volume%3D39%26spage%3D1904%26epage%3D1909%26doi%3D10.1124%2Fdmd.111.040915" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pabst, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Hörsten, S.</span></span> <span> </span><span class="NLM_article-title">Behavioral phenotyping of mice in pharmacological and toxicological research</span>. <i>Exp. Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">69</span>– <span class="NLM_lpage">83</span>, <span class="refDoi"> DOI: 10.1078/0940-2993-00301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1078%2F0940-2993-00301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=12940631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A280%3ADC%252BD3svgtF2jtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2003&pages=69-83&author=T.+Karlauthor=R.+Pabstauthor=S.+van+H%C3%B6rsten&title=Behavioral+phenotyping+of+mice+in+pharmacological+and+toxicological+research&doi=10.1078%2F0940-2993-00301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Behavioral phenotyping of mice in pharmacological and toxicological research</span></div><div class="casAuthors">Karl Tim; Pabst Reinhard; von Horsten Stephan</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">69-83</span>
        ISSN:<span class="NLM_cas:issn">0940-2993</span>.
    </div><div class="casAbstract">The evaluation of behavioral effects is an important component for the in vivo screening of drugs or potentially toxic compounds in mice.  Ideally, such screening should be composed of monitoring general health, sensory functions, and motor abilities, right before specific behavioral domains are tested.  A rational strategy in the design and procedure of testing as well as an effective composition of different well-established and reproducible behavioral tests can minimize the risk of false positive and false negative results in drug screening.  In the present review we describe such basic considerations in planning experiments, selecting strains of mice, and propose groups of behavioral tasks suitable for a reliable detection of differences in specific behavioral domains in mice.  Screening of general health and neurophysiologic functions (reflexes, sensory abilities) and motor function (pole test, wire hang test, beam walking, rotarod, accelerod, and footprint) as well as specific hypothesis-guided testing in the behavioral domains of learning and memory (water maze, radial maze, conditioned fear, and avoidance tasks), emotionality (open field, hole board, elevated plus maze, and object exploration), nociception (tail flick, hot plate), psychiatric-like conditions (porsolt swim test, acoustic startle response, and prepulse inhibition), and aggression (isolation-induced aggression, spontaneous aggression, and territorial aggression) are described in further detail.  This review is designed to describe a general approach, which increases reliability of behavioral screening.  Furthermore, it provides an overview on a selection of specific procedures suitable for but not limited to behavioral screening in pharmacology and toxicology.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRS5l4UT704azEwO064Z95rfW6udTcc2ea2c5PxQk14u7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD3svgtF2jtw%253D%253D&md5=90cc625f983720eb940c43660245af3c</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1078%2F0940-2993-00301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1078%252F0940-2993-00301%26sid%3Dliteratum%253Aachs%26aulast%3DKarl%26aufirst%3DT.%26aulast%3DPabst%26aufirst%3DR.%26aulast%3Dvan%2BH%25C3%25B6rsten%26aufirst%3DS.%26atitle%3DBehavioral%2520phenotyping%2520of%2520mice%2520in%2520pharmacological%2520and%2520toxicological%2520research%26jtitle%3DExp.%2520Toxicol.%2520Pathol.%26date%3D2003%26volume%3D55%26spage%3D69%26epage%3D83%26doi%3D10.1078%2F0940-2993-00301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shuman, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Omstein, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paschal, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gesellchen, P. D.</span></span> <span> </span><span class="NLM_article-title">An improved synthesis of homoproline and derivatives</span>. <i>J. Org. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1990</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">738</span>– <span class="NLM_lpage">741</span>, <span class="refDoi"> DOI: 10.1021/jo00289a058</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jo00289a058" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADyaK3cXls1eqtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=1990&pages=738-741&author=R.+T.+Shumanauthor=P.+L.+Omsteinauthor=J.+W.+Paschalauthor=P.+D.+Gesellchen&title=An+improved+synthesis+of+homoproline+and+derivatives&doi=10.1021%2Fjo00289a058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">An improved synthesis of homoproline and derivatives</span></div><div class="casAuthors">Shuman, Robert T.; Ornstein, Paul L.; Paschal, Jonathan W.; Gesellchen, Paul D.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">1990</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">738-41</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    </div><div class="casAbstract">Homoproline derivs. I (R = 3-Me, 4-Me, 6-Me, 4-Et, 4-OMe, 4-CMe3) were prepd. from the corresponding pyridines II in 4 steps.  A key step was the treatment of N-oxides III (R = same) with Me3SiCN and Me2NCOCl in CH2Cl2 to give nitriles IV (R = same).  5,6-Benzohomoprolines V (R1 = H, Me) were also prepd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoC2ygcm4nNZrVg90H21EOLACvtfcHk0lhRXvqNRZFgpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXls1eqtg%253D%253D&md5=0a4c88f7f1c4a3c1e98f033e5df6a7bd</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjo00289a058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo00289a058%26sid%3Dliteratum%253Aachs%26aulast%3DShuman%26aufirst%3DR.%2BT.%26aulast%3DOmstein%26aufirst%3DP.%2BL.%26aulast%3DPaschal%26aufirst%3DJ.%2BW.%26aulast%3DGesellchen%26aufirst%3DP.%2BD.%26atitle%3DAn%2520improved%2520synthesis%2520of%2520homoproline%2520and%2520derivatives%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D1990%26volume%3D55%26spage%3D738%26epage%3D741%26doi%3D10.1021%2Fjo00289a058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="note"><p class="first last">and references cited therein</p></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sreedhar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiva Kumar, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srinivas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balasubrahmanyam, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Venkanna, G. T.</span></span> <span> </span><span class="NLM_article-title">CuI/L-histidine catalyzed <i>N</i>-arylation of heterocycles</span>. <i>J. Mol. Catal. A: Chem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>265</i></span>,  <span class="NLM_fpage">183</span>– <span class="NLM_lpage">185</span>, <span class="refDoi"> DOI: 10.1016/j.molcata.2006.10.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2Fj.molcata.2006.10.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD2sXis1Oqu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=265&publication_year=2007&pages=183-185&author=B.+Sreedharauthor=K.+B.+Shiva+Kumarauthor=P.+Srinivasauthor=V.+Balasubrahmanyamauthor=G.+T.+Venkanna&title=CuI%2FL-histidine+catalyzed+N-arylation+of+heterocycles&doi=10.1016%2Fj.molcata.2006.10.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">CuI/L-histidine catalyzed N-arylation of heterocycles</span></div><div class="casAuthors">Sreedhar, B.; Shiva Kumar, K. B.; Srinivas, P.; Balasubrahmanyam, V.; Venkanna, G. T.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Catalysis A: Chemical</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">265</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">183-185</span>CODEN:
                <span class="NLM_cas:coden">JMCCF2</span>;
        ISSN:<span class="NLM_cas:issn">1381-1169</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">CuI/L-histidine is an effective catalyst for N-arylation of heterocycles, using K2CO3 as base in DMSO solvent.  N-Arylated products were isolated in good to excellent yields, demonstrating the versatility of the reaction.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtKByHHZyCkbVg90H21EOLACvtfcHk0lhRXvqNRZFgpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXis1Oqu7g%253D&md5=aca04bbec7c03e4824c363f335d948ea</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.molcata.2006.10.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcata.2006.10.002%26sid%3Dliteratum%253Aachs%26aulast%3DSreedhar%26aufirst%3DB.%26aulast%3DShiva%2BKumar%26aufirst%3DK.%2BB.%26aulast%3DSrinivas%26aufirst%3DP.%26aulast%3DBalasubrahmanyam%26aufirst%3DV.%26aulast%3DVenkanna%26aufirst%3DG.%2BT.%26atitle%3DCuI%252FL-histidine%2520catalyzed%2520N-arylation%2520of%2520heterocycles%26jtitle%3DJ.%2520Mol.%2520Catal.%2520A%253A%2520Chem.%26date%3D2007%26volume%3D265%26spage%3D183%26epage%3D185%26doi%3D10.1016%2Fj.molcata.2006.10.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="note"><p class="first last">Compound <b>85</b> was prepared according to the method described in:</p></div><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Deng, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paone, D. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ginnetti, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurihara, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dreher, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weissman, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauffer, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burgey, C. S.</span></span> <span> </span><span class="NLM_article-title">Copper-facilitated Suzuki reactions: application to 2-heterocyclic boronates</span>. <i>Org. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">345</span>– <span class="NLM_lpage">347</span>, <span class="refDoi"> DOI: 10.1021/ol802556f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ol802556f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhsFWqsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2009&pages=345-347&author=J.+Z.+Dengauthor=D.+V.+Paoneauthor=A.+T.+Ginnettiauthor=H.+Kuriharaauthor=S.+D.+Dreherauthor=S.+A.+Weissmanauthor=S.+R.+Staufferauthor=C.+S.+Burgey&title=Copper-facilitated+Suzuki+reactions%3A+application+to+2-heterocyclic+boronates&doi=10.1021%2Fol802556f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Copper-Facilitated Suzuki Reactions: Application to 2-Heterocyclic Boronates</span></div><div class="casAuthors">Deng, James Z.; Paone, Daniel V.; Ginnetti, Anthony T.; Kurihara, Hideki; Dreher, Spencer D.; Weissman, Steven A.; Stauffer, Shaun R.; Burgey, Christopher S.</div><div class="citationInfo"><span class="NLM_cas:title">Organic Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">345-347</span>CODEN:
                <span class="NLM_cas:coden">ORLEF7</span>;
        ISSN:<span class="NLM_cas:issn">1523-7060</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The palladium-catalyzed Suzuki-Miyaura reaction has been utilized as one of the most powerful methods for C-C bond formation.  However, Suzuki reactions of electron-deficient 2-heterocyclic boronates generally give low conversions and remain challenging.  The successful copper(I) facilitated Suzuki coupling of 2-heterocyclic boronates that is broad in scope is reported.  Use of this methodol. affords greatly enhanced yields of these notoriously difficult couplings.  E.g., reaction of 2-heterocyclic boronate I and 4-IC6H4Ph in presence of Pd(OAc)2, dppf, and CuCl gave 89% pyridine deriv. II.  Furthermore, mechanistic investigations suggest a possible role of copper in the catalytic cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo10K3bNpyQq7Vg90H21EOLACvtfcHk0lhRXvqNRZFgpQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhsFWqsrvI&md5=da568b6dd09940f183fe8c331db88734</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fol802556f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fol802556f%26sid%3Dliteratum%253Aachs%26aulast%3DDeng%26aufirst%3DJ.%2BZ.%26aulast%3DPaone%26aufirst%3DD.%2BV.%26aulast%3DGinnetti%26aufirst%3DA.%2BT.%26aulast%3DKurihara%26aufirst%3DH.%26aulast%3DDreher%26aufirst%3DS.%2BD.%26aulast%3DWeissman%26aufirst%3DS.%2BA.%26aulast%3DStauffer%26aufirst%3DS.%2BR.%26aulast%3DBurgey%26aufirst%3DC.%2BS.%26atitle%3DCopper-facilitated%2520Suzuki%2520reactions%253A%2520application%2520to%25202-heterocyclic%2520boronates%26jtitle%3DOrg.%2520Lett.%26date%3D2009%26volume%3D11%26spage%3D345%26epage%3D347%26doi%3D10.1021%2Fol802556f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwanowicz, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pitts, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murali
Dhar, T. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleener, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouleau, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheney, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollenbaugh, D. L.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of inosine monophosphate dehydrogenase: SARs about the <i>N</i>-3-methoxy-4-(5-oxazolyl)phenyl moiety</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">2059</span>– <span class="NLM_lpage">2063</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(03)00258-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2FS0960-894X%2803%2900258-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=12781195" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD3sXktVGqtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2003&pages=2059-2063&author=E.+J.+Iwanowiczauthor=S.+H.+Wattersonauthor=J.+Guoauthor=W.+J.+Pittsauthor=T.+G.+Murali%0ADharauthor=Z.+Shenauthor=P.+Chenauthor=H.+H.+Guauthor=C.+A.+Fleenerauthor=K.+A.+Rouleauauthor=D.+L.+Cheneyauthor=R.+M.+Townsendauthor=D.+L.+Hollenbaugh&title=Inhibitors+of+inosine+monophosphate+dehydrogenase%3A+SARs+about+the+N-3-methoxy-4-%285-oxazolyl%29phenyl+moiety&doi=10.1016%2FS0960-894X%2803%2900258-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of inosine monophosphate dehydrogenase: SARs about the N-[3-Methoxy-4-(5-oxazolyl)phenyl] moiety</span></div><div class="casAuthors">Iwanowicz, Edwin J.; Watterson, Scott H.; Guo, Junqing; Pitts, William J.; Murali Dhar, T. G.; Shen, Zhongqi; Chen, Ping; Gu, Henry H.; Fleener, Catherine A.; Rouleau, Katherine A.; Cheney, Daniel L.; Townsend, Robert M.; Hollenbaugh, Diane L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2059-2063</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The first reported structure-activity relationships (SARs) about the N-[3-methoxy-4-(5-oxazolyl)phenyl] moiety for a series of recently disclosed inosine monophosphate dehydrogenase (IMPDH) inhibitors are described.  The syntheses and in vitro inhibitory values for IMPDH II, and T-cell proliferation (for select analogs) are given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR1qsIn2bQ5rVg90H21EOLACvtfcHk0lhXjQM1yd_t6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXktVGqtrc%253D&md5=7ac330eb05076313669d1a6ba866d19c</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2803%2900258-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252803%252900258-0%26sid%3Dliteratum%253Aachs%26aulast%3DIwanowicz%26aufirst%3DE.%2BJ.%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DPitts%26aufirst%3DW.%2BJ.%26aulast%3DMurali%2BDhar%26aufirst%3DT.%2BG.%26aulast%3DShen%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DP.%26aulast%3DGu%26aufirst%3DH.%2BH.%26aulast%3DFleener%26aufirst%3DC.%2BA.%26aulast%3DRouleau%26aufirst%3DK.%2BA.%26aulast%3DCheney%26aufirst%3DD.%2BL.%26aulast%3DTownsend%26aufirst%3DR.%2BM.%26aulast%3DHollenbaugh%26aufirst%3DD.%2BL.%26atitle%3DInhibitors%2520of%2520inosine%2520monophosphate%2520dehydrogenase%253A%2520SARs%2520about%2520the%2520N-3-methoxy-4-%25285-oxazolyl%2529phenyl%2520moiety%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2003%26volume%3D13%26spage%3D2059%26epage%3D2063%26doi%3D10.1016%2FS0960-894X%2803%2900258-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lieberman, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Connor, R.</span></span> <span> </span><span class="NLM_article-title"><i>p</i>-Nitrobenzaldehyde</span>. <i>Org. Syn. Collect.</i> <span class="NLM_year" style="font-weight: bold;">1943</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">441</span>– <span class="NLM_lpage">443</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1943&pages=441-443&author=S.+V.+Liebermanauthor=R.+Connor&title=p-Nitrobenzaldehyde"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLieberman%26aufirst%3DS.%2BV.%26aulast%3DConnor%26aufirst%3DR.%26atitle%3Dp-Nitrobenzaldehyde%26jtitle%3DOrg.%2520Syn.%2520Collect.%26date%3D1943%26volume%3D2%26spage%3D441%26epage%3D443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cassayre, J. Y.</span>; <span class="NLM_string-name">Pitterna, T.</span>; <span class="NLM_string-name">Corsi, C.</span>; <span class="NLM_string-name">Maienfisch, P.</span></span> <span> </span><span class="NLM_article-title">Insecticidal compounds</span>. World Patent Appl. <span class="NLM_patent">WO 2011/3684 A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=J.+Y.+Cassayre&author=T.+Pitterna&author=C.+Corsi&author=P.+Maienfisch&title=Insecticidal+compounds"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCassayre%26aufirst%3DJ.%2BY.%26atitle%3DInsecticidal%2520compounds%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="note"><p class="first last">See reference <a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Supporting Information for additional in vitro assay details.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kieltyka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vath, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baglieri, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferraro, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zvyaga, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drexler, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, H. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shou, W. Z.</span></span> <span> </span><span class="NLM_article-title">A high throughput bioanalytical platform using automated infusion for tandem mass spectrometric method optimization and its application in a metabolic stability screen</span>. <i>Rapid Commun. Mass Spectrom.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">1579</span>– <span class="NLM_lpage">1591</span>, <span class="refDoi"> DOI: 10.1002/rcm.4037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1002%2Frcm.4037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=19399765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD1MXmtVKmt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=1579-1591&author=K.+Kieltykaauthor=J.+Zhangauthor=S.+Liauthor=M.+Vathauthor=C.+Baglieriauthor=C.+Ferraroauthor=T.+A.+Zvyagaauthor=D.+M.+Drexlerauthor=H.+N.+Wellerauthor=W.+Z.+Shou&title=A+high+throughput+bioanalytical+platform+using+automated+infusion+for+tandem+mass+spectrometric+method+optimization+and+its+application+in+a+metabolic+stability+screen&doi=10.1002%2Frcm.4037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">A high-throughput bioanalytical platform using automated infusion for tandem mass spectrometric method optimization and its application in a metabolic stability screen</span></div><div class="casAuthors">Kieltyka, Kasia; Zhang, Jun; Li, Shu; Vath, Marianne; Baglieri, Chris; Ferraro, Cheryl; Zvyaga, Tatyana A.; Drexler, Dieter M.; Weller, Harold N.; Shou, Wilson Z.</div><div class="citationInfo"><span class="NLM_cas:title">Rapid Communications in Mass Spectrometry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1579-1591</span>CODEN:
                <span class="NLM_cas:coden">RCMSEF</span>;
        ISSN:<span class="NLM_cas:issn">0951-4198</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Liq. chromatog./tandem mass spectrometry (LC/MS/MS) is the bioanal. method of choice to support plate-based, in vitro early ADME (Absorption, Distribution, Metab. and Excretion) screens such as metabolic stability (Metstab) assessment.  MS/MS method optimization has historically been the bottleneck in this environment, where samples from thousands of discrete compds. are analyzed on a monthly basis, mainly due to the lack of a high-quality com. available platform to handle the necessary MS/MS method optimization steps for sample anal. by selected reaction monitoring (SRM) on triple quadrupole mass spectrometers.  To address this challenge, we recently developed a highly automated bioanal. platform by successfully integrating QuickQuan 2.0, a unique high-throughput soln. featuring MS/MS method optimization by automated infusion, with a customized inhouse software tool in support of a Metstab screen.  In this platform, a dual-column setup running parallel chromatog. was also implemented to reduce the bioanal. cycle time for LC/MS/MS sample anal.  A set of 45 validation compds. was used to demonstrate the speed, quality and reproducibility of MS/MS method optimization, sample anal., and data processing using this automated platform.  Metstab results for the validation compds. in microsomes from multiple species (human, rat, mouse) showed good consistency within each batch, and also between batches conducted on different days.  We have achieved and maintained a monthly throughput of 1300 compd. assays representing 500 discrete compds. per instrument per mo on this platform, and it has been used to generate metabolic stability data for more than 25 000 compds. to date with an overall success rate of more than 95%.  Copyright © 2009 John Wiley & Sons, Ltd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8W1PNTqYnALVg90H21EOLACvtfcHk0lhXjQM1yd_t6w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXmtVKmt70%253D&md5=57977322942dc41955c1d9cf015e5b05</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1002%2Frcm.4037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Frcm.4037%26sid%3Dliteratum%253Aachs%26aulast%3DKieltyka%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DVath%26aufirst%3DM.%26aulast%3DBaglieri%26aufirst%3DC.%26aulast%3DFerraro%26aufirst%3DC.%26aulast%3DZvyaga%26aufirst%3DT.%2BA.%26aulast%3DDrexler%26aufirst%3DD.%2BM.%26aulast%3DWeller%26aufirst%3DH.%2BN.%26aulast%3DShou%26aufirst%3DW.%2BZ.%26atitle%3DA%2520high%2520throughput%2520bioanalytical%2520platform%2520using%2520automated%2520infusion%2520for%2520tandem%2520mass%2520spectrometric%2520method%2520optimization%2520and%2520its%2520application%2520in%2520a%2520metabolic%2520stability%2520screen%26jtitle%3DRapid%2520Commun.%2520Mass%2520Spectrom.%26date%3D2009%26volume%3D23%26spage%3D1579%26epage%3D1591%26doi%3D10.1002%2Frcm.4037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madari, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paiva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, H.</span></span> <span> </span><span class="NLM_article-title">Addition of optimized bovine serum albumin level in a high-throughput Caco-2 assay enabled accurate permeability assessment for lipophilic compounds</span>. <i>SLAS Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">738</span>– <span class="NLM_lpage">744</span>, <span class="refDoi"> DOI: 10.1177/2472555219848483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1177%2F2472555219848483" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=31076010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFams7rJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2019&pages=738-744&author=X.+Caiauthor=S.+Madariauthor=A.+Walkerauthor=A.+Paivaauthor=Y.+Liauthor=J.+Herbstauthor=W.+Shouauthor=H.+Weller&title=Addition+of+optimized+bovine+serum+albumin+level+in+a+high-throughput+Caco-2+assay+enabled+accurate+permeability+assessment+for+lipophilic+compounds&doi=10.1177%2F2472555219848483"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Addition of Optimized Bovine Serum Albumin Level in a High-Throughput Caco-2 Assay Enabled Accurate Permeability Assessment for Lipophilic Compounds</span></div><div class="casAuthors">Cai, Xianmei; Madari, Shilpa; Walker, Aaron; Paiva, Anthony; Li, Ying; Herbst, John; Shou, Wilson; Weller, Harold</div><div class="citationInfo"><span class="NLM_cas:title">SLAS Discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">738-744</span>CODEN:
                <span class="NLM_cas:coden">SDLIBT</span>;
        ISSN:<span class="NLM_cas:issn">2472-5560</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">The Caco-2 permeability assay is a well-accepted in vitro model to evaluate compds.' potential for oral absorption at early discovery.  However, for many lipophilic compds., no meaningful Caco-2 data could be generated due to their low soly. in assay buffer and/or poor recovery from the assay.  In our previous study, we reported an org. catch approach to improve compd. recovery.  To further reduce compd. loss and increase soly. in aq. buffer, we explored the addn. of bovine serum albumin (BSA).  However, in contrast to the commonly used BSA level at 4%, a lower level of BSA was selected in an effort to minimize the potential risk of missing the identification of efflux substrates, and to avoid the extensive sample cleanup needed for 4% BSA.  Through a systematic evaluation, it was found that 0.5% BSA was effective in enhancing compd. soly. and reducing nonspecific binding, which allowed reliable assessment of the permeability and efflux potential for lipophilic compds.  Also, with an optimized sample handling process, no extra sample cleanup was required before liq. chromatog.-mass spectrometry (LC-MS) anal.  The implementation of this assay has enabled accurate permeability assessment for compds. that had poor soly. and/or poor mass balance under the non-BSA assay conditions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWB9jtL5enBrVg90H21EOLACvtfcHk0lj0a9gyKT6EBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFams7rJ&md5=f5cad97c5d624a513f88887eaefb2b73</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1177%2F2472555219848483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F2472555219848483%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DMadari%26aufirst%3DS.%26aulast%3DWalker%26aufirst%3DA.%26aulast%3DPaiva%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHerbst%26aufirst%3DJ.%26aulast%3DShou%26aufirst%3DW.%26aulast%3DWeller%26aufirst%3DH.%26atitle%3DAddition%2520of%2520optimized%2520bovine%2520serum%2520albumin%2520level%2520in%2520a%2520high-throughput%2520Caco-2%2520assay%2520enabled%2520accurate%2520permeability%2520assessment%2520for%2520lipophilic%2520compounds%26jtitle%3DSLAS%2520Discovery%26date%3D2019%26volume%3D24%26spage%3D738%26epage%3D744%26doi%3D10.1177%2F2472555219848483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cai, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paiva, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kolb, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herbst, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weller, H.</span></span> <span> </span><span class="NLM_article-title">Approach to improve compound recovery in a high-throughput Caco-2 permeability assay supported by liquid chromatography–tandem mass spectrometry</span>. <i>J. Pharm. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">2755</span>– <span class="NLM_lpage">2762</span>, <span class="refDoi"> DOI: 10.1002/jps.23194</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1002%2Fjps.23194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=22611052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BC38Xnt1Cgu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2012&pages=2755-2762&author=X.+Caiauthor=A.+Walkerauthor=C.+Chengauthor=A.+Paivaauthor=Y.+Liauthor=J.+Kolbauthor=J.+Herbstauthor=W.+Shouauthor=H.+Weller&title=Approach+to+improve+compound+recovery+in+a+high-throughput+Caco-2+permeability+assay+supported+by+liquid+chromatography%E2%80%93tandem+mass+spectrometry&doi=10.1002%2Fjps.23194"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Approach to improve compound recovery in a high-throughput Caco-2 permeability assay supported by liquid chromatography-tandem mass spectrometry</span></div><div class="casAuthors">Cai, Xianmei; Walker, Aaron; Cheng, Charles; Paiva, Anthony; Li, Ying; Kolb, Janet; Herbst, John; Shou, Wilson; Weller, Harold</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmaceutical Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2755-2762</span>CODEN:
                <span class="NLM_cas:coden">JPMSAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-3549</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">The Caco-2 cell culture system is widely employed as an in vitro model for prediction of intestinal absorption of test compds. in early drug discovery.  Poor recovery is a commonly encountered issue in Caco-2 assay, which can lead to difficulty in data interpretation and underestimation of the apparent permeability of affected compds.  In this study, we systematically investigated the potential sources of compd. loss in our automated, high-throughput Caco-2 assay, sample storage, and anal. processes, and as a result found the nonspecific binding to various plastic surfaces to be the major cause of poor compd. recovery.  To minimize the nonspecific binding, we implemented a simple and practical approach in our assay automation by preloading collection plates with org. solvent contg. internal std. prior to transferring incubations samples.  The implementation of this new method has been shown to significantly increase recovery in many compds. previously identified as having poor recovery in the Caco-2 permeability assay.  With improved recovery, permeability results were obtained for many compds. that were previously not detected in the basolateral samples.  In addn. to recovery improvement, this new approach also simplified sample prepn. for liq. chromatog.-tandem mass spectrometric anal. and therefore achieved time and cost savings for the bioanalyst. © 2012 Wiley Periodicals, Inc. and the American Pharmacists Assocn. J Pharm Sci.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr3d7jZyPfxPLVg90H21EOLACvtfcHk0lj0a9gyKT6EBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xnt1Cgu70%253D&md5=16cfacab071344c98a95dc8c6f4483af</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1002%2Fjps.23194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjps.23194%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DX.%26aulast%3DWalker%26aufirst%3DA.%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DPaiva%26aufirst%3DA.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DKolb%26aufirst%3DJ.%26aulast%3DHerbst%26aufirst%3DJ.%26aulast%3DShou%26aufirst%3DW.%26aulast%3DWeller%26aufirst%3DH.%26atitle%3DApproach%2520to%2520improve%2520compound%2520recovery%2520in%2520a%2520high-throughput%2520Caco-2%2520permeability%2520assay%2520supported%2520by%2520liquid%2520chromatography%25E2%2580%2593tandem%2520mass%2520spectrometry%26jtitle%3DJ.%2520Pharm.%2520Sci.%26date%3D2012%26volume%3D101%26spage%3D2755%26epage%3D2762%26doi%3D10.1002%2Fjps.23194" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sack, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kish, K. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duke, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tredup, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiefer, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Newitt, J. A.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">705</span>– <span class="NLM_lpage">710</span>, <span class="refDoi"> DOI: 10.1107/S0907444908010032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1107%2FS0907444908010032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD1cXntlCrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2008&pages=705-710&author=J.+S.+Sackauthor=K.+F.+Kishauthor=M.+Pokrossauthor=D.+Xieauthor=G.+J.+Dukeauthor=J.+A.+Tredupauthor=S.+E.+Kieferauthor=J.+A.+Newitt&title=Structural+basis+for+the+high-affinity+binding+of+pyrrolotriazine+inhibitors+of+p38+MAP+kinase&doi=10.1107%2FS0907444908010032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the high-affinity binding of pyrrolotriazine inhibitors of p38 MAP kinase</span></div><div class="casAuthors">Sack, John S.; Kish, Kevin F.; Pokross, Matthew; Xie, Dianlin; Duke, Gerald J.; Tredup, Jeffrey A.; Kiefer, Susan E.; Newitt, John A.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">705-710, S705/1</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The crystal structure of unphosphorylated p38α MAP kinase complexed with a representative pyrrolotriazine-based inhibitor led to the elucidation of the high-affinity binding mode of this class of compds. at the ATP-binding site.  The ligand binds in an extended conformation, with one end interacting with the adenine-pocket hinge region, including a hydrogen bond from the carboxyl O atom of Met-109.  The other end of the ligand interacts with the hydrophobic pocket of the binding site and with the backbone N atom of Asp-168 in the DFG activation loop.  Addn. of an extended benzylmorpholine group forces the DFG loop to flip out of position and allows the ligand to make addnl. interactions with the protein.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoA3XUI3FjZC7Vg90H21EOLACvtfcHk0lj0a9gyKT6EBA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXntlCrsLg%253D&md5=a3d643539a2c89187e9bf4faf842f3c2</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1107%2FS0907444908010032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444908010032%26sid%3Dliteratum%253Aachs%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DKish%26aufirst%3DK.%2BF.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DDuke%26aufirst%3DG.%2BJ.%26aulast%3DTredup%26aufirst%3DJ.%2BA.%26aulast%3DKiefer%26aufirst%3DS.%2BE.%26aulast%3DNewitt%26aufirst%3DJ.%2BA.%26atitle%3DStructural%2520basis%2520for%2520the%2520high-affinity%2520binding%2520of%2520pyrrolotriazine%2520inhibitors%2520of%2520p38%2520MAP%2520kinase%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2008%26volume%3D64%26spage%3D705%26epage%3D710%26doi%3D10.1107%2FS0907444908010032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="note"><p class="first last">Compound <b>112</b> is Example 9 in</p></div><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dzierba, C. D.</span>; <span class="NLM_string-name">Dasgupta, B.</span>; <span class="NLM_string-name">Macor, J. E.</span>; <span class="NLM_string-name">Bronson, J.</span>; <span class="NLM_string-name">Rajamani, R.</span>; <span class="NLM_string-name">Karageorge, G. N.</span></span> <span> </span><span class="NLM_article-title">Pyrrolotriazine kinase inhibitors</span>. World Patent Appl. <span class="NLM_patent">WO 2015/054358 A1</span>, <span class="NLM_year">2015</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=C.+D.+Dzierba&author=B.+Dasgupta&author=J.+E.+Macor&author=J.+Bronson&author=R.+Rajamani&author=G.+N.+Karageorge&title=Pyrrolotriazine+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDzierba%26aufirst%3DC.%2BD.%26atitle%3DPyrrolotriazine%2520kinase%2520inhibitors%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winn, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Storoni, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span> <span> </span><span class="NLM_article-title">Phaser crystallographic software</span>. <i>J. Appl. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>40</i></span>,  <span class="NLM_fpage">658</span>– <span class="NLM_lpage">674</span>, <span class="refDoi"> DOI: 10.1107/S0021889807021206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1107%2FS0021889807021206" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=19461840" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2007&pages=658-674&author=A.+J.+McCoyauthor=R.+W.+Grosse-Kunstleveauthor=P.+D.+Adamsauthor=M.+D.+Winnauthor=L.+C.+Storoniauthor=R.+J.+Read&title=Phaser+crystallographic+software&doi=10.1107%2FS0021889807021206"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Phaser crystallographic software</span></div><div class="casAuthors">McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D.; Winn, Martyn D.; Storoni, Laurent C.; Read, Randy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Applied Crystallography</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">658-674</span>CODEN:
                <span class="NLM_cas:coden">JACGAR</span>;
        ISSN:<span class="NLM_cas:issn">0021-8898</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">Phaser is a program for phasing macromol. crystal structures by both mol. replacement and exptl. phasing methods.  The novel phasing algorithms implemented in Phaser have been developed using max. likelihood and multivariate statistics.  For mol. replacement, the new algorithms have proved to be significantly better than traditional methods in discriminating correct solns. from noise, and for single-wavelength anomalous dispersion exptl. phasing, the new algorithms, which account for correlations between F+ and F-, give better phases (lower mean phase error with respect to the phases given by the refined structure) than those that use mean F and anomalous differences ΔF.  One of the design concepts of Phaser was that it be capable of a high degree of automation.  To this end, Phaser (written in C++) can be called directly from Python, although it can also be called using traditional CCP4 keyword-style input.  Phaser is a platform for future development of improved phasing methods and their release, including source code, to the crystallog. community.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPeVyjN_FMGbVg90H21EOLACvtfcHk0lgqzKRIlfCGEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXnslWqsLk%253D&md5=c63b722ae97e0a74e6a5a079d388f09f</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1107%2FS0021889807021206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0021889807021206%26sid%3Dliteratum%253Aachs%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DWinn%26aufirst%3DM.%2BD.%26aulast%3DStoroni%26aufirst%3DL.%2BC.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26atitle%3DPhaser%2520crystallographic%2520software%26jtitle%3DJ.%2520Appl.%2520Crystallogr.%26date%3D2007%26volume%3D40%26spage%3D658%26epage%3D674%26doi%3D10.1107%2FS0021889807021206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="note"><p class="first last">The compound used as an internal standard was Example 6a in</p></div><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Vrudhula, V. M.</span>; <span class="NLM_string-name">Pan, Senliang</span>; <span class="NLM_string-name">Rajamani, R.</span>; <span class="NLM_string-name">Macor, J. E.</span>; <span class="NLM_string-name">Bronson, J. J.</span>; <span class="NLM_string-name">Dzierba, C. D.</span>; <span class="NLM_string-name">Nara, S. J.</span>; <span class="NLM_string-name">Karatholuvhu, M. S.</span></span> <span> </span><span class="NLM_article-title">Aryl ether-base kinase inhibitors</span>. World Patent Appl. <span class="NLM_patent">WO 2013/134036 A1</span>, <span class="NLM_year">2013</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2013&author=V.+M.+Vrudhula&author=Senliang+Pan&author=R.+Rajamani&author=J.+E.+Macor&author=J.+J.+Bronson&author=C.+D.+Dzierba&author=S.+J.+Nara&author=M.+S.+Karatholuvhu&title=Aryl+ether-base+kinase+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DVrudhula%26aufirst%3DV.%2BM.%26atitle%3DAryl%2520ether-base%2520kinase%2520inhibitors%26date%3D2013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wheeler-Aceto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cowan, A.</span></span> <span> </span><span class="NLM_article-title">Standardization of the rat paw formalin test for the evaluation of analgesics</span>. <i>Psychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>104</i></span>,  <span class="NLM_fpage">35</span>– <span class="NLM_lpage">44</span>, <span class="refDoi"> DOI: 10.1007/BF02244551</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1007%2FBF02244551" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1882002" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADyaK3MXkt1Wms7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=1991&pages=35-44&author=H.+Wheeler-Acetoauthor=A.+Cowan&title=Standardization+of+the+rat+paw+formalin+test+for+the+evaluation+of+analgesics&doi=10.1007%2FBF02244551"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Standardization of the rat paw formalin test for the evaluation of analgesics</span></div><div class="casAuthors">Wheeler-Aceto, Helen; Cowan, Alan</div><div class="citationInfo"><span class="NLM_cas:title">Psychopharmacology (Berlin, Germany)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-44</span>CODEN:
                <span class="NLM_cas:coden">PSCHDL</span>;
        ISSN:<span class="NLM_cas:issn">0033-3158</span>.
    </div><div class="casAbstract">Administration of 5% formalin into the rat or guinea pig hind paw evokes two spontaneous responses: flinching/shaking and licking/biting of the injected paw.  The temporal and behavioral characteristics of these objective endpoints are described.  Addnl., several practical suggestions aimed at standardizing this test for the evaluation of analgesics are presented.  The early/acute and late/tonic (0-10 and 20-35 min post-formalin, resp.) phases of flinching were used to quantitate antinociception in the rat.  PD 117302, the kappa selective agonist, was three times more potent than morphine against tonic flinching after s.c. administration.  Formalin may therefore be a noxious stimulus of choice in the evaluation of kappa agonists.  Morphine was only twice as potent against tonic flinching as against acute flinching or the tail-dip reflex to water (50°).  In contrast, PD 117302 was 27 times less potent on early phase and was inactive in the tail-dip test.  Thus, while morphine is essentially equipotent across tests, PD 117302 shows a spectrum of activity with impressive potency and efficacy being obtained against tonic pain.  Kappa receptors may therefore be prominently involved in tonic pain states.  Aspirin given orally was not consistently antinociceptive in either phase of the formalin test.  Spinal transection completely abolished late phase responding but only partly attenuated flinching in the early phase.  This suggests that the relative involvement of spinal (as opposed to supraspinal) processing of noxious inputs may, at least in part, be a function of stimulus intensity and underlie the differences in antinociceptive potency obsd. in this work.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqddB-QBhf6z7Vg90H21EOLACvtfcHk0lgqzKRIlfCGEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXkt1Wms7Y%253D&md5=8516037add46a95f4b55c733b7f0db48</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1007%2FBF02244551&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252FBF02244551%26sid%3Dliteratum%253Aachs%26aulast%3DWheeler-Aceto%26aufirst%3DH.%26aulast%3DCowan%26aufirst%3DA.%26atitle%3DStandardization%2520of%2520the%2520rat%2520paw%2520formalin%2520test%2520for%2520the%2520evaluation%2520of%2520analgesics%26jtitle%3DPsychopharmacology%26date%3D1991%26volume%3D104%26spage%3D35%26epage%3D44%26doi%3D10.1007%2FBF02244551" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shimoyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimoyama, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gorman, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elliott, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inturrisi, C. E.</span></span> <span> </span><span class="NLM_article-title">Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite, norketamine</span>. <i>Pain.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>81</i></span>,  <span class="NLM_fpage">85</span>– <span class="NLM_lpage">93</span>, <span class="refDoi"> DOI: 10.1016/S0304-3959(98)00269-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2FS0304-3959%2898%2900269-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10353496" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=1%3ACAS%3A528%3ADyaK1MXjtFajsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=81&publication_year=1999&pages=85-93&author=M.+Shimoyamaauthor=N.+Shimoyamaauthor=L.+A.+Gormanauthor=K.+J.+Elliottauthor=C.+E.+Inturrisi&title=Oral+ketamine+is+antinociceptive+in+the+rat+formalin+test%3A+role+of+the+metabolite%2C+norketamine&doi=10.1016%2FS0304-3959%2898%2900269-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite, norketamine</span></div><div class="casAuthors">Shimoyama, Megumi; Shimoyama, Naohito; Gorman, A. Laurel; Elliott, Kathryn J.; Inturrisi, Charles E.</div><div class="citationInfo"><span class="NLM_cas:title">Pain</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">81</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">85-93</span>CODEN:
                <span class="NLM_cas:coden">PAINDB</span>;
        ISSN:<span class="NLM_cas:issn">0304-3959</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">The present study was designed to evaluate the oral efficacy and bioavailability of ketamine.  Antinociceptive efficacy was detd. with the rat formalin test and oral bioavailability by the measurement of plasma and brain concns. of ketamine and its major metabolite, norketamine.  Oral ketamine in a dose range from 30 to 180 mg/kg or saline was given prior to intraplantar formalin and the flinching behavior was measured.  Oral ketamine dose-dependently reduced the flinching during phase 2, while flinching during phase 1 was reduced only with the highest dose given.  Following oral ketamine at 100 mg/kg, blood and brain samples were obtained and plasma and brain ketamine and norketamine levels were measured using high-performance liq. chromatog. (HPLC).  The av. concn. ratio of norketamine/ketamine, as expressed by the area under the curve (AUC) value, was 6.4 for plasma and 2.9 for brain.  These results demonstrate that a significant amt. of norketamine is formed by first pass biotransformation of ketamine and is distributed to the brain.  Competition binding assays for the [3H]MK-801-labeled non-competitive site of the N-methyl-d-aspartate receptor (NMDA) receptor revealed that both norketamine and ketamine displaced [3H]MK-801 at low micromolar concns. with Ki values of 2.5 and 0.3 mM in the forebrain, and 4.2 and 1.0 mM in the spinal cord, resp.  Spinal norketamine was approx. equipotent to ketamine in producing antinociceptive effects during phase 2 of the formalin test.  Thus, norketamine appears to contribute to the antinociceptive effects of oral ketamine through its NMDA receptor antagonist activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol23fCP1OXFrVg90H21EOLACvtfcHk0lgqzKRIlfCGEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjtFajsr0%253D&md5=5779f585c19a90c10d191133d0d7cea3</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2FS0304-3959%2898%2900269-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0304-3959%252898%252900269-3%26sid%3Dliteratum%253Aachs%26aulast%3DShimoyama%26aufirst%3DM.%26aulast%3DShimoyama%26aufirst%3DN.%26aulast%3DGorman%26aufirst%3DL.%2BA.%26aulast%3DElliott%26aufirst%3DK.%2BJ.%26aulast%3DInturrisi%26aufirst%3DC.%2BE.%26atitle%3DOral%2520ketamine%2520is%2520antinociceptive%2520in%2520the%2520rat%2520formalin%2520test%253A%2520role%2520of%2520the%2520metabolite%252C%2520norketamine%26jtitle%3DPain.%26date%3D1999%26volume%3D81%26spage%3D85%26epage%3D93%26doi%3D10.1016%2FS0304-3959%2898%2900269-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munro, G.</span></span> <span> </span><span class="NLM_article-title">Pharmacological assessment of the rat formalin test utilizing the clinically used analgesic drugs gabapentin, lamotrigine, morphine, duloxetine, tramadol and ibuprofen: influence of low and high formalin concentrations</span>. <i>Eur. J. Pharmcol.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>605</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">102</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2009.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=10.1016%2Fj.ejphar.2009.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;key=19168051" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=605&publication_year=2009&pages=95-102&author=G.+Munro&title=Pharmacological+assessment+of+the+rat+formalin+test+utilizing+the+clinically+used+analgesic+drugs+gabapentin%2C+lamotrigine%2C+morphine%2C+duloxetine%2C+tramadol+and+ibuprofen%3A+influence+of+low+and+high+formalin+concentrations&doi=10.1016%2Fj.ejphar.2009.01.004"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2009.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2009.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DMunro%26aufirst%3DG.%26atitle%3DPharmacological%2520assessment%2520of%2520the%2520rat%2520formalin%2520test%2520utilizing%2520the%2520clinically%2520used%2520analgesic%2520drugs%2520gabapentin%252C%2520lamotrigine%252C%2520morphine%252C%2520duloxetine%252C%2520tramadol%2520and%2520ibuprofen%253A%2520influence%2520of%2520low%2520and%2520high%2520formalin%2520concentrations%26jtitle%3DEur.%2520J.%2520Pharmcol.%26date%3D2009%26volume%3D605%26spage%3D95%26epage%3D102%26doi%3D10.1016%2Fj.ejphar.2009.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LVH" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LVH','PDB','7LVH'); return false;">PDB: 7LVH</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LVI" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LVI','PDB','7LVI'); return false;">PDB: 7LVI</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i180"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00472">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_36821"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.1c00472?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.1c00472</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Crystallographic data and refinement statistics for X-ray crystal structures of <b>19</b> and <b>(<i>R</i>,<i>R</i>)-40</b> complexed with AAK1, the structure of the parent compound in the X-ray co-crystal structures (<b>112</b>), amino acid residue differences between mouse and human AAK1 kinase domains; a comparison of the IC<sub>50</sub> values of AAK1 inhibitors for human, mouse, and rat AAK1; IC<sub>50</sub> curves for human, mouse, and rat full-length AAK1; an overlay of <b>(<i>S</i>,<i>S</i>)-40</b> superimposed onto the X-ray structure of <b>(<i>R</i>,<i>R</i>)-40</b>; the Ambit kinase panel heat map for <b>59</b>; binding assay results for off-target activity for compound <b>59</b>; Western blots associated with Figure 9; analytical HPLC traces for compounds <b>19</b>, <b>41</b>, and <b>59</b> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00472/suppl_file/jm1c00472_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and SAR data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.1c00472/suppl_file/jm1c00472_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00472/suppl_file/jm1c00472_si_001.pdf">jm1c00472_si_001.pdf (1.82 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.1c00472/suppl_file/jm1c00472_si_002.csv">jm1c00472_si_002.csv (3.27 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Atomic coordinates for the X-ray structures of compound <b>19</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LVH">7LVH</a>) and <b>(<i>R</i>,<i>R</i>)-40</b> (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=7LVI">7LVI</a>) bound to AAK1 are available from the RSCB Protein Data Bank (<a href="http://www.rscb.org" class="extLink">www.rscb.org</a>). The authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.1c00472&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.1c00472" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.1c00472" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                8MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799340e3a8d3d0c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
